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ABSTRACT 
Reolysin® is a naturally occurring, replication competent formulation of reovirus 
Type 3 Dearing (T3D), which has displayed oncolytic activity in a variety of human 
cancers in vitro and in clinical trials.  Reolysin® shows great promise as a cancer 
therapeutic, but further optimisation is needed to maximise its oncolytic potential.   
Previous work has failed to uncover the full mechanism of reovirus oncolysis, and this 
has hindered the discovery of a reliable biomarker of reovirus treatment response.  
Through gene expression profiling, knock-down, and over-expression experiments, 
we have identified Yes-Associated Protein-1 (YAP1) as a host-cell factor that predicts 
the susceptibility of squamous cell carcinoma of the head and neck (SCCHN) cell 
lines to reovirus-induced cell death.  YAP1 is a downstream effector of the Hippo 
pathway that regulates cellular growth and, sometimes, cancer progression.  
Mechanistic studies revealed that YAP1-mediated restriction of reovirus oncolysis 
may partially affect direct reovirus replication, but does not occur at the cell surface 
via the main reovirus receptor, JAM-A, nor is it linked to the type I interferon anti-
viral response.  YAP1 protein expression appears to be cancer-specific; 13% of head 
and neck carcinoma tissues stained positive for YAP1, but expression was negligible 
in tissue derived from normal organs.  Therefore, YAP1 shows potential as a clinical 
biomarker to help characterise the most responsive SCCHN patient subgroup to 
reovirus treatment, which warrants further investigation.   
Additionally, combining reovirus with 3 weekly chemotherapy regimens at the 
standard maximum tolerated dose (MTD) may not be the optimum mode of 
administration, as the drug-free breaks often allow tumour-vasculature re-growth, 
resulting in disease progression.  Metronomic chemotherapy (MC) primarily targets 
endothelial cells that support tumour-associated angiogenesis, and is less toxic than 
the MTD.  We have investigated a novel treatment combination of reovirus and low 
doses of taxane chemotherapy agents in prostate cancer (PCa) cell lines.  The 
interaction of reovirus and Cabazitaxel or Docetaxel at doses considerably less than 
their IC50 values was measured by using cell viability assays and the Bliss statistical 
model, which demonstrated synergistic anti-cancer activity.  This was partly due to 
enhanced microtubule stabilisation.  Our data provides substance to assess the 
efficacy of this type of combination therapy in vivo, and subsequently in human trials.   
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1.  INTRODUCTION 
1.1. CANCER 
1.1.1. Hallmarks 
According to Hanahan and Weinberg, there are six main hallmarks that govern the 
transformation of a normal cell to a neoplastic state.  There are also emerging 
hallmarks such as the ability of cancer cells to evade immune destruction (Figure 1.1) 
[1].  Cancer cells can sustain chronic proliferative signalling by synthesising growth 
factor (GF) ligands, to which they can become hyper-responsive to by over-
expression or structural alteration of associated cell-surface receptors [1].  In normal 
cells, tumour suppressor genes (TSGs) function to halt cell cycle progression if 
exposed to genomic damage, and if un-repairable, induce apoptosis.  Two TSGs that 
are commonly inactivated in human cancers are TP53 and RB, which encode tumour 
protein 53 (p53) and retinoblastoma (pRb) proteins respectively [1].   
Tumour cells have developed a number of strategies to evade programmed cell death, 
for example, through increased expression of the anti-apoptotic factors Bcl-2 or Bcl-
xL, or by down-regulation of the pro-apoptotic factors Puma, Bax or Bim [1].  During 
autophagy, cytoplasmic constituents are degraded and recycled, and in doing so, 
release metabolites that provide energy to the stressed cell [1].  Hence, autophagy can 
paradoxically mediate tumour cell survival and death [2].  In contrast, necrotic cells 
rupture to spill their contents into the tissue microenvironment.  Recruitment of 
inflammatory immune cells to remove necrotic debris may benefit surviving tumour 
cells by providing growth-stimulatory factors [1].   
Normal cells have a limited number of growth and division cycles before they die [1].  
However, cells can occasionally overcome the state of crisis and become 
immortalised, for example, through over-expression of the DNA polymerase enzyme, 
telomerase [1].  In healthy cells, angiogenesis is transiently activated in response to 
physiological processes such as wound healing.  Tumours may obtain nutrients and 
oxygen to sustain growth by inducing angiogenesis permanently, often via up-
regulation of vascular endothelial growth factor-A (VEGF-A) [1].  Another hallmark 
of cancer is the activation of invasion and metastasis, which is frequently stimulated 
by a process called epithelial-mesenchymal transition (EMT) [1].   
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Figure 1.1.  A diagram showing the main hallmarks of cancer.  Adapted from [1].   
 
 
1.1.2. Head and Neck Cancer 
1.1.2.1. Incidence 
Human head and neck cancers can occur in the oral cavity, pharynx, larynx, salivary 
gland, paranasal sinuses and nasal cavity, as depicted in Figure 1.2 [3].  In the United 
Kingdom (UK) in 2013, there were 7,591 new cases, making it the 14th most common 
cancer [4].  Worldwide in 2012, lip and oral cavity cancer was the 15th leading cancer 
by incidence, accounting for more than 300,000 newly diagnosed cases [4].  These 
cancers usually manifest in the fifth, sixth or seventh decades of life, and are twice as 
common in men as in women [4].   
 
 
 
 
 
 
 
Figure 1.2.  A diagram illustrating the different head and neck cancer regions [3].   
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Approximately 90% of these cancers are biologically similar and originate from the 
squamous cells that line the mucosal surfaces.  These cancers are therefore called 
squamous cell carcinomas of the head and neck (SCCHN) [3]. 
1.1.2.2. Risk factors and symptoms 
The two most important risk factors are tobacco and alcohol use.  Infection with 
human papillomavirus (HPV) is also a major risk factor, especially for oropharyngeal 
cancers [3-5].  Other risk factors may include genetic predisposal via inherited 
disorders such as Fanconi anaemia, radiation exposure, and occupational exposure to 
wood dust, asbestos or synthetic fibres [3-5].  General symptoms may include a 
persistent sore throat, a sore that does not heal, hoarseness in the voice and difficulty 
in swallowing.  There may be a persistent earache or frequent headaches [3, 4].   
1.1.2.3. Heterogeneity  
SCCHN is a heterogeneous disease.  The HPV-status of a SCCHN tumour is 
considered to be important in predicting a patient’s prognosis [5].  HPV is a double-
stranded DNA (dsDNA) virus that contains two oncogenes, E6 and E7, whose 
expression inactivates the p53 and pRb tumour suppressors respectively [5].  This is 
believed to be the onset of HPV-mediated carcinogenesis in some SCCHNs.  
Interestingly, HPV-positive SCCHN cancers are typically TP53 wild type and occur 
predominantly in patients without a history of tobacco and/or alcohol use.  In contrast, 
TP53 mutations are frequently observed in smoking and/or alcohol-related HPV-
negative SCCHN tumours, and these patients have a less favourable prognosis [5].  
These characteristics are summarised in Table 1.1.   
 
Table 1.1.  Clinical and biological characteristics of HPV negative and positive SCCHN.  Adapted 
from [5].  
 
 
 
 
 
 
 
 
 
 
 
Feature HPV-negative SCCHN HPV-positive SCCHN References 
Incidence Decreasing Increasing [6] 
Aetiology Smoking, excessive alcohol use Oral sex [7] 
Age Above 60 years Under 60 years [6] 
Field cancerisation Yes Unknown [8] 
TP53 mutations Frequent Infrequent [9] 
Predilection site None Oropharynx [10] 
Prognosis Poor Favourable [11, 12] 
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In addition to abrogation of the p53 and pRb signalling pathways, cell cycle 
regulation can be perturbed by inactivation of CDKN2A (encoding the p16INK4A 
tumour suppressor protein) [13] or over-expression of CCND1 (encoding Cyclin D1; a 
protein that regulates cell cycle progression) [9], in many SCCHN tumours.  Increased 
activity of telomerase or its catalytic subunit, telomerase reverse transcriptase 
(TERT), is frequently detected [5].  A subgroup of SCCHNs over-express the 
epidermal growth factor receptor gene (EGFR) giving rise to enhanced proliferation 
[5, 14], whereas other SCCHNs escape from the tumour suppressing effects of the 
transforming growth factor-β (TGF-β) pathway by somatic mutation or chromosomal 
loss of certain genes, including SMAD2 and SMAD4 [15].  Also linked to the 
development of 10-20% of SCCHNs are activating mutations in the 
phosphatidylinositol-3 kinase (PI3K) -PI3K-phosphatase and tensin homolog deleted 
on chromosome 10 (PTEN) -Akt pathway.  For example, somatic mutations may 
occur in PIK3CA and PTEN genes that effectively reduce apoptosis and allow 
proliferation [5, 16, 17].   
1.1.2.4. Pathogenesis 
Evidence suggests that SCCHN may arise from a precursor lesion known as a 
leukoplakia.  Surgical removal or treatment of the leukoplakia is largely ineffective in 
preventing malignant transformation and hence, clinicians normally employ watchful 
waiting [5].  Additionally, various genetic precursor changes arise in the squamous 
epithelium that are not visible to the naked eye.  Such changes are referred to as field 
cancerisation, and may include a mutated p53, decreased cytokeratin 4 and loss of 
heterozygosity at chromosome 9p.  It is thought that this may be the source of local 
recurrences and second primary tumours after resection of the original SCCHN [5].    
1.1.2.5. Diagnosis, treatment and prognosis 
The most common method for staging head and neck cancers is the tumour, node, 
metastasis (TNM) system [18, 19].  ‘T’ describes the characteristics of the tumour at 
the primary site, which may be based on size, location or both.  ‘N’ indicates the 
degree of regional lymph node involvement, and ‘M’ describes the absence or 
presence of distant metastases.  The specific TNM status of each patient is then 
tabulated to give a numerical status of Stage I, II, III, or IV.  In general, early-stage 
6 
 
disease is denoted as Stage I or II and advanced-stage disease as Stage III or IV.  
SCCHN patients that present with early-stage disease can be treated with surgery or 
radiotherapy and generally have a favorable prognosis [5].  However, up to 50% of 
SCCHN patients present with advanced disease [20].  The standard treatment for 
advanced cases is surgery combined with chemotherapy (typically Paclitaxel, 
Carboplatin or Docetaxel) and radiotherapy, and more recently the use of the EGFR-
inhibitor, Cetuximab.  Unfortunately, the relapse rate at 2 years for patients with 
locally advanced SCCHN is 30-50%, as loco-regional recurrences, distant metastasis 
and second primary tumours often develop [5, 21].  The patients in the relapsed and 
metastatic group have an overall 5-year survival rate of less than 10% [21].  
Therefore, new therapeutic strategies are needed.  Oncolytic viruses are biological 
anti-cancer agents that may be an attractive option for SCCHN, as discussed in 
Section 1.2 and 1.3. 
 
 
 
 
1.1.3. Prostate Cancer 
1.1.3.1. Incidence 
In 2011 there were 41,736 new cases of prostate cancer (PCa) in the UK, making it 
the most common cancer in men.  Worldwide, it is the fourth most common cancer 
overall, with more than 1,111,000 new cases diagnosed in 2012 [4].  The incidence of 
PCa rises from the ages of 50-54, reaching a peak in the 75-79 age group [4].  Acinar 
adenocarcinoma is the most common type, amounting to more than 90% of cases [22].   
1.1.3.2. Risk factors and symptoms 
Deleterious mutations in the BRCA1 and BRCA2 TSGs have been shown to be 
important risk factors in PCa development [23, 24].  Men with Lynch syndrome, an 
autosomal dominant genetic condition, are also at higher risk than the general 
population [22].  Men whose father or brother has/had PCa [25], or whose mother 
has/had breast cancer [26], are at greater risk of developing the disease than men 
without such a family history.  A study published by Hoffman et al concluded that 
PCa more commonly affects African American and Hispanic men than non-Hispanic 
white men [27].  Elevated circulating levels of insulin-like growth factor-1 (IGF-1) 
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[28, 29] and testosterone [22, 30] have been linked to an increased risk of PCa.  A 
small number of studies associate occupational exposure to arsenic, ionising radiation 
or rubber, as possible risk factors [22, 30].  Early PCa generally does not cause any 
symptoms.  However, some PCa growths may cause symptoms similar to benign 
prostatic hyperplasia, such as frequent urination, haematuria and dysuria [22].   
1.1.3.3. Heterogeneity and pathogenesis 
The development and progression of PCa is usually dependent on androgen receptor 
(AR) signalling.  Testosterone is the main circulating androgen hormone produced by 
the testes and is converted by 5α-reductase into dihydrotestosterone.  The binding of 
androgens to their cognate AR gives rise to a conformational change that causes the 
receptor to dissociate from heat shock proteins in the cytoplasm [31, 32].  The 
receptor then translocates to the nucleus, where it acts as a transcription factor and 
binds to androgen response elements in the promoter regions of target genes, such as 
prostate specific antigen (PSA).  Transcription and expression of these target genes 
are essential for both normal prostate development and prostate carcinogenesis [31, 
32].  Therefore, PCa patients are usually treated with androgen deprivation therapy 
(ADT).  However, patients will eventually no longer respond to ADT, relapse, and 
develop castration-resistant PCa (CRPC).  This may be due to enhanced sensitivity of 
the AR to its agonists, AR mutations that cause the receptor to be responsive to other 
non-androgen ligands, or ligand-independent AR activation [32].  Like SCCHN, PCa 
displays a high level of heterogeneity.  There is evidence to suggest that the 
transcriptional activity of the AR in CRPC is maintained by up-regulation of growth 
factors such as epidermal growth factor (EGF) (and its EGFR receptor) [33], and IGF-
1 [34], as well as the cytokines interleukin-6 and -8 (IL-6 and IL-8) [35-37].  PCa 
proliferation and survival may also be mediated by activation of the mitogen-activated 
protein kinase (MAPK) and PI3K-PTEN-Akt signalling pathways [38, 39].  
Expression of the PTEN tumour suppressor protein was found to be lost in 20-27% of 
primary tumours and 79% of CRPC cases [38].  Approximately 50% of prostate 
tumours contain gene fusions between the E-twenty-six (ETS) family of transcription 
factors and the androgen receptor (AR) gene promoter, which contributes to 
neoplastic development [32].   
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1.1.3.4. Diagnosis, treatment and prognosis 
A high serum PSA may help indicate whether a man has PCa.  According to the 
American Cancer Society, a PSA level above 4ng/mL is deemed abnormal, and these 
patients are advised to undergo a biopsy [32].  Histopathological analysis of biopsy 
tissue (Gleason score) is key in determining a patient’s treatment and prognosis [31], 
and the stage of PCa is usually determined by the TNM system [22].  Low risk 
localised PCa is unlikely to develop for many years and is monitored by active 
surveillance.  If the cancer starts to grow then the patient may be offered surgery to 
remove the prostate gland or internal radiotherapy to the prostate (brachytherapy) 
[22].  For locally advanced cases where the cancer has broken through the capsule 
surrounding the prostate gland, the usual treatments are surgery to remove the prostate 
gland or external radiotherapy to the prostate [22].  ADT is also given before, during 
or after treatment, which usually improves symptoms transiently before tumours 
become castration resistant, enabling disease progression.  Cryotherapy and high 
frequency ultrasound therapy may also be offered, but these are not standard 
treatments [22].  The first line of standard care for patients with CRPC is the 
chemotherapeutic Docetaxel, which has shown to have a median survival benefit of 
up to 3 months [40].  Cabazitaxel, a newer taxane analogue, is used for treatment of 
patients with CRPC previously treated with a Docetaxel-containing regimen [22].  For 
disease that is confined to the prostate, the 5-year survival for patients in England in 
1999-2002 was ≥90%.  However, if the disease was metastatic at diagnosis the 5-year 
survival dropped to 30% [4, 22], and  clearly more efficacious treatments are required.  
Oncolytic viruses are one such option (Section 1.2 and 1.3).   
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1.2. ONCOLYTIC VIROTHERAPY 
Oncolytic Viruses (OVs) display anti-cancer activity in a wide range of tumour types, 
including SCCHN and PCa.  They preferentially infect and lyse cancer cells either 
naturally, or through modification to include a therapeutic gene that aids targeting of 
the tumour.  Many different OVs have been investigated in pre-clinical and clinical 
settings (as summarised in Table 1.2 and 1.3 respectively) and overall, have a good 
safety profile.  As a monotherapy, OVs are probably not potent enough to achieve 
complete tumour regressions or to generate sustained clinical responses [41].  
However, the combination of OVs with conventional cancer treatment modalities 
have shown to enhance their efficacy [42].  Naturally occurring OVs are considered to 
be safer than their genetically modified counterparts.  Moreover, modifications to 
reduce the pathogenicity of an OV can also compromise its anti-cancer efficacy.   
1.2.1. History 
Using viruses for the treatment of cancer is not a new concept.  In the early twentieth 
century, it was noticed that cancer patients who contracted naturally occurring viral 
infections sometimes went into brief periods of clinical remission [43].  Advances in 
cell and virus culture techniques in the 1950’s and 1960’s sparked investigation of 
different viruses for the treatment of cancer in animal models and in humans [44]. 
However, poor efficacy led to a temporary halt in oncolytic virotherapy research [45].  
In 1991, there was a resurgence of interest following a publication that described the 
use of a thymidine kinase-negative mutant of HSV-1 as a possible treatment for 
glioma [46].  Since the arrival of recombinant technology, there has been much focus 
on engineering viruses to eliminate their pathogenicity without destroying their 
oncolytic potency [45].  Six OVs in current use are reviewed below, before focussing 
in depth on oncolytic reovirus (Section 1.3).     
1.2.2. Oncolytic Adenovirus 
Adenoviruses contain dsDNA and are non-enveloped.  They have been engineered to 
enhance their anti-tumour potency, delivery and safety.  Various oncolytic 
adenoviruses have been tested in pre-clinical models [21].  A significant anti-tumour 
effect was observed in a SCCHN murine tumour model after subcutaneous injection 
of Ad5/3-Δ24FCU1 [47].  Ad5/3-Δ24FCU1 features a 5/3 serotype chimeric capsid to 
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enhance gene delivery; a 24-base pair (bp) deletion in the pRb-binding domain of the 
viral E1A protein to enable selective replication in tumour cells; and a FCU1 suicide 
gene that encodes a protein that catalyses the conversion of 5-fluorocytosine (5-FC) to 
the active drug 5-fluorouridine (5-FU), in order to enhance selective cancer cell kill 
[21, 47].  Ad5/35 is another genetically modified adenovirus that substitutes Ad5 for 
the Ad35 fiber, which recognises the CD46 receptor on the surface of many tumour 
cells and thus, increases tumour selectivity.  In combination with cisplatin or 
radiation, Ad5/35 demonstrated delayed tumour progression in xenograft mice models 
of head and neck cancer or melanoma [21, 48, 49].  Arming adenovirus with anti-
angiogenesis genes that encode human endostatin (Ad-Endo) has shown to promote 
anti-tumour activity in a nasopharyngeal carcinoma model [21, 50].  OBP-301, an 
adenovirus that displays anti-tumour selectivity in cancer cells expressing telomerase, 
was shown to overcome radio-resistance in oral squamous cell carcinomas in vivo [21, 
51], and supressed LNCaP tumour growth in a PCa mouse model [52].  Hu et al tested 
two oncolytic adenoviruses that targeted TGF-β (a regulator of PCa metastasis) in a 
PCa mouse model.  Significant inhibition of tumour growth and bone metastasis was 
observed, indicating the potential of the viruses to treat metastatic PCa [53].   
Enadenotucirev (EnAd; previously known as ColoAd1) is an Ad11p/Ad3 chimeric 
OV that has specific activity in human colon cancer, and has entered Phase I clinical 
testing to examine its therapeutic potential [54].  ONYX-015 is an E1B gene deleted 
adenovirus that selectively replicates in and lyses tumour cells with a deficient TP53 
[21].  Normal cells with a functioning TP53 gene should remain un-harmed after virus 
infection, as replication should be prevented by p53-mediated cell cycle arrest [21, 
55].  In patients with malignant glioma, ONYX-015 was injected into the 
peritumoural region after surgical removal of the tumour.  Results showed that 
ONYX-015 was safe but had little therapeutic effect [56].  Conversely, in a Phase II 
clinical study, significant tumour regression was observed following peritumoural and 
intratumoural injection of ONYX-015 in patients with recurrent head and neck 
cancers [21, 57].  However, it was later demonstrated that ONYX-015 could kill 
tumour cells regardless of p53 status and therefore, the exact mechanism of its 
selectively remains to be found [21].  In 2005, Chinese regulators approved the 
modified oncolytic adenovirus H101 for the treatment of head and neck cancer.  H101 
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is an E1B-deleted adenovirus that is similar to ONYX-015 but lacks all E3 proteins 
[21], and has shown to improve overall response rates in these patients [21].   
1.2.3. Oncolytic Herpes Simplex virus 
Herpes simplex virus (HSV) is an enveloped dsDNA virus.  Infected host cells would 
normally initiate an anti-viral response pathway to prevent production of HSV virions 
via phosphorylation of protein kinase R (PKR).  However, expression of the viral 
protein ICP34.5 inhibits the action of PKR by de-phosphorylating its downstream 
component, eukaryotic initiation factor-2α (eIF-2α), allowing viral replication to 
proceed [21].  Expression of another viral protein, ICP47, allows HSV to evade the 
effects of the immune system by inhibiting major histocompatibility complex (MHC) 
class I, therefore preventing virus clearance [21].  Deletion of these genes responsible 
for viral pathogenicity and immunogenicity has improved the cancer cell selectivity of 
HSV and has provided increased safety to normal bystander cells [21].   
Talimogene laherparepvec (T-VEC) (originally named Onco-VEXGM-CSF), is a 
genetically engineered HSV-1 that secretes granulocyte macrophage colony-
stimulating factor (GM-CSF) to enhance systemic anti-tumour immune responses 
[58], and contains deletions in ICP47 and ICP34.5.  T-VEC was the first OV in the 
western world to complete a Phase III clinical trial, and was approved by the United 
States (US) Food and Drug Administration (FDA) in 2015 for the treatment of 
melanoma in patients with in-operable tumours.  T-VEC was well-tolerated and some 
patients showed a complete response, demonstrating its capability to induce a 
systemic immune effect that kills distant, un-injected tumours [59].  In a Phase I/II 
clinical study, TVEC showed signs of efficacy in patients with advanced stage 
SCCHN who were also being treated with cisplatin and radiotherapy [21, 60].  A 
naturally occurring mutant of HSV-1 named HF10, lacks the expression of several 
functional genes, and caused considerable cancer cell death after intratumoral 
injection in recurrent SCCHN tumours [21, 61].   
Multiple pre-clinical studies with different HSV mutants have displayed oncolytic 
potential, as summarised in Table 1.3.  For example, a study involving combination 
therapy of two HSV-1 mutants demonstrated enhanced oncolytic activity compared to 
using either virus alone concurrently, in an oral squamous cell carcinoma xenograft 
mouse model [21, 62].  Additionally, a number of HSV-1 strains have shown promise 
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in treating PCa in in vivo models, including viruses armed with prostatic acid 
phosphatase (PAP), interleukin-12 (IL-12) or inhibitor of growth 4 (Ing4) [63].  
1.2.4. Oncolytic Vaccinia virus 
Vaccinia virus is a large, enveloped member of the poxvirus family, and contains a 
linear dsDNA genome [64].  Deletion of non-essential genes increases the selective 
replication of oncolytic vaccinia virus in tumour cells and improves safety by 
attenuating infection in normal cells.  For example, tumours with Ras or p53 
mutations are more susceptible to viral replication when the viral gene encoding 
thymidine kinase is deleted.  GLV-1h68 is an attenuated, replication competent 
vaccinia virus that has anti-tumour activity in head and neck cancer cell lines, as well 
as in in vivo mouse models of SCCHN [21, 65].  The oncolytic effect of this virus has 
also been shown in pancreatic and prostate tumour xenografts [66, 67].   
In a Phase I clinical study, a recombinant vaccinia virus expressing PSA (rV-PSA) 
provoked PSA-specific immune responses and clinical activity in men with advanced 
PCa [68].  An oncolytic thymidine kinase-deleted vaccinia virus called JX-594 
expresses gene encoding GM-CSF.  This Wyeth strain vector has demonstrated 
enhanced anti-tumour immunity and selective oncolytic activity in solid tumours [21].  
A Phase III clinical trial aiming to assess the efficacy of JX-594 in combination with 
Sorafenib, is now recruiting patients with advanced hepatocellular carcinoma [69].   
1.2.5. Oncolytic Newcastle Disease virus 
Newcastle Disease virus (NDV) is an enveloped, negative-sense, single stranded (ss) 
RNA paramyxovirus that causes fatal disease in birds, but is non-pathogenic in 
humans [21].  Oncolytic NDV, for example, the MTH-68/H attenuated strain, has 
anti-tumour activity in human cancer cells with aberrant antiviral or apoptotic 
signalling pathways [44, 70].  In contrast, normal cells are able to halt viral replication 
because they have intact interferon signalling.  A vaccine named ATV-NDV 
(autologous tumour cell vaccine, modified with non-lytic NDV) has been trialled in 
various clinical studies and has so far shown positive results in patients with 
colorectal cancer [71], breast cancer, glioblastoma [72] and SCCHN [73].  In order to 
enhance the cancer therapeutic efficacy, Vigil et al used reverse genetics to create a 
modified NDV containing a fusogenic F protein (NDV/F3aa) that is capable of 
forming syncytia.  NDV/F3aa caused significant reduction in tumour development in 
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a colon carcinoma xenograft mouse model, compared to mice treated with unmodified 
virus [74].  It also exerted potent oncolytic activity against SCCHN cell lines and 
murine flank tumours [21, 75].  Interestingly, the combination of Reovirus Type 3 
Dearing (T3D) and the Hitcher B1 strain of NDV showed synergistic oncolytic 
activity against human glioblastoma cell lines and glioma xenografts [76].   
1.2.6. Oncolytic Vesicular Stomatitis virus 
Vesicular Stomatitis virus (VSV) is a member of the rhabdoviridae family and has a 
negative-sense RNA genome.  VSV has shown to have some oncolytic activity, and it 
is believed that tumours with defective antiviral responses are most susceptible [63]. 
There have been concerns over the ability of wild type strains of VSV to replicate in 
the central nervous system, and thus, recombinant attenuated VSVs have been 
developed to improve oncolysis and safety [63].  VSV has been engineered to express 
antibodies for prostate membrane-specific antigen (PSMA), EGFR and folate receptor 
(FR), which were shown to replicate specifically in PCa cells expressing the 
corresponding target receptor on their cell surface [63, 77].  VSV has also been 
genetically engineered to express interferon-β (IFN-β) in order to enhance its efficacy, 
and is now being tested in a Phase I liver cancer trial [78].   
1.2.7. Oncolytic Coxsackie virus 
Coxsackie virus is a non-enveloped, positive-sense, ssRNA virus that belongs to the 
picornaviridae family [21].  The oncolytic therapeutic potential of non-engineered 
strains such as coxsackie virus B3 (CVB3) has been demonstrated in pre-clinical 
cancer models.  When administered into the local tumour microenvironment, CVB3 
stimulated immunogenic cytotoxicity through the release of adenosine triphosphate 
(ATP), calreticulin, and high mobility group box-1 (HMGB-1) [79].  This aided 
priming of adaptive immunity through recruitment of dendritic cells and natural killer 
(NK) cells [70].  Cancer cells over-expressing the intercellular adhesion molecule-1 
(ICAM-1) and decay-accelerating factor (DAF) receptors are susceptible to infection 
and lysis of another coxsackie virus, Coxsackie virus A21 (CVA21; CavatakTM) [80].  
Anti-tumour activity of CVA21 has been confirmed in various cancer types in the pre-
clinical setting, including multiple myeloma [81], prostate cancer [82], breast cancer 
[83], and advanced stage melanoma [84].  A Phase II clinical trial has shown signs of 
efficacy after administration of CVA21 in patients with melanoma [85, 86].   
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Table 1.2.  A selection of oncolytic viruses in pre-clinical studies.  Adapted from [21, 70]. 
PRE-CLINICAL STUDIES 
Virus Strain Mechanism of selectivity Route Tumour type Model Reference 
Adenovirus 
Ad5/3-Δ24FCU1 
The knob fiber of serotype 5 is replaced with the knob of serotype 3, resulting in a 5/3 
chimera, which enhances gene delivery and cancer cell killing.  Has a 24-bp deletion (Δ24) in 
the constant region 2 domain of the viral E1A gene, therefore EIA is unable to bind to pRb for 
effective replication in normal cells, and only replicates in cancer cells with defective pRb.  
Expresses the FCU1 fusion protein that catalyses the conversion of 5-FC to 5-FU, thus 
bypassing resistance of cancer cells to 5-FU.     
IT SCCHN Xenograft mice [47] 
Ad5/35 
Substitution of Ad5 for the Ad35 fiber knob to recognise the CD46 receptor, which is 
abundant on cancer cells, allowing improved viral entry and anti-tumour activity.  E1A 
expression is controlled by the tumour specific E2F-1 promoter to limit viral replication to 
cancer cells with defective pRb.   
IT SCCHN, melanoma Xenograft mice [48, 49] 
Ad-Endo 
Replication deficient due to deletion of viral E1 region and part of the E3 region, for 
improved safety.  Encodes human endostatin to inhibit tumour angiogenesis.    
IT SCCHN Xenograft mice [50] 
OBP-301 
E1A and E1B genes are driven by the human telomerase reverse transcriptase (hTERT) 
promoter, which positively regulates telomerase.  This replication competent virus is selective 
for cancer cells with activated telomerase.   
IT + radiation 
 
IT 
Radio-resistant SCCHN,  
 
PCa 
Orthotopic mice 
 
Xenograft mice 
[51, 52] 
Ad.sTβRFc and 
TAd.sTβRFc 
E1 deleted.  Ad.sTβRFc expresses TGF-β receptor II and is fused with human Fc.  It reduces 
tumour growth by binding to TGF-β, thus inhibiting TGF-β signalling.  TAd.sTβRFc 
replication is driven by hTERT promoter in cancers with activated telomerase.   
Tail vein PCa Orthotopic mice [53] 
HSV 
HSV-IR849 + HSV-1 HF γ34.5 gene deficiency restricts the ability of the virus to replicate in the adult nervous system.   IT SCCHN Xenograft mice [62] 
bPΔ6-hPAP 
Deleted ICP6 gene restricts virus replication in normal cells, making it selective for cancer 
cells.  Expresses human prostatic acid phosphatase (PAP) to generate an anti-tumour 
response. 
IT PCa Xenograft mice [87] 
NV1042 oHSV 
A HSV-1/HSV-2 intertypic recombinant that expresses IL-12 to generate anti-tumour and 
anti-angiogenic responses.  Retains one copy of the γ34.5 gene, and gene deletion of α47 
enhances immunosurveillance of host cell.   
IT + Vinblastine PCa Xenograft mice 
[88] 
 
HSV1716Ing4 
HSV1716 contains a gene deletion in ICP34.5, thus improving tumour-selective replication.  
Expresses inhibitor of growth 4 (Ing4) to enhance oncolytic potency. 
IT PCa Xenograft mice [89] 
Vaccinia GLV-1h68 
Genetically modified by creating interruptions in the thymidine kinase, F14.5L, and 
heamagglutinin genes.  This decreases virulence in normal cells and enables tumour 
selectivity of the virus.   
IT 
 
IT 
 
IT 
SCCHN 
 
Pancreatic 
 
PCa 
Orthotopic mice 
 
Xenograft mice 
 
Xenograft mice 
[65-67] 
NDV NDV (F3aa) 
Conatins the attenuated NDV Hitchner B1 strain (NDV-B1), with the cleavage site of the F 
protein modified with three amino acid changes, making it more fusogenic and has the ability 
to form syncytia. 
IT 
 
IV 
SCCHN 
 
Colorectal 
Xenograft mice 
 
Xenograft mice 
[74, 75] 
CVA CVB3, CVA21 
Non-engineered strains are selective for cancer via associated cell surface receptors ICAM-1 
and DAF. 
IV 
Melanoma, PCa, 
multiple myeloma, 
breast, lung 
Xenograft or 
orphotopic mice 
[79, 81-84] 
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Table 1.3.  A selection of oncolytic viruses in clinical studies. Adapted from [21, 70]. 
CLINICAL STUDIES 
Virus Strain Mechanism of selectivity Route Tumour type Type of study Reference 
Adenovirus 
ONYX-015 
E1B-55 gene deletion.  Selective 
replication and lysis of p53-deficient 
cancer cells.  
IT 
Various malignancies  
including head and neck 
Phase II [56, 57] 
H101 E1B-55 and E3 gene deletion. 
IT 
  
IT + chemotherapy 
 
IT + cisplatin and 5-FU 
Various malignancies 
 
Various malignancies 
 
Head and neck, oesophageal  
Phase I 
 
Phase II 
 
Phase III 
[90-92] 
HSV 
T-VEC 
ICP34.5 and ICP47 gene deletion and 
GM-CSF expression. 
IT 
 
 
IT + chemo-radiation 
Breast, gastrointestinal, head 
and neck and malignant 
melanoma 
 
SCCHN 
Phase I/III 
 
 
Phase I/II 
[60, 93] 
[59] 
HF10 Lack of UL56 protein IT SCCHN, breast, melanoma Phase I [61, 94] 
Vaccinia 
rV-PSA 
Recombinant vaccinia virus expressing 
PSA to induce PSA-specific immune 
responses. 
IT PCa Phase I [68] 
JX-594 
Thymidine kinase-deleted virus 
expressing GM-CSF. 
IV 
 
 
IT 
 
 
 
IT 
Colorectal cancer 
 
Refractory, primary or 
metastatic liver cancer 
 
Paediatric cancers including 
neuroblastoma, hepatocellular 
carcinoma and Ewing sarcoma  
Phase I 
 
 
Phase I 
 
 
 
Phase 1b 
[95-97] 
NDV ATV-NDV 
Non-engineered, stimulates anti-cancer 
immune response. 
 
IT 
 
Colorectal, breast, glioblastoma 
and SCCHN 
 
Pilot studies 
 
[71-73] 
VSV Recombinant VSV Gene insertion for IFN-β production. IT 
Refractory or intolerant 
hepatocellular carcinoma 
Phase I [78] 
CVA CVA-21 
Non-engineered, targets ICAM-1 and 
DAF receptors on surface of tumour cells.  
Stimulates immunogenic tumour 
cytotoxicity and priming of an adaptive 
immune response.   
IT Metastatic melanoma Phase II  [85, 86] 
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1.3. ONCOLYTIC REOVIRUS 
1.3.1. dsRNA genome and molecular structure 
Reoviruses belong to the orthoreovirus genus of the reoviridae family [98].  They are 
commonly found in un-treated sewage and stagnant water, and infect a wide range of 
hosts including horses, cattle, cats, dogs, mice, birds, crustaceans and humans.  These 
viruses were isolated from the respiratory or enteric tracts of children during the 
1950’s who had been hospitalised with diarrheal illnesses [99].  Reoviruses can 
occasionally cause mild gastrointestinal or flu-like symptoms, but are not associated 
with serious human disease and are therefore known as orphan viruses [100].  Most 
people have been exposed to reovirus infection during infancy, and approximately 50-
60% of the adult population test positive for reovirus-specific antibodies [101].  There 
are three serotypes and four subtypes of mammalian reoviruses, type 1 Lang (T1L), 
type 2 Jones (T2J), type 3 Dearing (T3D), and type 3 Abney (T3A) [99, 102].   
Reoviruses are non-enveloped, but contain an inner and outer capsid that surrounds 
the dsRNA genome.  There are ten linear dsRNA segments, consisting of three large 
(L), three medium (M), and four small (S) segments, which encode eleven viral 
proteins (Table 1.4) [99].  Eight of the eleven primary translation products are 
structural proteins that are present in mature reovirus particles, called virions, as 
depicted in Figure 1.3.  The other three proteins, namely µNS, σNS and σ1s, are non-
structural and have roles in reovirus replication.   
 
Table 1.4.  The 11 viral proteins encoded by the 10 dsRNA segments of the reovirus genome [99]. 
Gene Encoded protein(s) Protein function / property 
L1 𝜆3 RNA-dependent RNA polymerase 
L2 𝜆2 Guanylyltransferase and possible methyltransferase 
L3 𝜆1 Binds dsRNA, zinc metalloprotein 
M1 µ2 Associates with and stabilises cellular microtubules 
M2 µ1 
N-myristoylated, cleaved into fragments, role in 
penetration and transcriptase activation 
M3 µNS 
Binds ssRNA, associates with cytoskeleton, role in 
assortment and secondary transcription 
S1 σ1 + σ1s σ1 is the cell attachment protein 
S2 σ2 Binds dsRNA 
S3 σNS Binds ssRNA, role in assortment 
S4 σ3 
Sensitive to protease degradation, binds dsRNA, 
zinc metalloprotein, effects on translation 
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Figure 1.3.  Molecular structure of the reovirus virion.  Image adapted from [102]. 
 
 
1.3.2. Replication life cycle 
The first step in the replication cycle is the attachment of the virus to host cell surface 
receptors, which is mediated by the viral σ1 protein [99, 103-105].  The σ1 protein 
initially binds to sialic acid (N-acetylneuraminic) on the cell surface with low affinity 
[106-108], before making contact with the junction adhesion molecule-A (JAM-A) 
receptor with high affinity [109, 110].  Reovirus particles are then internalised by 
receptor β1-integrin-mediated endocytosis [111], which occurs in a clathrin-dependent 
manner [112].  Once inside the cell, the virions are surrounded within vacuoles that 
resemble endosomes, where they are converted into infectious subvirion particles 
(ISVPs).  This occurs by degradation of the outer capsid σ3 protein by endosomal 
proteases, conversion of protein µ1C to δ (its stable cleavage product), and 
conformational changes in σ1 [113, 114].  Reovirus particles are therefore activated 
through proteolysis, an acid dependent step [115].  Proteolytic activation of virions 
can also occur extracellularly to generate ISVPs that directly penetrate the membrane, 
thus bypassing clathrin-dependent endocytosis [99, 116, 117].  In order to form the 
transcriptionally active core particle, the ISVP needs to be further processed.  
Conformational rearrangements in the µ1 protein expose its myristoylated N-
terminus, before being auto-cleaved to form µ1N.  µ1N then interacts with membrane 
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lipids to form pores that mediate the release of the viral core into the cytoplasm [118-
121].  Following this step, the core particle becomes transcriptionally active, and 
contains all the necessary enzymes for primary transcription of the ten capped (at the 
5’ end) plus-sense mRNA strands [98].  The plus-sense strands exit from the core into 
the cytoplasm through channels in the λ2 core spike pentons, and are then translated 
into viral proteins by the cellular protein synthesis machinery [99].  Early transcripts 
associate with newly made viral proteins to form viral inclusions, where the plus-
strands serve as templates for minus-strand synthesis [98, 122, 123].  Secondary 
transcription may also take place in the newly formed viral particles, which forms late 
transcripts that serve as primary templates for viral protein synthesis later in infection 
[99].  Upon assembly of the outer capsid, virions are released after cell lysis and may 
subsequently infect adjacent cells [98].  This process is summarised in Figure 1.4.   
 
 
Figure 1.4.  The reovirus replication cycle [98].   
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1.3.3. Mechanism of selective replication in cancer cells 
It was first noted in 1977 that transformed cell lines were more susceptible to 
reovirus-induced cell death than un-transformed cell lines [124].  Similarly, data 
published the following year showed that human lung fibroblast cells transformed 
with the simian virus 40 (SV40) T-antigen became more sensitive to reovirus 
oncolysis [125].  Since then, most of the research exploring the oncolytic potential of 
reovirus has been based on the T3D subtype.  This has resulted in the development of 
Reolysin® (Oncolytics Biotech Inc); a naturally occurring, unmodified, replication 
competent formulation of human reovirus T3D.  Reolysin® has been used extensively 
in clinical testing for the treatment of different cancers (Table 1.6).  The two main 
differences between the four reovirus subtypes are their abilities to agglutinate bovine 
erythrocytes and their cell attachment protein sequences [99].  For example, T1L and 
T3D share only 25% identity in their σ1 protein, but the outer capsid and viral core 
proteins are highly conserved, showing 90-98% identity [126].  Data exploring the 
oncolytic ability of the other subtypes is scarce, although Alloussi et al found that all 
reovirus subtypes were able to lyse human glioma cell lines [127].  Reovirus T3D 
(Reolysin®) is the main focus of this thesis.   
 
1.3.3.1. Targeting of an aberrant Ras signalling pathway 
Ras proteins are small GTP-binding hydrolysing proteins (GTPases) that exist in two 
conformational states; GTP-bound active and GDP-bound inactive.  Extracellular 
signals through cell membrane receptors cause guanine nucleotide exchange factors 
(GEFs) to replace GDP for GTP-bound Ras.  Activated Ras then binds to a variety of 
downstream effector molecules to stimulate the regulation of cellular proliferation, 
differentiation and survival.  Hydrolysis of GTP by Ras is facilitated by GTPase-
activating proteins (GAPs) [128, 129].  Mutations in the Ras gene renders its protein 
product unresponsive to GAPs, chronically GTP-bound and active [129].  Activating 
mutations in Ras genes have been found in >30% of all human cancers (not including 
mutations in upstream activators or downstream effectors of Ras), thus promoting 
angiogenesis, metastasis and loss of growth control [130, 131].   
Several reports have shown that reovirus selectively replicates in cells with an 
activated Ras pathway.  Two reovirus-resistant mouse cell lines became highly 
susceptible to the virus after transfection with the gene encoding EGFR, suggesting 
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that reovirus takes advantage of a functional EGFR signalling pathway for sufficient 
oncolysis [132].  Further supporting this finding, the NIH-3T3 fibroblast cell line, that 
is naturally resistant to reovirus and exhibits low EGFR expression, became highly 
sensitive to reovirus-mediated cell death after transformation with the v-erbB 
oncogene.  This gene possesses ligand-independent, constitutive tyrosine kinase 
activity, and encodes a protein structurally related to the EGFR [133].  Downstream 
elements of Ras such as RalGEF and p38 have also been shown to mediate reovirus 
oncolysis in NIH-3T3 cells [134].  It is thought that Ras transformed cells fail to 
activate PKR after reovirus infection.  PKR is a serine/threonine kinase that plays a 
role in the antiviral interferon (IFN) response.  In normal cells, PKR is activated via 
trans-auto-phosphorylation in the presence of viral dsRNA.  Activated PKR then 
phosphorylates eIF-2α, resulting in an increased affinity for eIF-2B (a guanine 
nucleotide exchange factor) and prevention of the exchange of GDP for GTP.  Viral 
protein synthesis is inhibited, as phosphorylated GDP-bound eIF-2α cannot partake in 
the formation of the 43S pre-initiation complex [102].  Conversely, in cells with an 
aberrant Ras signalling pathway, Ras, or one of its downstream elements, prevents the 
phosphorylation of PKR.  Thus, PKR remains in an inactivated state and cannot 
terminate viral translation, allowing reovirus replication to proceed.  This ultimately 
leads to cell death [135].  This is demonstrated in Figure 1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.  The proposed ‘reovirus-Ras’ model of selective oncolysis.  Adapted from [131].   
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1.3.3.2. Studies that conflict the involvement of aberrant Ras signalling  
Based on the reovirus-Ras model of selective oncolysis, it would seem logical to use 
reovirus in tumours with a high occurrence of Ras mutations.  However, a possible 
limitation to the studies that investigated the involvement of the Ras pathway is that 
they were based on experiments using murine fibroblasts rather than cancerous cell 
lines.  Later publications did show that the susceptibility of human pancreatic, 
malignant glioma, and colon cancer cell lines (that often harbour the KRAS mutation) 
to reovirus induced-cell death was associated with Ras activity [136-138].  However, 
it has since been reported that active Ras signalling alone does not control the 
susceptibility to reovirus oncolysis [139], as demonstrated in colon cancer cells and 
non-small cell lung cancer (NSCLC) cell lines [140, 141].  Protease mediated-
disassembly of the reovirus outer capsid was shown to be a key determinant of 
reovirus oncolysis that was independent of increased Ras activity [142, 143].  
Terasawa et al found no correlation between Ras activation status and reovirus-
mediated cell killing in a number of different human tumour cell lines [144].  
Likewise, Twigger et al carried out an extensive investigation on a panel of human 
SCCHN cell lines with diverse sensitivities to reovirus oncolysis, but found no 
significant association with Ras activation status or with the active signalling 
component of EGFR [145].  They found that reovirus cytotoxicity did not depend on 
major signalling pathways downstream of Ras, including MAPK, PI3K and p38, and 
that PKR activation did not control the oncolytic effect of reovirus in SCCHN cell 
lines [145].  As a result of these findings, Ras is not used as a routine biomarker of 
reovirus sensitivity to a patient’s tumour in the clinic.  Many cancer cell lines are 
highly sensitive to reovirus oncolysis compared to normal cells.  However, some are 
surprisingly resistant, as demonstrated with certain SCCHN cell lines [145], and this 
may reflect on the fact that a sub-population of patient’s tumours may not be as 
responsive to reovirus therapy.      
Ras signalling likely has an involvement in reovirus oncolysis in some cancer types, 
but it is not the sole contributor.  The full mechanism of reovirus-induced cancer cell 
death is clearly much more complex and still remains to be elucidated.  If this process 
can be better understood, then biomarkers may be used to select only the patients 
whose tumours will be responsive to reovirus treatment, and hence improve clinical 
trial design.  This would be of particular interest in the context of SCCHN, as this 
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cancer type has reached Phase III clinical status (the REO 018 trial), and it is not 
certain as to whether the trial has reached its primary endpoint.   
 
1.3.4. Biomarkers of treatment response 
The field of oncology has entered an era of personalised medicine, where each cancer 
patient’s treatment is customised according to their specific disease [146].  The 
National Cancer Institute defines a biomarker as ‘a biological molecule found in 
blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or 
of a condition or disease’ [147].  Biomarkers may be used to help distinguish the most 
responsive patient subgroup to a cancer treatment [148], and thus have the potential to 
lower costs and time.  This type of marker is termed a predictive biomarker of 
treatment response, and those that are in current use in the UK are displayed in Table 
1.5.  For example, KRAS is a predictive biomarker in tumour biopsy tissue of patients 
with colorectal cancer, as somatic mutations in KRAS are associated with poor 
response to EGFR-based therapies [149].  In breast and gastric tumours, gene 
amplification or over-expression of the HER2 gene predicts for resistance to anti-Her2 
agents, including trastuzumab [149].  Likewise, over-expression of the oestrogen 
receptor in breast cancer is a marker of resistance to anti-endocrine therapies such as 
tamoxifen [149].   
To date, the only suggested biomarker of reovirus treatment response are cathepsins B 
and L, which are proteases that are involved in the proteolytic disassembly of the 
outer reovirus capsid proteins during infection.  The activity level of these proteases 
was shown to be higher in human tumour cell lines that are more susceptible to 
reovirus-mediated oncolysis [144].  Although this study is encouraging, further 
research is needed to establish host-cell factors that may be important in predicting the 
anti-cancer effect after reovirus treatment, which is the purpose of Chapters 3, 4, and 
5.  In fact, the entire OV field lacks the use of such biomarkers, and an extensive 
search of the literature revealed only two related publications.  Flak et al used a 
microarray approach to identify host cell factors that can influence the efficacy of 
oncolytic adenovirus dl922-947 in ovarian cancer cell lines.  They found that the 
cyclin-dependent kinase inhibitor, p21, may be an important biomarker of treatment 
response in clinical trials [150].  In another study, a microarray revealed that down-
regulation of immunoglobulin-like transcript 2 (ILT2) is a predictive biomarker of 
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clinical response in patients treated with oncolytic vaccinia virus B7.1 immunotherapy 
[151].   
 
Table 1.5.  Tumour markers of treatment response currently in use in the UK.  Adapted from [148]. 
Tumour marker Cancer type(s) Tissue analysed 
ALK gene re-arrangements and over-
expression 
Non-small cell lung cancer, anaplastic large cell 
lymphoma 
Tumour 
Alpha-fetoprotein (AFP) Germ cell tumours Blood 
Beta-2-microglobulin (β2M) 
Multiple myeloma, chronic lymphocytic 
leukaemia  
Blood, urine, 
cerebrospinal fluid 
Beta-human chorionic gonadotropin 
(β-hCG) 
Choriocarcinoma, germ cell tumours Urine, blood 
BRCA1 and BRCA2 gene mutations Ovarian cancer Blood 
BCR-ABL fusion gene (Philadelphia 
chromosome) 
Chronic myeloid leukaemia, acute lymphoblastic 
leukaemia, acute myelogenous leukaemia 
Blood and/or bone 
marrow 
BRAF V600 mutations Cutaneous melanoma, colorectal cancer Tumour 
C-kit/CD117 
Gastrointestinal stromal tumour, mucosal 
melanoma 
Tumour 
CA-125 Ovarian cancer Blood 
CD20 Non-Hodgkin-lymphoma Blood 
Chromogranin A (CgA) Neuroendocrine tumours Blood 
EGFR gene mutation analysis Non-small cell lung cancer Tumour 
Oestrogen receptor/progesterone 
receptor 
Breast cancer Tumour 
Fibrin/fibrinogen Bladder cancer Urine 
HE4 Ovarian cancer Blood 
HER2/neu gene amplification or 
protein over-expression 
Breast cancer, gastric cancer, gastroesophageal 
junction adenocarcinoma 
Tumour 
Immunoglobulins 
Multiple myeloma, Waldenström 
macroglobulinemia 
Blood and urine 
KRAS gene mutation analysis Colorectal cancer, non-small cell lung cancer Tumour 
Lactate dehydrogenase 
Germ cell tumours, lymphoma, leukaemia, 
melanoma, neuroblastoma 
Blood 
Neuron-specific enolase (NSE) Small cell lung cancer, neuroblastoma Blood 
Nuclear matrix protein 22 Bladder cancer Urine 
Programmed death ligand 1 (PDL-1) Non-small cell lung cancer Tumour 
Prostate specific antigen (PSA) Prostate cancer Blood 
 
 
1.3.5. Pre-clinical testing of oncolytic reovirus T3D 
Pre-clinical testing of reovirus T3D (Reolysin®) as a monotherapy, has shown anti-
cancer activity in a variety of different tumour cell lines, ex vivo specimens, and 
murine SCID/NOD xenograft models [152, 153].  These pioneering studies 
investigated reovirus oncolysis in cancers of the breast [154], brain [137], colon [138], 
ovary [138], prostate [155], bladder [156], pancreas [136], and lung [157], and not to 
mention various different blood cancers [152, 158, 159].   
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When combined with either chemotherapy or radiation, reovirus has demonstrated an 
enhanced anti-tumour effect.  For example, it was speculated that reovirus may target 
radiation-resistant cell populations in tumours.  This is because reovirus may replicate 
in some cells with a constitutively activated Ras pathway, and resistance to radiation 
in vitro is associated with over-expression of EGFR [160], activating mutations of Ras 
[161], phosphorylation of Akt [162] and expression of PI3K [163].  Indeed, Twigger 
et al found that combining reovirus with radiotherapy synergistically enhanced 
cytotoxicity in a panel of tumour cells in vitro and in vivo [164].  Co-administration of 
reovirus and the nucleoside analogue gemcitabine was more effective at killing human 
colorectal cell lines than when the agents were used individually [152].  Synergistic 
cell kill was evident in in vitro and in vivo malignant melanoma models after 
treatment with reovirus and the chemotherapy drug cisplatin [165].   
 
 
1.3.6. Clinical trials involving oncolytic reovirus T3D 
Table 1.6 summarises the objectives and results of the 36 clinical trials involving 
Reolysin® that have either been completed or are currently on-going.  Phase I clinical 
trials have demonstrated reovirus to be safe when administered systemically or 
intratumourally.  The maximum tolerated dose (MTD) has never been achieved and at 
most, virus infection has caused fever, fatigue, muscle pain and headache [153].  As a 
monotherapy, reovirus has exhibited modest anti-cancer activity in a variety of 
different solid tumours, including glioma, PCa, metastatic melanoma, colorectal 
cancer, and metastatic ovarian, peritoneal and fallopian tube cancers [166].  An 
ongoing translational study is also assessing the safety and overall response rate of 
patients with the haematological malignancy, multiple myeloma, after intravenous 
reovirus treatment [166].  However, activation of innate and adaptive immune 
responses can rapidly clear the virus and subsequently hinder its efficacy [153].  
Hence, other clinical studies have combined reovirus with conventional treatments 
such as radiation or chemotherapy, in an attempt to achieve an anti-cancer synergistic 
effect.   
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Table 1.6.  A summary of the Reolysin® clinical trials that have been completed or are currently ongoing.   Monotherapy trials involving treatment only with Reolysin® are highlighted 
in blue, whereas combination therapy trials are highlighted in orange.  MTD = maximum tolerated dose.  DLT = dose limiting toxicity.  PR = partial response.  Sd = stable disease.  CR = 
complete response.  MED = minimum effective dose.  PD = progressive disease.  Adapted from [166].   
 
Trial Number and Name 
Phase, 
Status, and 
Location 
Objectives of study Results of study Ref 
REO 001:  Local monotherapy of 
REOLYSIN® for patients with 
subcutaneous tumours 
Phase I 
Complete 
Canada 
To determine the safety (DLT) and MTD of REOLYSIN® in 
patients with advanced solid tumours, who had otherwise 
failed to improve on standard interventions. 
None of the 18 terminal cancer patients receiving REOLYSIN® intralesionally experienced any serious 
adverse events, nor were there any DLTs.  The MTD was not reached even at a dose of 1010 PFU.  No viral 
shedding was observed. 
[167] 
REO 002:  Local monotherapy of 
REOLYSIN® for patients with T2 
prostate cancer 
Translational 
Complete 
Canada 
To examine the safety and the histopathological efficacy of 
intratumoral administration of REOLYSIN® for the treatment 
PCa restricted to the prostate gland. 
Evidence of apoptotic tumour cell death in 4 of 6 patients after REOLYSIN® injection into the prostate gland 3 
weeks prior to surgical removal of the prostate, with no safety concerns. CD8 T-cell infiltration within reovirus 
injected areas was also observed.  One patient’s PSA levels dropped by 53% and observed prostate shrinkage 
of 67% during the 3 week period prior to surgical removal. 
[155] 
REO 003:  Local monotherapy of 
REOLYSIN® for Patients with 
recurrent malignant gliomas 
Phase I/II 
Complete 
Canada 
To determine the MTD, DLT, and safety of REOLYSIN® 
when delivered intratumorally to patients with malignant 
glioma. The secondary objective was to examine antitumor 
activity. 
12 patients were treated with a single injection at dosages of 1 x 107 TCID50, 1 x 10
8 TCID50 and 1 x 10
9 TCID50 
in a delivery volume of 0.9 mL.  MTD was not reached and REOLYSIN® was well tolerated.  3 patients lived 
longer than 1 year, and 1 patient was still alive approximately 45 months post treatment.  For the group as a 
whole, the medium overall survival was 21 weeks. 
[168] 
REO 004:  Systemic administration 
of REOLYSIN® for patients with 
metastatic tumours 
Phase I 
Complete 
US 
To determine the MTD, DLT and safety of REOLYSIN® in 
patients with advanced or metastatic solid tumours. Secondary 
objectives were to evaluate viral replication, immune 
responses and antitumor activity. 
18 patients were administered IV single doses of 1x108 or multiple doses every 4 weeks of 3x1010 TCID50. 8 
patients showed Sd.  A patient with progressive breast cancer experienced a 34% shrinkage in tumour volume. 
Treatment was well tolerated and toxicities were mild (chills, fever, fatigue).  All patients developed 
neutralising antibodies.  Viral shedding was observed in 6 patients and was associated with higher clinical 
benefit rate.  Overall clinical benefit rate was 45%. 
 
REO 005:  Systemic administration 
of REOLYSIN® for patients with 
metastatic tumours 
Phase I 
Complete 
UK 
To determine the safety of REOLYSIN® when administered 
intravenously. The secondary objective was to observe anti-
tumour and immune responses. 
Patients were entered into the trial at a range of dose levels and treated to a maximum daily dose of 1 x 1011 
TCID50.  MTD was not reached and the treatment was well tolerated by the patients (grade 1 to 2 toxicities), 
with notable changes in stabilisation of disease, in addition to some minor tumour regressions in patients who 
had failed all previous treatments. 
[169, 
170] 
REO 006:  Local administration of 
REOLYSIN® in combination with 
radiation for patients with advanced 
cancers 
Phase I 
Complete 
UK 
To determine the MTD, DLT and safety of REOLYSIN® 
when administered intratumorally to patients receiving 
radiation treatment. A secondary objective was to examine any 
evidence of antitumor activity. 
23 patients with various solid tumours received 2 to 6 intratumoral doses of REOLYSIN® at escalating 
dosages up to a maximum of 1 x 1010 TCID50 with a constant localised radiation dose of 20 Gy or 36 Gy. 2 
patients in the low-dose (20 Gy) radiation group had a PR and 5 had Sd. 5 patients in the high-dose (36 Gy) 
radiation group had PRs and 2 had Sd, for a clinical benefit rate (PR + Sd + CR) of 100%. The treatment was 
tolerated well in all cohorts, with no DLT, and the MTD was not reached.  No viral shedding was observed. 
[171] 
REO 007:  Infusion of REOLYSIN® 
for patients with recurrent malignant 
gliomas 
Phase I/II 
Complete 
US 
To determine the MTD, DLT and safety of REOLYSIN®. 
Secondary objectives included the evaluation of viral 
replication, immune response and evidence of antitumor 
activity. 
A single dose of REOLYSIN® was administered by infusion to patients with recurrent malignant gliomas that 
were refractory to standard therapy.  The phase I portion of the trial treated 5 patients in 5 cohorts with doses 
escalating from 1x108 TCID50 to 1x10
10 TCID50. The treatment was shown to be safe and well tolerated and 
MTD was not reached.   
 
REO 008:  Intratumoral 
Administration of REOLYSIN® plus 
low-dose radiation for patients with 
advanced malignancies 
Phase II 
Complete 
UK 
To assess the antitumor activity of REOLYSIN® plus low 
dose radiotherapy in treated and untreated lesions. Secondary 
objectives were to evaluate viral replication, immune 
response, safety, and tolerability. 
16 patients who were heavily pre-treated with chemotherapy or radiation were enrolled in the trial. Of the 14 
patients evaluable for response, 13 had Sd or better in the treated target lesions. Of these, PRs were observed in 
4 patients (2 with melanoma and 1 each with lung and gastric cancer) and minor responses were observed in 2 
patients (thyroid, ovarian), for a total disease control rate (Sd + PR + CR) of 93% in the treated lesions. 
Treatment was well tolerated.   
[172] 
REO 009: Intravenous administration 
of REOLYSIN® plus gemcitabine for 
patients with advanced malignancies 
Phase I 
Complete 
UK 
To determine the MTD, DLT and safety. Secondary objectives 
were to evaluate the immune response to the drug combination 
compared to chemotherapy alone and evidence of antitumor 
activity. 
16 patients were enrolled. 2 initial patients treated with up to 3x1010 TCID50 reovirus, and 1 patient in the final 
cohort, experienced DLTs due to a grade 3 rise in liver enzymes, likely caused by concomitant aminocetophen 
use.  The liver enzyme increase was however transitory and reversible.  Reovirus dose was lowered to 1x109 
TCID50.  No viral shedding was observed.  Of the 10 patients evaluable for response, 2 patients (breast and 
nasopharyngeal) had PRs and/or clinical response, and 5 patients had Sd for between 4 and 8 cycles, for a total 
disease control rate (CR + PR + Sd) of 70%. 
[173] 
26 
 
REO 010: Intravenous administration 
of REOLYSIN® plus docetaxel for 
patients with advanced malignancies 
Phase I 
Complete 
UK 
To determine the MTD, DLT, recommended dose, dosing 
schedule and safety. Secondary objectives were to evaluate 
immune response compared to chemotherapy alone and any 
evidence of antitumor activity. 
25 patients were enrolled, with 24 being exposed to treatment and 23 completing at least 1 cycle of therapy.  16 
patients were suitable for response assessment. Combination of docetaxel (75mg/m2on day 1) and reovirus 
(escalating doses up to 3x1010 TCID50 on days 1-5) every 3 weeks, was deemed to be safe and well tolerated, 
and MTD was not reached.  Antitumor activity was seen, with one complete response and three PRs.  A disease 
control rate (CR +PR + Sd) of 88% was observed. 
[174] 
REO 011: Intravenous administration 
of REOLYSIN® plus paclitaxel and 
carboplatin for patients with advanced 
head and neck cancers 
Phase I/II 
Complete 
UK 
To determine MTD, DLT, recommended dose, dosing 
schedule and safety. Secondary objectives were to evaluate 
immune response compared to chemotherapy alone and any 
evidence of antitumor activity.   
Triple therapy of REOLYSIN®, paclitaxel and carboplatin was well tolerated when administered 
intravenously.  Of 19 evaluable patients with SCCHN refractory to prior platinum-based chemotherapy for 
recurrent, metastatic disease, 8 experienced PRs and 6 had Sd. The total clinical benefit rate (CR + PR + Sd) 
was 74%. 
[175] 
REO 012: Intravenous administration 
of REOLYSIN® plus 
cyclophosphamide for patients with 
advanced malignancies 
Phase I 
Complete 
UK 
To determine MED of cyclophosphamide for successful 
immune modulation. Secondary objectives were to assess 
safety and evidence of antitumor activity. 
Patients received REOLYSIN® on days 1 to 5 of each 28 day treatment cycle, with cyclophosphamide 3 days 
prior to the start of the first cycle and then on day 26 of each cycle, in the absence of DLTs.  30 patients were 
enrolled. Treatment combination was safe, with Grade 3 or 4 toxicities seen only in patients at or above the 
MTD of cyclophosphamide.  Thus, cyclophosphamide did not attenuate host antiviral responses, but 
association with PBMCs may allow reovirus to persist and evade even high levels of neutralizing antibodies. 
[176] 
NCI 7853:  Systemic and 
intraperitoneal administration of 
REOLYSIN® for patients with 
metastatic ovarian, peritoneal and 
fallopian tube cancers 
Phase I 
Complete 
US 
The primary objectives were safety, tolerability and MTD. 
Patients received a constant dose of intravenous REOLYSIN® on days 1 to 5 of each 28 day cycle, as well as 
an escalating dose of intraperitoneal REOLYSIN® on days 1 and 2. 14 patients were enrolled.  Treatment was 
safe and well tolerated, with no DLTs observed. 
[177] 
NCI-7848: Intravenous 
administration of REOLYSIN® for 
patients with metastatic melanoma 
Phase II 
Complete 
US 
Assess antitumor effects of REOLYSIN®, as well as its safety 
profile. Secondary objectives included assessment of 
progression free survival and overall survival. 
21 patients received systemic administration of REOLYSIN® at a dose of 3 x 1010 TCID50 per day on days 1 to 
5 of each 28 day cycle, for up to 12 cycles of treatment.  Treatment was well tolerated.  Median time to 
progression-free and overall survival were 45 days and 165 days respectively.  Viral replication was 
demonstrated in biopsy samples.   
[178] 
REO 013: Intravenous administration 
of REOLYSIN® for patients with 
metastatic colorectal cancer 
Translational 
Complete 
UK 
Assess presence, replication and anti-cancer effects of reovirus 
within liver metastases after intravenous administration of 
REOLYSIN®. Secondary objectives were to assess antitumor 
activity, safety, and monitoring the humoral and cellular 
immune responses.   
REOLYSIN® was given for 5 consecutive days in advance of surgery to remove colorectal cancer deposits 
metastatic to the liver.  Patients comprised 2 groups receiving REOLYSIN®, either at an early (10 to 21 days) 
or late (less than 10 days) time point before surgical resection.  All patients had pre-existing immunity to the 
virus, but reovirus could still target and infect metastatic liver tumours in 90% of the patients. Reovirus was 
able to evade these neutralizing effects of the immune system by binding to specific blood cells that in turn 
delivered the virus to the tumour. Analysis of surgical specimens demonstrated greater expression of reovirus 
protein in malignant cells compared to either tumour stroma or surrounding normal liver tissue. 
[179] 
REO 014: Intravenous administration 
of REOLYSIN® for patients with 
metastatic sarcomas 
Phase II 
Complete 
US 
To measure tumour responses, duration of response, and 
evidence of antitumor activity after multiple-dose 
REOLYSIN® treatment. 
Treatment was well tolerated.  19 of 44 evaluable patients experienced Sd ranging from 2 to 22 months, 
resulting in a total clinical benefit rate of 43%.  The response objective for the study was 3 or more patients 
having prolonged stabilisation of disease (at least 6 months) or better, in order for the agent to be considered. 
The trial exceeded its established objective with 6 patients experiencing Sd for more than 6 months. At the time 
of reporting, 2 patients had experienced Sd for more than 19 months. 
 
REO 015: Intravenous administration 
of REOLYSIN® plus paclitaxel and 
carboplatin for patients with advanced 
head and neck cancers 
Phase II 
Complete 
US 
Measure duration of response and evidence of antitumor 
activity. The secondary objective were to determine the safety 
and tolerability.   
This was a confirmatory study using same combination treatment as the REO 011 trial.  Of the 14 enrolled 
patients, all had received prior chemotherapy, radiotherapy, or combinations thereof for their metastatic or 
recurrent disease. 10 of the 14 patients received prior chemotherapy treatment with taxanes. Of the 13 patients 
evaluable for response, 4 had PRs, for an objective response rate of 31%. 6 patients had Sd or better for 12 
weeks or longer for a disease control rate (stable disease or better) of 46%.  
 
REO 016: Intravenous administration 
of REOLYSIN® plus paclitaxel and 
carboplatin for patients with non-
small cell lung cancer 
Phase II 
Complete 
US 
Determine the objective response rate in patients with KRAS 
or EGFR-activated tumours, and to measure progression-free 
survival at 6 months. Secondary objectives were median 
survival, duration of progression-free survival, safety and 
tolerability.     
Patients received paclitaxel and carboplatin on day 1 of each 21 day cycle, with REOLYSIN® administered on 
days 1 to 5.  37 patients were enrolled.  Median progression-free survival for the study was 4 months, and 
median overall survival was 13.1 months. Of the 35 patients evaluable for clinical response, 11 patients 
(5 KRAS mutant) had a PR, 20 had Sd and 4 had PD, for an objective response rate of 31%. 
 
REO 017: Intravenous administration 
of REOLYSIN® plus gemcitabine for 
patients with advanced pancreatic 
cancer 
Phase II 
Complete 
US 
Determine the clinical benefit rate of treatment.  The 
secondary objectives were to determine the progression-free 
survival, safety and tolerability. 
Patients received gemcitabine on days 1 and 8 of each 21 day cycle, and REOLYSIN® on days 1, 2, 8 and 9.  
33 patients were enrolled in the study.  Median progression-free survival for the study was 4 months, and 
median overall survival was 10.2 months.  The data suggested that the drug combination resulted in 
approximately 2-fold increase in one-year survival rates.  Of the 29 patients evaluable for clinical response, 1 
patient had a PR, 23 had Sd and 5 had PD. This translated into a clinical benefit rate of 83%. 
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REO 018: Intravenous administration 
of REOLYSIN® in combination with 
paclitaxel and carboplatin for patients 
with platinum-refractory head and 
neck cancers 
 Phase III 
Complete 
International 
A double-blinded, randomized, 2-arm study assessing triple 
therapy versus chemotherapy alone.  The primary endpoint 
was overall survival, and secondary objectives were 
progression-free survival, objective response rate, safety, and 
best percentage tumour-specific response in loco-regional and 
metastatic disease.    
 
A total of 167 patients were enrolled into 2 groups: patients with local recurrent disease with or without distal 
metastases, and those with only distal metastases. Patients received standard doses of paclitaxel and carboplatin 
on day 1 of each 21-day cycle, and on days 1 to 5 with either intravenous placebo or REOLYSIN® at 3x1010 
TCID50.  Test arm patients with loco-regional disease demonstrated a progression-free and overall survival 
benefit over control arm patients through 5 cycles of therapy (p=0.0072 and p=0.0146 respectively).  The 118 
patients with loco-regional disease, with or without distal metastases, were evaluated for percentage magnitude 
of tumour shrinkage at the first post-treatment scan. The test arm showed a statistical trend towards increased 
tumour shrinkage over the control arm (p=0.076).  REOLYSIN® was found to be safe. Patients on the test arm 
experienced a higher incidence of flu-like symptoms.   
 
REO 020: Intravenous administration 
of REOLYSIN® plus paclitaxel and 
carboplatin for patients with 
metastatic melanoma 
Phase II 
Complete 
US 
Measure the objective response rate of the treatment 
combination. Secondary objectives included assessment of 
progression-free and overall survival, as well as assessment of 
disease control rate, safety and tolerability of the combination 
treatment. 
Patients received paclitaxel and carboplatin on day 1 of each 21 day cycle, with REOLYSIN® administered on 
days 1 to 5.  Up to 43 patients were to be enrolled in the study: 18 evaluable patients were enrolled in the first 
stage and, subject to meeting response endpoints, the remainder in the second stage.  The endpoint was met 
after 14 evaluable patients were enrolled. 3 of 14 patients exhibited a PR, and an additional seven patients had 
Sd for a disease control rate of 71.5%.  Final data pending.   
 
REO 021: Intravenous administration 
of REOLYSIN® plus paclitaxel and 
carboplatin for patients with 
squamous cell carcinoma lung cancer 
Phase II 
Complete 
US 
Assess the antitumor effect in terms of objective response rate. 
Secondary objectives were to assess progression-free and 
overall survival, the proportion of patients receiving the 
treatment who are alive and free of disease progression at 6 
months, and to assess safety. 
Patients received paclitaxel and carboplatin on day 1 of each 21 day cycle, with REOLYSIN® administered on 
days 1 to 5.  25 evaluable patients received between 2 and 12 cycles of therapy.  Of these, 92% exhibited 
overall tumour shrinkage. When evaluated for overall response, 40% had PRs, 48% showed Sd and 12% had 
PD.  31.8% of patients with sufficient follow up had progression-free survivals greater than 6 months. 
 
REO 022: Intravenous administration 
of REOLYSIN® plus FOLFIRI for 
patients with colorectal cancer  
Phase I 
Ongoing 
US 
To determine a MTD and DLT with the combination. Results pending.    
GOG-0186H (NCI): Intravenous 
administration of REOLYSIN® plus 
paclitaxel for patients with persistent 
or recurrent ovarian, fallopian tube or 
primary peritoneal cancer 
Phase II 
Ongoing 
US 
Primary objectives are progression-free survival and toxicity. 
The secondary objectives are overall survival by treatment 
group, progression-free survival group, and tumour response 
Results pending.    
COG-ADVL1014 (NCI): 
Intravenous administration of 
REOLYSIN® plus cyclophosphamide 
for paediatric patients with relapsed or 
refractory solid tumours 
Phase I 
Complete 
US 
Estimate MTD and toxicities of treatment.  Secondary 
objectives are to measure antitumor activity and neutralising 
antibodies. 
Patients received REOLYSIN® on days 1 through 5 of each 28 day cycle, with some patients also receiving 
cyclophosphamide on days 1 through 21. 29 patients were enrolled.  There were no hematologic DLTs. The 
median time to clear reovirus viremia was 6.5 days. 
[180] 
NCI-8601: Intravenous 
administration of REOLYSIN® plus 
paclitaxel and carboplatin for patients 
with metastatic pancreatic cancer 
Phase II 
Ongoing 
US 
The primary objective is progression-free survival. Secondary 
objectives include toxicity, overall response rate, overall 
survival, measurement of immunologic markers, and 
examination of whether a relationship may exist between Ras 
pathway activation and response. 
Results pending.  
NCI-9030: Intravenous 
administration of REOLYSIN® in 
patients with relapsed multiple 
myeloma  
Phase I 
Complete 
US 
Primary objectives were toxicity and MTD. Secondary 
objectives were duration of response, objective response rate, 
progression-free survival and time to progression. 
Patients received REOLYSIN® on days 1 to 5 of each 28 day treatment cycle for up to 12 cycles in the absence 
of disease progression or unacceptable toxicity. 12 patients were enrolled and the treatment was safe and well 
tolerated. 
[181] 
IND 209: Intravenous administration 
of REOLYSIN® plus docetaxel in 
patients with recurrent or metastatic 
castration resistant prostate cancer 
Phase II 
Ongoing 
Canada 
The primary objective is the efficacy of the treatment, based 
on disease progression at 12 weeks. Secondary objectives 
include the effect on circulating tumour cell status, objective 
response rate, overall survival, and the measurement of 
molecular factors which may be prognostic or predictive of 
response. 
Results pending.    
IND 210: Intravenous administration 
of REOLYSIN® plus FOLFOX-6 and 
bevacizumab, versus FOLFOX-6 and 
Phase II 
Ongoing 
Canada 
The primary objective is progression-free survival. Secondary 
objectives include changes in CEA levels, objective response 
rate, overall survival, quality of life, the tolerability and 
Results pending.    
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bevacizumab alone in patients with 
advanced or metastatic colorectal 
cancer 
toxicity of the treatment combination, and measurement of 
molecular factors which may be prognostic or predictive of 
response. 
IND 211: Intravenous administration 
of REOLYSIN® plus docetaxel or 
pemetrexed for patients with 
advanced or metastatic non-small cell 
lung cancer 
Phase II 
Ongoing 
Canada 
Primary objective is progression-free survival. Secondary 
objectives include tolerability and toxicity of treatment, 
progression rates at 3 months, objective response rate, overall 
survival and measurement of molecular factors which may be 
prognostic or predictive of response. 
Results pending.    
IND 213: Intravenous administration 
of REOLYSIN® plus paclitaxel for 
patients with advanced or metastatic 
breast cancer 
Phase II 
Ongoing 
Canada 
The primary objective is progression-free survival. Secondary 
objectives are objective response rate, overall survival, 
circulating tumour cell counts, toxicity of the treatment, and 
measurement of molecular factors which may be prognostic or 
predictive of response. 
Results pending.  
REO 019:  Intravenous 
administration of REOLYSIN® plus 
bortezomib and dexamethasone in 
patients with relapsed or refractory 
multiple myeloma 
Phase 1b 
Ongoing  
US 
Primary objectives are to determine the safety, MTD, and 
overall objective response rate. The secondary objectives 
include objective response rate at escalating doses, and 
progression-free and overall survival. 
Results pending.  
REO 024:  Intravenous 
administration of REOLYSIN® plus 
pembrolizumab and chemotherapy in 
patients with advanced or metastatic 
pancreatic adenocarcinoma 
Phase 1b 
Ongoing  
US 
Primary objectives are safety and DLT. Secondary objectives 
are overall response rate and progression-free survival by 
immune-related response criteria, overall survival, and the 
effects of the treatment combination by analysis of pre- and 
post-treatment biopsies and blood-based immune markers. 
Results pending.  
MAYO-(MC-1472):  Intravenous 
administration of REOLYSIN® plus 
GM-CSF in paediatric patients with 
relapsed or refractory brain tumours 
Phase 1 
Ongoing  
US 
The primary objective is safety and tolerability. Secondary 
objectives include median progression-free and overall 
survival. 
Results pending.  
NCI-9603:  Intravenous 
administration of REOLYSIN® plus 
dexamethasone and carfilzomib for 
patients with relapsed or refractory 
myeloma 
Translational 
Ongoing  
US 
Primary objectives include measuring reovirus replication and 
safety. Secondary objectives include examining objective 
response, duration of response, clinical benefit, progression-
free survival, time to progression, and the measurement of 
immunologic correlative markers. 
Results pending.  
REO-013 Brain: Intravenous 
administration of REOLYSIN® in 
patients prior to surgical resection of 
recurrent high grade primary or 
metastatic brain tumours 
Translational 
Ongoing  
UK 
The primary objective is to assess the presence of reovirus 
within specimens taken from resected brain tumours. The 
secondary objectives are safety, humoral and cellular immune 
response, and to assess the replication and antineoplastic 
effects of reovirus. 
Results pending.  
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1.3.7. Combining reovirus T3D with metronomic doses of taxane chemotherapy 
drugs 
Taxane chemotherapy drugs display anti-cancer properties by binding to 
microtubules, the intracellular filaments that form part of the cell’s cytoskeleton.  
Microtubules are composed of α-tubulin and β-tubulin heterodimers, and have a key 
role in chromosome separation during cell division and mitosis [182].  The binding of 
taxanes to tubulin promotes the stabilisation of GDP-bound tubulin in the microtubule 
resulting in inhibition of disassembly and prevention of subsequent mitosis and cell 
division [183], which ultimately leads to cell death.  Taxane drugs selectively target 
cancer cells as they are able to rapidly grow through continuous mitotic division, and 
are therefore more sensitive to inhibition of mitosis than normal healthy cells.  The 
first generation taxane drug, Paclitaxel (trade name Taxol®), was isolated in the 
1960’s from the bark of the pacific yew Taxus brevifolia, and was first approved in 
1992 by the FDA for the treatment of ovarian cancer.  Docetaxel (trade name 
Taxotere®) is a second generation semisynthetic analogue of Paclitaxel, and was 
shown to be more cytotoxic than Paclitaxel on proliferating tumour cells [184].  The 
FDA first approved Docetaxel in 1996 for the treatment of advanced breast cancer, 
and then for the treatment of metastatic CRPC in 2004 [182].  Both Paclitaxel and 
Docetaxel show the ability to inhibit tumour growth and improve patient survival in 
different cancer types [185].  However, the limitation of these drugs is the 
development of resistance in cancer cells, which is mainly associated with increased 
expression of the multidrug resistance protein-1 (MDR1) gene that encodes P-
glycoprotein [185].  P-glycoprotein is an ATP-dependent drug efflux pump which 
decreases the concentration of these drugs in tumour cells.   A newer semisynthetic 
taxane drug called Cabazitaxel (trade name Jevtana®) was approved by the FDA in 
2010 for the treatment of castration resistant metastatic PCa, in patients who had 
previously been treated with a regimen containing Docetaxel [182].  Cabazitaxel has 
poorer affinity to P-glycoprotein compared with Paclitaxel and Docetaxel, due to the 
presence of extra methyl groups in its chemical structure [186].  It therefore represents 
a promising antitumour therapeutic as it retains activity against Docetaxel-resistant 
cancer cell lines.  Cabazitaxel was also shown to have greater penetration of the 
blood-brain barrier compared with Docetaxel and Paclitaxel, and stabilises 
mictotubules against cold-induced depolymerisation in vitro as potently as Docetaxel 
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[187, 188].  Reovirus has been shown to associate with and stabilise microtubules by 
the viral µ2 protein, and viral growth was reliant on µ2-mediated recruitment of viral 
factories to microtubules [189-191].  The combination of two microtubule stabilisers 
(reovirus and Docetaxel) promoted synergistic PCa cell death in vitro and reduced 
tumour growth in vivo, in a PC3 xenograft murine model.  This led to an increase in 
apoptotic and necrotic cell populations, and the mechanism of synergy was partially 
explained by an increase in microtubule stability, which was accompanied by an 
increase in viral titre at early time points in cells treated with the combined therapy 
[192].  This observation was also noted in an earlier study that treated NSCLC cell 
lines with reovirus in combination with Paclitaxel [141].  
Conventional chemotherapy treatment normally involves treating patients with the 
maximum tolerated dose (MTD) in order to kill as many cancer cells as possible.  
This is considered the highest concentration of drug that can be tolerated in regards to 
toxicity and side-effects.  Typically, the MTD would be given in 3 week cycles.  A 
cycle is the time between one round of treatment and the start of the next.  There is a 
drug-free break in-between each cycle of treatment to allow the patient to recover 
from the harmful effects of the cytotoxic drugs.  For example, a patient with CRPC 
may be given Paclitaxel on day 1, and will then be drug-free until day 21 when the 
cycle is repeated.  It has been shown that shortening of the drug-free period between 
each chemotherapy cycle limits the amount of tumour vasculature re-growth, thus 
enhancing the anti-cancer effect [193].  The primary targets of conventional 
chemotherapy regimens are the cancer cells, although unwanted side effects are also 
commonly observed due to the cytotoxic drugs affecting all dividing cells, including 
healthy normal cells [194].  Angiogenesis has been shown to be a key driver in the 
growth of cancer [195].  Angiogenesis inhibitors have been developed, such as the 
monoclonal antibody Bevacizumab (trade name Avastin®) that inhibits VEGF-A, a 
protein that stimulates the growth of blood vessels.  There has been a debate on how 
to optimally use Bevacizumab and that using it continuously would be costly [196].   
Metronomic chemotherapy (MC) is defined as the frequent administration of 
chemotherapy agents at doses below the MTD and with no prolonged drug-free 
breaks.  It is believed that MC mainly targets endothelial cells involved in tumour 
angiogenesis [197].  This may occur by directly killing circulating endothelial cells 
(CEC) in the tumour vasculature or by killing bone-marrow-derived endothelial 
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progenitor cells (EPC) [195].  MC can also stimulate the immune system to initiate an 
anti-tumour response [198-202].  There is limited Phase III clinical trial data on the 
use of MC.  However, effective anti-cancer responses and a better quality of life due 
to the low toxicity of MC have been demonstrated in various pilot and phase II 
clinical studies [203].  Cyclophosphamide, Methotrexate, Trofosfamide and Etoposide 
are examples of agents that have been tested in a metronomic fashion in patients with 
breast cancer, ovarian cancer, metastatic melanoma, prostate cancer, recurrent 
glioblastoma and NSCLC [204-210].  MC also has the potential to be a relatively 
inexpensive treatment [203], yet the manner in which MC is applied needs to be 
further validated in order to achieve the best outcome.  This includes finding the 
minimally effective dose, the frequency of treatment and the choice of agent to use 
[203].  Tubulin inhibitors may be effective in the metronomic setting [211, 212].  
Paclitaxel was shown to selectively inhibit the proliferation of endothelial cells in 
vitro at very low picomolar concentrations, much lower than the standard dose [213].  
In addition, low dose Docetaxel was four times stronger than low dose Paclitaxel in 
causing organic and functional damage of human endothelial cells in vitro, and also in 
vivo by using the chick embryo chorioallantoic membrane (CAM) model [214].  MC 
treatment of Cabazitaxel has not yet been explored, nor has the combination of MC 
with oncolytic viruses.  Although the MTD model is a convenient way to administer 
drugs to patients, it is not necessarily the most beneficial way to use them clinically 
[203].  As taxanes are used as a first line of care for PCa, it would be of particular 
interest to determine whether an anti-cancer synergistic effect can be achieved with 
the combination of reovirus and low doses of Cabazitaxel or Docetaxel, in 
experimental models of PCa.  This is addressed in Chapter 6.   
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Figure 1.6.  A schematic representation of metronomic and conventional chemotherapy.  
Metronomic chemotherapy (blue line) is administered in low doses below the maximum tolerated dose 
(MTD) at regular intervals (weekly or daily), and aims to reduce the number of rapid proliferating 
vascular endothelial cells (EC) or endothelial precursor cells (EPC) from the bone marrow that support 
the growth of the tumour.  Conventional chemotherapy (orange line) is given at high doses at the MTD, 
and in cycles with relatively long drug-free breaks.  Initially, conventional treatment kills many of the 
cancer cells and some of the EC and EPC.  However, the drug-free intervals allow the EC and EPC to 
re-populate, which contributes to enhanced angiogenesis and eventual tumour re-growth.   
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1.4. SUMMARY 
Reovirus T3D has demonstrated oncolytic activity across a wide range of 
malignancies and has a relatively low toxicity profile.  However, the use of reovirus 
as an anti-cancer agent needs to be further optimised in order to progress through 
clinical development.   
Based on the fact that the mechanism of reovirus oncolysis is not fully understood, 
and that there is no current biomarker of reovirus treatment response used in the 
clinic, the objective of this research was to identify host-cell factors that may predict 
for the susceptibility to reovirus-induced cell death in SCCHN cell lines.  SCCHN is 
of particular importance as this cancer type has entered Phase III clinical testing with 
Reolysin®.  If such a factor could be found, it may potentially help target the patients 
whose tumours are most responsive to reovirus therapy, which may improve their 
quality of life, as well as time, cost and trial outcome.   
Conventional chemotherapy regimens at the maximum tolerated dose frequently cause 
toxic side-effects and tumour vasculature re-growth.  Given the paucity of data 
describing the combination of reovirus and metronomic doses of chemotherapeutic 
drugs, the work in the following chapters also attempts to determine whether the co-
administration of reovirus and low doses of taxane drugs achieves a synergistic anti-
cancer effect in PCa cell lines, compared to single-agent treatment.  If in vitro models 
of this system are successful, then this work may have a translational focus; it may 
limit cytotoxicity and keep the number of endothelial cells that support tumour-
associated angiogenesis at bay, thus resulting in sustained clinical responses.  
 
 
 
 
 
 
 
 
 
34 
 
1.5. HYPOTHESIS AND OBJECTIVES 
Firstly, we hypothesise that a predictive biomarker of reovirus treatment response 
could be identified in SCCHN cell lines.  In order to investigate this, the objectives of 
this research are to: 
 Assess what effect the candidate genes, which were isolated by gene 
expression profiling and microarray hybridisation, have on reovirus oncolysis 
in SCCHN cell lines, using an siRNA-knock-down screen (Chapter 3).   
 Determine the effects of lipid-mediated over-expression or pharmacological 
inhibition of any interesting target genes found in the siRNA screen, on 
reovirus oncolysis (Chapter 4).   
 Study the biological mechanism of how these target genes influence the 
reovirus oncolysis process in SCCHN cell lines (Chapter 5).   
 Compare the expression level of the corresponding target protein in head and 
neck cancer and normal tissues (Chapter 5).   
 
Secondly, we hypothesise that low, metronomic doses of taxane drugs in combination 
with reovirus achieves a synergistic anti-cancer effect in PCa cell lines.  To test this, 
the objectives are to: 
 Determine the IC50 concentrations of reovirus, Cabazitaxel and Docetaxel in 
PCa cell lines (Chapter 6).   
 Assess the interaction of reovirus and Cabazitaxel or reovirus and Docetaxel in 
PCa cells at doses equal to or less than the IC50 values, by using two statistical 
models.  Concurrent and sequential dosing schedules will also be compared 
(Chapter 6).   
 Study the biological mechanism of the interaction between the two agents 
(Chapter 6).   
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2. MATERIALS AND METHODS 
2.1.  REOVIRUS AND CHEMOTHERAPEUTIC TAXANE DRUGS 
Reovirus and the chemotherapeutic taxane drugs used in this study are shown in 
Table 2.1, with details of their supplier and storage conditions.  The reovirus stock 
was titred via the plaque assay (Section 2.24) on the highly sensitive L929 cell line.   
 
Table 2.1.  Reovirus and Taxane drugs 
 
 
 
 
 
2.2.   CELL CULTURE MEDIA 
 
All cell culture media used in this study are displayed in Table 2.2, along with their 
supplier and supplements.  Working cell culture media was prepared in the same way, 
but was supplemented with 2% Fetal bovine serum (FBS).   
 
Table 2.2.  Cell Culture Media used in this study.   
 
Reagent Supplier Storage conditions 
Reovirus Type 3 Dearing 
(T3D) (Reolysin®) 
Oncolytics Biotech Inc, Canada 
Stored at -80°C in aliquots at 
3×109pfu/mL 
Cabazitaxel (Jevtana®) 
Produced by Sanofi Aventis, France.  Kindly 
donated by The Royal Surrey Hospital, UK.   
Stored at -20°C in aliquots at 
40mg/mL in ethanol 
Docetaxel (Taxotere®) Sigma, UK 
Stored at -20°C in aliquots at 
10mM in ethanol  
Medium Supplements  Supplier 
Dulbecco's Modified 
Eagle's Medium 
(DMEM) 
100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin (Sigma, UK), 
2mM L-Glutamine (Sigma, UK) and 10% FBS (Life Technologies, UK). 
Sigma (UK) 
Minimum Essential 
Medium Eagle (MEM) 
100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin (Sigma, UK), 
2mM L-Glutamine (Sigma, UK) and 10% FBS (Life Technologies, UK). 
Sigma (UK) 
RPMI-1640 
100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin (Sigma, UK), 
2mM L-Glutamine (Sigma, UK) and 10% FBS (Life Technologies, UK). 
Sigma (UK) 
F-12K 
100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin (Sigma, UK), 
2mM L-Glutamine (Sigma, UK) and 10% FBS (Life Technologies, UK). 
American Type 
Culture Collection 
(ATCC, UK) 
TRAMP-C2 DMEM 
100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin (Sigma, UK), 
2mM L-Glutamine (Sigma, UK), 5% FBS (Life Technologies, UK), 5% 
Nu-Serum IV (Corning, UK), 10nM dehydroisoandrosterone (Fisher 
Scientific, UK) and 0.005mg/mL bovine insulin (Sigma, UK). 
Sigma (UK) 
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2.3. CELL LINES 
All cell lines (summarised in Table 2.3) were purchased from the American Type 
Culture Collection (ATCC, USA), with the exception of PJ41 and PJ34 which were 
obtained from the European Collection of Authenticated Cell Cultures (ECACC, UK), 
and HN5 which was gifted to us by Professor Kevin Harrington at The Institute of 
Cancer Research (ICR), London, UK [215].  The cells were adherent lines that were 
maintained in a 37°C incubator in an atmosphere of 5% CO2, apart from the WPMY-1 
cell line, which was maintained at 10% CO2.  All tissue culture work was performed 
in a sterile class II biosafety cabinet (Kendro, UK).  Mycoplasma testing was carried 
out regularly using a MycoAlert™ Mycoplasma Detection Kit (Lonza, UK).  Cell 
lines that were purchased prior to the start of this project were authenticated using 
short tandem repeat (STR) profiling (LGC, USA), which confirmed ≥80% shared 
alleles with a common ancestry.   
 
Table 2.3.  Cell lines used in this study, their growth media, tissue type and source.   
 
 
 
Cell Line 
Cell culture medium 
and supplements 
Tissue Type Source 
PJ41 DMEM 
Human squamous cell carcinoma of the head 
and neck 
ECACC, UK 
HN5 DMEM 
Human squamous cell carcinoma of the head 
and neck 
ICR, UK. [215] 
PJ34 DMEM 
Human squamous cell carcinoma of the head 
and neck 
ECACC, UK 
MRC-5 MEM Human normal lung fibroblast ATCC, USA 
COS-1 DMEM African green monkey kidney fibroblast ATCC, USA 
HEK293A MEM Human embryonic kidney epithelial ATCC, USA 
L929 DMEM 
Mouse fibroblast from subcutaneous 
connective tissue; areolar and adipose 
ATCC, USA 
DU145 MEM 
Human prostate carcinoma, derived from 
brain metastasis 
ATCC, USA 
PC3 F-12K 
Human prostate adenocarcinoma, derived 
from bone metastasis 
ATCC, USA 
LNCaP RPMI-1640 
Human prostate carcinoma, derived from 
lymph node metastasis 
ATCC, USA 
WPMY-1 
DMEM (with 5% 
FBS) 
Human normal prostate stroma/fibroblasts ATCC, USA 
TRAMP-C2 TRAMP-C2 DMEM Mouse transgenic prostate adenocarcinoma ATCC, USA 
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2.4. PASSAGING OF ADHERENT CELLS 
Media was removed from the culture flask and the cell sheet was washed using 
Hanks’ balanced salt solution (Sigma, UK) before discarding.  Cells were detached 
using Trypsin-EDTA (x1) solution (Sigma, UK) for 5-15 minutes at 37°C.  When the 
cells were completely detached, cell culture media was added to the flask to disperse 
cells, which was then transferred to a universal tube.  After centrifuging the tube at 
1500rpm for 3 minutes, the supernatant was poured off to leave the cell pellet at the 
bottom, which was re-suspended in 1mL cell culture media.  To split the cells 1:4, 
0.25mL of the cell suspension was added to a new T-75 flask containing 12.5mL fresh 
cell culture medium and incubated at 37°C.  To set up cells for an experiment, the re-
suspended cells were counted to enable seeding at an appropriate cell density.   
 
 
2.5. EVALUATION OF CELL NUMBER 
A 1:10 dilution of cell suspension in trypan blue (Sigma, UK) was made and 10µL of 
the mixture was loaded onto the grid of a Neubauer haemocytometer.  Trypan blue is 
membrane impermeable and can only penetrate dead cells, and therefore viable cells 
remain unstained.  Only viable cells were counted in the four corner squares of the 
haemocytometer.  The following formula determined the cell number: 
Mean number of cells per quadrant × dilution factor × 104 = number of cells/mL 
 
2.6. CRYOPRESERVATION OF CELLS 
Cells were harvested in cell culture medium and centrifuged at 1500rpm for 3 
minutes.  The supernatant was removed and the cell pellet was re-suspended to 1x106 
to 1x107 cells/mL in freezing medium containing 50% cell culture medium, 40% FBS 
(Life Technologies, UK) and 10% Dimethyl sulphoxide (DMSO) (Sigma, UK).  The 
cell suspension was transferred to sterile cryovials and stored at -80°C in a cryo-
freezing container, ensuring a controlled decrease in temperature, before being 
transferred to liquid nitrogen for long-term storage.    
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2.7. REVITALISATION OF CRYOPRESERVED CELLS 
Cryopreserved cells were removed from liquid nitrogen and thawed rapidly in a 37°C 
waterbath for 2 minutes.  Cells were then transferred to a universal tube containing 
10mL warm cell culture medium and centrifuged at 1500rpm for 3 minutes.  The 
supernatant was poured off to remove traces of DMSO and the cell pellet was re-
suspended in 8mL cell culture media, which was transferred to a T-25 flask and 
incubated at 37°C.   
 
 
2.8. CALCULATING THE VOLUME OF REOVIRUS NEEDED FOR A 
CERTAIN MULTIPLICITY OF INFECTION (MOI)  
The definition of an MOI is the ratio of the number of infectious virus particles to the 
number of target cells present in a defined space.  However, the actual number of 
virus particles that will enter any given cell is a statistical process, as some cells may 
absorb more than one virus whereas others may not absorb any.  The probability ‘P’ 
that a cell will absorb ‘n’ virus particles when inoculated with an MOI of ‘m’ can be 
calculated for a given population using the Poisson distribution [99, 216]: 
 
 
To calculate the volume of reovirus needed for a certain MOI, the following 
calculations were performed: 
1. number of cells/well × required MOI = pfu/well 
2. (pfu/well ÷ 3.00×109pfu/mL reovirus stock) = mL/well reovirus needed 
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2.9. CELL TITRE 96® AQUEOUS NON-RADIOACTIVE CELL 
PROLIFERATION (MTS) ASSAY 
The Cell Titer 96® AQueous One Solution Reagent (Promega, UK) contains an MTS 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt], and an electron coupling reagent 
(phenazine ethosulfate; PES).  PES has enhanced chemical stability that allows it to 
be combined with MTS to form a stable solution.  The MTS compound is bio-reduced 
by cellular oxidoreductase enzymes into a coloured formazan product (Figure 2.1), 
which is directly proportional to the number of living cells in culture.   
Cells were seeded (100µL per well) in 96-well plates at the required seeding density 
in cell culture media for 24 hours at 37°C, to ensure an 80% confluence.  100µL 
diluted reovirus (Section 2.8), chemotherapeutic drug or working media (un-treated 
cells) was added to the wells of the plate in triplicate for an appropriate time-period at 
37°C.  100µL Cell Titre 96® AQueous One Solution Reagent (Promega, UK), diluted 
1:10 in RPMI working media, was added to each well, including empty wells for use 
as a background control.  The plates were incubated for 1-4 hours at 37°C, making 
sure to incubate for the same duration within each individual experiment, before 
reading the Optical Density (OD) absorbance readings on the Variskan® Flash plate 
reader (Thermo Scientific, UK) at wavelength 492nm.  The data was then analysed.  
The average OD of the background control was subtracted from the average OD of 
each sample.  The % cell survival in each treatment was then calculated relative to the 
un-treated cells by using the following formula: 
% cell survival = (average OD treated sample ÷ average OD un-treated sample) × 100 
The fraction of dead cells affected by reovirus or chemotherapeutic drug was then 
calculated: 
Fraction affected = 1 – (% cell survival ÷ 100) 
The fraction affected at each dose was inputted into CalcuSyn software (Biosoft, UK) 
to find the concentration of reovirus or drug needed to produce a 50% inhibitory 
effect (IC50), using the median effect methods of Chou [217] (Section 2.27.4).   
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Figure 2.1.  Chemical structures of the MTS tetrazolium compound and its formazan product.  
Image adapted from the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay manual: 
http://www.promega.co.uk/resources/protocols/technical-bulletins/0/celltiter-96-aqueous-
nonradioactive-cell-proliferation-assay-protocol/.   
 
 
 
 
2.10.   RNA EXTRACTION FROM CELL LINES 
Total RNA was extracted from cell lines using the RNeasy® Plus Micro Kit (Qiagen, 
UK), according to the manufacturer’s instructions.  In summary, cells were lysed and 
homogenised using β-mercaptoethanol (Sigma, UK) diluted 1:100 in Buffer RLT Plus 
for 5 minutes at room temperature.  The lysate was then passed through a gDNA 
eliminator spin column to remove genomic DNA.  Ethanol (Fisher Scientific, UK) 
was added to the flow through to provide appropriate binding conditions for the RNA, 
before transferring the sample to an RNeasy spin column.  Contaminants were washed 
away using specific buffers, leaving the RNA bound to the silica membrane of the 
column.  The RNA was eluted with 14µL RNase-free water and the concentration 
(ng/µL) was analysed using the NanoDrop® ND-1000 Spectrophotometer (Labtech 
International, UK).  RNA samples were used immediately for cDNA synthesis or 
stored at -80°C. 
 
 
2.11. COMPLEMENTARY DNA (cDNA) SYNTHESIS FROM CELL LINES 
cDNA was reverse transcribed from total RNA using the Cloned AMV First-Strand 
cDNA Synthesis Kit (Life Technologies, UK), by following the manufacturer’s 
instructions.  Prior to cDNA synthesis, the RNA template and primer was denatured in 
the absence of reaction buffer and enzyme to remove secondary structure that may 
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impede full-length cDNA synthesis.  For each reaction, 1µL 50µM Oligo (dT)20 
primer, 500ng RNA, and 2µL 10mM dNTP mix was combined, and the volume was 
adjusted to 12µL with DEPC-treated water.   The samples were incubated at 65°C for 
5 minutes and then placed directly onto ice.  Next, 4µL 5x cDNA Synthesis buffer, 
1µL 0.1M DTT, 1µL 40U/µL RNaseOUT, 1µL DEPC-treated water, and 1µL 
15U/µL Cloned AMV reverse transcriptase was added to each RNA reaction tube, to 
give a total volume of 20µL.  The reaction tubes were transferred to a pre-heated 
thermal cycler (Applied Biosystems, UK), and incubated at 50°C for 1 hour.  The 
reaction was terminated by incubating at 85°C for 5 minutes.  Assuming that the 
cDNA synthesis was 100% efficient, 500ng cDNA was produced in 20µL to give a 
concentration of 25ng/µL, which was further diluted to 5ng/µL in DEPC-treated 
water.  The cDNA’s were used immediately in the RT-qPCR reaction or stored at -
20°C.      
 
 
2.12. REAL TIME–QUANTITATIVE POLYMERASE CHAIN REACTION 
(RT-qPCR)  
RT-qPCR analysis was performed using the Stratagene Mx3005P qPCR machine 
(Agilent Technologies, USA), using SYBR Green fluorescence to measure the 
amount of PCR product.  A RT-qPCR master mix was prepared by adding 12.5µL 
SYBR Green Jumpstart Taq Ready Mix (Sigma, UK), 0.25µL Reference Dye (ROX) 
(Sigma, UK), 5.25µL RNase-free water and 2µL cDNA (5ng/µL), giving a total 
volume of 20µL per reaction.  5µL target primer was added to the appropriate wells of 
the 96-well plate containing the master mix, in duplicate.  The house-keeping gene β-
actin was used as an endogenous control.  The reaction conditions were:  1 cycle (10 
minutes at 95°C), followed by 40 cycles (30 seconds at 95°C, 1 minute at 60°C and 1 
minute at 72°C).    
The forward and reverse primers for all human target genes used in the RT-qPCR 
reaction are displayed in Table 2.4, and were designed by Professor Richard Morgan 
using the Primer3 and BLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
All primers were purchased from Sigma (UK) and were stored at -20°C.   
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Table 2.4.  The forward and reverse primer sequences of all target genes used in the RT-qPCR 
reaction.   
 
Using MxPro software (Agilent Technologies, USA), the cycle threshold (Ct) was 
determined in each sample, which is the number of cycles required for the fluorescent 
signal to exceed the background level.  Ct values are inversely proportional to the 
amount of target nucleic acid in the sample.  The 2-∆CT relative quantitation method 
[218] was used to analyse the RT-qPCR data.  Thus, in each sample, the expression of 
the gene of interest is shown relative to β-actin (×1000).   
 
 
 
 
 
 
 
 
 
 
 
Gene 
Accession 
number 
Forward primer Reverse primer 
β-actin NM_001101.3 ATGTACCCTGGCATTGCCGACA GACTCGTCATACTCCTGCTTGT 
YAP1 NM_006106 TCCCGGGATGTCTGAGGAAT GGTTCGAGGGACACTGTAGC 
P2RY6 NM_176798 GCCACCCACTATATGCCCTA GAAAAGGCAGGAAGCTGATG 
MGMT NM_002412 TGGAGCTGTCTGGTTGTGAG CTGGTGAACGACTCTTGCTG 
 SLCO1B3 NM_019844 GGGTGAATGCCCAAGAGATA ATTGACTGGAAACCCATTGC 
SLC36A4 NM_152313 CTGCCACCTTTGGTTGAAAT CTGTGGAGTGCCAGCTACAA 
ZNF600 NM_198457 AACAGGGCAAGGCAATACAG GTGCTTCATGGCCATTTCTT 
BIRC2 NM_001166 CACCATCAGAATTGGCAAGA ATTCGAGCTGCATGTGTCTG 
LARP1B NM_178043 TTGCCTATTTCCCTGATTGC GGCCTGGTACAAACTCTGGA 
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2.13. siRNA-MEDIATED GENE KNOCK-DOWN IN THE PJ41 CELL LINE 
2.13.1. KDalert™ GAPDH Assay kit for detection of GAPDH knock-down 
The KDalert™ GAPDH Assay kit (Life Technologies, UK) includes the reagents 
needed to detect silencing of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
in cultured cells at the protein level.  The assay serves as a marker for cellular toxicity 
resulting from transfection, and enables the optimal assay conditions to be identified.    
The PJ41 SCCHN cell line was re-suspended in cell culture medium at two different 
seeding densities (Table 2.5), and stored at 37°C until ready to use.   
Table 2.5.  Cell seeding densities used 
Cell seeding density per mL Cell seeding density per well (80µL/well) 
6.4×105 8.0×103 
9.6×105 1.2×104 
 
The siPORT Neo FX transfection agent (Life Technologies, UK) was diluted in Opti-
MEM medium (Life Technologies, UK) to a total volume of 10µL/well at three 
different concentrations, as shown in Table 2.6. The samples were mixed and 
incubated for 10 minutes at room temperature.   
Table 2.6:  Volumes of siPORT NeoFX and Opti-MEM used per well 
 
 
 
 
 
GAPDH siRNA and negative control#1 siRNA (Life Technologies, UK) were re-
suspended to 2µM in nuclease-free water (Life Technologies, UK).  1.5µL siRNA 
was then mixed with 8.5µL Opti-MEM (Life Technologies, UK) to give a total 
volume of 10µL/well, and incubated for 10 minutes at room temperature.   
The siPORT NeoFX samples were mixed with each siRNA in a 1:1 volume ratio and 
incubated for 10 minutes at room temperature.  20µL of the transfection-complex was 
dispensed into a 96-well tissue culture plate in triplicate.  As a non-transfected 
control, 20µL of Opti-MEM (Life Technologies, UK) was added to separate wells in 
triplicate.  80µL of each cell suspension was dispensed into the wells and the plate 
was incubated at 37°C for 24 hours, before replacing with 100µL fresh cell culture 
siPORT NeoFX (µL/well) Opti-MEM (µL/well) 
0.2 9.8 
0.5 9.5 
0.8 9.2 
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medium for a further 24 hours.  Cells were checked under a light microscope for 
cytotoxicity.  A KDalert™ master mix was then prepared on ice (Table 2.7).   
Table 2.7.  Volumes of each component of the KDalert™ master mix used per well 
Component Volume (µL/well) 
KDalert™ Solution A 88.80 
KDalert™ Solution B 0.68 
KDalert™ Solution C 0.47 
 
The 96-well plate containing the transfected cells was aspirated, replaced with 
100µL/well lysis buffer and incubated at 4°C for 20 minutes.  The lysates were 
homogenised by pipetting up and down, before transferring 10µL to a new 96-well 
plate.  10µL of water was also added to separate wells.  90µL of the master mix was 
added to each well, mixed, and incubated for 15 minutes at room temperature.  The 
absorbance was measured using the Variskan® Flash plate reader (Thermo Scientific, 
UK) at wavelength 620nm.  The average absorbance for each sample (A620-sample) was 
subtracted from the average absorbance of the water + master mix control (A620-WMM) 
to determine a GAPDH activity (ΔA620-sample):   
ΔA620-sample = A620-WMM  −  A620-sample 
Next, the % remaining expression of GAPDH in each sample was calculated by 
dividing the GAPDH activity in GAPDH siRNA-transfected cells (ΔA620-GAPDH) by 
the GAPDH activity in negative control#1 siRNA-transfected cells (ΔA620-Negative):   
% remaining expression = 100 x (ΔA620-GAPDH ÷ ΔA620-Negative) 
 
The % GAPDH knock-down was then calculated:   
% GAPDH knock-down = 100 − % remaining expression 
The Optimal transfection conditions were those that maximised GAPDH knock-down 
whilst lessening transfection-associated toxicity.  This was predicted by using the 
Optimal Balance Factor (OBF) (KDalert™ GAPDH assay kit User Guide, Thermo 
Fisher website: https://tools.thermofisher.com/content/sfs/manuals/1639M.pdf).  The 
GAPDH activity in the negative control#1 siRNA-transfected cells (ΔA620-Negative) was 
multiplied by the % GAPDH knock-down.  The optimal conditions were those that 
showed the greatest OBF value: 
OBF = ΔA620-Negative × % GAPDH knock-down 
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2.13.2. siRNA-mediated knock-down of a target gene 
Like the KDalert™ GAPDH assay, this procedure uses RNA interference (RNAi), a 
biological mechanism found in eukaryotic cells.  During this pathway, long dsRNA is 
cleaved by the cytoplasmic nuclease Dicer, into small interfering RNAs (siRNAs).  
The siRNA unwinds into two single-stranded RNAs (ssRNAs).  The passenger strand 
is degraded, whereas the guide strand assembles onto RNA-induced silencing 
complexes (RISCs) that then pairs with a complementary messenger RNA (mRNA) 
molecule.  The catalytic component of the RISC complex cleaves the mRNA, leading 
to specific gene silencing.   
In this assay, standard cell culture media without FBS and antibiotics was used, which 
will be referred to as media*.  PJ41 cells were re-suspended to 9.6×105 cells/mL 
(1.2×104 cells/well) in cell culture medium and stored at 37°C.  0.5µL/well siPORT 
Neo FX (Life Technologies, UK) was mixed with 9.5µL/well media* and incubated 
for 10 minutes at room temperature.  1.5µL/well 2µM negative control#1 siRNA (Life 
Technologies, UK) or 2µM siRNA for the gene of interest (Table 2.8) were mixed 
with 8.5µL/well media* and incubated for 10 minutes at room temperature.  The 
negative control#1 siRNA contained a nonsense sequence that served to monitor any 
non-specific effects caused by unintended off-targeting.   
Table 2.8.  The siRNAs used in this study.  Two different siRNAs were used for each target gene.   
Target gene siRNA ID Supplier 
SLCO1B3 
s26261 Life Technologies, UK 
s26262 Life Technologies, UK 
MGMT 
s8750 Life Technologies, UK 
s8752 Life Technologies, UK 
SLC36A4 
s42350 Life Technologies, UK 
s42351 Life Technologies, UK 
YAP1 
s20366 Life Technologies, UK 
s20368 Life Technologies, UK 
ZNF600 
s46376 Life Technologies, UK 
s46378 Life Technologies, UK 
P2RY6 
sc-42584 Santa Cruz Biotechnology, USA 
s224151 Life Technologies, UK 
BIRC2 
s1448 Life Technologies, UK 
s1449 Life Technologies, UK 
LARP1B 
s30246 Life Technologies, UK 
s30247 Life Technologies, UK 
 
Next, siPORT Neo FX was mixed with an equal volume of each siRNA or media* for 
10 minutes at room temperature.  The sample containing transfection agent and 
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media* served as an endogenous positive control for the protein of interest and as a 
negative control for siRNA silencing, and enabled the cytotoxicity effects caused by 
the transfection agent to be determined.  80µL of cell suspension and 20µL of each 
transfection complex was added to each well of the plate, giving a total volume of 
100µL/well.  20µL media* alone was also added to separate wells containing 80µL 
cells, which served as an additional positive control for the protein of interest and a 
negative control for siRNA silencing.  The plate was incubated at 37°C for 24 hours, 
before replacing the wells with 100µL fresh cell culture medium for a further 24 
hours.  Cells were then viewed under a light microscope for cytotoxicity.  
Subsequently, RNA was extracted from the cells (Section 2.10) for cDNA synthesis 
(Section 2.11) and RT-qPCR (Section 2.12) to determine the mRNA expression of 
each target gene.  Alternatively, cells were lysed for western blot analysis (Section 
2.14) to evaluate YAP1 knock-down efficiency at the protein level.   
 
 
2.13.3. siRNA-mediated knock-down of a target gene and infection with reovirus 
The procedure described in Section 2.13.2 was followed to knock-down the gene of 
interest by siRNA-mediated transfection.  24 hours after the final media change, the 
cells were checked under a light microscope for cytotoxicity.  Ten wells from each 
treatment condition were carefully trypsinised, spun and re-suspended in working 
media, before counting the cells using a haemocytometer.  The cell counts were used 
to calculate the volume of reovirus required for a certain multiplicity of infection 
(MOI) in each well (Section 2.8), and then subsequent serial dilutions were made in 
working media.  The wells of the plate were replaced with 100µL diluted reovirus, or 
100µL working media (un-infected sample) in triplicate, and incubated at 37°C for the 
appropriate time-period.  The development procedure described in Section 2.9 using 
the Cell Titre 96® AQueous One Solution Reagent (Promega, UK) was then followed.  
The average OD of the background control was subtracted from the average OD of 
each sample.  The % cell survival in each treatment condition was calculated by 
dividing the reovirus infected sample by the un-infected sample, multiplied by 100: 
% cell survival = (average OD infected sample ÷ average OD un-infected sample) × 100 
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2.14. WESTERN BLOTTING FOR PROTEIN DETECTION IN CELL 
LYSATES 
2.14.1. Lysate preparation and protein separation by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
To prepare cell lysates, cells were washed twice with cold PBS (×1) (Fisher Scientific, 
UK) and then lysed using RIPA buffer (Life Technologies, UK), which sometimes 
contained the protease and phosphatase inhibitor cocktail mix (Life Technologies, 
UK), diluted 1:100.  After 5 minutes of gentle shaking on ice, the cell lysates were 
collected and sheared three times with 21 gauge needles and 1mL syringes.  Lysates 
were then centrifuged at 13,000rpm for 5 minutes, before transferring the supernatants 
to clean tubes and storing at -80°C.  Total protein in the lysates was determined using 
the Pierce™ BCA Protein Assay kit (Life Technologies, UK) by following the 
manufacturer’s protocol.  In brief, 25µL samples or albumin-containing standards 
were added in duplicate to a 96-well plate, before adding 200µL working reagent for 
30 minutes at 37°C.  The purple-coloured reaction product was measured at 562nm on 
the Variskan® Flash plate reader (Thermo Scientific, UK), and the protein 
concentration in each sample was interpolated from the standard curve.   
The samples were then diluted in RIPA buffer (Life Technologies, UK) to the 
required concentration to ensure uniform protein loading.  13µL of the diluted lysate, 
2µL NuPAGE® sample reducing agent (Life Technologies, UK) and 5µL NuPAGE® 
LDS loading buffer (Life Technologies, UK) was mixed and placed on a heating 
block at 70°C for 10 minutes.  The XCell Surelock™ Mini-Cell Electrophoresis 
apparatus (Life Technologies, UK) was assembled, containing NuPAGE® 4-12% Bis-
Tris gels (Life Technologies, UK) and NuPAGE® MOPS or MES SDS running 
buffer (Life Technologies, UK), diluted 1:20 in water.  10µL Novex® Sharp pre-
stained markers (Life Technologies, UK) and 20µL lysate samples were loaded onto 
the lanes of the gels.   Electrophoresis was carried out at 200V for 1 hour using a 
PowerPac (Bio-Rad, UK).   
2.14.2.   Protein transfer, blocking, antibody probing and band detection 
Proteins from the gel were transferred to a nitrocellulose membrane by electroblotting 
at 20 volts for 7 minutes using the iBlot® gel transfer device (program 3) (Life 
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Technologies, UK).  The membrane blot was incubated overnight at 4°C in blocking 
buffer (PBS/0.1% Tween-20 (Sigma, UK) containing 5% milk powder), with gentle 
shaking.  It was then probed with the required primary antibody diluted in blocking 
buffer for 2 hours at room temperature.  After washing for 3 × 10 minutes with 
PBS/0.1% Tween-20, the appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibody (diluted in blocking buffer) was added to the blot for 2 hours at 
room temperature.  The optimum working antibody dilution was established prior to 
use (Table 2.9).  This was followed by another 3 × 10 minute wash in PBS/0.1% 
Tween-20.  The blot was then covered in the SuperSignal® West Pico 
chemiluminescent substrate (Life Technologies, UK) for 3 minutes, before being 
exposed to Carestream® Kodac® BioMax® autoradiography film (Sigma, UK) for an 
appropriate period of time.  The film was then dipped into Fixer and Developer 
reagent (Sigma, UK) to observe protein bands.  Alternatively, after exposure to 
chemiluminescent substrate, protein bands were visualised using the ChemiDoc-It2 
imager (UVP, UK).  The molecular weight of the protein bands was confirmed by 
direct comparison to the Novex® Sharp pre-stained marker.  The blot was placed back 
into PBS/0.1% Tween-20 and stored at 4°C until ready for stripping.   
2.14.3. Stripping the membrane and antibody re-probing 
To ensure uniform protein loading in each lane, the blot was stripped and re-probed 
with β-actin or α-tubulin primary antibodies (Sigma, UK), whose expression should 
remain constant in the test samples.  15mL of Restore™ PLUS stripping buffer 
(Fisher Scientific, UK) was added to the blot with gentle agitation for 15 minutes, 
before washing for 3 × 5 minutes with PBS/0.1% Tween.  The blot was then blocked, 
re-probed with the relevant antibodies, and developed as described in Section 2.14.2.    
2.14.4. Densitometry analysis 
The scanned images of the blots were uploaded to the Image Studio™ Lite Version 
4.0 software (LI-COR Biotechnology, UK), and the signal for each protein band was 
quantified.  To directly compare the protein expression level between samples, the 
band density of the protein of interest was normalised to the band density of the 
loading control in their respective lanes.  The relative protein density in each sample 
was then plotted graphically.   
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Table 2.9.  Primary and secondary antibodies used for western blotting. 
 
 
 
2.15. BACTERIAL TRANSFORMATION AND PURIFICATION OF 
PLASMID DNA  
Plasmid DNA vectors were used to deliver and over-express the YAP1 gene in cell 
lines.  To generate enough plasmid DNA, bacterial transformation was performed.  
Bacteria are used as hosts for making copies of DNA, as they are easy to grow and 
their cellular machinery naturally carries out DNA replication and protein synthesis.   
2.15.1. Bacterial transformation and making a glycerol stock 
Bacterial growth mediums, LB Broth with agar (Sigma, UK) and LB Broth (Sigma, 
UK), were dissolved in water (1 tablet in 50mL water) and autoclaved.  After 
warming the LB Broth with agar to 50°C in a waterbath, Ampicillin (Sigma, UK) was 
added at a dilution of 1:1000 (for example, 50µL ampicillin in 50mL LB agar), under 
sterile conditions.  25mL was added to non-tissue culture petri dishes.  Once set, the 
petri dishes were pre-warmed to 37°C, and the DNA plasmid was diluted in sterile, 
autoclaved water to 1ng/µL.  The One Shot® TOP10 chemically competent E.Coli 
Primary antibodies 
Antibody Supplier Dilution 
Molecular 
Weight (kDa) 
Anti-YAP1 mouse monoclonal IgG1 Abcam, UK 1:2000 54 
Anti-phospho-YAP (S127) rabbit polyclonal IgG Cell Signalling, USA 1:1000 65 
Anti-T3D rabbit polyclonal IgG reovirus antiserum 
Cocalico Biologicals, USA.  
Kindly donated by Dr Dermody, 
Vanderbilt University, USA. 
1:2000 
λ = 160 
µ = 80 
σ = 40 
Anti-acetylated α-tubulin mouse monoclonal IgG2b Sigma, UK 1:30000 50 
Anti-β-actin mouse monoclonal IgG1 Sigma, UK 2000 42 
Anti-α-tubulin mouse monoclonal IgG1 Sigma, UK 1:4000 50 
Secondary antibodies 
Antibody Supplier Dilution - 
Rabbit anti-mouse IgG-HRP Life Technologies, UK 1:2000 - 
Goat anti-rabbit IgG-HRP Cell Signalling, USA 1:2000 - 
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protocol (Life Technologies, UK) was then followed, according to the manufacturer’s 
instructions.  In summary, one vial of competent cells was thawed on ice, before 
adding 1-5µL DNA.  The vial was mixed gently by inversion and incubated on ice for 
30 minutes.  The cells were heat-shocked in a 42°C waterbath for 30 seconds and then 
placed directly onto ice for 2 minutes.  250µL of S.O.C medium was added aseptically 
to the vial and incubated in the orbital shaker at 37°C for 1 hour at 225rpm.  
Subsequently, 5µL, 20µL or 200µL of each transformation was spread onto the pre-
warmed petri dishes using a cell scraper, to ensure that at least one dish would have 
well-spaced colonies.  A negative control dish was also included that did not contain 
any transformation.  The dishes were incubated for 24 hours at 37°C.  Colonies were 
then picked with a sterile pipette tip and placed into a T-150 tissue culture flask 
containing 120mL LB Broth (Sigma, UK) and 120µL Ampicillin (Sigma, UK).  The 
flask was incubated in the orbital shaker at 37°C and 100rpm for 24 hours.  A 
negative control flask containing LB Broth and Ampicillin (with no colony) was 
included to check for contamination.  To make a bacterial glycerol stock for long-term 
storage of the plasmid, 500µL of the liquid bacterial culture was added to a 1.5mL 
Eppendorf tube containing 500µL of 100% glycerol (Sigma, UK).  The tube was 
mixed and frozen at -80°C.   
2.15.2. Purification of the plasmid DNA 
The plasmid DNA was isolated from the bacterial culture using the QIAfilter Plasmid 
Midi prep kit (Qiagen, UK), following the manufacturer’s instructions.  In brief, the 
bacterial cells in the liquid culture were pelleted by centrifugation and subsequently 
lysed using a series of buffers.  Bacterial lysates were incubated in a QIAfilter 
cartridge and cleared by filtration.  The cleared lysate was then loaded onto an anion-
exchange QIAGEN-tip where the plasmid DNA could selectively bind, under 
appropriate low-salt and pH conditions.  Impurities were removed by a medium-salt 
wash and then the plasmid DNA was eluted in a high-salt buffer.  Consequently, the 
DNA was concentrated and de-salted by isopropanol precipitation.  After centrifuging 
the DNA sample, the resulting pellet was collected and air-dried for 1 minute, before 
dissolving it in 100µL sterile, autoclaved water.  The concentration of the purified 
plasmid DNA was determined using the NanoDrop® ND-1000 Spectrophotometer 
(Labtech International, UK), and stored at -20°C.   
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2.16. LIPID-MEDIATED OVER-EXPRESSION OF YAP1 IN CELL LINES 
2.16.1. Transient over-expression of YAP1 
In order to over-express the YAP1 gene, cell lines were transfected with a DNA 
plasmid containing a YAP1 cDNA insert.  Lipofectamine® is a cationic lipid 
transfection reagent that mediates the interaction of the nucleic acid with the 
negatively charged cell surface membrane.  Once bound to the cell membrane, the 
liposome/nucleic acid complex enters the cell via endocytosis, which then diffuses 
through the cytoplasm and into the nucleus for gene expression.   
Cells were seeded (100µL/well) in 96-well plates to the appropriate seeding density in 
cell culture media and incubated overnight at 37°C.  The cell concentration was 
optimised to ensure an 80% confluence on the day of the transfection.  Plasmid DNA 
was transformed and purified (Section 2.15), and then reconstituted in sterile, 
autoclaved water to 100ng/µL.  A DNA mix was prepared by adding plasmid DNA, 
Opti-MEM (Life Technologies, UK) and PLUS reagent (Life Technologies, UK), as 
shown in Table 2.10.  A ‘no plasmid DNA’ control containing Opti-MEM (Life 
Technologies, UK) and PLUS reagent (Life Technologies, UK) was also prepared.  
The samples were mixed and incubated at room temperature for 5 minutes.  
Table 2.10.  The preparation of plasmid DNA and the ‘no plasmid DNA’ control.   
 
Condition 
100ng/µL Plasmid 
DNA (µL/well) 
Opti-MEM (µL/well) 
PLUS reagent 
(µL/well) 
Plasmid DNA + transfection 1 8.85 0.15 
No plasmid DNA control - 9.85 0.15 
 
The transfection conditions were optimised in the PJ34 SCCHN cell line by using 
three different concentrations of Lipofectamine® LTX (Life Technologies, UK) 
diluted in Opti-MEM (Life Technologies, UK), as displayed in Table 2.11.  In the 
COS-1 cell line, a single concentration of 0.45µL/well Lipofectamine® was used.  
The samples were mixed and incubated at room temperature for 5 minutes.   
Table 2.11.  The preparation of Lipofectamine® LTX. 
Lipofectamine® LTX (µL/well) Opti-MEM (µL/well) 
0.25 9.75 
0.35 9.65 
0.45 9.55 
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Each Lipofectamine® sample was mixed with an equal volume of the plasmid DNA 
or ‘no plasmid DNA’ samples, and incubated for 30 minutes at room temperature.  
The ‘no plasmid DNA’ sample therefore served as a control for any cytotoxicity 
caused by the transfection agent alone.  Meanwhile, the wells of the 96-well plate 
were aspirated and replaced with 100µL Opti-MEM (Life Technologies, UK), before 
returning it to the 37°C incubator.  The wells were then replaced with 20µL 
transfection mix and 80µL Opti-MEM (Life Technologies, UK).  100µL DMEM cell 
culture medium was also added to separate wells of the plate for use as a un-
transfected control.  The contents of the wells were gently mixed on a plate shaker 
and then incubated for 5.5 hours at 37°C.  The transfection was aspirated from the 
wells and replaced with 100µL cell culture medium before returning the plate to the 
37°C incubator for 24 hours.  The visual appearance of the cells was checked under a 
light microscope for signs of cytotoxicity.   To determine the mRNA expression of 
YAP1, RNA was extracted from the cells (Section 2.10) for cDNA synthesis (Section 
2.11) and RT-qPCR analysis (Section 2.12).  To evaluate YAP1 over-expression at 
the protein level, cells were lysed for western blot analysis (Section 2.14).  For the 
PJ34 cell line, the optimal concentration of Lipofectamine® was 0.45µL/well, which 
ensured limited cytotoxicity whist maintaining a reasonable expression level of YAP1.  
2.16.2. Stable over-expression of YAP1 in the HN5 SCCHN cell line 
Unlike transient transfection where the introduced DNA persists in cells only for 
several days, stable transfection introduces DNA into cells long-term.  This is because 
the transfected DNA has been incorporated into the cells’ genome and thus, is passed 
into their progeny.  To determine the optimal antibiotic concentration for selecting 
stable cell colonies, a dose-response experiment (kill curve) was performed using the 
G418 (Geneticin disulfate salt) antibiotic (Sigma, UK).  Cells were seeded to the 
required density in cell culture medium in a 24-well plate for 24 hours at 37°C.  G418 
was serially diluted in cell culture medium to make an 8-point dilution curve.  The 
wells of the plate were aspirated and replaced with 1mL diluted G418 in duplicate, 
before returning to the 37°C incubator.  A ‘no antibiotic’ control was also added to 
separate wells in duplicate, which contained cell culture media only.  The wells were 
replaced with fresh G418-containing media every 2 days for up to one week, and the 
cells were examined under a light microscope each day for signs of toxicity.  The 
54 
 
optimal G418 concentration was the lowest concentration that killed all cells within 1 
week.  In the case of the HN5 cell line, this was 650µg/mL.   
Having found the optimal concentration of G418, the protocol described in Section 
2.16.1 was followed to transfect cells with the required DNA plasmid in 96-well 
plates.  24 hours after the final media change, the cells were examined under a 
microscope for signs of toxicity.  100µL trypsin was added to each well to detach 
adherent cells from the surface.  The cells were centrifuged at 1500rpm for 3 minutes 
and re-suspended in 1mL cell culture medium, which was added to 10cm tissue 
culture petri dishes containing 10mL cell culture media.  The dishes were incubated 
for 24 hours at 37°C, before replacing with fresh cell culture medium containing the 
650µg/mL G418 antibiotic, and returning to the 37°C incubator.  Fresh G418-
containing media was replaced every 2-3 days until circular colonies formed.  Since 
the DNA plasmids used for transfection contained the neomycin antibiotic resistance 
gene, it was assumed that these surviving colonies contained the transfected gene of 
interest, whereas cells that failed to uptake the plasmid were killed by G418.  Under 
sterile conditions, the colonies were picked with a pipette tip and transferred to wells 
of a 96-well plate.  The cells were transferred to culture wells of increasing surface 
area containing G418-media until confluent in T-150 flasks, before being stored in 
liquid nitrogen (Section 2.6).  Several stable clones were lysed for western blot 
analysis (Section 2.14) to determine YAP1 over-expression at the protein level, 
compared to the parental HN5 cell line or empty-vector (EV) stable clones.  All DNA 
plasmid sequences used for transfection were validated by the Sanger sequencing 
facility, University of Cambridge, UK, and are listed in Table 2.12.   
 
Table 2.12.  The DNA plasmids used for transient or stable transfection of cell lines. 
 
 
DNA plasmid name 
cDNA 
insert 
Vector type Supplier 
Promoter 
type 
Selection 
marker 
Reference 
Human Flag-tagged YAP1 YAP1 pcDNA™3.1 
A gift from Dr Nic Tapon, 
Cancer Research UK. 
CMV Neomycin  [219] 
Human EYFP-tagged YAP1 YAP1 
pBK-CMV 
phagemid vector 
A gift from Dr Nic Tapon, 
Cancer Research UK. 
CMV Neomycin   
Empty vector (EV) control - pcDNA™3.1 
A gift from Dr Lisi Meira, 
University of Surrey, UK.  
CMV Neomycin  [219] 
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2.16.3. Over-expression of YAP1 and reovirus infection 
Cell lines were transiently or stably transfected with the required DNA plasmid in 96-
well plates, as described in Sections 2.16.1 and 2.16.2 respectively.  Ten wells 
containing cells from each treatment condition were carefully trypsinised, spun, re-
suspended in 200µL working media, and counted using a haemocytometer.  Cell 
counts were used to calculate the volume of reovirus required for a certain MOI per 
well (Section 2.8).  From this, subsequent serial dilutions of reovirus were made in 
working media.  The plate was aspirated and replaced with 100µL/well diluted 
reovirus or 100µL/well working media (un-infected sample) in triplicate, and 
incubated at 37°C for the appropriate period of time.  The development procedure 
described in Section 2.9 with the Cell Titre 96® AQueous One Solution Reagent 
(Promega, UK) was then followed.  The average OD of the background control was 
subtracted from the average OD of each sample.  The % cell survival in each 
treatment condition was calculated by dividing the reovirus infected sample by the un-
infected sample, multiplied by 100: 
% cell survival = (average OD infected sample ÷ average OD un-infected sample) × 100 
 
 
2.17. DETECTION OF A PROTEIN USING IMMUNOFLUORESCENCE 
STAINING AND CONFOCAL MICROSCOPY IN CELL LINES 
Immunofluorescence staining was used to demonstrate both the presence and cellular 
localisation of total YAP1, phospho-YAP-S127, or reovirus proteins in SCCHN cell 
lines.  Cells were seeded (500µL/well) in 8-well tissue culture-treated glass chamber 
slides (BD BioSciences, UK).  The chamber slides were incubated for 24 hours at 
37°C to ensure an 80% confluence.  Wheat Germ Agglutinin (WGA) Alexa Fluor® 
594 conjugate (Life Technologies, UK), a plasma membrane stain, was diluted 1:200 
in warm Hanks media (Sigma, UK).  The wells of the chamber slide were aspirated 
replaced with 300µL/well of WGA for 10 minutes at 37°C.  To fix the cells, the WGA 
stain was removed and replaced with 300µL warm 4% paraformaldehyde for 10 
minutes at 37°C (made fresh in-house by adding 20mL PBS (×1) (Fisher Scientific, 
UK) and 0.8g paraformaldehyde (Sigma, UK) on a magnetic stirrer at 60°C until 
dissolved).  The wells were then rinsed three times with 500µL PBS (×1) (Fisher 
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Scientific, UK), before permeabilising the cells with 300µL 0.2% Triton X-100 
(Sigma, UK) for 10 minutes at 37°C.   
After three rinses in 500µL PBS (×1) (Fisher Scientific, UK), non-specific binding 
sites were blocked in 300µL/well 10% Goat serum diluted in PBS (×1) (Fisher 
Scientific, UK) for 20 minutes at 37°C.  The wells were aspirated and 300µL/well of 
the required primary antibody, diluted in PBS/1%BSA, was added for 2 hours at 
37°C.  A ‘no primary antibody’ sample was also included containing 300µL 
PBS/1%BSA for use as a negative control.  The wells were rinsed three times with 
500µL PBS (×1) (Fisher Scientific, UK), before simultaneously adding 300µL/well of 
the appropriate Alexa Fluor® secondary antibody and the TOPRO®-3 nuclear stain 
(Life Technologies, UK), diluted 1:400 in PBS/1%BSA, for 1 hour at 37°C.  Both the 
WGA and TOPRO®-3 stains helped to localise the protein of interest in the cells.  
The wells were then aspirated and rinsed three times with 500µL PBS (×1) (Fisher 
Scientific, UK).  The plastic chamber was removed carefully using the white comb 
supplied (BD BioSciences, UK), revealing the glass slide underneath.  2 drops of 
Vectashield for fluorescence (Vector Laboratories, UK) was added to the slide before 
being cover-slipped. The cells were imaged after 24 hours using the Nikon A1M 
confocal microscope and NIS elements acquisition software (Nikon, UK).  Primary 
and secondary antibodies used in this procedure are listed in Table 2.13.   
 
Table 2.13.  Primary and secondary antibodies used for immunofluorescence staining.   
Primary antibodies 
Antibody Supplier Dilution 
Anti-YAP1 mouse monoclonal IgG1 Abcam, UK 1:200 
Anti-phospho-YAP (S127) rabbit polyclonal IgG Cell Signalling, USA 1:200 
Anti-T3D rabbit polyclonal IgG reovirus antiserum 
Cocalico Biologicals, USA.  Kindly 
donated by Dr Dermody, Vanderbilt 
University, USA. 
1:1000 
Secondary antibodies 
Antibody Supplier Dilution 
Alexa Fluor® 488 goat anti-mouse IgG1 Life Technologies,UK 1:200 
Alexa Fluor® 488 goat anti-rabbit IgG Life Technologies,UK 1:200 
Alexa Fluor® 546 goat anti-rabbit IgG Life Technologies,UK 1:200 
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2.18. THE EFFECT OF SPHINGOSINE-1-PHOSPHATE (S1P) ON YAP1 
ACTIVITY AND REOVIRUS ONCOLYSIS 
S1P has been previously shown to cause de-phosphorylation of the YAP1 protein on 
residue serine 127 (S127).  This consequently resulted in the nuclear migration of 
YAP1 in certain cell lines [220].  To determine the effect of S1P treatment on reovirus 
oncolysis, the PJ41 cell line was re-suspended to a concentration of 1×105cells/mL.  
100µL/well cell suspension was added to a 96-well plate for 24 hours at 37°C to 
ensure an 80% confluence.  Cells were then treated with 100µL/well S1P (Sigma, 
UK) diluted to 1µM in working cell culture media, or with media alone (un-treated 
cells), for 60 minutes at 37°C.  After this time, ten wells containing cells from each 
treatment condition were carefully trypsinised, spun, re-suspended in 200µL working 
media, and counted using a haemocytometer.  Cell counts were used to calculate the 
volume of reovirus required for MOI 500 per well (Section 2.8).  From this, 
subsequent serial dilutions of reovirus were made in working media.  The plate was 
aspirated and replaced with 100µL/well of each dilution of reovirus, or with 
100µL/well working media (un-infected cells) in triplicate, and incubated at 37°C for 
24 hours.  The development procedure described in Section 2.9 with the Cell Titre 
96® AQueous One Solution Reagent (Promega, UK) was then followed.  The average 
OD of the background control was subtracted from the average OD of each sample.  
The % cell survival in each treatment condition was calculated by dividing the 
reovirus infected sample by the un-infected sample, multiplied by 100: 
% cell survival = (average OD infected sample ÷ average OD un-infected sample) × 100 
 
In order to assess the de-phosphorylation of YAP1 caused by S1P, PJ41 cells were 
seeded in 96-well plates at 1×105cells/mL (100µL/well) for 24 hours at 37°C.  Cells 
were then treated with 100µL/well S1P (Sigma, UK) diluted to 1µM for 20, 30 and 60 
minutes at 37°C, or with media alone for 60 minutes as an un-treated control.  Cells 
were then lysed for western blot analysis (Section 2.14) to determine the protein 
expression levels of phosphor-YAP-S127 and total YAP1 in each sample.    
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2.19. DETECTION OF A PROTEIN BY INDIRECT FLOW CYTOMETRY 
Flow cytometry was used to analyse the expression of cell surface JAM-A, as well as 
intracellular YAP1 and reovirus proteins in SCCHN cell lines.  Cells were harvested 
and re-suspended to a concentration of 2×106cells/mL in ice-cold FACS buffer 
(prepared in-house with PBS (×1) (Fisher Scientific, UK), 10% bovine serum albumin 
(BSA) (Sigma, UK) and 1% sodium azide (Sigma, UK)).  200µL cell suspension was 
added to FACS tubes.  The tubes were centrifuged at 2000rpm for 2 minutes and the 
supernatant was poured off.  The cell pellet was re-suspended in 200µL/tube 80% 
methanol (Fisher Scientific, UK) and incubated for 5 minutes at room temperature.  
This enabled cells to be fixed, allowing the target protein to be retained in the original 
cellular location.  The methanol fixative was washed off by adding 1mL ice cold 
PBS/0.1% Tween to each tube that were then centrifuged at 2000rpm for 2 minutes.  
After discarding the supernatant, the cells were permeabilised with 200µL/tube 
PBS/0.1% Tween and incubated for 20 minutes at room temperature.  The tubes were 
centrifuged at 2000rpm for 2 minutes and the supernatant was removed.  Non-specific 
binding sites were blocked by adding 100µL/tube 10% normal goat serum (Dako, 
UK) diluted in PBS (×1) (Fisher Scientific, UK) and incubated for 10 minutes at room 
temperature.  1mL ice cold PBS/0.1% Tween was added to each tube and 
subsequently centrifuged at 2000rpm for 2 minutes.  After discarding the supernatant, 
the primary antibody was diluted in FACS buffer to the appropriate concentration.  
50µL was added to each tube and incubated for 30 minutes at room temperature.  
Negative control samples were treated with 50µL FACS buffer alone without primary 
antibody.  1mL ice cold PBS/0.1% Tween was added to each tube and centrifuged at 
2000rpm for 2 minutes, before discarding the supernatant.  100µL/tube Alexa Fluor® 
secondary antibody (Life Technologies, UK) diluted in FACS buffer, was added and 
incubated in the dark for 30 minutes at room temperature.  Following a final wash in 
1mL ice cold PBS/0.1%, each tube was centrifuged at 2000rpm for 2 minutes and the 
supernatant was poured off.  Cells were re-suspended in 200µL FACS buffer before 
being analysed by flow cytometry on the MACS Quant® Analyser (Miltenyi Biotec, 
UK).  The Mean Fluorescence Intensity (MFI) of the negative control sample was 
subtracted from the MFI value of each positive sample, resulting in an overall MFI 
protein expression value.  Primary and secondary antibodies used in this procedure are 
listed in Table 2.14.   
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Table 2.14.  Primary and secondary antibodies used for indirect flow cytometry protein detection.   
 
 
2.20. ONE STEP GROWTH CURVE ANALYSIS BY THE 50% TISSUE 
CULTURE INFECTIVE DOSE (TCID50) ASSAY 
TCID50 is a measure of infectious virus titre.  In this endpoint dilution assay, the 
amount of virus needed to kill 50% of infected host cells was quantified.  TCID50 is 
not equivalent to plaque forming unit (pfu) due to differences in assay methods 
(Section 2.24), although the theoretical relationship is 0.69 pfu = 1 TCID50 based on 
the Poisson distribution (Section 2.8).   
2.20.1. Preparation of intracellular or extracellular viral samples 
To prepare viral samples for the assay, the relevant SCCHN cell line was seeded in 
96-well tissue culture plates for 24 hours at 37°C, to reach 80% confluency.  The cells 
were then infected with reovirus at MOI 5 (Section 2.8) for different time increments 
of up to 72 hours.  Intracellular viral samples were made by removing the supernatant 
from the wells and adding 100µL/well fresh cell culture medium.  Subsequently, the 
plate was freeze-thawed three times to release cellular viral particles into the culture 
medium.  Extracellular viral samples were made by transferring the viral supernatant 
to a 1.5mL Eppendorf tube, which was centrifuged at 300 × g for 2 minutes to remove 
cell debris.  The resulting supernatant was carefully removed and transferred to a fresh 
1.5mL Eppendorf tube.   
Primary antibodies 
Antibody Supplier Dilution 
Anti-YAP1 mouse monoclonal IgG1 Abcam, UK 1:200 
Anti-JAM-A rabbit polyclonal IgG Santa Cruz Biotechnology, USA 1:200 
Anti-T3D rabbit polyclonal IgG reovirus antiserum 
Cocalico Biologicals, USA.  Kindly 
donated by Dr Dermody, Vanderbilt 
University, USA. 
1:1000 
Secondary antibodies 
Antibody Supplier Dilution 
Alexa Fluor® 546 goat anti-mouse IgG1 Life Technologies,UK 1:500 
Alexa Fluor® 546 goat anti-rabbit IgG Life Technologies,UK 1:500 
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2.20.2. Infection of the host-cell monolayer and determining the cytopathic effect 
Host L929 cells were seeded (100µL/well) in 96-well tissue culture plates at a density 
of 2×105 cells/mL in cell culture medium for 24 hours at 37°C, to ensure a 90% 
confluence.  1:10 dilutions of the relevant reovirus sample was made in working 
media.  For example, using a sterile filtered tip, 150µL of the viral sample was mixed 
with 1350µL working media to make a 1×10-1 dilution.  With a new tip, 150µL of this 
mixture was transferred to the next tube containing 1350µL working media to make 
1×10-2 dilution.  The series was repeated through to a 1×10-9 dilution.  The 96-well 
plates were aspirated and infected with 100µL of each virus sample (12 wells per 
dilution), or with working media for use as a non-infected control.  The virus was 
absorbed for 3 hours before replacing each well with 100µL cell culture medium for 3 
days at 37°C.  Using a light microscope, the cytopathic effect (CPE) in each well was 
observed.  The number of positive and negative wells was recorded for each dilution 
and used to calculate the reovirus titre (TCID50/mL) in each sample, according to the 
Spearman and Karber algorithm [221].   
 
 
2.21. VERIKINE™ HUMAN INTERFERON BETA (IFN-β) ENZYME-
LINKED IMMUNOSORBENT ASSAY (ELISA) 
IFN-β is secreted by fibroblasts and many other cell types in response to pathogens, 
including viruses.  Secretion of IFN-β is known to inhibit viral replication as part of 
the body’s innate anti-viral response.  The concentration of IFN-β in reovirus-infected 
or non-infected cell line supernatants was quantified by using The Verikine™ Human 
IFN-β ELISA kit (PBL Assay Science, USA), according to the manufacturer’s 
instructions.   
2.21.1. Isolation of peripheral blood mononuclear cells (PBMCs) from whole 
blood 
PBMCs (lymphocytes, macrophages and monocytes) were used as a positive control 
for IFN-β secretion.  In order to isolate PBMCs, 10mL whole blood from a healthy 
human donor was diluted in 20mL Hanks’ balanced salt solution (Sigma, UK).  This 
was carefully layered onto 15mL Histopaque®-1077 (Sigma, UK) in a 50mL falcon 
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tube, which was then subjected to density-gradient centrifugation at 690 x g for 25 
minutes.  The PBMC layer was removed and placed into a 50mL Falcon tube 
containing 30mL Hanks’ balanced salt solution (Sigma, UK) and centrifuged at 690g 
for 10 minutes.  The supernatant was discarded and the cell pellet was gently re-
suspended in 1mL Hanks’ balanced salt solution (Sigma, UK), before adding a further 
29mL to the tube.   After being centrifuged at 690g for 10 minutes, the supernatant 
was removed and the pellet was re-suspended in 1mL RPMI cell culture medium.  
The cells were counted with a haemocytometer, as described in Section 2.5.   
2.21.2.   Preparation of cell supernatants  
100µL/well human SCCHN cell lines or PBMCs were seeded in 96-well tissue culture 
plates and incubated for 24 hours at 37°C, to ensure an 80% confluence.  The wells 
were aspirated and replaced with 100µL working media as a non-infected control, or 
with 100µL reovirus diluted to the desired MOI (Section 2.8) in working media for 24 
hours at 37°C.  The supernatants were then harvested in 1.5mL Eppendorf tubes and 
centrifuged for 2 minutes at 300 × g to remove cell debris.  The supernatants were 
transferred to fresh tubes and stored at -80°C.    
To determine whether over-expression or knock-down of YAP1 affected IFN-β 
production, supernatants were also collected after stable cell line generation from the 
parental HN5 cell line, or from siRNA-transfected PJ41 cells, infected with or without 
reovirus (Sections 2.16.3 and 2.13.3 respectively).   
2.21.3.   The Verikine™ Human IFN-β ELISA assay 
A 7-point human IFN-β standard curve was prepared, ranging from 4000 to 50pg/mL.  
A blank sample was also included containing sample diluent alone, which served as a 
background control.  At room temperature, 50µL sample diluent was added to all 
wells of the pre-coated IFN-β 96-well plate, before adding 50µL of the diluted 
standards, blank or test samples for 1 hour, in duplicate.  After three washes with the 
provided buffer, 100µL of antibody solution was added to each well for 1 hour.  The 
plate was washed three times and then 100µL/well of HRP solution was added for 1 
hour.  Following a final three washes, 100µL/well of TMB substrate was added for 15 
minutes in the dark.  100µL stop solution was dispensed into each well before reading 
the absorbance at 450nm on the Variskan® Flash plate reader (Thermo Scientific, 
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UK), to generate OD raw data values.  The average OD of the blank was subtracted 
from the average OD of the standards and test samples.  The OD values for the 
standard curve were then plotted using a 4-parameter fit (GraphPad Prism version 6 
software, USA), enabling the IFN-β titre in the test samples to be determined.   
 
 
2.22. DETECTION OF THE YAP1 PROTEIN IN TISSUE BY ENZYMATIC 
IMMUNOHISTOCHEMISTRY (IHC) STAINING 
The presence and location of the YAP1 protein was visualised in intact head and neck 
cancer or normal tissue sections by enzymatic IHC staining.  The following tissue 
microarrays were purchased from US Biomax (USA) and used for this purpose: 
 HN803a:  a tissue microarray containing 60 cases of squamous cell carcinoma of 
the head and neck, 1 case of head and neck sarcomatodes and 8 cases of head and 
neck metastatic carcinoma.  Additionally, the array contained 1 cancer adjacent 
normal tissue and 10 normal tissues derived from the tongue.   
 FDA999c:  a multiple organ normal tissue microarray containing 99 cases, 
including 12 normal head and neck tissues.  
Human PCa tissue was used as a positive control for the YAP1 protein, as 
recommended by the manufacturer of the YAP1 primary antibody (Abcam, UK) and 
published data [222].  PCa tissues were fixed in 10% neutral buffered formalin for 18-
24 hours, before being embedded in paraffin and cut on a microtome.  Once affixed to 
the slide, the tissue was dried at room temperature and then baked for 1 hour at 60°C.  
The PCa tissue sample was obtained with patient consent from The Royal Surrey 
Hospital.  Tissue microarrays were not coated with an extra layer of paraffin, and 
were therefore placed directly into xylene for the de-paraffinization procedure.   
2.22.1. Deparaffinization and antigen retrieval  
The removal of paraffin from the slides was imperative in order to achieve the desired 
staining on the section.  Slides were placed into 3 × 5 minute changes of 100% xylene 
(Sigma, UK) followed by two changes in 100% ethanol (Fisher Scientific, UK), 
before being placed in methanol (Sigma, UK) containing 0.3% hydrogen peroxide 
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(Sigma, UK) for 20 minutes to block endogenous peroxidases.  The slides were 
rehydrated in 100%, 70%, and 50% ethanol (Fisher Scientific, UK) and then placed 
into distilled water.  For the antigen retrieval step, the slides were subjected to boiling 
in 0.01M citrate buffer (pH 6.0) and microwaved for 12 minutes on the high setting.  
After this time, the slides were left to cool at room temperature in the citrate buffer for 
1-2 hours.  The antigen retrieval step serves to break the methylene bridges that are 
formed during fixation, and helps to expose antigenic sites to allow antibodies to bind.  
The slides were then washed in distilled water for 3 minutes, followed by 2 × 3 
minute washes in PBS (×1) (Fisher Scientific, UK).   
2.22.2. Blocking of the tissue and addition of antibodies 
After placing the slides into a moist chamber, an ImmEdge pen (Vector Laboratories, 
UK) was used to create a barrier around the tissue sections.  The slides were blocked 
by adding 3 drops of normal horse serum, as supplied in the RTU Vectastain 
Universal Elite ABC kit (Vector Laboratories, UK), for 15 minutes.  A further 
blocking step was performed using the Avidin/Biotin blocking kit (Vector 
Laboratories, UK).  3 drops per section of Avidin D solution was added for 15 
minutes.  Following a quick wash in PBS (×1) (Fisher Scientific, UK), the slides were 
then exposed to 3 drops of biotin solution for 15 minutes.  Each section was 
subsequently incubated with 200µL anti-YAP1 mouse monoclonal IgG1 primary 
antibody (Abcam, UK), diluted 1:400 in PBS/0.1% BSA, for 24 hours.  As a negative 
control, 200µL PBS/0.1% BSA alone was added to corresponding slides.  The slides 
were washed for 3 × 3 minutes in PBS (×1) (Fisher Scientific, UK), before adding 3 
drops of universal secondary antibody, as supplied in the RTU Vectastain Universal 
Elite ABC kit (Vector Laboratories, UK), to each section for 30 minutes.  The 
secondary antibody used in this kit was a cocktail of biotinylated anti-mouse IgG and 
anti-rabbit IgG, designed for use with both rabbit and mouse primary antibodies.   
2.22.3. Addition of the Avidin-biotin complex (ABC) and 3,3’diaminobenzidine 
(DAB) substrate 
Following a 3 × 3 minute wash in PBS (×1) (Fisher Scientific, UK), the slides were 
placed back into the chamber.  3 drops of ABC reagent, supplied in the RTU 
Vectastain Universal Elite ABC kit (Vector Laboratories, UK), was dropped onto the 
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sections for 30 minutes.  DAB substrate solution was prepared by adding 4 drops of 
DAB Peroxidase substrate solution (Vector Laboratories, UK) to 5mL distilled water.  
After another 3 × 3 minute wash in PBS (×1) (Fisher Scientific, UK), 3 drops of the 
diluted DAB solution was added to the sections for 2-10 minutes, which produced a 
brown reaction product in the presence of HRP enzyme.  The slides were then washed 
in distilled water for 5 minutes.  The sections were counterstained with 3 drops of 
haematoxylin (Vector Laboratories, UK) for 45 seconds, before immediately washing 
the slides with water under a running tap for 5 minutes.  Haematoxylin is a blue 
nuclear stain that provided contrast to the tissue. 
2.22.4.   Dehydration of the tissue section, cover-slipping and scoring 
Slides were dehydrated in 50% ethanol, 70% ethanol, three changes of 100% ethanol 
(Fisher Scientific, UK) and three changes of 100% xylene (Sigma, UK).  After being 
left to dry for 1 hour, 1 drop of Vector mounting media (Vector Laboratories, UK) 
was added to each section.  A glass coverslip (VWR International) was placed directly 
over the top.  The slides were placed on a hot rack for 30 minutes and stored at room 
temperature, before being analysed under the light microscope.   
A system was used to score the tissues according to the intensity of YAP1 brown 
colouration, where 0 = negative, +1 = weak positive, +2 = moderate positive and +3 = 
strong positive staining.  The diagnosis, staining intensity, and localisation of YAP1 
in all tissues was confirmed by a consultant head and neck pathologist at The Royal 
Surrey Hospital (Dr Silvana Di Palma).   
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2.23. ASSESSING THE INTERACTION BETWEEN REOVIRUS AND 
TAXANE CHEMOTHERAPY DRUGS IN PCa CELL LINES 
The procedure described in Section 2.9 was followed in order to determine the IC50 
values of reovirus, Cabazitaxel and Docetaxel in prostate cell lines.  These values 
were then used to establish the doses of each agent in combination assays.    
2.23.1. Concurrent combination of two agents at fixed-dose ratios  
DU145 and LNCaP PCa cell lines were seeded (100µL per well) in 96-well plates in 
cell culture media for 24 hours at 37°C, to ensure an 80% confluence.  Cells were 
treated with 100µL/well working cell culture media as an un-treated control, or with 
reovirus, Cabazitaxel or Docetaxel as single agents, at doses representing 4, 2, 1, 0.5 
and 0.25 times their respective IC50 values.  Reovirus was also combined with 
Cabazitaxel or Docetaxel at these fixed-dose ratios and added to the wells 
concurrently (100µL/well).  All treatments were added in triplicate wells and 
incubated at 37°C for 96 hours, before developing the plates with the Cell Titre 96® 
AQueous One Solution Reagent (Promega, UK) (Section 2.9).  After calculating the % 
cell survival relative to un-treated cells, the fraction of dead cells affected in each 
treatment condition was evaluated, as described in Section 2.9, and inputted into 
CalcuSyn software (BioSoft, UK).  The level of interaction between reovirus in 
combination with Cabazitaxel or Docetaxel was determined by the Chou and Talalay 
equation (Section 2.27.5).   
2.23.2. Comparing sequential and concurrent combinations at fixed-dose ratios 
The DU145 PCa cell line was seeded (100µL per well) in 96-well plates in cell culture 
media for 24 hours at 37°C, to ensure an 80% confluence.  Cells were treated with 
working cell culture medium alone as an un-treated control, or with reovirus or 
Cabazitaxel as single agents at doses representing 1.00, 0.50, 0.25, 0.13 and 0.06 
×IC50 values.  In addition, reovirus was combined with Cabazitaxel at these doses, 
only this time concurrent combination treatment was directly compared to five 
different sequential combinations, in order to determine the most synergistic 
sequencing strategy.  Cells were treated in triplicate for a total of 96 hours at 37°C.   
 Concurrent treatment:  reovirus and Cabazitaxel added simultaneously  
 Sequential treatment 1:  1 hour Cabazitaxel alone, followed by reovirus 
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 Sequential treatment 2:  4 hours Cabazitaxel alone, followed by reovirus 
 Sequential treatment 3:  24 hours Cabazitaxel alone, followed by reovirus 
 Sequential treatment 4:  24 hours reovirus alone, followed by Cabazitaxel  
 Sequential treatment 5:  48 hours reovirus alone, followed by Cabazitaxel 
 
The plates were developed with Cell Titre 96® AQueous One Solution Reagent 
(Promega, UK) and the % cell survival was calculated relative to untreated cells 
(Section 2.9).  The fraction of dead cells affected in each treatment was evaluated 
(Section 2.9) and inputted into CalcuSyn software (BioSoft, UK).  The interaction 
between reovirus and Cabazitaxel was determined by the Chou and Talalay equation 
(Section 2.27.5).   
2.23.3. Concurrent combination of two agents at non-fixed dose ratios 
The DU145 PCa cell line was seeded (100µL per well) in 96-well plates in cell 
culture media for 24 hours at 37°C, to ensure an 80% confluence.  As an un-treated 
control, cells were treated with working cell culture medium alone. Cells were also 
treated with single agent reovirus at doses representing 0.13, 0.26, 0.44, 0.88, 1.75, 
3.51 and 7.02 ×IC50; Cabazitaxel at 0.05, 0.11, 0.22, 0.44, 0.88, 1.75, 2.63 and 3.51 
×IC50; or Docetaxel at 0.07, 0.14, 0.29, 0.57, 0.86, 2.86 and 5.71 ×IC50.  Additionally, 
reovirus was combined with Cabazitaxel or Docetaxel at each dose.  Cells were 
treated in triplicate for a total of 96 hours at 37°C, before developing the plates with 
Cell Titre 96® AQueous One Solution Reagent (Promega, UK), as described in Section 
2.9.  The % cell survival was calculated relative to untreated cells, before evaluating 
the fraction of dead cells affected in each treatment (Section 2.9), which was inputted 
into the Bliss Independence analysis spreadsheet [223] (provided by Professor Kevin 
Harrington’s laboratory, with permission from MedImmune LLC, USA).  Thus, the 
Bliss equations [224] provided a powerful statistical model to analyse the in vitro 
interaction between reovirus and Cabazitaxel or Docetaxel at doses much lower than 
the IC50 of each agent, at non-fixed dose ratios (Section 2.27.6).   
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2.24. ONE STEP GROWTH CURVE ANALYSIS BY THE VIRUS PLAQUE 
ASSAY 
The plaque assay is a standard method used to determine the infectious virus titre in a 
sample, by manually counting the number of plaque forming units (pfu) formed after 
infecting a monolayer of host cells.  A plaque is formed when a virus infects a host 
cell, which will lyse, enabling the virus to spread to and lyse neighbouring cells.  It is 
assumed that each plaque formed is representative of one infectious viral particle.   
The DU145 PCa cell line was treated with reovirus alone at the IC50 dose, or with 
reovirus (at the IC50) in combination with Cabazitaxel or Docetaxel at concentrations 
representing 1.00, 0.25 and 0.06 ×IC50.  Intracellular and extracellular viral samples 
were then prepared as described in Section 2.20.1.   
2.24.1. Infection of the host-cell monolayer and counting plaques 
L929 cells were seeded (1mL per well) in 6-well tissue culture plates at a 
concentration of 1x106cells/mL in cell culture medium.  Plates were incubated for 24 
hours at 37°C to enable cells to reach 90% confluence.  1:10 dilutions of the relevant 
reovirus sample was made in working media, ranging from 1×10-1 to a 1×10-9 
dilution.  The wells were aspirated and replaced with 1mL of each virus dilution in 
duplicate, or with 1mL working cell culture media for use as an un-infected control.  
The virus was absorbed for 3 hours at 37°C, with intermittent rocking of the plate.  
The wells were then aspirated and replaced with 2mL/well warm overlay agar (made 
by mixing warm 2% SeaPlaque agarose (Lonza, UK) with an equal volume of 
2×MEM (Sigma, UK)).  The agar was allowed to set at room temperature for 30 
minutes before transferring the plates to the incubator at 37°C for 3 days.  Each well 
was stained with 1mL Neutral Red solution (Sigma, UK) diluted 1:10 in PBS (×1) 
(Fisher Scientific, UK) and incubated at 37°C for 3 hours.  The number of plaques 
was counted in each well with the aid of a lightbox.  The pfu/mL was calculated using 
the formula:  
pfu/mL = (number of plaques/well) × (volume of sample added in mL) × (stock 
viral titre) 
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2.25. INHIBITION OF APOPTOSIS BY z-VAD-FMK  
z-VAD-FMK (Sigma, UK) is a competitive, irreversible inhibitor of caspase-1 and 
caspase-3-related proteases, and was used to determine whether apoptosis was 
contributing to cell death after combination treatment with reovirus and chemotherapy 
drugs.  The DU145 PCa cell line was seeded (100µL per well) in 96-well plates in cell 
culture media for 24 hours at 37°C, to ensure an 80% confluence.  After aspirating the 
wells, cells were treated with 100µL/well reovirus, Cabazitaxel or Docetaxel as single 
agents at doses representing 0.25, 0.5, 1.0, 2.0 and 4.0 ×IC50 values.  In addition, cells 
were treated with reovirus in combination with Cabazitaxel or Docetaxel at 1.0, 0.50, 
0.25, 0.13, 0.06 and 0.03 ×IC50.  After 90 minutes, the wells were aspirated and 
replaced with 100µL/well 50µM z-VAD-FMK (Sigma, UK) or with 100µL/well 
working cell culture media alone as an un-treated control, for 96 hours at 37°C.  All 
treatments were added in triplicate wells. The plates were developed with the Cell 
Titre 96® AQueous One Solution Reagent (Promega, UK) and the % cell survival 
relative to un-treated cells was calculated, as described in Section 2.9.   
 
2.26. INHIBITION OF NECROPTOSIS BY NECROSTATIN-1 (NCS-1) 
NCS-1 is an inhibitor of necroptosis, and was used to study the mode of cell death 
after combination treatment of reovirus and chemotherapy drugs.  The DU145 PCa 
cell line was seeded (100µL per well) in 96-well plates in cell culture media for 24 
hours at 37°C, to ensure an 80% confluence.  The wells were aspirated and 
100µL/well 30µM NCS-1 (Sigma, UK) or working cell culture media (un-treated 
control) was added for 45 minutes and incubated at 37°C.  Subsequently, the wells 
were aspirated and replaced with 100µL/well reovirus, Cabazitaxel or Docetaxel as 
single agents at doses representing 0.25, 0.5, 1.0, 2.0 and 4.0 ×IC50 values.  Cells were 
also treated with reovirus in combination with Cabazitaxel or Docetaxel at 1.0, 0.50, 
0.25, 0.13, 0.06 and 0.03 ×IC50.  All treatments were added in triplicate and incubated 
at 37°C for 90 minutes.  After this time, the plate was aspirated and replaced with 
100µL/well cell culture media, and incubated at 37°C for the remaining time totalling 
96-hours.  The plates were developed with the Cell Titre 96® AQueous One Solution 
Reagent (Promega, UK), and the % cell survival relative to un-treated cells was 
calculated, as described in Section 2.9.   
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2.27. STATISTICAL ANALYSIS 
 
2.27.1. Significance levels 
All statistical calculations were performed using GraphPad Prism Version 6.0 
software, unless otherwise specified.  For all tests, a 5% significance level was used.  
Therefore, the following symbols were used in figures to show the level of 
significance:  
*p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001 
 
 
2.27.2. Comparing % cell survival, protein expression or viral titre between 
sample means 
An un-paired student’s t-test was used to compare statistical differences in % cell 
survival between the means of two treatment groups, after subsequent reovirus 
infection at a specific MOI.  These experiments included siRNA-mediated gene 
knock-down in the PJ41 cell line; transient and stable YAP1 over-expression in PJ34 
and HN5 cell lines; S1P treatment of the PJ41 cell line; and z-VAD-FMK or NCS-1 
treatment of the DU145 cell line.  An un-paired student’s t-test was also used to 
compare between two means to analyse protein expression levels of JAM-A in 
SCCHN cell lines, IFN-β secretion in cell supernatants, and intra- and extra- cellular 
reovirus titre.  A one-way ANOVA and Tukey’s post-hoc test was used to compare 
statistical differences in vial titre between 3 or more cell lines or treatments.  Various 
research groups have used these tests for similar purposes [225-231].    
 
 
2.27.3. Comparing YAP1 protein expression in human tissue samples 
The Chi squared (χ) statistical test was used to compare YAP1 positive and negative 
IHC staining in head and neck carcinoma or normal tissue cores [232, 233].  It was 
also used to compare YAP1 cellular localisation with staining intensity, and to test the 
association of YAP1 with clinical factors including tumour grade, tumour stage, age 
and sex of the patient.  
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2.27.4. Determining an IC50 value by the median-effect equation 
To determine an IC50 value after treatment of a cell line with reovirus or drug, the 
median-effect equation of Chou [217] was used via CalcuSyn software (Biosoft, UK).  
The median-effect equation is: 
Fa/fu = (D/Dm)
m  
Where D is the dose of drug, Dm is the median-effect dose (IC50), fa is the fraction 
affected by the dose, fu is the fraction unaffected (fu = 1-fa) and m is an exponent 
indicating the sigmoidicity of the dose effect curve.   
 
 
2.27.5. The Chou and Talalay equation for measuring the interaction between 
two agents at fixed-dose ratios 
The interaction of reovirus and Cabazitaxel or Docetaxel in combination was assessed 
using CalcuSyn software (BioSoft, UK), which uses the combination index (CI) 
equation derived by Chou and Talalay [234].  Generally, a CI of 1 denoted an additive 
interaction, >1 antagonism and <1 synergy.  The CI equation is: 
 
 
 
The denominators of this equation dictate that (Dx)1 and (Dx)2 are the doses of drug 1 
and drug 2 alone, respectively, that cause x% cell death.  The numerators dictate that 
(D)1 and (D)2 are the concentrations of drug 1 and drug 2 in combination that cause 
x% cell death.  When CI=1, isobolograms can be generated at different effect levels.  
For example, ED50, ED75 and ED90 represent the effective dose of two drugs in 
combination required to cause 50, 75 and 90% cell death respectively.  Combination 
data points below the line of additivity on the isobologram plot represent synergism, 
whereas data points above the line indicate an antagonistic interaction.  Table 2.15 
shows the symbols used for describing the interaction in drug combination studies.   
 
 
 
(D)1 (D)2                    (D)1 (D)2
CI  = +                +
(Dx)1 (Dx)2                   (Dx)1 (Dx)2
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Table 2.15.  Recommended symbols for describing the interaction between reovirus and Cabazitaxel or 
Docetaxel when analysed by the CI equation of Chou and Talalay. 
Range of CI Symbol Description 
<0.1 +++++ Very strong synergism 
0.1-0.3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism 
0.85-0.90 + Slight synergism 
0.90-1.10 ± Nearly additive 
1.10-1.20 - Slight antagonism 
1.20-1.45 -- Moderate antagonism 
1.45-3.3 --- Antagonism 
3.3-10 ---- Strong antagonism 
>10 ----- Very strong antagonism 
 
 
2.27.6. The Bliss Independence equations for measuring the interaction between 
two agents at non-fixed dose ratios 
Supposing that two drugs, a and b, both inhibit cancer cell growth, and fractions 
affected are Fa and Fb respectively.  If two drugs work independently, the combined 
inhibition effect can be predicted using the complete additivity probability theory (the 
Bliss Independence equation) [223, 224]:   
Eexp = (Fa + Fb) – (Fa × Fb) 
To illustrate synergy or antagonism from Bliss analysis, a second equation was 
applied.  If the observed effect (Eobs) was equal to the expected effect (Eexp) (i.e. the 
difference in effect (ΔE) and its 95% confidence interval was equal to zero), then the 
conclusion was Bliss independence (or addition).  If ΔE and its 95% confidence 
interval was greater than zero, the combination treatment was thought to be more 
efficacious than expected and was synergistic.  If ΔE and its 95% confidence interval 
was less than zero, the combination treatment was worse than expected and was 
antagonistic.  The second Bliss equation is [223, 224]: 
ΔE = Eobs - Eexp 
In the results, for each dose of reovirus and Cabazitaxel or Docetaxel used in 
combination, both the ΔE value and upper and lower confidence intervals (Ci) were 
presented in a table format, and expressed as a percentage.  For example, a 20% 
synergistic effect equated to ΔE=0.20.  A colour-coded contour map of the ΔE values 
was also plotted for easy visualisation of the level of interaction at each combination.   
72 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
 
 
TESTING TARGET GENES THAT MAY 
INFLUENCE THE SUSCEPTIBILITY OF SCCHN 
CELL LINES TO REOVIRUS ONCOLYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
3. TESTING TARGET GENES THAT MAY INFLUENCE THE 
SUSCEPTIBILITY OF SCCHN CELL LINES TO REOVIRUS ONCOLYSIS 
3.1.   INTRODUCTION 
Squamous cell carcinoma of the head and neck (SCCHN) is the most common type of 
head and neck cancer.  Up to 50% of SCCHN patients present with advanced disease 
[20], and standard treatments are surgery combined with chemotherapy and 
radiotherapy.  However, patients often relapse and develop loco-regional recurrences, 
distant metastasis and second primary tumours [5, 21].  These patients have an overall 
5-year survival rate of less than 10% [21], a statistic that has not significantly changed 
in decades.  New treatment strategies are needed to tackle the genetic and biological 
heterogeneity of SCCHN, and the resistance that these tumours often develop to 
chemotherapy and radiotherapy [5].    
Preclinical data has demonstrated reovirus T3D (Reolysin®) to have anti-cancer 
activity in SCCHN cell lines [235].  It was also recently shown that HPV-negative 
SCCHN cell lines were significantly more susceptible to reovirus oncolysis compared 
to HPV-positive SCCHN cell lines.  This suggested that reovirus is an appropriate 
therapy for HPV-negative SCCHN tumours, which are associated with poor patient 
prognosis [236].  A randomized, double-blind Phase III clinical trial is evaluating 
overall survival and progression free survival following intravenous (IV) 
administration of Reolysin® in combination with paclitaxel and carboplatin versus 
chemotherapy alone, in patients with metastatic or recurrent SCCHN [237].  Results 
of the primary and secondary endpoints are yet to be published. 
Early in vitro studies suggested that reovirus selectively replicates in cells with a 
constitutively activated Ras signalling pathway, either through Ras mutation or 
upregulated receptor tyrosine kinases, such as the EGFR.  This in part provided a 
mechanism for the selective oncolysis in tumour cells, as activating mutations in Ras 
genes alone have been found in >30% of all human cancers [130, 238].  It would 
therefore seem logical to use reovirus in tumours with a high occurrence of Ras 
mutations.  However, other reports have shown that active Ras signalling alone does 
not control the susceptibility to reovirus oncolysis [139], as demonstrated in various 
different cancer cell lines [140-144].  Importantly, Twigger et al performed a 
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correlative analysis between reovirus IC50 and EGFR level on a panel of human 
SCCHN cell lines with diverse sensitivities to reovirus oncolysis, but found no 
association between these two parameters.  They also inhibited or stimulated EGFR 
signalling and downstream components of Ras, but this was found to have no effect 
on reovirus oncolysis [145], nor did pharmacological inhibition of PKR [145].  Ras 
signalling may play a role in reovirus oncolysis in certain cancer types, but the full 
mechanism of reovirus-induced cancer cell death is more complex and still remains to 
be found.  Understanding this process may lead to the discovery of predictive 
biomarkers of reovirus treatment response that may improve clinical trial design.  
Table 3.1 shows the reovirus IC50 dilution values for 9 previously characterised 
human SCCHN cell lines [239], as performed by Professor Kevin Harrington’s 
laboratory at The Institute of Cancer Research, London [145].  The SCCHN cell lines 
showed a broad range of sensitivities to reovirus-induced cell death.   
 
Table 3.1.  Professor Kevin Harrington’s laboratory showed that 9 SCCHN cell lines had 
different sensitivities to reovirus-induced cell death [145].  SCCHN cell lines were infected with 
reovirus at 1.4x109 TCID50/mL diluted 2-fold, starting from a 1:500, a 1:1000 or a 1:5000 dilution.  
Cell survival was assessed by an MTS assay at 96 hours post infection.  Data were logged transformed 
and plotted as sigmoidal dose response curves, with un-infected controls assigned an arbitrary value of 
1x108.  The IC50 values were interpolated from the dose response curves [145].  The cell lines had a 5-
log range in reovirus IC50 dilution values and were ranked from left-most sensitive to right-most 
resistant.   
Cell line PJ34 011A O13 Cal 27 
SIHN 
5B 
HN3 
SIHN 
11B 
HN5 PJ41 
Reovirus IC50 dilution 
values 1.70e
-7
 1.80e
-7
 3.80e
-7
 1.20e
-6
 1.50e
-5
 3.00e
-4
 >2.00e
-3
 >2.00e
-3
 >2.00e
-2
 
 
 
 
Many cancer cell lines are highly sensitive to reovirus oncolysis compared to normal 
cells, including NSCLC cells, which displayed reovirus IC50 values of 1.46 to 2.68 
log10 pfu/cell at 48 hours post-infection [141].  Pancreatic cancer cell lines infected 
with MOI 0.1 virus particles/cell were all relatively sensitive and less than 50% viable 
after 2-7 days infection with reovirus [136].  The breast cancer cell lines T47D and 
MCF-7 were particularly sensitive to reovirus infection (<20% viability) at MOI 20 
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for 48 hours, as were U87 glioblastoma cells and HepG2 liver cancer cells [144].  
However, some cancer cell lines are surprisingly resistant to reovirus-mediated cell 
death, including some of the SCCHN cells tested by Twigger et al [145].  For 
example, a high percentage of the PJ41 SCCHN cell line population were still viable 
after 96 hours infection with reovirus at a concentration of 1.4×107 TCID50/mL [145].  
It is difficult to directly compare data in these studies as the experiments were all 
performed slightly differently, and thus, we can only estimate the susceptibility to 
reovirus in different cancer cell lines.   
One approach to studying the host cell response to virus infection is by a technique 
called stable isotope labelling by amino acids in cell culture (SILAC).  Up- and down- 
regulated proteins were examined in HEK293 cells infected with or without reovirus 
[240].  This revealed novel host proteome factors that may be involved in virus 
infection, including branched chain amino-acid transaminase 2 (BCAT), target of 
myb1 (TOM1), paternally expressed 10 (PEG10), tubulin beta 4B (TUBB4B) and 
histone cluster 2 H4b (HIST2H4B) [240].  These proteins are good targets for further 
analysis and have roles in DNA replication, recombination and repair, as well as 
functions in cellular immunology, cell death and survival [240].  Alternatively, gene 
expressing profiling using DNA microarrays has been used considerably in cancer 
research [241], as it allows the expression of thousands of genes to be measured 
simultaneously, in a quick and efficient manner.  Two studies have utilised this 
method to identify host cell factors that may influence the efficacy of oncolytic 
viruses in cancer cell lines [150, 151].  Our laboratory used gene expression profiling 
and microarray analysis on a panel of SCCHN cell lines derived from advanced 
cancer patient tumours, to detect host-cell factors that may influence their 
susceptibility to reovirus oncolysis.  Table 3.2 summarises the 8 genes identified in 
the microarray screen and the known functions of their corresponding proteins.  
Although the function of ZNF600 is generally un-known, the protein products of other 
genes, notably SLCO1B3, MGMT, SLC36A4, YAP1 and BIRC2 have been linked to 
cancer.  The cellular inhibitor of apoptosis-1 (cIAP1) protein (encoded by BIRC2) can 
also be proteolytically cleaved and degraded to promote reovirus-induced apoptosis 
[242, 243], as discussed in more detail in Chapter 5.  Surprisingly, none of the genes 
appear to be involved in any known intracellular host-cell anti-viral response 
pathway.   
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Table 3.2.  Summary of the 8 genes identified as potential predictors of susceptibility to reovirus oncolysis in SCCHN cell lines and their corresponding protein 
functions.  The genes were identified by Professor Richard Morgan, Oncology Department, University of Surrey (R.Morgan, 2007, unpublished). 
Gene name Definition 
Accession 
number 
Known functions of the corresponding protein References 
SLCO1B3 
 
Homo sapiens solute carrier organic 
anion transporter family member 1B3. 
Synonyms: OATP1B3, LST-3, 
HBLRR, LST-2, LST-3TM13, OATP-
8, OATP8 and SLC21A8. 
NM_019844 
LST-3 is a member of the solute carrier organic anion transporter superfamily, and is 
expressed predominantly in the sinusoidal membrane of the liver.  It is an important 
membrane transport protein that mediates hepatic uptake of endogenous compounds and 
environmental toxins. It also mediates uptake of various drugs including anti-cancer agents, 
immunosuppressants, lipid-lowering statins and antibiotics.   Its Expression has been shown 
to be higher in Indocyanine green (IGC)-accumulated hepatocellular carcinoma (HCC) than 
in ICG-low HCC.  Mutations predicted to cause complete and simultaneous deficiencies of 
OATP1B3 has been linked to Rotor syndrome, an autosomal recessive disorder 
characterized by conjugated hyperbilirubinemia and coproporphyrinuria.   
[244-246] 
MGMT 
Homo sapiens O-6-methylguanine-
DNA methyltransferase  
NM_002412 
MGMT is a DNA repair protein that is involved in cellular defence against mutagenesis and 
toxicity.  It catalyses the transfer of methyl groups from O(6)-alkylguanine and other 
methylated regions of DNA to its own molecule, thus repairing the toxic lesions.   
Alkylating agents are used to treat various cancers, but their function has been found to be 
limited when MGMT is present.  However, if the MGMT promoter region is methylated 
then the cells no longer produce MGMT, and are therefore more receptive to alkylating 
agents.  Methylation of the MGMT gene promoter has been associated with several cancer 
types, including glioblastoma, lung cancer and colorectal cancer.   
[247] 
SLC36A4 
Homo sapiens solute carrier family 36 
(proton/amino acid symporter), 
member 4, transcript variant 1. 
Synonyms:  PAT4.   
NM_152313 
The solute carrier (SLC) family are amino acid transporters and are grouped into two main 
clusters, the α- and β-families.  SLC36 has four members, SLC36 A1-A4.  The proteins 
from this family are named proton/amino acid transporters (PATs) and are numbered PAT1 
to PAT4.  PATs have been shown to modulate the activity of mammalian target of 
rapamycin complex 1 (mTORC1), which promotes normal growth and is frequently 
hyperactivated in tumour cells.   
 
[248, 249] 
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YAP1 
Homo sapiens Yes associated protein-
1, transcript variant 2. 
Synonyms:  COB1, YAP, YAP2, 
YAP65 and YKI 
NM_006106 
YAP1 is a major downstream target protein of the mammalian Hippo signalling pathway, an 
evolutionary conserved regulator of cell proliferation and apoptosis.  Activation of upstream 
serine/threonine kinases phosphorylate down-stream YAP1 on a specific serine residue 
(S127) leading to its cytoplasmic retention and inactivation.  In the absence of Hippo 
signalling, YAP1 migrates to the nucleus of the cell where it interacts with transcription 
factors which stimulates expression of genes that promote proliferation.  Impairment of 
Hippo signalling and nuclear location of YAP1 has been detected in liver, colon, ovarian, 
lung and prostate cancers. 
[250-256] 
ZNF600 
Homo sapiens zinc finger protein 600. 
Synonyms:  KR-ZNF1. 
NM_198457 
The precise function of the ZNF600 protein is unknown, although it has suspected roles in 
DNA binding, metal ion binding and transcriptional factor activity.  The ZNF600 gene was 
recently associated with circulating phospholipid levels.   
[257] 
P2RY6 
Homo sapiens pyrimidinergic receptor 
P2Y, G-protein coupled 6, transcript 
variant 2 
NM_176798 
The family of P2 receptors is subdivided into P2X ligand-gated ion channels and P2Y G-
protein coupled receptors, which are activated by extracellular nucleotides.  Eight P2Y 
receptors have been cloned in humans and are expressed in most epithelia.  P2RY6 is a Gq/11 
coupled receptor and is responsive to UDP, partially responsive to UTP and ADP, but not 
responsive to ATP.  Nucleotides released from airway epithelial cells during asthmatic 
inflammation activate P2RY6 receptors, leading to release of inflammatory cytokines IL-6 
and IL-8, thus regulating immune functions.  
[258, 259] 
BIRC2 
Homo sapiens baculoviral IAP repeat 
containing 2, transcript variant 1. 
Synonyms:  API1, c-IAP1, cIAP1, 
Hiap-2, HIAP2, MIHB and RNF48. 
NM_001166 
The BIRC2 gene encodes a protein that belongs to the inhibitors of apoptosis protein (IAP) 
family.  These proteins serve as endogenous inhibitors of apoptosis by inhibiting proteases 
caspase -3 and -7 and by binding to tumour necrosis factor receptor-associated factors 
(TRAF1/2).  cIAP1 and cIAP2 have been shown to facilitate cancer cell survival by 
functioning as E3 ligases that promote the ubiquitination of receptor interacting protein 1 
(RIP1).   
[260-262] 
LARP1B 
Homo sapiens La ribonucleoprotein 
domain family member 1B, transcript 
variant 2. 
Synonyms:  LARP2. 
NM_178043 
The LARP1B gene encodes a protein containing a La motif.  La proteins are ubiquitous in 
eukaryotic cells and associate with the 3-termini of newly synthesised small RNAs to protect 
them from exonucleases, which is required for pre-tRNA maturation.  Hypermethylation of 
the LARP1B gene may be epigenetically inherited, and has the potential to be used as a 
marker for early prenatal diagnosis of -thalassemia.   
[263, 264] 
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3.2. STUDY OBJECTIVE 
The objective of this chapter was to determine whether any of the 8 target genes 
identified in the DNA microarray screen, influenced the susceptibility of human 
SCCHN cell lines to reovirus-mediated cell death.   
In order to test this, the following experiments were performed: 
1. Infection of 3 representative SCCHN cell lines with reovirus and assessment 
of oncolysis by the Cell Titer 96® AQueous Non-radioactive Cell Proliferation 
Assay (MTS assay), to validate previous findings. 
2. Infection of non-cancerous, un-transformed human cells with reovirus and 
assessment of oncolysis by the MTS assay, to validate the use of reovirus as an 
anti-cancer agent.   
3. Measurement of the mRNA expression levels of the 8 target genes in 3 
representative SCCHN cell lines by RT-qPCR, to validation previous findings.   
4. siRNA-mediated knock-down of the 8 genes in the reovirus-resistant PJ41 
SCCHN cell line by lipid transfection, and measurement of the mRNA 
expression by RT-qPCR to ensure efficient knock-down of the genes.  
5. siRNA-mediated knock-down of the 8 target genes in the PJ41 SCCHN cell 
line and subsequent infection of the cells with reovirus, to assess the efficiency 
of reovirus oncolysis by the MTS assay. 
6. Assessment of the efficiency of siRNA-mediated knock-down at the protein 
level in the PJ41 SCCHN cell line by western blotting.   
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3.3.  RESULTS 
3.3.1. Host cell mRNA expression of 8 genes directly correlated with reovirus 
IC50 in SCCHN cell lines 
In order to identify host cell factors that may influence the susceptibility to reovirus 
oncolysis, gene expression profiling was carried out on 5 of the SCCHN cell lines 
using microarray hybridisation, via the Low Impact Quick Amp Labelling Kit, one-
color (Agilent Technologies, USA).  PJ34, O11A and PJ41 cell lines were analysed in 
duplicate, whereas O13 and SIHN 11B were analysed as single samples.  A total of 
44,000 gene probes were tested and the extracted data was subsequently analysed 
using Genespring software (Agilent Technologies, USA).  Results showed that the 
expression of 8 gene probes increased as the cell lines became progressively more 
resistant to reovirus-induced cell death.  The mRNA expression of the 8 genes 
(SLCO1B3, MGMT, SLC36A4, YAP1, ZNF600, P2RY6, BIRC2 and LARP1B) 
identified in the microarray was then measured by RT-qPCR in all 9 SCCHN cell 
lines (PJ34, O11A, O13, Cal27, SIHN 5B, HN3, SIHN 11B, HN5 and PJ41).  The 
same correlation was observed, i.e. as the resistance to reovirus oncolysis increased 
across the panel of cell lines, the mRNA expression of all 8 genes also generally 
increased (Figure 3.1).   This research was performed in-house by Professor Richard 
Morgan, Oncology Department, University of Surrey (R.Morgan, 2007, unpublished).  
The accession number of these genes and the known functions of their corresponding 
proteins are summarised in Table 3.2.  The correlation coefficient (r value) between 
the relative mRNA expression of the 8 genes and the reovirus IC50 value (Table 3.1) 
in the cell lines was computed, which confirmed a positive trend (Figure 3.2).   
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Figure 3.1.   RT-qPCR analysis of microarray-identified up-regulated genes in 9 SCCHN cell lines.  cDNA from PJ34, 011A, 013, Cal27, SIHN 5B, HN3, 
SIHN 11B, HN5 and PJ41 cell lines was analysed by RT-qPCR.  The mRNA expression of 8 genes (SLCO1B3 (dark pink bars), MGMT (blue bars), SLC36A4 (green 
bars), YAP1 (yellow bars), ZNF600 (orange bars), P2RY6 (light pink bars), BIRC2 (grey bars) and LARP1B (black bars)) is shown on a log10 scale relative to the 
housekeeping gene β-actin (×1000).  As the mRNA expression of these genes increased across the panel of SCCHN cell lines, so did the resistance to reovirus 
oncolysis (R.Morgan, 2007, unpublished).  The graph represents the mean of duplicate samples.  
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Figure 3.2.  Pearson correlation coefficient between the relative mRNA expression of the 8 genes and the reovirus IC50 dilution value in SCCHN cell lines.  
The mRNA expression of A. SLCO1B3, B. MGMT, C. SLC36A4, D. YAP1, E. ZNF600, F. P2RY6, G. BIRC2 and H. LARP1B, was plotted against the reovirus IC50 
dilution value in each cell line.  PJ34, 011A, 013, Cal27, SIHN 5B, HN3, SIHN 11B, HN5 and PJ41 cell lines are represented as black circles.  The correlation 
coefficient (r value) is shown in red on each graph, and all showed a positive trend.  The data are shown on a log10 scale.   
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3.3.2. Validation of SCCHN cell line susceptibility to reovirus-induced cell death 
The first step in this project was to validate the reovirus IC50 data published by 
Twigger et al (Professor Kevin Harrington’s laboratory) [145].  First, the reovirus 
stock was titred by a standard plaque assay on the highly sensitive L929 mouse 
fibroblast cell line.  Using this stock titre, the amount of virus needed to kill 50% of 
different cell populations (IC50 dilution) could be calculated and compared.  The 
experiment from the Twigger et al paper [145] was then performed on 3 of the 
SCCHN cell lines; PJ34, HN5 and PJ41.  These cell lines were chosen because their 
IC50 values represented low, medium and high levels of resistance to reovirus-induced 
cell death (1.7e-7, >2.00e-3 and >2.00e-2 TCID50/mL respectively, as shown in Table 
3.1).  The cells lines were infected with serial dilutions of reovirus T3D for 24 or 48 
hours and then the % cell viability was calculated using the MTS assay (Section 2.9).  
The IC50 values were calculated using CalcuSyn software (Biosoft, UK) (Section 
2.27.4).  Results were consistent with the findings produced by Twigger et al.  PJ34, 
HN5 and PJ41 still represented SCCHN cell lines that had low, medium and high 
resistance to reovirus oncolysis (IC50s were MOI 572.6, 29.5 and 6.7 at 24 hours post 
infection (hpi) and MOI 248.5, 11.3 and 2.7 at 48hpi respectively) (Figure 3.3 and 
Table 3.3).    
It has been extensively documented that reovirus T3D has a natural propensity to 
infect and lyse various different cancerous or transformed cells.  In order to validate 
the reovirus stock in our laboratory, 2 representative normal cell types were used.  A 
normal human head and neck cell line was not available.  Therefore an untransformed 
normal human lung fibroblast cell line, MRC-5, and PBMCs isolated from the blood 
of a healthy human donor (Section 2.21.1), were infected with reovirus T3D at 
various MOIs for 24 or 48 hours.  The % cell survival was then assessed by the MTS 
assay (Section 2.9) and the IC50 values were calculated (Section 2.27.4).  As 
expected, both MRC-5 and PBMCs showed high levels of resistance to reovirus 
induced cell death compared to SCCHN cell lines (IC50s were MOI 8040.6, 2094.9 at 
24hpi and MOI 2769.7, 1509.6 at 48hpi respectively) (Figure 3.3 and Table 3.3).  
This confirmed that the reovirus T3D stock was cancer-cell specific and suitable for 
this study.   
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Figure 3.3.  Validation of the susceptibility to reovirus oncolysis in 3 SCCHN cell lines and in 2 
non-cancerous, untransformed cell types.  PJ34 (yellow triangles), HN5 (orange squares), PJ41 (red 
circles), PBMC (open circles) and MRC-5 (open triangles) cells, were infected with serial dilutions of 
reovirus, starting at a multiplicity of infection (MOI) 1000 or 4000 for A. 24 hours or B. 48 hours.  The 
% cell survival was measured using the MTS assay.  SCCHN cell lines PJ34, HN5 and PJ41 
represented low, medium and high resistance to reovirus-induced cell death respectively.  MRC-5 and 
PBMC (both non-cancerous, untransformed cell types) were considerably more resistant to reovirus 
oncolysis than the SCCHN cell lines.  The graphs show the mean of 3 assay repeats and error bars 
represent SEM.   
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Table 3.3.  Reovirus IC50 values of 3 SCCHN cell lines, the MRC-5 human fibroblast cell line and 
PBMCs isolated from a healthy donor, were calculated using CalcuSyn software.  The values 
represent the mean IC50 of 3 independent experiments ± SEM.  The cell lines were ranked from left-
most sensitive to right-most resistant to reovirus oncolysis.   
 
 
Cell type PJ34 HN5 PJ41 PBMC MRC-5 
IC50 of reovirus 
(MOI) at 24 
hours ± SEM 
6.7 ± 0.781 29.5 ± 1.600 572.6 ± 76.074 2094.9 ± 169.034 8040.6 ± 221.003 
IC50 of reovirus 
(MOI) at 48 
hours ± SEM 
2.7 ± 0.470 11.3 ± 1.155 248.5 ± 13.119 1509.6 ± 90.204 2769.7 ± 316.300 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncolysis levels
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3.3.3. Validation of mRNA expression of the 8 genes in SCCHN cell lines 
In order to study the potential role of the 8 genes identified by Professor Richard 
Morgan in reovirus oncolysis, we intended to repeat the RT-qPCR experiment to 
clarify whether expression of these genes in SCCHN cell lines is reproducible.  The 
same 3 cell lines were chosen for analysis; PJ34, HN5 and PJ41.  This was because 
they previously displayed low, medium and high expression of the 8 target genes 
respectively (Figure 3.1).  The cDNA template from each cell line was used to 
quantify SLCO1B3, MGMT, SLC36A4, YAP1, ZNF600, P2RY6, BIRC2 and LARP1B 
expression via RT-qPCR.  The relative expression value was calculated as a ratio to 
the housekeeping gene β-actin for 2 independent experiments (Sections 2.10, 2.11 
and 2.12).   
Evaluation of the 3 SCCHN cell lines revealed the same pattern of expression of these 
genes, i.e. PJ34<HN5<PJ41 (Figure 3.4).  The only exception to this was LARP1B, as 
its expression in the HN5 cell line was marginally higher than in PJ41s.  The melting 
curves for each target gene displayed a single peak, suggesting that the desired 
amplicon was detected in the PCR reaction.  Having validated Professor Morgan’s 
work in 3 SCCHN cell lines, we were confident that our hypothesis was justified; that 
7 out of the 8 genes could potentially influence the susceptibility to reovirus 
oncolysis.   
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Figure 3.4.  mRNA expression validation of the 8 genes in 3 SCCHN cell lines.  cDNA from PJ34, 
HN5 and PJ41 cell lines was analysed by RT-qPCR.  The mRNA expression of SLCO1B3 (dark pink 
bars), MGMT (blue bars), SLC36A4 (green bars), YAP1 (yellow bars), ZNF600 (orange bars), P2RY6 
(light pink bars), BIRC2 (grey bars) and LARP1B (black bars) is shown on a log10 scale relative to the 
housekeeping gene β-actin (×1000).  The pattern of expression of these genes was generally 
PJ34<HN5<PJ41, which was consistent with Professor Richard Morgan’s data.  As the mRNA 
expression of these genes increased in the SCCHN cell lines, so did the resistance to reovirus 
oncolysis.  Error bars represent the SEM from two assay repeats.   
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3.3.4. Optimisation of siRNA-transfection conditions in the PJ41 reovirus-
resistant cell line using the KDalert™ GAPDH assay kit  
To study the possible role of the 8 genes (SLCO1B3, MGMT, SLC36A4, YAP1, 
ZNF600, P2RY6, BIRC2 and LARP1B) on reovirus-oncolysis, an siRNA screen was 
performed in the PJ41 SCCHN cell line.  This cell line was chosen because it was the 
most resistant to reovirus-induced cell death and exhibited the highest expression of 7 
out of the 8 genes.  The LARP1B gene was included in this screen, even though its 
expression was lower than expected in this cell line.   
First, the transfection conditions were optimised in the PJ41 cell line using the 
KDalert™ GAPDH assay kit, which is an indirect method of determining GAPDH 
knock-down at the protein level (Section 2.13.1).  The efficiency of siRNA delivery 
can be monitored by measuring the reduction in GAPDH in cells transfected with 
GAPDH siRNA relative to cells transfected with a negative control siRNA.  The kit 
also serves as a marker for identifying cellular toxicity resulting from transfection.  
The efficiency of siRNA transfection is strongly influenced by the concentration of 
transfection reagent and the cell seeding density used.  Therefore, PJ41 cells were 
seeded at 2 different concentrations; 8.0×103 and 1.2×104 cells/well.  3 different 
concentrations of siPORT Neo FX transfection agent (0.2, 0.5 and 0.8µL/well) were 
used to deliver GAPDH or negative control siRNAs.  48 hours after initial incubation 
with the siRNAs, the KDalert™ GAPDH assay was performed.   
The greatest % GAPDH knock-down was achieved using 8.0×103 cells/well and 
0.8µL/well siPORT Neo FX (Figure 3.5 A).  However taking into account both the % 
GAPDH knock-down and the transfection-associated toxicity, the optimal conditions 
were 1.2×104 cells/well and 0.5µL/well siPORT Neo FX.  This was determined by the 
Optimal Balance Factor (OBF), which multiplied the GAPDH activity by the % 
GAPDH knock-down in the samples transfected with negative control siRNA 
(Section 2.13.1).  The optimal transfection conditions were those which show the 
greatest OBF value (Figure 3.5 B).   
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B 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.   Optimisation of siRNA-mediated transfection conditions in the PJ41 cell line by the 
KDalert™ GAPDH assay.  A.  Shows the % GAPDH knock-down using 0.2, 0.5 and 0.8µL/well Neo 
FX transfection agent and 2 cell seeding densities, 8000 and 12000 cells/well.  Error bars represent the 
SD from triplicate samples.  B.  Optimal Balance Factor (OBF) was calculated, which makes a 
compromise between the % knock-down efficiency and the toxicity of the transfection.  OBF multiplies 
the GAPDH activity by the % GAPDH knock-down in the samples transfected with negative control 
siRNA.  The optimal conditions for transfection were 12000 cells/well and 0.5µL/well Neo FX, as this 
displayed the greatest OBF value.   
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3.3.5. siRNA-mediated knock-down of the 8 target genes in the PJ41 cell line 
Having optimised the transfection conditions, the PJ41 cell line was transiently 
transfected with 2 different siRNAs for each of the 8 target genes, as well as a 
negative control siRNA.  As positive controls, cells were treated with the siPORT Neo 
FX transfection agent alone or with media alone (un-transfected sample) (Section 
2.13.2).  At 48 hours post-transfection, RNA was extracted from the cells and the 
cDNA template was used to quantify SLCO1B3, MGMT, SLC36A4, YAP1, ZNF600, 
P2RY6, BIRC2 and LARP1B mRNA expression by RT-qPCR.  The relative 
expression value was calculated as a ratio to the housekeeping gene β-actin (Section 
2.12).   
Figure 3.6 displays the reduction in relative mRNA expression of each independent 
target gene using the 2 different siRNAs.  For each target gene, the siRNA that 
achieved the greatest reduction compared to the negative control siRNA-treated cells 
was chosen for future experiments.  Knock-down of all genes using the most effective 
siRNA ranged from 79.1 to 99.9% (Table 3.4).   
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Figure 3.6.  mRNA expression of the 8 target genes in the PJ41 cell line after siRNA-mediated 
knock-down.  The mRNA expression of A. SLCO1B3, B. MGMT, C. SLC36A4, D. YAP1, E. ZNF600, 
F. P2RY6, G. BIRC2 and H. LARP1B, was assessed in cells treated with 2 target siRNAs, negative 
control siRNA, Neo FX transfection agent alone or media only, by RT-qPCR. The % knock-down of 
each target gene was very efficient and ranged from 79.1 to 99.9% compared to the negative control 
siRNA.  The mRNA expression of each target gene is shown relative to the housekeeping gene β-actin 
(×1000).  The graphs show the mean of 2 assay repeats and error bars represent SEM.   
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Table 3.4.  A summary of the % knock-down of each target gene in the PJ41 cell line by 
transfection with 2 different siRNAs.  siRNAs highlighted in bold achieved the greatest reduction in 
relative mRNA expression.    
 
Target gene siRNA ID 
% knock-down of target gene 
SLCO1B3 
s26261 
79.1 
s26262 
77.7 
MGMT 
s8750 
51.6 
s8752 
94.5 
SLC36A4 
s42350 
90.5 
s42351 
97.7 
YAP1 
s20366 
95.9 
s20368 
96.4 
ZNF600 
s46376 
99.9 
s46378 
93.7 
P2RY6 
sc-42584 
62.5 
s224151 
94.2 
BIRC2 
s1448 
97.8 
s1449 
91.3 
LARP1B 
s30246 
83.6 
s30247 
85.4 
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3.3.6. siRNA-mediated knock-down of YAP1 sensitised the PJ41 cell line to 
reovirus-induced cell death 
Having achieved successful knock-down of the 8 target genes, the plan was to 
evaluate the sensitivity of these cells to reovirus treatment, in comparison to negative 
and positive controls (Section 2.13.3).  PJ41 cells were transiently transfected with 
the siRNA that caused the greatest decrease in mRNA expression of the 8 target genes 
(Table 3.4).  Cells were also transfected with a negative control siRNA to assess the 
non-specific effect caused by scrambled sequences.  Cells treated with siPORT Neo 
FX transfection agent alone or with media alone served as the positive controls.  After 
48 hours post-transfection, to account for any differences in transfection-associated 
cytotoxicity, viable cells from each treatment condition were counted.  The cell counts 
were used to calculate the required MOI per well (Section 2.8), which ensured that 
the same number of virus particles per cell was used for each treatment condition.  
Cells were then subsequently infected with serial dilutions of reovirus starting at MOI 
1000.  At 48 hours post-infection with reovirus, the % cell survival in each treatment 
condition was assessed by the MTS assay (Section 2.9).   
In all experiments, the reovirus IC50 value of the negative siRNA treated cells was 
somewhat lower than the IC50 obtained for the transfection agent alone treated cells, 
suggesting that there was some non-specific sensitisation to reovirus treatment. 
Therefore, in order to assess the specific effect of reduced target gene expression, all 
comparisons were made directly to the negative control siRNA-treated cells.   
Compared to negative control siRNA-treated cells, knock-down of SLCO1B3, 
MGMT, SLC36A4, ZNF600, P2RY6, BIRC2 and LARP1B had minimal effect on 
reovirus-induced cell death (Figure 3.7 A, B, C, E, F, G and H respectively).  
Although there were statistically significant differences at some reovirus 
concentrations tested, there was considerable over-lap with the cell survival curves of 
the controls.  However, Figure 3.7 D shows that siRNA-mediated knock-down of 
YAP1 (which encodes the Yes-associated protein-1 (YAP1) protein) caused 
significant sensitisation to reovirus-induced cell death at all reovirus MOIs tested 
(p<0.05 by un-paired t-test), apart from MOI 1000.  YAP1 knock-down cells were 
greater than 3-fold more sensitive to reovirus oncolysis than the negative siRNA 
control cells (IC50 MOI 115.9 and MOI 385.7 respectively), and there was a clear 
94 
 
separation in the % cell survival curves.  This suggested that reduced YAP1 
expression in a resistant SCCHN cell line may contribute to sensitisation to reovirus-
induced cell death.   
The average optical density (OD) of each un-infected transfection condition was also 
compared.  After 48 hours post-transfection, cells were treated with media alone for a 
further 48 hours before analysis via the MTS assay (Section 2.9).  There was no 
noticeable differences in OD values between cells treated with negative control 
siRNA and the target-gene siRNAs (Figure 3.8).  This was also reflected in the cell 
counts, which were very similar for each treatment condition.  This implied that the 
observed differences in reovirus sensitivity was not due to differences in transfection-
associated cytotoxicity, but was indeed caused by the reduced expression of the target 
genes.  Thus, as YAP1 was the only gene that showed sensitisation to reovirus 
treatment upon knock-down, it was considered an important host-cell factor and was 
selected for further investigation.   
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Figure 3.7.  Evaluation of reovirus-induced cell death after siRNA-mediated knock-down of the 8 
target genes in the PJ41 cell line.  Cells were transfected with specific siRNAs (red circles) for A. 
SLCO1B3, B. MGMT, C. SLC36A4, D. YAP1, E. ZNF600, F. P2RY6, G. BIRC2 and H. LARP1B, and 
then subsequently infected with serial dilutions of reovirus, starting at MOI 1000.  Cells were also 
transfected with a negative control siRNA (purple squares), Neo FX transfection agent alone (green 
triangles) or treated with media only (blue triangles).  The % cell survival in each treatment condition 
was then assessed using the MTS assay.  The IC50 values of each treatment condition were determined 
using CalcuSyn software and are shown in a table below each graph.  Out of the 8 genes tested, knock-
down of YAP1 had the most discernible effect compared to negative control siRNA treated cells, and 
sensitised cells to reovirus-induced cell death at nearly all MOIs tested.  *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001 by un-paired t-test, with respect to the negative control siRNA.  Error 
bars represent the SD from 2 assay repeats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8.  The transfection-associated toxicity in each treatment condition.  After 48 hours post-
transfection, PJ41 cells were treated with media alone for a further 48 hours before analysis via the 
MTS assay.  The raw Optical Density (OD) values for each treatment were compared.  There were no 
major differences in OD between cells transfected with negative control siRNA and the cells 
transfected with each target siRNA, suggesting that transfection-associated cytotoxicity was not a 
concern.  The graph shows the mean OD of 2 assay repeats and error bars represent SD.   
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3.3.7. siRNA-mediated knock-down of the YAP1 protein in the PJ41 cell line 
Next, having identified YAP1 as an important target of reovirus resistance at the 
mRNA level, siRNA-mediated knock-down of the Yes-Associated-Protein-1 (YAP1) 
protein in the PJ41 cell line was also determined.  Cells were treated with 2 different 
YAP1 siRNAs (ID: s20366 and s20368), negative control siRNA, Neo FX 
transfection agent alone, or media alone (Section 2.13.2).  At 48 hours post-
transfection, cell lysates were collected and YAP1 protein expression was determined 
by western blotting (Section 2.14).  Transfection with siRNA s20368 caused the 
greatest reduction in the YAP1 54kDa band compared to the positive control lysates 
(Figure 3.9 A).  To ensure uniform protein loading, the blot was re-probed with a β-
actin loading control (Section 2.14.3).  The intensity of the YAP1 band in each 
sample was quantified and normalised to their corresponding β-actin bands by 
densitometry analysis (Section 2.14.4) (Figure 3.9 B).  Despite a 96.4% reduction in 
YAP1 mRNA expression, a modest 58.4% reduction of the YAP1 protein was 
achieved compared to negative control cells.  Efforts were made to improve this 
reduction by altering the parameters of the transfection assay, but this did not improve 
the knock-down.  This emphasises the difficulty in achieving complete attenuation of 
the YAP1 protein in the PJ41 cell line.   However, the reduction of the YAP1 protein 
was substantial enough to observe a 3-fold decrease in the reovirus IC50 value 
compared to the negative control (Figure 3.7 D).   
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Figure 3.9.  YAP1 protein detection in the PJ41 cell line after YAP1 siRNA-mediated knock-
down.  Cells were transfected with 2 different YAP1 siRNAs (s20368 and s20366), or with negative 
control siRNA.  Cells were also treated with Neo FX transfection agent alone or media alone, which 
served as additional positive controls for the YAP1 protein.  A.  Cell lysates were collected and YAP1 
protein expression was detected by western blotting.  siRNA s20368 caused the greatest decrease in 
YAP1 protein expression compared to the negative control siRNA, Neo FX alone and media only 
treated cells.  B.  YAP1 protein expression in each sample was normalised to the -actin loading 
control and quantified by densitometry using LI-COR Image Studio Lite 4.0.21 software.  There was a 
58.4% reduction in YAP1 compared to negative control siRNA treated cells.   
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3.4. DISCUSSION 
Previously published work by Twigger et al showed that several SCCHN cell lines 
had diverse sensitivities to reovirus-mediated cell death [145].  Furthermore, gene 
expression profiling and RT-qPCR analysis performed by Professor Richard Morgan, 
revealed that expression of 8 genes increased as the SCCHN cell lines became 
progressively more resistant to reovirus oncolysis.  These genes were SLCO1B3, 
MGMT, SLC36A4, YAP1, ZNF600, P2RY6, BIRC2 and LARP1B.  The aim of this 
chapter was to determine whether any of these genes are essentially host cell factors 
that influence the susceptibility to reovirus oncolysis.  In order to address this, the 
mRNA expression profile of these genes and reovirus IC50 values in 3 of the SCCHN 
cell lines, was reproduced.  Additionally, individual knock-down of the 8 genes and 
the resulting effect on reovirus oncolysis was assessed in the PJ41 cell line, as this cell 
line was the most resistant to reovirus and generally displayed the highest expression 
of the target genes.   
Our findings showed that PJ34, HN5 and PJ41 represented SCCHN cell lines that had 
low, medium and high resistance to reovirus oncolysis respectively, and concurred 
with the data published by Twigger et al [145].  These cell lines were derived from 
the primary tumours of advanced SCCHN patients.  It is not surprising that these cell 
lines have such variable susceptibilities to reovirus treatment, as SCCHN tumours are 
known to be heterogeneous and often present with genetic mutations in p53, pRb, 
EGFR, TGF-β, and P13K-PTEN-Akt signalling pathways [5].  Furthermore, there are 
two distinct groups of SCCHN patients; HPV-negative and HPV positive.  HPV-
negative SCCHN tumours have frequent p53 mutations, normally occur in patients 
over the age of 60 and have a poor prognosis.  HPV-positive SCCHN tumours on the 
other hand have infrequent p53 mutations and generally affect younger people who 
have a favourable prognosis [5].  HPV-negative SCCHN cell lines were recently 
shown to be significantly more susceptible to reovirus oncolysis compared to HPV-
positive SCCHN cell lines, suggesting that reovirus is an appropriate therapy for 
HPV-negative head and neck cancers [236].  The HPV-status of the SCCHN cell lines 
used in our study is unknown.  It would therefore be interesting to determine whether 
HPV-status correlates with their reovirus susceptibilities, and is something to consider 
for future work.   
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We found that PJ34, HN5 and PJ41 cell lines displayed in turn, low, medium and high 
mRNA expression of SLCO1B3, MGMT, SLC36A4, YAP1, ZNF600, P2RY6, BIRC2, 
which is in agreement with the preliminary work implemented by Professor Richard 
Morgan (R.Morgan, 2007, unpublished).  However, we found that LARP1B 
expression was slightly higher in HN5 than PJ41, which did not correspond to 
previous findings, but was still lowest in PJ34.  As the preliminary experiment shown 
in Figure 3.1 was conducted several years ago, the cell lines used to validate this data 
at the beginning of this project were from different stocks, and were either later 
provided to us by another laboratory or bought-in from an authenticated source.  Thus, 
the inconsistency in LARP1B expression could be a result of genetic instability and 
phenotypic drift between different cell line batches.  Many cancer cell lines have 
defects in genes that monitor and repair DNA damage, giving rise to an increased 
mutation rate.  Therefore, the genotype of continuous cell lines can change with time 
and is likely to progress the longer the cell line is cultured [265].  Genetic instability 
in a cell line can also be influenced by the confluence of the cells at the time of 
subculture and their maintenance in the correct growth media.  As LARP1B was only 
one gene out of eight whose expression was inconsistent with previous data, we 
decided to include it in the siRNA-mediated knock-down screen.   
As expected, reovirus infection caused very little cytotoxicity in an untransformed 
normal human lung fibroblast cell line (MRC-5) and PBMCs isolated from the blood 
of a healthy human donor, compared to the SCCHN cell lines.  Cell lines derived from 
normal human tissue are extremely difficult to grow and maintain, and therefore a 
normal head and neck cell line was not available to us for direct comparison to the 
SCCHN cell lines.  It could be argued that both MRC-5 and PBMCs have limitations 
as they do not originate from the head and neck region and do not contain any 
epithelial features.  However, our findings still demonstrate the selective nature of 
reovirus as an oncolytic agent, just as a plethora of research has documented since the 
1970s [124].   Further strengthening this point, many studies have used both human 
and mouse fibroblast cell lines (most notably NIH-3T3) for similar purposes [125, 
133, 134, 142].  PBMCs have been shown to transport and protect reovirus particles 
from neutralising-anti-reovirus antibodies after IV injection in cancer patients [179, 
225], but are not known to be susceptible to reovirus oncolysis, which is consistent 
with our data.   
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Having successfully optimised the conditions for siRNA-mediated transfection in the 
PJ41 cell line using the KDalert™ GAPDH assay kit, we transiently transfected PJ41 
cells with 2 specific siRNAs for SLCO1B3, MGMT, SLC36A4, YAP1, ZNF600, 
P2RY6, BIRC2 and LARP1B.  The reduction in mRNA expression of all genes proved 
to be very efficient and ranged from 79.1 to 99.9% knock-down compared to negative 
siRNA control treated cells.  Knock-down of SLCO1B3, MGMT, SLC36A4, ZNF600, 
P2RY6, BIRC2 and LARP1B had little effect on reovirus-mediated cell death.  
However, most interestingly, siRNA-mediated knock-down of YAP1 caused 
significant sensitisation to reovirus treatment at all MOIs tested (apart from MOI 
1000).  At MOI 1000, a high percentage of cells had succumbed to death, and this 
could explain why no major sensitization was seen when YAP1 was reduced.  The 
reovirus IC50 value of the PJ41 cells with YAP1 knock-down was MOI 115.9, whilst 
the IC50 for the negative control siRNA-treated cells was MOI 365.7.  Therefore 
knock-down of YAP1 caused approximately a 3-fold increase in the sensitivity of the 
cells to reovirus, although still not to the level of the HN5 and PJ34 cell lines.  There 
was no major differences in OD values between un-infected cells treated with 
negative control siRNA and un-infected cells treated with the target-gene siRNA.  
This implied that the reovirus sensitivity was indeed due to reduced YAP1, and was 
not simply a result of differences in transfection-associated cytotoxicity.   
siRNA-mediated knock-down of the YAP1 protein proved to be less efficient than 
knock-down of YAP1 at the mRNA level.  It is well-known that levels of RNA and 
their protein products can vary considerably, as there are many processes that occur 
between transcription and translation, including RNA processing, alternative and 
differential splicing, and protein modifications.  Efforts were made to improve this 
reduction by altering the transfection conditions such as the cell seeding density, the 
concentration of the transfection agent and the concentration of the siRNAs, but this 
did not enhance the knock-down, or compromised the cellular viability.  Although the 
reduction in YAP1 was substantial enough to influence reovirus-induced cell death, 
perhaps an even greater sensitisation would have been observed if YAP1 had been 
completely eliminated.  We now know that there are techniques that are capable of 
permanently modifying genomic DNA, such as Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR).  However, this is a relatively new system that was 
not available for commercial use when this research was conducted.  Our results 
105 
 
suggest that YAP1 may contribute to reovirus-resistance in SCCHN, but probably 
functions in combination with other proteins to supress reovirus-induced cell death.  
An extensive search of the literature revealed no evidence linking YAP1 to an anti-
viral intracellular host response pathway, but this research suggests that it could be 
part of one.  Oka et al found that YAP2, an alternative YAP isoform, forms 
complexes with zona-occluden-2 (ZO-2) at tight junctions via their PDZ-binding 
domains [266].  The main reovirus cellular receptor, junction-adhesion molecule-A 
(JAM-A), has been shown to associate with several different PDZ-domain containing 
proteins, including ZO-2 [267, 268].  Thus, one possible theory is that YAP1 
indirectly prevents viral entry to the cell through ZO-2 interaction with JAM-A at the 
cell-surface membrane.  These are hypothetical mechanisms that may support YAP1-
associated reovirus-resistance in SCCHN.  However, more evidence is required to 
claim that YAP1 is an important factor in more SCCHN cell lines, which will be 
explored in later chapters.   
YAP1 is a major downstream target of the Hippo signalling pathway.  This pathway 
becomes activated to inhibit cell proliferation by preventing the nuclear localisation 
and activation of YAP1 [250, 252], as detailed in Chapter 4.  Intriguingly, there is 
evidence suggesting that two out of the eight genes tested in this project are 
interlinked.  BIRC2 and YAP1 are located in close proximity on chromosome 11q, and 
they can act independently as oncogenes or can synergise to promote tumorigenesis 
by virtue of their co-amplification at the same genomic locus [255].  Elevated 
expression of cIAP1 (the protein product of BIRC2) and YAP mRNA and protein was 
found in human and mouse hepatocellular carcinoma tumours that contained an 
amplicon in the 11q22 region [255].  Coincidentally, cIAP1 can also be degraded to 
allow reovirus-induced apoptosis to proceed in some infected cells [242, 243].  Our 
results showed that knock-down of BIRC2 in the PJ41 cell line had no significant 
effect on reovirus-induced cell death, suggesting that YAP1 promotes resistance to 
reovirus independently of BIRC2.  It would however, be of value to analyse the effect 
of the simultaneous knock-down of YAP1 and BIRC2 in PJ41 cells after infection with 
reovirus, and whether the expression level of one gene affects the other.  The YAP1 
gene locus is also often amplified in other human cancers, including oral squamous 
cell carcinoma tissues [269, 270].  Impairment of Hippo signalling and nuclear 
location of YAP often results in tumorigenesis.  Increased YAP1 protein expression 
106 
 
has been observed in ovarian, colon, lung, breast and prostate cancers [219, 254, 255, 
271].  The expression and localisation of YAP1 in head and neck carcinoma tissues in 
comparison to normal tissues will be explored in Chapter 5.  
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3.5. CONCLUSION 
PJ34, HN5 and PJ41 SCCHN cell lines displayed low, medium and high resistance to 
reovirus oncolysis respectively.  The same 3 cell lines in turn showed, low, medium 
and high mRNA expression of SLCO1B3, MGMT, SLC36A4, YAP1, ZNF600, P2RY6, 
BIRC2, but not LARP1B.  Our findings generally agreed with earlier published data 
and preliminary work performed elsewhere.  This justified testing the potential 
influence that these genes may have in predicting the susceptibility of SCCHN cell 
lines to reovirus oncolysis.  siRNA-mediated knock-down of SLCO1B3, MGMT, 
SLC36A4, ZNF600, P2RY6, BIRC2 and LARP1B had little effect on reovirus-
mediated cell death in the PJ41 cell line.  However, knock-down of YAP1 caused 
significant sensitisation to reovirus treatment, suggesting that a certain level of YAP1 
expression in the cell may contribute to reovirus resistance in SCCHN.  Further 
experiments in the other SCCHN cell lines are needed to draw more comprehensive 
conclusions, which will be explored in later chapters.   
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4. TARGETING YES-ASSOCIATED PROTEIN-1 (YAP1) AS A FACTOR  THAT 
INFLUENCES REOVIRUS ONCOLYSIS IN SCCHN CELL LINES 
4.1.   INTRODUCTION 
Understanding the mechanism of reovirus-induced cancer cell death could lead to the 
discovery of new biomarkers of treatment response in patients receiving reovirus 
therapy.  Such biomarkers would be particularly beneficial to squamous cell 
carcinoma of the head and neck (SCCHN) patients, as Reolysin® has reached Phase 
III clinical testing status in this cancer type.  Although the initial results of this trial 
looked encouraging, it is not certain whether the primary endpoints of evaluating 
overall survival and progression-free survival after administration with Reolysin®, 
have been met.  Biomarkers of treatment response may help improve clinical trial 
design and outcome.  The previous chapter demonstrated that siRNA-mediated knock-
down of yes-associated protein-1 (YAP1) in the PJ41 SCCHN cell line caused 
significant sensitisation to reovirus oncolysis.  Further experiments were needed to 
establish whether YAP1 influences the other SCCHN cell lines to reovirus treatment, 
which is the purpose of this chapter.    
The Hippo signalling pathway is an evolutionary conserved regulator of cell 
proliferation and apoptosis.  The components of the pathway were originally 
identified in Drosophila melanogaster using genetic screens that were devised to 
discover novel tumour suppressor genes [272].  The pathway is conserved in 
vertebrates, including mammals.  The Hippo pathway is activated to prevent cell 
proliferation when cells become too confluent, or by cell stress to induce apoptosis 
[273].  The core of the mammalian pathway is composed of a pair of serine/threonine 
kinases, mammalian STE20-like protein kinase-1 and -2 (MST1 and MST2), and 
large tumour suppressor-1 and -2 (LATS1 and LATS2).  The core also comprises the 
adaptor proteins Salvador homologue 1 (SAV1), and MOB kinase activator 1A and 
1B (MOB1A and MOB1B) [251].  When the Hippo pathway becomes stimulated, 
MST1/2 kinases become activated, which phosphorylate and subsequently activate 
other members of the complex [272].  LATS1/2 directly phosphorylate downstream 
YAP and its co-protein, transcriptional co-activator with PDZ-binding motif (TAZ).  
Phosphorylation of YAP on serine 127 (S127) and TAZ at serine 89 (S89) serve as 
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docking sites for 14-3-3 proteins, and this interaction leads to the cytoplasmic 
retention of YAP and TAZ where they remain inactive.  Mutation of the S127 residue 
has been shown to activate YAP [252], highlighting the importance of this residue in 
Hippo signalling.  The phosphorylation of another serine residue, serine 381 (S381) of 
YAP1 and S311 of TAZ, leads to the poly-ubiquitination and degradation of YAP and 
TAZ [274].  In the absence of Hippo signalling, YAP/TAZ migrate to the nucleus.  
YAP/TAZ do not directly bind to DNA in the nucleus, but are cofactors that regulate 
gene expression by interacting with transcription factors, including the TEA domain-
containing transcription factor family (TEAD).  This interaction stimulates expression 
of genes such as c-myc, SOX4, AFP, MK167, AREG, CTGF and CCND1, which 
promote proliferation and inhibit apoptosis [219, 253, 275].  Figure 4.1 illustrates the 
known proteins involved in Hippo pathway signalling.    
There are multiple upstream signals that are known to activate the Hippo pathway.  At 
cell-cell junctions, the Merlin protein (encoded by the NF2 gene), has been shown to 
aid the assembly of protein scaffolds such as Kibra, that allows the activation of the 
LATS kinases and the phosphorylation of YAP [276].  The Crumbs complex (CRB) is 
a polarity protein that can bind to and sequester YAP/TAZ to the cytoplasm, as can 
the angiomotin (AMOT) protein [276].  Complexes of -catenin at E-cadherin 
junctions can inhibit YAP nuclear accumulation [276].  Apicobasal cell polarity 
(ABCP) proteins, such as mammalian Scribble (SCRIB) can serve as an adaptor to 
facilitate activation of the core kinase cassette [251].  Delocalisation of SCRIB from 
the plasma membrane is common in cancer, and is associated with epithelial-
mesenchymal transition (EMT) and YAP/TAZ nuclear activation [276].   Yu et al 
showed that G-Protein coupled receptors (GPCRs) can positively or negatively 
regulate the Hippo pathway.  Activation of Gs-coupled receptors increases LATS1/2 
kinase activity, whereas activation of G12/13 or Gq/11-coupled receptors inhibits 
LATS1/2 kinases, resulting in YAP activation.  Rho GTPases and the actin 
cytoskeleton are located between these GPCRs and the LATS kinases, and appear to 
be involved in this process [220].   
There are at least eight known isoforms of the YAP protein that are generated by 
differential splicing.  The two major isoforms are YAP1 and YAP2, which differ by 
the presence of one or two WW domains respectively (Figure 4.2).  At the amino 
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terminus, there is a TEAD factor binding domain that contains the S127 residue [277].  
Complexes between the YAP WW domain(s) and the PPxY motif-containing LATS1 
kinase are important in inhibiting the proliferative activity of YAP by preventing its 
localisation to the nucleus [277].  YAP also contains a SH3 binding motif, a 
transcriptional activation domain (TAD) and a PDZ-binding motif.  The PDZ-binding 
motif is composed of amino acids that are essential for the nuclear translocation of 
YAP [277].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.  A schematic representation of the proteins involved in the mammalian Hippo 
pathway.  Supposed tumour suppressors are shown in blue and supposed oncogenes are shown in red.  
Imaged adapted from [251].  Compared to other well-defined pathways, Hippo signalling is a relatively 
new concept and more components of this pathway have yet to be characterised [278].   
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Figure 4.2.  Functional domains of YAP1 and YAP2; the two major isoforms of the YAP protein 
[277].   
 
 
In human cancers, germline or somatic mutations in Hippo pathway genes are rare.  
An exception to this is the inherited mutation of the NF2 gene, which causes an 
autosomal dominant syndrome called type 2 neurofibromatosis, giving rise to tumours 
of the brain and spinal cord [251].  Although mutations in Hippo pathway genes are 
not common in human cancers, convincing evidence supports a role of this pathway in 
human tumourigenesis.  Down-regulation of upstream kinases LATS1/2 and MST1/2 
has been reported in various cancer types in humans, including soft tissue sarcomas 
[279], retinoblastomas [280] and acute lymphoblastic leukemia [281].  Studies in mice 
have implicated MST1/2 as tumour suppressors.  Zhou et al demonstrated that 
MST1/2 deficiency in the liver results in loss of inhibitory phosphorylation at S127 of 
YAP1, huge overgrowth, and hepatocellular carcinoma (HCC) [282].  The nuclear 
location of YAP/TAZ often results in tissue overgrowth and tumourigenesis.  In 
normal human tissues, YAP is reported to be infrequently nuclear [251, 254].  
Deregulation of the Hippo pathway is commonly associated with poor patient 
prognosis [251, 271, 283].    
Interestingly, there is evidence linking the interaction of oncogenic viruses to Hippo 
signalling [284], but information of this pathway being modulated by oncolytic 
viruses is scarce.  For example, Hepatitis B virus (HBV) disturbs the normal control 
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of Hippo signalling through up-regulation of YAP [285].  Human papillomavirus 
(HPV) and Epstein-Barr virus (EBV) both down-regulate E-cadherin expression and 
promote WNT signalling, which is closely inter-linked with the Hippo pathway [286-
289].  Human T lymphotropic virus type 1 (HTLV-1) perturbs the expression of 
complexes such as SCRIB that are central to the regulation of cell polarity, and 
modulates WNT signalling [290].  The Hippo pathway has been shown to mediate the 
oncogenic activity of Kaposi-sarcoma-associated herpesvirus (KSHV).  KSHV 
encodes a viral G-protein-coupled receptor (vGPCR) that acts through the G-proteins, 
Gq/11 and G12/13, to inhibit the Hippo pathway kinases LATS1/2, thus promoting the 
activation and nuclear accumulation of YAP and TAZ to initiate the progression of 
the AIDS-defining cancer, Kaposi sarcoma (KS) [291].  The authors of this paper 
suggest using inhibitors of YAP for the prevention of KS.  Our results so far imply 
that high expression of YAP1 contributes to resistance to oncolytic reovirus in 
SCCHN.  In this context, inhibitors of YAP might increase the likelihood of an 
effective anti-cancer response to reovirus infection in SCCHN.   
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4.2. STUDY OBJECTIVE  
The objective of this chapter was study to the effect of plasmid-mediated over-
expression of YAP1 in SCCHN cell lines that exhibited low endogenous expression 
of YAP1 and a high level of sensitivity to reovirus oncolysis.   
In order to test this, the following experiments were performed: 
1. Transient over-expression of YAP1 in the PJ34 SCCHN cell line and assessment 
of the resultant effect on cell survival after infection with reovirus by the MTS 
assay. 
2. Stable over-expression of YAP1 in the HN5 SCCHN cell line and determination 
of the resultant effect on cell survival after infection with reovirus by the MTS 
assay.   
3. Transient over-expression of YAP1 in the COS-1 monkey fibroblast cell line and 
assessment of the resultant effect on cell survival after infection with reovirus by 
the MTS assay, to assess whether the effect is SCCHN cell line specific.   
4. Immunofluorescent staining and confocal imaging in SCCHN cell lines to 
determine the cellular localisation and possible function of the YAP1 protein, 
which may be an important factor in how it mediates reovirus oncolysis.   
5. Treatment of the PJ41 SCCHN cell line with sphingosine-1-phosphate (S1P) to 
stimulate the de-phosphorylation and nuclear expression of YAP1, and the 
subsequent determination of the effect on cell survival after infection with 
reovirus by the MTS assay.   
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4.3.  RESULTS 
4.3.1. Transient over-expression of YAP1 in the PJ34 SCCHN cell line 
In order to over-express the YAP1 gene in the PJ34 cell line, which displayed the 
lowest expression of YAP1 and was the most sensitive to reovirus oncolysis, a 
transient transfection with 2 YAP1-containing plasmids was performed (Section 
2.16.1).  An EYFP-tagged-YAP1 plasmid and a Flag-tagged-YAP1 plasmid was 
provided to us by Dr Nic Tapon, Cancer Research UK London Research Institute.  
Cells were also treated with lipofectamine transfection agent alone, or with media 
alone (un-transfected sample), which served as controls.  At 24 hours post-
transfection, RNA was extracted from the cells and the cDNA template was used to 
quantify YAP1 mRNA expression by RT-qPCR (Sections 2.10, 2.11 and 2.12).  The 
relative expression value was calculated as a ratio to the housekeeping gene β-actin.   
The transfection conditions were initially optimised by using 3 different 
concentrations of lipofectamine (0.25, 0.35 and 0.45µL/well).  Figure 4.3 shows that 
YAP1 expression was enhanced when higher concentrations of lipofectamine was 
used to deliver the plasmids.  The relative mRNA expression of YAP1 in cells 
transfected with the EYFP-YAP1 and Flag-YAP1 plasmids was 91-fold and 94-fold 
higher than the lipofectamine control respectively, when 0.45µL/well was used.   
PJ34 cell lysates were also analysed for YAP1 protein expression by western blotting 
(Section 2.14).  There was considerably more YAP1 protein in the cells transfected 
with both YAP1 plasmids compared to cells treated with lipofectamine and media 
alone.  A band at 81kDa was detected in the cells transfected with the EYFP-YAP1 
plasmid, which corresponded to the expected combined molecular weight of the 
YAP1 protein (54kDa) and the EYFP-tag (27kDa).  Similarly, a band at 56kDa was 
detected in the cells treated with the Flag-YAP1 plasmid, which related to the 
combined molecular weights of YAP1 (54kDa) and the Flag-tag (2kDa).  Endogenous 
YAP1 was detected in the samples at 54kDa.  Again, there was a lipofectamine-dose-
response increase in YAP1, with 0.45µL/well showing the greatest YAP1 protein 
over-expression (Figure 4.4 A).  The combined intensity of the endogenous and 
exogenous YAP1 bands in each sample was quantified and normalised to their 
corresponding β-actin bands by densitometry analysis (Section 2.14.4) (Figure 4.4 
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B).  This revealed a 9-fold and 16-fold increase in total YAP1 protein expression in 
cells transfected with EYFP-YAP1 and Flag-YAP1 plasmids respectively, compared to 
cells treated with 0.45µL/well lipofectamine alone.  Thus, 0.45µL/well was chosen as 
the optimal concentration of lipofectamine to deliver the plasmids.   
 
 
 
 
 
Figure 4.3.  YAP1 mRNA expression in the PJ34 SCCHN cell line after transient over-expression 
of YAP1. cDNA from PJ34 cells treated with the Flag-YAP1 plasmid (blue bars), EYFP-YAP1 plasmid 
(red bars), and lipofectamine or media alone (green bars), was analysed by RT-qPCR. The mRNA 
expression of YAP1 is shown relative to the housekeeping gene β-actin (×1000).  The highest 
concentration of lipofectamine (0.45µL/well) caused the greatest increase in YAP1 expression.  Cells 
transfected with the EYFP-YAP1 and Flag-YAP1 plasmids generated a 91-fold and 94-fold increase in 
YAP1 expression compared to the lipofectamine control respectively, when 0.45µL/well was used.  
Error bars represent the SD from triplicate samples. 
 
 
 
0
50
100
150
200
250
300
350
0
.4
5
µ
L
/w
el
l 
L
ip
o
0
.3
5
µ
L
/w
el
l 
L
ip
o
0
.2
5
µ
L
/w
el
l 
L
ip
o
0
.4
5
µ
L
/w
el
l 
L
ip
o
0
.3
5
µ
L
/w
el
l 
L
ip
o
0
.2
5
µ
L
/w
el
l 
L
ip
o
0
.4
5
µ
L
/w
el
l 
L
ip
o
0
.3
5
µ
L
/w
el
l 
L
ip
o
0
.2
5
µ
L
/w
el
l 
L
ip
o
Flag-YAP1 EYFP-YAP1 Lipofectamine only Media
only
R
el
a
ti
v
e 
m
R
N
A
 e
x
p
re
ss
io
n
117 
 
A 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  YAP1 protein expression in the PJ34 cell line after transient over-expression of 
YAP1.  Whole cell lysates were collected from cells treated with the Flag-YAP1 plasmid, EYFP-YAP1 
plasmid, lipofectamine alone and media alone.  A.  YAP1 protein expression was determined by 
western blotting.  Endogenous YAP1 was detected in the samples at 54kDa.  EYFP-tagged-YAP1 was 
detected at 81kDa, whereas Flag-tagged-YAP1 was detected at 56kDa.  There was a clear over-
expression of YAP1 in the plasmid-transfected cells compared to the cells treated with lipofectamine or 
media alone.  B.  Total YAP1 protein expression (endogenous and exogenous combined) in each 
sample was normalised to the -actin loading control and quantified by densitometry using LI-COR 
Image Studio Lite 4.0.21 software.  This confirmed that transfection with EYFP-YAP1 (red bars) and 
Flag-YAP1 (blue bars) plasmids caused a 9-fold and 16-fold increase in YAP1 expression respectively, 
compared to cells treated with 0.45µL/well lipofectamine alone (green bars).   
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4.3.2. Transient YAP1 over-expression caused increased resistance of the PJ34 
cell line to reovirus-induced cell death 
Having successfully achieved transient YAP1 over-expression in the PJ34 cell line, the 
susceptibility of these cells to reovirus infection was evaluated, in comparison to cells 
treated with lipofectamine or media alone (Section 2.16.3).  First, the average OD of 
each un-infected transfection condition was compared to check for cytotoxic effects.  
After 24 hours post-transfection, cells were treated with media alone for a further 48 
hours before analysis via the MTS assay (Section 2.9).  There was no cytotoxicity 
observed in the cells treated with 0.45µL/well lipofectamine alone.  However, there 
was some cytotoxicity observed in the cells transfected with the DNA plasmids 
(Figure 4.5).   
In order to account for the differences in transfection-associated cytotoxicity, after 24 
hours post-transfection, cells from each treatment condition were counted prior to 
infection with reovirus.  The cell counts were used to calculate the required MOI per 
well (Section 2.8), which ensured that the same number of virus particles per cell was 
used in each treatment condition.  Cells were infected with serial dilutions of reovirus 
starting at MOI 1000.  At 48 hours post-infection with reovirus, the % cell survival in 
each treatment condition was assessed by the MTS assay (Section 2.9) and the IC50 
values were determined using CalcuSyn software (Biosoft, UK) (Section 2.27.4) 
Figure 4.6 shows that plasmid-mediated over-expression of YAP1 in the PJ34 cell line 
caused a significant increase in resistance to reovirus oncolysis at all MOIs tested 
(p<0.05 by un-paired t-test).  Compared to cells treated with lipofectamine or media 
alone (both had reovirus IC50 values of MOI 6.7), there was a 12-fold and 4-fold 
increase in resistance in cells transfected with EYFP-YAP1 (IC50 MOI 77.6) and Flag-
YAP1 (IC50 MOI 27.9) plasmids respectively.  This suggested that over-expression of 
YAP1 may be a factor that promotes reovirus resistance in the PJ34 SCCHN cell line.   
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Figure 4.5.  The transfection-associated toxicity in the PJ34 cell line.  After 24 hours transient-
transfection, PJ41 cells were treated with media alone for a further 48 hours before analysis via the 
MTS assay. The raw Optical Density (OD) values for each treatment was compared. There was some 
cytotoxicity observed in the cells transfected with EYFP-YAP1 and Flag-YAP1 plasmids.  The graph 
shows the mean OD of 2 assay repeats and error bars represent SD.   
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Figure 4.6.  Evaluation of reovirus-induced cell death after plasmid-mediated over-expression of 
YAP1 in the PJ34 cell line.  Cells were transiently transfected with A. the EYFP-YAP1 plasmid, or B.  
the Flag-YAP1 plasmid (red circles).  Cells were also treated with lipofectamine only (green triangles) 
or media only (blue triangles).  After counting the cells in each treatment condition, cells were 
subsequently infected with serial dilutions of reovirus, starting at MOI 1000. The % cell survival in 
each treatment condition was then assessed using the MTS assay. The IC50 values of each treatment 
condition were determined using CalcuSyn software and are shown in a table below each graph.  Over-
expression of YAP1 enhanced the resistance to reovirus-induced cell death at all MOIs tested. *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001 by un-paired t-test, with respect to the cells treated with 
lipofectamine alone.  Error bars represent the SD from 2 assay repeats. 
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4.3.3. Stable over-expression of YAP1 in the HN5 cell line 
Next, we intended to create stable transfected cell lines that over-expressed YAP1 
long-term.  Although transiently transfected cells express the foreign gene, they do 
not integrate it into their genomes.  Because the new gene will not be replicated, the 
cells can only express the gene for a finite period of time.  Conversely, stable 
transfected cell lines incorporate the foreign gene into their genome, which means that 
descendants of these transfected cells will also express the new gene [292].  The 
plasmids used in this study contained a neomycin antibiotic resistance gene, which 
allowed the selection of cell colonies with the G418 antibiotic.  Therefore cells that 
had successfully incorporated the plasmid into their genomes were able to survive, 
whereas cells that failed to uptake the plasmid were killed by the antibiotic.  Several 
attempts were made to create a stable cell line that over-expressed YAP1 in PJ34 cells, 
but none of the clones survived long enough in culture to test their reovirus 
susceptibilities, even after modifying the transfection parameters.  We attempted to 
transfect PJ34 cells with three other YAP1-containing plasmids from Origene 
Technologies (Rockville, USA).  Stable colonies using these plasmids did survive in 
culture, but compared to PJ34 parental cells, none of them significantly over-
expressed YAP1 at the mRNA or protein levels.  Thus, stable clones were created 
using the HN5 cell line (Section 2.16.2), which was the second most sensitive line to 
reovirus oncolysis and expressed lower endogenous levels of YAP1 than the PJ41 cell 
line.  Stable clones were created after transfection with the Flag-YAP1 plasmid or an 
empty vector (EV) control plasmid.  The EV plasmid was a pcDNA3.1 vector, which 
contained the same components as the Flag-YAP1 plasmid but without the YAP1-tag 
insert, and was provided to us by Dr Lisi Meira (The University of Surrey).   
Therefore, the EV plasmid served as a non-specific negative control to the Flag-YAP1 
plasmid.  In addition, stable clones were generated after transfection with the EYFP-
YAP1 plasmid (Section 2.16.2).  The EYFP-YAP1 plasmid was a different vector type 
(i.e. not a pcDNA3.1 vector), and an EV control was not available for direct 
comparison. The HN5 parental cell line was therefore used as a negative control for 
the EYFP-YAP1 plasmid.    
13 EYFP-YAP1 clones were selected and the resultant YAP1 protein expression levels 
were compared to the HN5 parental cell line by western blotting (Section 2.14).  9 of 
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the clones produced an EYFP-YAP1 exogenous band at 81kDa, as well as a band at 
54kDa, which signified endogenous YAP1 expression (Figure 4.7A).  The combined 
intensity of the exogenous and endogenous YAP1 bands in each sample was 
quantified and normalised to their corresponding β-actin bands by densitometry 
analysis (Section 2.14.4) (Figure 4.7 B).  EYFP-YAP1-clone 6 produced the greatest 
increase in total YAP1 protein expression, and was 5-fold higher than total YAP1 in 
the HN5 parental cell line.  Out of the 5 Flag-YAP1 clones tested, clone 2 produced 
the most intense band at 56kDa, and there was a 4-fold increase in total YAP1 
compared to the HN5 parental cell line, as confirmed by densitometry analysis 
(Figure 4.8 A and B).  As expected, there was no change in total YAP1 protein 
expression in the EV-clones compared to the HN5 parental cell line (Figure 4.8 A 
and B). 
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Figure 4.7.  YAP1 protein expression in HN5 SCCHN cell line clones after stable over-expression 
of YAP1 using the EYFP-YAP1 plasmid.  Whole cell lysates were collected from 13 EYFP-YAP1 
stable clones and from the HN5 parental cell line.  A.  YAP1 protein expression was determined by 
western blotting.  Endogenous YAP1 was detected in the samples at 54kDa, whereas exogenous YAP1 
was detected at 81kDa.  The 42kDa -actin bands in each sample generally showed uniform protein 
loading.  B.  Total YAP1 expression of each band was quantified and normalised to the corresponding 
-actin loading control bands by densitometry analysis.  This confirmed that out of all the clones tested 
(purple bars), clone 6 expressed the highest levels of YAP1 compared to the HN5 parental cell line 
(black bar), as shown by the red arrow.   
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Figure 4.8.  YAP1 protein expression in HN5 SCCHN cell line clones after stable over-expression 
of YAP1 using the Flag-YAP1 plasmid.  Whole cell lysates were collected from 5 Flag-YAP1 stable 
clones, 3 empty vector (EV) stable clones, and from the HN5 parental cell line.  A.  YAP1 protein 
expression was determined by western blotting.  Endogenous YAP1 was detected in the samples at 
54kDa, whereas exogenous YAP1 was detected at 56kDa.  The 42kDa -actin bands in each sample 
showed uniform protein loading.  B.  Total YAP1 expression of each band was quantified and 
normalised to the corresponding -actin loading control bands by densitometry analysis.  This 
confirmed that out of the 5 Flag-YAP1 clones tested (green bars), Flag-YAP1 clone 2 expressed the 
highest levels of YAP1 compared to the HN5 parental cell line (black bar).  There was no alteration in 
YAP1 protein expression in the EV clones (blue bars).  Flag-YAP1 clone 2 and EV-clone 1 were 
chosen for further analysis, as shown by the red arrows.   
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4.3.4. Stable over-expression of YAP1 caused increased resistance to reovirus-
mediated cell death in the HN5 cell line 
Having achieved stable over-expression of the YAP1 protein in the HN5 cell line, the 
next step was to determine the susceptibility of the stable clones to reovirus oncolysis 
(Section 2.16.3).  Unlike transient transfection, stable transfection of a gene of 
interest persists after several cellular passages.  Therefore, this allowed us to study the 
effect of YAP1 over-expression at earlier and later times of reovirus infection.   EYFP-
YAP1-clone 6 and Flag-YAP1-clone 2 were selected because they exhibited the 
highest protein levels of YAP1.  EV-clone 1 was also selected for use as a non-
specific control to the Flag-YAP1-clone 2.   
Prior to determining the susceptibility of the stable clones to reovirus-induced cell 
death, we evaluated the proliferation rate of each clone compared to the HN5 parental 
cell line.  The average OD was compared at 48, 72 and 96 hours after seeding the cells 
in tissue culture plates, via analysis by the MTS assay (Section 2.9).  Figure 4.9 
demonstrates that stable over-expression of YAP1 using both YAP1-plasmids caused 
an increase in cellular proliferation over time, compared to the EV-clone 1 and HN5 
parental cell line.   
In order to account for the differences in proliferation rate, HN5 parental cells, and 
cells from each stable clone, were counted prior to infection with reovirus.  The cell 
counts were used to calculate the required MOI per well (Section 2.8), which ensured 
that the same number of virus particles per cell was used for each clone or cell line.  
Cells were infected with serial dilutions of reovirus starting at MOI 500 or 1000.  At 
24, 48, and 72 hours post-infection with reovirus, the % cell survival in each treatment 
condition was assessed by the MTS assay (Section 2.9) and the IC50 values were 
determined using CalcuSyn software (Section 2.27.4).  
Figure 4.10 shows that the stable EYFP-YAP1-clone 6 (which exhibited a 5-fold 
over-expression of YAP1 compared to HN5 parental cells) caused a significant 
increase in resistance to reovirus oncolysis at all time-points and at all MOIs tested 
(p<0.05 by un-paired t-test), compared to the HN5 parental cell line.  The reovirus 
IC50 of EYFP-YAP1-clone 6 was 8-fold, 6-fold and 3-fold more resistant than the 
HN5 parental cell line at 24, 48 and 72 hours post infection respectively.   
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The reovirus sensitivity was also evaluated between the Flag-YAP1-clone 2 and EV-
clone 1 stable cell lines (Figure 4.11).  Compared to the HN5 parental cell line, there 
was some non-specific reovirus resistance observed in the EV-clone 1 control.  
However, this non-specific effect was less apparent at later times of infection (48 and 
72 hours post infection).  To check that the non-specific effect caused by the EV 
plasmid was not due to an erroneous gene insert, the plasmid was sent for DNA 
sequencing analysis (Sanger sequencing facility, Department of Biochemistry, 
University of Cambridge).  Results showed that the EV plasmid contained no extra 
elements, which confirmed its use as a valid negative control.   Both the EYFP-YAP1 
and Flag-YAP1 plasmids were also sent for analysis and the results verified that both 
vectors contained the correct YAP1 nucleotide sequence.  Therefore, in order to assess 
the specific effect of YAP1 over-expression, all statistical comparisons were made 
directly to the EV-clone 1 stable cell line.  Compared to EV-clone 1, Flag-YAP1 clone 
6 (which displayed a 4-fold over-expression of YAP1 compared to HN5 parental 
cells) was 2-fold more resistant to reovirus at 24 hours, and 3-fold more resistant at 48 
and 72 hours post-infection.  This was statistically significant at the majority of MOIs 
tested, apart from at the very high MOIs, which expectedly caused considerable cell 
death.  Taking into account both the transient over-expression of YAP1 in PJ34 and 
the stable over-expression of YAP1 in HN5, these results implied that a certain level 
of YAP1 expression in SCCHN cells may contribute to reovirus resistance. 
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Figure 4.9.  The differences in proliferation rates between the stable clones and the HN5 parental 
cell line.  The average Optical Density (OD) values were compared over a time-course of 48 hours 
(pink bars), 72 hours (green bars) and 96 hours (blue bars) in culture between A. the EYFP-YAP1-clone 
6 and the HN5 parental cell line, and B. the Flag-YAP1-clone 2, the empty vector (EV)-clone 1 and the 
HN5 parental cell line.  OD values were determined by analysis via the MTS assay.  The clones that 
over-expressed YAP1 proliferated more quickly over time than the HN5 parental cell line and the EV-
clone 1 control.  The graph shows the mean OD of 2 assay repeats and error bars represent SD.  
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Figure 4.10.  Stable over-expression of the YAP1 protein using the EYFP-YAP1 plasmid, promoted resistance to reovirus in the HN5 SCCHN cell line.  
Stable clones were generated from the HN5 cell line by transfection with the EYFP-YAP1 plasmid.  The HN5 parental cell line (blue triangles) and EYFP-YAP1-
clone 6 (which displayed a 5-fold over-expression of YAP1 compared to wild-type HN5) (red circles) were infected with serial dilutions of reovirus starting at MOI 
500 for A. 24, B. 48 or C. 72 hours.  The % cell survival was then assessed using the MTS assay.  The IC50 values of the cell lines were determined using CalcuSyn 
software and are shown in a table below each graph.  Stable over-expression of YAP1 enhanced the resistance to reovirus-induced cell death at all MOIs tested 
compared to the HN5 parental cell line. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 by un-paired t-test.  Error bars represent the SD from 2 assay repeats. 
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Figure 4.11.  Stable over-expression of the YAP1 protein using the Flag-YAP1 plasmid, promoted resistance to reovirus in the HN5 SCCHN cell line.  Stable 
clones were generated from the HN5 cell line by transfection with the Flag-YAP1 plasmid or the empty vector (EV)-control plasmid.  The HN5 parental cell line 
(blue triangles), EV-clone1 (green triangles), and Flag-YAP1-clone 2 (which displayed a 4-fold over-expression of YAP1 compared to wild-type HN5) (red circles) 
were infected with serial dilutions of reovirus starting at MOI 1000 for A. 24, B. 48 or C. 72 hours.  The % cell survival was then assessed using the MTS assay.  
The IC50 values of the cell lines were determined using CalcuSyn software and are shown in a table below each graph.  There was some non-specific resistance 
caused by the EV-clone 1, although this did decline at later times of infection.  Compared to EV-clone 1, stable over-expression of YAP1 using Flag-YAP1-clone 2 
enhanced the resistance to reovirus at most MOIs tested (*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 by un-paired t-test).  Error bars represent the SD from 2 
assay repeats. 
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4.3.5. Transient-over-expression of YAP1 in the non-cancerous COS-1 monkey 
fibroblast cell line 
This chapter so far demonstrates that over-expression of YAP1 promoted resistance to 
reovirus oncolysis in 2 SCCHN cell lines.  We consequently planned to over-express 
YAP1 in COS-1, which is an African green monkey kidney fibroblast-like, simian 
virus 40 (SV40) transformed, non-cancerous cell line.  COS-1 cells are recognised as 
easy transfection hosts.  Therefore, we intended to check the transfection efficiency of 
YAP1 in COS-1 cells, and to determine whether reovirus resistance associated with 
over-expression of YAP1, is SCCHN cell line specific.  
To over-express YAP1 in the COS-1 cell line, a transient transfection with the Flag-
tagged-YAP1 plasmid was performed (Section 2.16.1).  Cells were also transfected 
with the EV-control plasmid, or treated with 045.µL/well lipofectamine alone or with 
media alone, which served as controls.  At 24 hours post-transfection, COS-1 cell 
lysates were collected and analysed for YAP1 protein expression by western blotting 
(Section 2.14).   
Figure 4.12 A demonstrates YAP1 protein over-expression in the cells transfected 
with the Flag-YAP1 plasmid compared to cells treated with the EV-control plasmid, 
lipofectamine alone or media alone.  An exogenous YAP1 band at 56kDa was 
detected in the cells treated with the Flag-YAP1 plasmid, and endogenous YAP1 was 
detected in the samples at 54kDa.  The combined intensity of the endogenous and 
exogenous YAP1 bands in each sample was quantified and normalised to their 
corresponding β-actin bands by densitometry analysis (Section 2.14.4) (Figure 4.12 
B).  A 21-fold increase in total YAP1 was observed in cells transfected with the Flag-
YAP1 plasmid compared to EV-control plasmid-transfected cells.   
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Figure 4.12.  YAP1 protein expression in the COS-1 cell line after transient over-expression of 
YAP1.  Whole cell lysates were collected from cells treated with the Flag-YAP1 plasmid, media alone, 
lipofectamine alone and the empty vector (EV)-control plasmid.  A.  YAP1 protein expression was 
determined by western blotting.  Endogenous YAP1 was detected in the samples at 54kDa, whereas 
exogenous YAP1 was detected at 56kDa.  Over-expression of YAP1 in the cells transfected with the 
YAP1-plasmid was observed compared to the cells treated with the EV-plasmid, lipofectamine 
transfection agent alone, or media alone.  B.  Total YAP1 protein expression in each sample was 
normalised to the -actin loading control and quantified using densitometry.  This confirmed that 
transfection with the Flag-YAP1 plasmid caused a 21-fold increase in YAP1 expression with respect to 
the EV-plasmid.   
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4.3.6. Transient YAP1 over-expression caused increased resistance of the non-
cancerous COS-1 cell line to reovirus-induced cell death 
Having confirmed transient YAP1 over-expression in the COS-1 cell line, the 
susceptibility of these cells to reovirus oncolysis was investigated, in comparison to 
cells treated with the EV-control plasmid, lipofectamine alone or media alone 
(Section 2.16.3).  The average OD of each un-infected transfection condition was 
initially compared to check for cytotoxic effects.  At 24 hours post-transfection, cells 
were treated with media alone for an additional 48 hours before analysis via the MTS 
assay (Section 2.9).  There appeared to be some cytotoxicity in the cells transfected 
with the Flag-YAP1 plasmid, compared to cells treated with media or lipofectamine 
alone.  However, minimal toxicity was observed in cells transfected with the EV-
control plasmid.  This suggested that presence of YAP1 cDNA was responsible for the 
cytotoxicity and was not simply due to cellular uptake of the vector (Figure 4.13).   
Before infecting the cells with reovirus, the differences in transfection-associated 
cytotoxicity was taken into account by counting cells from each treatment condition.  
The cell counts were used to calculate the required MOI per well (Section 2.8), which 
ensured that the same number of virus particles per cell was used in each treatment 
condition.  Cells were infected with serial dilutions of reovirus starting at MOI 250.  
At 48 hours post-infection with reovirus, the % cell survival in each treatment 
condition was assessed by the MTS assay (Section 2.9) and the IC50 values were 
determined using CalcuSyn software (Section 2.27.4). Plasmid-mediated over-
expression of YAP1 in the COS-1 cell line caused a significant increase in resistance 
to reovirus oncolysis at all MOIs tested (p<0.05 by un-paired t-test) (Figure 4.14).  
Cells treated with lipofectamine alone, media alone or the EV-control plasmid had 
IC50 values of MOI 6.7, MOI 11.1, and MOI 9.9 respectively.  Compared to the EV-
control, there was a 10-fold increase in resistance to reovirus in cells transfected with 
the Flag-YAP1 plasmid (IC50 MOI 100.8).  This implied that over-expression of YAP1 
may be a factor that promotes reovirus resistance in other cell types and is not a 
phenomenon restricted only to SCCHN cell lines.  Unlike the SCCHN cell lines, no 
non-specific effect was caused by the EV-control plasmid in COS-1 cells.  Although 
this was an interesting result, in order to address our original study objectives, the 
remaining parts of the project focussed on the effect of YAP1 expression in SCCHN.     
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Figure 4.13.  The transfection-associated toxicity in COS-1 cells.  After 24 hours transient-
transfection, COS-1 cells were treated with media alone for a further 48 hours before analysis via the 
MTS assay. The raw Optical Density (OD) values for each treatment was compared. There was some 
toxicity observed in the cells transfected with the Flag-YAP1 plasmid, but limited toxicity in cells 
transfected with the empty vector (EV)-control plasmid.  The graph shows the mean OD of 3 assay 
repeats and error bars represent SD.   
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Figure 4.14.  Plasmid-mediated over-expression of YAP1 increased the resistance of the COS-1 
cell line to reovirus oncolysis.  COS-1 cells were transiently transfected with the Flag-YAP1 plasmid 
(red circles) or the empty vector (EV)-control plasmid (purple squares).  Cells were also treated with 
lipofectamine (green triangles) or media alone (blue triangles).  After counting the cells in each 
treatment condition, cells were subsequently infected with serial dilutions of reovirus, starting at MOI 
250.  The % cell survival in each treatment condition was then assessed using the MTS assay. The IC50 
values of each treatment condition were determined using CalcuSyn software and are shown in a table 
below each graph.  Over-expression of YAP1 caused a 10-fold increase in the resistance to reovirus 
oncolysis at all MOIs tested compared to the EV-control. *p<0.05, **p<0.01 and ***p<0.001 by un-
paired t-test.  Error bars represent the SD from 2 assay repeats. 
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4.3.7. Cellular localisation of YAP1 in PJ34 and PJ41 SCCHN cell lines  
The YAP1 protein has been shown to have dual functions in controlling cell 
proliferation and apoptosis, depending on its cellular localisation [256].  Therefore, 
the cellular location of YAP1 may be an important factor in understanding its 
biological role in SCCHN cell lines and how it may impede reovirus oncolysis.  There 
are several compounds that are known to affect the function of YAP in the cell.  In 
order to select the most appropriate compound that alters the function of YAP1 and to 
examine the resultant effect on reovirus oncolysis, it was necessary to perform an 
immunofluorescent stain to establish the localisation of YAP1 in SCCHN cell lines.   
The PJ41 and PJ34 SCCHN cell lines were permeabilised and then stained with a total 
YAP1 primary antibody or a phospho-YAP primary antibody, which detected 
endogenous levels of YAP only when phosphorylated at S127.  A secondary antibody 
conjugated to a fluorescent dye was then used to visualise the proteins by confocal 
microscopy under the 488nm wavelength of light.  A cell membrane marker, wheat 
germ agglutinin (WGA), and a nuclear marker, TO-PRO-3, were also used to help 
localise total YAP1 or phospho-YAP-S127 in the cells (Section 2.17).   
Total YAP1 was predominantly expressed in the cytoplasm of the PJ41 cell line, 
although there was also some expression in the nucleus, as demonstrated by the 
intensity profile (Figure 4.15 and Figure 4.16 A).  As expected, phospho-YAP-127 
was exclusively expressed in the cytoplasm of PJ41 cells (Figure 4.15 and Figure 
4.16 B).  This implied that the majority of YAP1 was being phosphorylated by 
upstream components of the Hippo pathway to sequester it to the cytoplasm where it 
remains in-active, but some YAP1 protein was not phosphorylated and was possibly 
having an oncogenic function in the nucleus.  Total YAP1 and phospho-YAP-S127 
were un-detectable in the PJ34 cell line.   The staining intensity of the YAP1 protein 
in these cell lines was consistent with the mRNA expression data obtained in Chapter 
3, Section 3.3.3, where PJ41 displayed highest YAP1 and PJ34 showed lowest YAP1 
expression.  Total YAP1 and phospho-YAP-S127 staining was performed on different 
days, but the two cell lines were stained simultaneously and imaged using the same 
confocal settings.  Thus, direct comparisons could be made between the cell lines, but 
there was variation in the staining intensity between total YAP1 and phospho-YAP-
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S127.  Despite this, the cellular localisation of YAP1 and phospho-YAP-S127 could 
be compared.   
 
 
 
 
 
Figure 4.15.  Immunofluorescent staining of PJ41 and PJ34 SCCHN cell lines for the YAP1 
protein.  All images were taken using the confocal microscope at ×40 magnification.  Total YAP1 and 
phospho-YAP-S127 (pYAP-S127) were detected predominantly in the cytoplasm of permeabilised 
PJ41 cells, as shown by green staining, but were un-detectable in permeabilised PJ34 cells.  There was 
no YAP1 or pYAP-S127 staining found in permeabilised cells treated only with secondary antibody, 
which served as a negative control for each cell line (inset, top right).  Wheat germ agglutinin (WGA) 
was used as a cell membrane marker (red stain) and TO-PRO-3 was used to detect the cell nucleus 
(blue stain).   
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Figure 4.16.  Intensity profiles of total YAP1 and phospho-YAP-S127 in the PJ41 cell line.  The 
intensity profiles were measured in PJ41 cells stained with A. total YAP1 and B. pYAP-S127.  The 
white arrow shows where the 3 different fluorescent labels were expressed through the cells.   The blue 
peak represented the nucleus, the red peak indicated the cell membrane, and the green intensity peak 
demonstrated the presence of total YAP1 or pYAP-S127.  Total YAP1 was expressed predominantly in 
the cytoplasm, but there was also some YAP1 detected in the nucleus.  pYAP-S127 was expressed 
solely in the cytoplasm.  Images were taken using the confocal microscope at ×40 magnification.   
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4.3.8. Treatment of the PJ41 cell line with Sphingosine-1-phosphate (S1P) 
caused sensitisation to reovirus oncolysis 
As the YAP1 protein was localised predominantly in the cytoplasm of the PJ41 cell 
line in its phosphorylated state, we intended to force YAP1 into the nucleus using 
sphingosine-1-phosphate (S1P) and then assess the effect on reovirus-induced cell 
death (Section 2.18).  S1P has been shown to cause de-phosphorylation of YAP on 
residue serine 127 (S127), resulting in nuclear migration of YAP in human embryonic 
kidney or breast epithelial cell lines [220].   
First, the toxicity associated with S1P treatment was taken into account by counting 
cells with or without S1P treatment.  The cell counts were used to calculate the 
required MOI per well (Section 2.8), which ensured that the same number of virus 
particles per cell was used in each treatment condition.  PJ41 cells were treated with 
1µM S1P for 60 minutes and then infected with serial dilutions of reovirus, starting at 
MOI 500, for 24 hours.  Cells were also treated with S1P alone (without reovirus 
infection) or with reovirus alone (without S1P treatment).  The % cell survival was 
determined by the MTS assay (Section 2.9) and the IC50 values were evaluated using 
CalcuSyn software (Section 2.27.4).  S1P treatment caused minimal toxicity 
compared to PJ41 cells treated with media alone (Figure 4.17 A).  S1P treatment 
sensitised PJ41 cells to reovirus-induced cell death by 10-fold (IC50 = MOI 1346.59) 
compared to cells treated with reovirus alone (IC50 = MOI 132.26) (Figure 4.17 B).   
The ability of S1P to induce de-phosphorylation of YAP1 in the PJ41 cell line was 
then assessed.  According to Yu et al, de-phosphorylation of YAP was detected in the 
human embryonic kidney HEK293A cell line treated with S1P at a concentration of 
1µM for 60 minutes.  Treatment with S1P at time-points longer than 60 minutes 
showed that the de-phosphorylation was less effective [220].  Therefore, we treated 
PJ41 cells with media alone, or with 1µM S1P for 20, 30 and 60 minutes.  We also 
treated HEK293A cells in the same way for use as a positive control (Section 2.18).  
Cell lysates were then collected and phospho-YAP-S127 or total YAP1 levels were 
detected by western blotting (Section 2.14).  Western blot analysis showed little 
quantifiable reduction in phosphorylated YAP after S1P treatment in the PJ41 cell 
line, compared to the un-treated control cells (Figure 4.18 A and B).  As expected, 
total YAP1 levels remained relatively constant after S1P treatment.  Unlike results 
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published by Yu et al, we did not detect any total YAP1 or phospho-YAP-S127 in 
HEK293A cell lysates treated with or without S1P.  We did increase the protein 
concentration of HEK293A lysates loaded on to the SDS-PAGE gel in the hope of 
detecting positive bands, but this was also unsuccessful.  Altogether, these results 
implied that S1P promoted reovirus oncolysis via a different mechanism to the de-
phosphorylation of YAP1, as discussed later in this chapter.   
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Figure 4.17. Treatment of the PJ41 SCCHN cell line with S1P caused sensitisation to reovirus-
mediated cell death.  A.  PJ41 cells were treated with 1µM S1P for 60 minutes and then replaced with 
fresh growth media for a further 24 hours.  Cells were also treated with media alone for the same 
duration of time before analysis via the MTS assay.  The raw Optical Density (OD) values showed that 
S1P caused little cytotoxicity.  The graph shows the mean OD of 2 assay repeats and error bars 
represent SD.  B.  PJ41 cells were treated with 1µM S1P (red circles) or with media alone (blue 
triangles) for 60 minutes, counted, and were then infected with serial dilutions of reovirus for 24 hours, 
starting at MOI 500.  Cells were also treated with 1µM S1P for 60 minutes, and then treated with media 
alone (without reovirus infection) for a further 24 hours (dotted grey line).  The % cell survival in each 
treatment group was determined by the MTS assay.  S1P treatment sensitised PJ41 cells to reovirus-
induced cell death by 10-fold compared to cells treated with reovirus and media alone.  The IC50 values 
were determined using CalcuSyn software and are shown in a table below the graph. *p<0.05 and 
**p<0.01 by un-paired t-test.  Error bars represent the SD from 2 assay repeats. 
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Figure 4.18.  Treatment of the PJ41 SCCHN cell line with S1P failed to de-phosphorylate YAP.  
Whole cell lysates were collected from un-treated cells, or cells treated with 1µM S1P for 20, 30, or 60 
minutes.  A. pYAP-S127 and total YAP1 protein expression was determined by western blotting.   
pYAP-S127 was detected in the samples at 65kDa, whereas total YAP1 was detected at 54kDa.  B. 
pYAP-S127 and C. total YAP1 protein expression in each sample was normalised to the -actin 
loading control and quantified using densitometry.  There was little de-phosphorylation of YAP 
observed in the cells treated with S1P compared to un-treated cells.  Total YAP1 expression remained 
almost unchanged after S1P treatment.   
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4.4. DISCUSSION 
Knock-down of YAP1 by siRNA-mediated transfection caused significant 
sensitisation of the PJ41 SCCHN cell line to reovirus oncolysis (Chapter 3).  The aim 
of this chapter was to explore the effect of YAP1 over-expression on reovirus 
oncolysis in SCCHN cell lines.  To test this, YAP1 was transiently over-expressed in 
the PJ34 SCCHN cell line, as it was the most sensitive to reovirus oncolysis and 
displayed the lowest expression of the YAP1 gene.  Stable-YAP1-over-expressing cells 
were also generated from the HN5 SCCHN cell line, before infection with reovirus 
and assessment of the effect on cell survival.  Transient over-expression of YAP1 in 
the non-cancerous COS-1 monkey fibroblast cell line was also performed in order to 
evaluate whether YAP1 expression affects the susceptibility of different cell types to 
reovirus oncolysis.  Furthermore, the plan was to use a compound that stimulated the 
de-phosphorylation and nuclear localisation of the YAP1 protein in the PJ41 SCCHN 
cell line, and subsequently test the efficiency of reovirus oncolysis.   
Our results showed that plasmid-mediated over-expression of YAP1 in the PJ34 cell 
line caused enhanced resistance to reovirus oncolysis at all MOIs tested compared to 
the negative controls.  The reovirus IC50 of the cells transfected with the EYFP-YAP1 
and Flag-YAP1 plasmids were MOI 77.6 and MOI 27.9 respectively.  This 
corresponded to a 12- and 4-fold increase in resistance to reovirus treatment compared 
to cells treated with lipofectamine or media alone (IC50 values = MOI 6.7).  However, 
it is important to note that empty-vector (EV) controls (i.e. the plasmids without the 
YAP1 insert) were not included in these experiments.  It is therefore probable that 
over-expression of YAP1 induces reovirus resistance in the PJ34 cell line, but we 
cannot confidently conclude this without knowing the effect of non-independent 
variables caused by an EV.  We then used stable transfection as a tool to study the 
effect of increased YAP1 expression on the cellular physiological response to reovirus 
infection over a time period of 72 hours.  Attempts to create stable-YAP1-over-
expressing clones from the PJ34 SCCHN cell line were unsuccessful.  The HN5 
SCCHN cell line proved to be a more efficient transfection host than PJ34 and 
therefore, stable-YAP1-over-expressing clones were created from parental HN5 cells.  
Out of the 3 SCCHN cell lines tested in this study, HN5 cells were the next cell line of 
choice because they were more sensitive to reovirus-induced cell death and had lower 
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endogenous expression of YAP1 than the PJ41 SCCHN cell line. Initially, the reovirus 
IC50 value of stable-EYFP-YAP1-clone 6 was evaluated against the IC50 of the HN5 
parental cell line.  This revealed that EYFP-YAP1-clone 6 (which showed a 5-fold 
over-expression of the YAP1 protein) was 8-, 6- and 3-fold more resistant to reovirus 
than the HN5 parental cell line at 24, 48 and 72 hours post infection respectively.  
This was an interesting result, but caution must be taken since an EV-control plasmid 
was not included for direct comparison.  To address this issue, later on in the project, 
we acquired a pcDNA3.1 EV control plasmid, which contained the same components 
as the Flag-YAP1 plasmid, but without the YAP1-tag insert.  Stable clones were made 
from HN5 parental cells transfected with the EV and Flag-YAP1 plasmids.  Out of all 
the clones tested, Flag-YAP1-clone 2 exhibited a 4-fold increase in total YAP1 protein 
expression.  As expected, the EV-clones did not over-express YAP1 compared to 
HN5 wild-type cells.  Subsequent infection with reovirus revealed that there was some 
non-specific-resistance caused by the EV-clone compared to HN5 parental cells, but 
this effect became less apparent at later times of infection.  Compared to EV-clone 1 
stable cells, Flag-YAP1 clone 6 cells were 2-fold more resistant to reovirus at 24 
hours, and 3-fold more resistant at 48 and 72 hours post-infection.  This was 
statistically significant at MOIs between 7.8 and 62.5 at all time-points tested, and the 
IC50 values of the HN5 parental cell line lied within this range.  There were no 
statistical differences in % cell survival between the EV and Flag-YAP1 stable cell 
lines treated with reovirus at higher MOIs, probably because a high proportion of cells 
were non-viable.  Overall, our results implied that the expression level of YAP1 is 
important in determining the degree of reovirus resistance in the HN5 SCCHN cell 
line, and this paralleled the result of the transient over-expression of YAP1 in the PJ34 
SCCHN cell line.   
It was interesting to discover that stable over-expression of the YAP1 protein in HN5 
cells caused an increase in cell growth rate compared to stable EV-control cells or the 
HN5 parental cell line.  Over-expression of YAP1 also stimulated cell proliferation in 
non-small-cell lung cancer (NSCLC), hepatocellular carcinoma and endometrial 
cancer cell lines [219, 293, 294].  YAP1 is a key regulator of organ size by 
orchestrating cell proliferation and apoptosis, and is a key down-stream target of the 
Hippo signalling pathway [219, 273, 295].  The cellular localisation of YAP has been 
shown to predict its function.  For example, core serine/threonine kinases of the Hippo 
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signalling pathway phosphorylate downstream YAP on serine 127 (S127)) [251], 
which leads to the cytoplasmic retention and inactivation of YAP.  Cell proliferation 
is therefore prevented [252].  In the absence of Hippo signalling, YAP migrates to the 
nucleus where it acts as a cofactor to stimulate expression of genes that promote 
proliferation and inhibit apoptosis [253, 275].  Further work would determine the 
cellular localisation of YAP1 following plasmid-mediated over-expression, and after 
reovirus infection.  Immunofluorescent staining for total YAP1 and cellular 
fractionation followed by immunoblotting would provide evidence for this.  One 
would assume that because over-expression of YAP1 caused an increase in cell 
growth rate, that some exogenous YAP1 would be observed in the nucleus.  However, 
YAP1 can be expressed in the cytoplasm and the nucleus at the same time [252], and 
molecular pathways may not be fixed but may actively change depending on the 
context and upstream input [219, 296].  An explanation for our findings may be that 
over-expression of YAP1 provides a survival advantage to HN5 cells by functioning 
simultaneously as part of an anti-viral response pathway and as a growth promoter, 
and can shuttle between the cytoplasm and the nucleus to meet the needs of the cell.   
Since the cellular location of YAP1 may be an important factor in understanding how 
it may impede reovirus oncolysis in SCCHN, an immunofluorescent stain was 
performed in the PJ41 cell line.   The PJ41 cell line was selected because it displayed 
the highest YAP1 expression and was the most resistant SCCHN cell line to reovirus-
induced cell death (Chapter 3).  Endogenous YAP1 was predominantly localised in 
the cytoplasm of PJ41 cells in its phosphorylated state.  Thus, we attempted to force 
YAP1 into the nucleus using sphingosine-1-phosphate (S1P) and then assess whether 
this affected the ability of reovirus to induce cell death.  S1P has been shown to signal 
through the Gα proteins G12/13 to activate Rho and the actin cytoskeleton, which 
inhibits the core kinases, LATS 1 and 2 of the Hippo signalling pathway.  This in turn 
has been shown to cause de-phosphorylation of YAP at S127, resulting in nuclear 
migration of YAP, enhanced target gene expression and cell proliferation in various 
different cell lines [220].  We were unable to detect significant de-phosphorylation of 
YAP by S1P treatment in the PJ41 cell line, despite repeating the experiment using 
fresh lysates.  However, we unexpectedly observed a 10-fold sensitisation to reovirus 
oncolysis in PJ41 cells treated with S1P (IC50 = MOI 1346.59) compared to PJ41 cells 
treated with reovirus alone (IC50 = MOI 132.26).  This suggested that S1P promotes 
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reovirus oncolysis via a different mechanism than the de-phosphorylation and nuclear 
migration of YAP.  It is therefore still uncertain whether the cellular localisation of 
YAP influences the fate of the cell after reovirus infection.  The fact that we did not 
detect total YAP or pYAP-S127 in HEK293A cell lysates made it difficult to gauge 
the repeatability of the experiment and perhaps the PJ41 cell line, being of different 
origin, needed longer treatment with S1P in order to notice adequate de-
phosphorylation of YAP.  Therefore, it is possible that the de-phosphorylation 
occurred later than 60 minutes and after the addition of reovirus to the cells, which 
may justify the observed S1P-induced sensitisation to reovirus oncolysis.  
Lysophosphatidic acid (LPA) and thrombin have also been shown to promote the 
nuclear accumulation of YAP through interaction with upstream Hippo signalling 
proteins [220, 297].  It may be of value to ascertain whether these small molecules can 
alter the cellular localisation of YAP1 in the PJ41 SCCHN cell line and subsequently 
evaluate the resultant effect on reovirus oncolysis.   It may also be meaningful to test 
these molecules on the stable-YAP1-over-expressing HN5 cells to see whether the 
level of resistance to reovirus changes in comparison to the EV-control stable cell 
line.  There are other known modulators of YAP that stimulate its non-oncogenic 
function, i.e. its phosphorylation, inactivation and cytoplasmic retention.  These 
include verteporforin [298], dobutamine [273], latrunculin A [299] and dasatinib 
[300].  It seemed more logical to use a compound that promoted the nuclear 
localisation of YAP1, as we found it to be mainly expressed in the cytoplasm and was 
phosphorylated at residue S127 in the PJ41 cell line.  However, as some nuclear un-
phosphorylated YAP1 was also detected, it may be interesting to investigate what 
effect the latter molecules have on reovirus oncolysis.    
Although we have identified the YAP1 protein to influence reovirus oncolysis in 
SCCHN cell lines, there are clearly other unknown factors that contribute to this.  
This is not surprising, considering the interconnectivity between molecular signalling 
pathways that tightly control cellular growth, proliferation, differentiation and death, 
and not to mention the biological heterogeneity of SCCHN.  It is important to note 
that S1P specifically targets the upstream kinases of the Hippo pathway.  Although 
this pathway seems to be the dominant regulator of YAP, components from other 
molecular pathways also have the ability to control its function.  Akt (also known as 
protein kinase B (PKB)) is a serine/threonine kinase that can phosphorylate YAP at 
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S127 independently of the Hippo pathway, leading to its cytoplasmic retention [301].  
Cross-talk between the WNT/-catenin [302], TGF [303], GPCR [220] signalling 
and Sonic hedgehog (Shh) [304] signal transduction pathways can cooperate with the 
Hippo pathway to control cell growth and proliferation [278].  Therefore, it is possible 
that the phosphorylated-S127 portion of YAP that we visualised in the cytoplasm of 
PJ41 cells is not due to upstream Hippo signalling.  If this was the case then this may 
explain why we did not detect de-phosphorylation of YAP1 by S1P treatment.  It 
would be interesting to confirm this by monitoring Hippo signalling activities in the 
SCCHN cell lines by using a PCR array, which allows the profile of nearly 400 
related genes to be measured at the same time.  Even if Hippo signalling is not the key 
regulator of YAP1 in these cells, if other up-stream YAP1-related genes could be 
identified, then several genes could be knocked-down or over-expressed all at once.  It 
is uncertain whether altering the expression of multiple genes at the same time would 
be detrimental to cell, but it would be interesting to determine whether this would 
enhance the effect on reovirus oncolysis, as oppose to targeting YAP1 on its own.  
Another factor to consider is the mammalian YAP co-protein, TAZ (see Figure 4.1).  
TAZ has a similar molecular structure and function to YAP and contains 
serine/threonine residues that can be phosphorylated by upstream Hippo kinases.  
Like YAP, TAZ binds to transcription factors in the nucleus to stimulate expression of 
growth promoting genes.  YAP is a relatively stable protein that is mainly regulated 
by cytoplasmic-nuclear shuttling.  Unlike YAP however, TAZ is a very unstable 
protein that has a short half-life of less than two-hours, which suggests that the main 
path of TAZ inhibition is through protein degradation [276].  TAZ was not one of the 
genes selected in our original DNA microarray screen, but it would be intriguing to 
see whether the simultaneous knock-down of YAP and TAZ augments the cells’ 
susceptibility to reovirus oncolysis even more so than knock-down of YAP1 alone.   
S1P is a downstream product of sphingolipids, which are bioactive lipid mediators 
[305].  S1P is an extracellular ligand for sphingosine-1-phosphate receptor 1 (S1PR1), 
a G-protein coupled receptor, and is a key regulator of the immune and vascular 
systems.  S1P-cell surface receptor signalling regulates angiogenesis, permeability, 
vascular stability and the trafficking of T- and B- cells from lymphoid organs into the 
lymphatic vessels [306].  S1P regulation has been shown to drive tumorigenesis and 
neovascularisation [307].  The effects of S1P on host cell defences against virus 
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infection is not well understood, but over-expression of sphingosine kinase-1 (SK1) 
(which converts sphingosine to S1P) increased the susceptibility of human HEK293 
embryonic kidney cells to influenza virus infection [305].  In a similar way, perhaps 
S1P treatment in PJ41 SCCHN cells heightened the cells’ susceptibility to reovirus 
infection.   
COS-1 is an SV40-transformed monkey fibroblast-cell line, and is an amenable 
transfection host.  Fibroblasts derived from other species are often used to study the 
function of human genes and their protein products [132, 133].  Our findings 
demonstrated a 21-fold over-expression of the YAP1 protein in COS-1 cells after 
plasmid-mediated transfection.  This consequently caused a 10-fold increase in 
resistance to reovirus oncolysis compared to EV-control treated cells.  This implied 
that over-expression of YAP1 may be a universal factor that promotes reovirus 
resistance in other cell types and is not only associated with SCCHN cell lines.  This 
would be worth further investigation and is something to consider for future work.   
However, in order to address our original study objectives, we concentrated on the 
effect of YAP1 expression in SCCHN.  Transfection with the EV-control plasmid had 
little effect on cell survival after reovirus infection in the non-cancerous COS-1 cell 
line, but caused a certain amount of non-specific resistance to reovirus in the SCCHN 
HN5 cell line.  This may have been a consequence of chromosomal instability caused 
by the combined dysfunctional effects of oncogenes and tumour suppressor genes in 
tumour cells [308], which would not be present in a non-cancerous genome.  
Therefore, integration of the EV-control plasmid in HN5 cells may have caused new 
mutations that affected anti-viral-related host genes, giving rise to a more resistant 
phenotype.  It is also worthy to note that the reovirus IC50 value of COS-1 cells at 48 
hours post-infection was MOI 11.1.   In contrast to the mean IC50 values calculated at 
the same time-point (Chapter 3, Section 3.3.2), transformed-COS-1 cells were more 
susceptible to reovirus oncolysis than the un-transformed MRC-5 human lung 
fibroblast cell line (IC50 = MOI 2769.7), and PBMCs isolated from the blood of a 
human healthy donor (IC50 = MOI 1509.6).  This concurs with what is documented in 
the literature, that transformed cell lines are more susceptible to reovirus-induced cell 
death than un-transformed cell lines [124, 125].  In relation to the SCCHN cell lines, 
COS-1 cells had approximately equal reovirus sensitivity to HN5 cells at 48 hours 
post-infection.   
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4.5.   CONCLUSION 
Stable over-expression of YAP1 in the HN5 SCCHN cell line significantly increased 
the resistance to reovirus oncolysis.  Transient over-expression of the YAP1 protein 
likely contributes to enhanced reovirus resistance in the PJ34 SCCHN cell line, and 
undoubtedly does so in COS-1 monkey kidney fibroblast cells.  Our attempts to 
detect de-phosphorylation of YAP1 by S1P in the PJ41 SCCHN cell line was 
unsuccessful, but treatment with S1P did consequently sensitise cells to reovirus 
oncolysis.  It is unclear how S1P mediates this effect as it appears to act 
independently of YAP, which emphasises the complexity of the cellular response to 
reoviral infection in the PJ41 cell line.  Overall, our results implied that the level of 
YAP1 expression is important in determining the susceptibility of SCCHN cell lines, 
and possibly other cell lines of different origin, to reovirus-induced cell death.  
Understanding how YAP1 facilitates this in SCCHN could potentially lead to its use 
as a biomarker of treatment response in clinical trial patients receiving reovirus 
therapy, and will therefore be studied in more detail in Chapter 5.  The expression of 
YAP1 will also be analysed in human head and neck carcinoma tissues compared to 
normal tissue samples.   
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5. MECHANISTIC STUDIES BEHIND THE INFLUENCE OF YAP1 ON 
REOVIRUS ONCOLYSIS IN SCCHN CELL LINES 
5.1   INTRODUCTION 
Reovirus T3D displays great promise as an anti-cancer therapeutic.  The mechanism 
of reovirus oncolysis has been a controversial subject and still remains to be fully 
elucidated.  Understanding this process is important as it could lead to the discovery 
of new biomarkers of reovirus treatment response and thus, improve clinical trial 
design and patient selection.  The most recognized model is based on the idea that 
reovirus exploits aberrant Ras signalling pathways in cancer cells.  However, it is 
becoming widely accepted that this is not always the case.  Ras-transformed tumour 
cells can actually develop resistance to reovirus-induced cytotoxicity [309].  In 
particular, no link between activated Ras signalling and reovirus oncolysis in SCCHN 
cell lines was found [145].  This finding formed the rationale for this project; to test a 
panel of target genes that may be involved in, or predict for, reovirus-mediated 
oncolysis.  We have so far established that host-cell expression of the YAP1 protein 
effects the susceptibility of SCCHN cell lines to reovirus-induced cell death.  Finding 
the mechanism of how YAP1 mediates this effect is the purpose of this chapter, and 
hence, it is imperative to discuss the known factors that can affect reovirus oncolysis.   
In addition to the components of Ras signalling, abnormalities in other signalling 
pathways may affect the oncolytic tropism of reovirus.  Both oncogene activations 
and inactivation of tumour suppressor genes contribute to carcinogenesis.  
Dysfunction of p53, ataxia telangiectasia mutated (ATM) and pRb tumour suppressor 
genes can increase genomic instability and disturb cell cycle control, apoptotic 
signalling and intact interferon responses to viral infection [310, 311].  It has been 
demonstrated that inactivating mutations in these tumour suppressor genes enhanced 
the susceptibility of human cancer cells to oncolytic viruses, including adenovirus, 
myxoma virus and reovirus, compared to cancer cells with normal p53, ATM and pRb 
activity [310, 312].  Another factor known to affect reovirus oncolysis is cell cycle 
phase.  Heinemann et al observed an increased sensitivity of B16.F10 mouse 
melanoma cells to reovirus-induced cell death after treatment with hydroxyurea, a cell 
synchronizer, which correlated with increased viral replication [313].   
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Apart from direct viral replication, reovirus can induce cancer cell death in different 
ways and thus, there are many potential pathways that YAP1 could be affecting.  
Firstly, programmed necrotic cell death (necroptosis) can be initiated by reovirus 
infection, and is induced by binding of agonists such as tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL), tumour necrosis factor-α (TNF-α) and Fas ligand 
(FasL), to death receptors on the cell surface, including TNFR1, TNFR2 and Fas [314, 
315].  This results in downstream regulation of receptor interacting protein 1 (RIP1) 
or 3 (RIP3), which are hallmark mediators of necroptosis [314-316].  Other known 
mediators of necroptosis include cylindromatosis (CYLD), TNF receptor-associated 
factors (TRAFs), adenine nucleotide translocase (ANT), poly ADP-ribose 
polymerases (PARPs) and reactive oxygen species (ROS) [315, 316].  Although the 
signalling pathways leading to necrosis and necroptosis are evidently separate, there 
are no distinct morphological differences [317].  Like all forms of necrotic cell death, 
necroptosis is characterised by an increase in cell volume, swelling of organelles, 
rupture of the cell membrane and leakage of intracellular contents [317].  Significant 
necrosis was identified in xenograft human SCCHN specimens treated with 
intratumoral injections of reovirus, with no signs of apoptosis [235].  Recent evidence 
suggests that there is substantial interplay between necroptosis and apoptosis, as some 
proteins are shared between both signalling pathways [316].   
Secondly, autophagy has been demonstrated to be yet another mode of reovirus-
induced cell death.  Autophagy is a regulated cellular process in eukaryotic cells that 
functions to deliver cytoplasmic organelles, proteins and macromolecules to the 
lysosome for degradation and recycling.  Reovirus infection of human multiple 
myeloma cell lines caused an induction of autophagy, which was suppressed by the 3-
methyladenine (3-MA) autophagy inhibitor [318].  Endoplasmic reticular (ER) stress 
triggered by Akt-mTOR signalling has been shown to induce autophagy [315, 319].  
Since recent studies have demonstrated that reovirus infection can stimulate ER-
stress-induced apoptosis, it is reasonable to predict that ER signalling can also cause 
autophagic cell death during mammalian reovirus oncolysis.  Supporting this theory, 
infection of Vero cells with avian reovirus induced autophagy through 
PI3K/Akt/mTOR signalling [320].   
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Thirdly, apoptosis is a major mechanism of reovirus-mediated cell death.  The 
morphological hallmarks of apoptosis are cell membrane blebbing, cell shrinkage, 
chromatin condensation and nuclear fragmentation.  Both the S1 and M2 gene 
segments of reovirus T3D play important roles in reovirus-induced apoptosis [243].  
S1 encodes the σ1 protein that is important for virus cell attachment, whereas M2 
encodes the µ1/µ1c outer capsid protein that is cleaved during proteolytic disassembly 
of virions to form ISVPs, suggesting that these are key processes needed for the 
initiation of reovirus-induced apoptosis [243, 321, 322].  There is a high level of 
cross-talk between the intrinsic (mitochondrial-related) and extrinsic (death receptor-
related) apoptotic signalling pathways during reovirus-induced apoptosis [315, 323].  
After infection, TRAIL ligands can bind to cell surface death receptors (DRs), DR4 
and DR5, resulting in the recruitment of Fas-associated death domain (FADD) (an 
adaptor molecule) and pro-caspase-8 and -10 to form the death-inducing signalling 
complex (DISC).  Pro-caspase-8 then becomes cleaved and activated, which in turn 
activates caspase-3 to induce the final apoptotic execution pathway [243, 323-325].  
Additionally, reovirus infection can stimulate mitochondrial signalling.  Activation of 
caspase-8 can induce the cleavage of Bid, a pro-apoptotic BH3-only Bcl-2 family 
protein.  Truncated Bid then migrates to the mitochondria and disrupts the interactions 
between pro-apoptotic (Bax and Bak) and anti-apoptotic (Bcl-2 and Bcl-xL) proteins, 
which forms a pore in the mitochondrial membrane, allowing the release of pro-
apoptotic proteins cytochrome c and second mitochondrion-derived activator of 
caspases (Smac) [242, 243].  Release of these proteins activates caspase-9 that then 
activates effector caspases-3 and -7 to induce apoptosis [242, 243].  Reovirus 
infection has been shown to activate the transcription factor nuclear factor kappa B 
(NF-κB) to induce apoptosis by stabilization of the p53 tumour suppressor protein 
[229] or by upregulation of TRAIL and DR expression [243].  Noxa, another pro-
apoptotic Bcl-2 family member, has an important role in reovirus-induced apoptosis, 
and its expression is dependent on NF-κB and interferon-regulatory 3 (IRF-3) 
transcription factor activity [326], but can be activated independently of interferon-
beta (IFN-β).  Activation of c-jun N-terminal kinase (JNK) and c-jun, a JNK-
associated transcription factor [327], have been connected to reovirus-induced 
apoptosis, as has increased expression of ER-stress-related genes such as GADD34, 
CHOP, GRP78 and the spliced form of XBP-1, in infected pancreatic cancer cell lines 
[228].  The purpose of the endoplasmic reticulum is to fold and process secretory and 
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transmembrane proteins.  A balance between ER protein load and the capacity to 
process must be achieved to enable the correct folding of proteins [328].  Certain 
stimuli such as viral infection can disrupt the normal function of the ER to cause a 
build-up of misfolded and unfolded proteins.  This is coined ER stress.  In an attempt 
to reduce ER stress, the unfolded protein response (UPR) becomes activated [328].  If 
however, normal conditions are not restored, ER stress can cause cell death by 
apoptosis, as demonstrated in reovirus infected human muliple myeloma [329] and 
mutant melanoma cell lines [330].  
Another critical factor that contributes to the efficiency of reovirus oncolysis in both 
in vitro and in vivo systems is the immune system.  Human Type III interferons (IFN), 
namely IFN-1, IFN-2 and IFN-3, are secreted in response to viral infection but 
their exact role remains to be determined.   The Type II IFN- cytokine is not 
produced in response to virus infection [331].  Human type I interferons are a family 
of cytokines that are a major part of the innate response against virus infection, and 
are comprised of one IFN-β and thirteen IFN-α members.  IFN-ώ, IFN-ε, IFN-τ, IFN-
δ, and IFN-κ cytokines are also members of this family but have less important roles 
in anti-viral responses [331].   The type I IFN response is initiated when a virus 
produces dsRNA during replication.  Cell sensors called pattern recognition receptors 
(PRR), including toll-like receptors (TLR), retinoic acid inducible gene-1 (RIG-I), 
melanoma differentiation-associated protein-5 (MDA5) and double-stranded RNA-
activated protein kinase (PKR), recognize and bind to the viral dsRNA, leading to 
activation of transcription factors NF-κB and IRF-3 [331-333].  This results in the 
expression and secretion of type I IFN- and IFN- that bind to the IFN-/ receptor 
(IFNAR) to activate janus kinase-1 (JAK1) and tyrosine kinase-2 (Tyk2), which 
phosphorylate and activate transcription factors, signal transducers and activators of 
transcription (STAT)-1 and -2 [331, 332].  The STAT1-STAT2 complex associates 
with a third transcription factor, interferon regulatory factor-9 (IRF-9), to form a 
heterotrimeric transcription factor complex (ISGF3), which migrates to the nucleus to 
bind to IFN-stimulated response elements (ISREs) that are present in the promoters of 
most IFN-responsive genes.  This interaction stimulates the transcription of anti-viral 
IFN-stimulated genes (ISGs) [331, 332], resulting in inhibition of viral replication.  
Shmulevitz et al showed that compared to non-transformed cells, Ras-transformed 
NIH-3T3 fibroblasts inhibited the expression of certain ISGs and IFN- to enhance 
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reoviral spread and oncolysis [333].  Cancer cells are less able to respond to IFN than 
normal cells, which may partly account for effective reovirus oncolysis [334].    
Reovirus infection of tumour cells can also generate adaptive immune responses.  
There is concern that systemic delivery of reovirus is hindered by B-cell production of 
neutralising anti-reovirus antibodies (NARA) before it reaches the site of the tumour 
[335]. However, anti-tumour activity was still notable after intravenous administration 
of reovirus in patients with advanced cancers, despite finding substantial neutralizing 
anti-reoviral antibody titers [169, 174].  Reovirus may evade NARA by attaching to 
circulating blood cells that carry, transport and protect this virus [179, 225, 336].   
Alternatively, animal models have demonstrated that infection of tumour cells with 
oncolytic viruses may facilitate priming of an anti-tumour response.  For example, 
intratumoral injection of reovirus altered the immune milieu of the tumour 
microenvironment in a melanoma xenograft in vivo model, and was associated with 
the release of inflammatory cytokines and chemokines, including interleukin-6 and -8 
(IL-6 and IL-8) to promote tumour cell killing [335].  
The Hippo signalling pathway functions to control organ size by modulating apoptosis 
and cell proliferation, but the upstream regulation of this pathway is not well 
understood.  To our knowledge, there is no published data directly linking 
Hippo/YAP1 signalling to reovirus infection, although there are potential connections 
that may be worth further exploration.  Firstly, the regulation of apoptosis by YAP1 
could be affecting the efficiency of reovirus oncolysis, as mentioned in the discussion 
of this chapter.  Secondly, the actin cytoskeleton is an upstream regulator of the Hippo 
pathway [337], and reovirus can stabilise cellular microtubules to aid its replication 
[123, 191, 192], suggesting that cytoskeletal components are possible influences.  
Thirdly, the main reovirus receptor, JAM-A, interacts with PDZ-domain containing 
proteins such as ZO-2 [267].  YAP also contains a PDZ-domain and the YAP2 
isoform has been shown to complex with ZO-2 at tight junctions [266].  It could 
therefore be hypothesised that YAP1 mediates resistance at the cell surface to prevent 
reovirus cell entry.  We aim to investigate how host-cell expression of YAP1 affects 
reovirus oncolysis, whether it be through the possible control of viral entry, viral 
replication, innate anti-viral immune responses, the cell cycle, necroptosis, autophagy 
or apoptosis. 
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5.2   STUDY OBJECTIVE  
The objective of this chapter was to investigate how YAP1 expression influences 
reovirus-mediated oncolysis in SCCHN cell lines.     
In order to test this, the following experiments were performed: 
1. Measurement of YAP1 protein levels in SCCHN cell lines and in stable-YAP1-
over-expressing cell lines pre- and post-infection with reovirus by flow cytometry 
analysis, to determine any changes in YAP1 expression after reovirus infection.   
2. Measurement of JAM-A protein levels in SCCHN cell lines and in stable-YAP1-
over-expressing cell lines by flow cytometry analysis, to determine whether 
reovirus entry is restricted at the cell surface.   
3. Immunofluorescent staining and confocal imaging of reovirus protein after 
infection of SCCHN cell lines and stable-YAP1-over-expressing cell lines, to 
assess whether reovirus entry is inhibited at the cell surface membrane.   
4. Measurement of intracellular and extracellular reovirus protein production in 
infected SCCHN cell lines and in stable-YAP1-over-expressing cell lines, by 
TCID50 assay, western blotting or flow cytometry analysis.  This would determine 
whether the rate of reovirus replication or release are being affected.  
5. Measurement of IFN-β secretion in SCCHN cell lines and in stable-YAP1-over-
expressing cells infected with reovirus by the Verikine™ Human IFN-β ELISA 
kit, to examine the influence of the type I interferon anti-viral response.     
6. Determination of YAP1 protein expression in human head and neck cancer tissue 
and normal tissue samples by immunohistochemistry (IHC) staining, in order to 
assess the applicability of using YAP1 as a predictive biomarker of reovirus 
treatment response.   
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5.3  RESULTS 
5.3.1 Total YAP1 protein expression fluctuates after infection with reovirus in 
SCCHN cell lines and in stable over-expressing YAP1 cell lines 
In order to assess the effect of reovirus infection on YAP1 protein expression, we 
measured total YAP1 levels pre- and post- infection with reovirus by flow cytometry 
in PJ34, HN5 and PJ41 SCCHN cell lines, as well as in the EYFP-YAP1-clone 6, 
Flag-YAP1-clone 2, and empty (EV)-clone 1 stable cell lines (Section 2.19).  Cells 
were permeabilised and stained with a total YAP1 primary antibody followed by an 
Alexa Fluor® 546 secondary antibody.  The cells were then analysed on the MACS 
Quant® flow cytometer.  Each cell line was also stained with secondary antibody 
alone, which served as a negative control.  The mean fluorescence intensity (MFI) 
values for the negative control were subtracted from the positive MFI values in each 
cell line.   
PJ34, HN5 and PJ41 cell lines displayed low, medium and high YAP1 expression 
respectively prior to infection with reovirus (0 hours post-infection (hpi)) (Figure 5.1 
A), which correlated with the YAP1 expression pattern in these cells at the mRNA 
level (Figure 3.4).  Numerically, YAP1 expression in PJ41 cells was 13-fold and 47-
fold higher than in HN5 and PJ34 respectively at 0hpi, and was 4-fold higher in HN5 
than in PJ34 cells.  YAP1 expression in EYFP-YAP1-clone 6 was 11-fold higher than 
in HN5, and was 8-fold higher in Flag-YAP1-clone 2 compared to empty (EV)-clone 1 
cells at 0hpi (Figure 5.1 B).  This supported our previous western blotting data 
(Figures 4.7 and 4.8).  Interestingly, EYFP-YAP1-clone 6 and Flag-YAP1-clone 2 
over-expressed YAP1 almost to the levels of the PJ41 cell line (Figure 5.1 A and B).   
There appeared to be a decrease in YAP1 expression after infection with reovirus in 
most of the cell lines, most notably in PJ41, stable EYFP-YAP1 and stable Flag-YAP1.  
However by 48 hours, the level of YAP1 was almost restored back to its natural levels 
(Figure 5.1 A and B).     
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Figure 5.1.  The YAP1 protein fluctuates after infection with reovirus in the SCCHN and stable cell lines.  The mean fluorescence intensity (MFI) of total 
YAP1 was measured at 0, 8, 16, 24 and 48 hours post-infection (hpi) with reovirus at MOI 5 on the MACS Quant® flow cytometer in A. PJ41, HN5 and PJ34 
SCCHN cell lines, and B. HN5 parental and stable empty-vector (EV), EYFP-YAP1 and Flag-YAP1 cell lines.  At 0hpi, PJ34, HN5 and PJ41 cells showed low, 
medium and high levels of YAP1 respectively which correlated with their susceptibilities to reovirus oncolysis.  Results also confirmed the stable over-expression of 
YAP1 in EYFP-YAP1 and Flag-YAP1 cell lines at 0hpi.  There was a decrease in total YAP1 protein expression after infection with reovirus in the cell lines at 16 
and 24hpi, but the level of YAP1 was almost restored back to its natural levels by 48hpi, particularly in PJ41, EYFP-YAP1 and Flag-YAP1 cell lines.   The graphs 
represent preliminary data generated from an independent experiment.   
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5.3.2 JAM-A protein expression did not correlate with the susceptibility of 
SCCHN cell lines to reovirus oncolysis, and was not altered by stable-
over-expression of YAP1 
To test whether the susceptibility of SCCHN cell lines to reovirus oncolysis correlated 
with the expression of the main reovirus cellular receptor, the level of JAM-A was 
determined by flow cytometry in PJ34, HN5 and PJ41 cell lines (Section 2.19).  We 
predicted to see greater JAM-A expression in the most sensitive cell line (PJ34), and 
the least JAM-A expression in reovirus-resistant PJ41 cells.  Cells were stained with a 
JAM-A primary antibody followed by an Alexa Fluor® 546 secondary antibody, and 
then analysed on the MACS Quant® flow cytometer.  Each cell line was also stained 
with secondary antibody alone, which served as a negative control.  The mean 
fluorescence intensity (MFI) values for the negative control were subtracted from the 
positive MFI values in each cell line.   
Figure 5.2 A demonstrates that cell surface expression of JAM-A was lowest in the 
most sensitive cell line (PJ34), and the highest level of JAMA-A was observed in the 
second most resistant cell line (HN5).  There were no statistical differences in JAM-A 
expression between the cell lines (un-paired t-test).  Therefore, there was no clear 
evidence that the level of JAM-A expression predicted for the differences in 
susceptibility to reovirus oncolysis in these cell lines.   
The level of JAM-A expression was also compared in HN5 parental cells, the stable 
empty vector (EV) clone-1, and the stable Flag-YAP1-clone 2 and EYFP-YAP1-clone-
6 over-expressing cell lines.  Cells were prepared and analysed in the same way as 
described above.  Figure 5.2 B shows that over-expression of YAP1 did not 
significantly alter the level of JAM-A expression in the HN5 SCCHN cell line.  There 
were no statistical differences in JAM-A expression between the cell lines (un-paired 
t-test).  This suggested that YAP1-mediated restriction of reovirus oncolysis does not 
occur at the cell surface, via the JAM-A receptor.   
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Figure 5.2.  JAM-A expression does not correlate with the level of reovirus oncolysis in SCCHN 
cell lines, and stable over-expression of YAP1 does not alter the level of JAM-A expression at the 
cell surface.  Cells were stained with a JAM-A primary antibody followed by an Alexa Fluor® 546 
secondary antibody, before analysis on the MACS Quant® flow cytometer.  A.  There was no 
correlation between JAM-A expression and the level of reovirus oncolysis in PJ34, HN5 and PJ41 
SCCHN cell lines.  B.  There was no difference in JAM-A expression between stable-YAP1-over-
expressing cell lines (Flag-YAP1 and EYFP-YAP1) and the stable empty-vector (EV) clone or the 
parental HN5 cell line.  The graphs show the mean of two assay repeats and error bars represent SEM. 
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5.3.3 Reovirus protein can be detected in the cytoplasm of resistant and 
sensitive SCCHN cell lines 
In order to visualise reovirus in the SCCHN cell lines, and to verify whether stable 
over-expression of YAP1 inhibits reoviral entry to the cell, an immunofluorescent 
stain was performed in cells treated with media alone as a negative control, or in cells 
infected with reovirus at MOI 5, 20 or 200 for 24 hours (Section 2.17).  Cells were 
permeabilised and stained with an anti-reovirus T3D antiserum.  A secondary 
antibody conjugated to a fluorescent dye was then used to visualise the reovirus 
protein by confocal microscopy.  PJ34 and PJ41 cell lines were probed with an Alexa 
Fluor® 488 secondary antibody.  Since the EYFP-tag fluoresces under the 488 
wavelength of light, a different secondary antibody (Alexa Fluor® 546) was used to 
compare reovirus infection between HN5 parental cells and the EYFP-YAP1 stable 
cell line.  A nuclear marker, TO-PRO-3, was used in all cell lines to help localise 
reovirus in the cells.  PJ34 and PJ41 cells were also stained with a cell membrane 
marker, wheat germ agglutinin (WGA).   
Reovirus was detected in the cytoplasm of all cell lines, which is where reovirus 
replication is known to take place [99].  Reovirus-positive cells were detected to 
similar levels at moderate MOI in sensitive PJ34 and resistant PJ41 cell lines.  At high 
MOI 200, PJ34 cells looked saturated with reovirus and there were fewer viable cells 
than PJ41 (Figure 5.3).  No co-localisation of reovirus and WGA was observed on the 
cell surface, as this would have resulted in a yellow pigmentation.  There appeared to 
be equal numbers of HN5 parental and stable EYFP-YAP1 cells positive for reovirus 
protein, although the staining intensity did appear slightly brighter in HN5 cells at 
MOI 5 and 20 (Figure 5.4).  However, it was difficult to definitively conclude this 
due to the subjective nature of the assay, and a more quantitative method was required 
to confirm any differences in intracellular reovirus protein production between these 
cell lines.  Although a cell membrane stain was not included for the HN5 and EYFP-
YAP1 cells, it was evident that reovirus protein was only localised inside the cells and 
not on the cell membrane.  Taken together with the JAM-A expression data, these 
results suggested that the variation in susceptibility to reovirus-induced cell death in 
PJ34 and PJ41 SCCHN cell lines, and the reovirus resistance accompanying YAP1 
over-expression, does not seem to be cell surface receptor-mediated.   
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Figure 5.3.  Reovirus infected both sensitive (PJ34) and resistant (PJ41) SCCHN cell lines at 
different multiplicities of infection (MOI).  Cells were treated with media alone (no reovirus) or 
infected with reovirus at MOI 5, 20 or 200 for 24 hours.  Resistant-PJ41 and sensitive-PJ34 cell lines 
were permeabilised, stained with an anti-reovirus T3D antiserum and an Alexa Fluor® 488 secondary 
antibody.  Cells were then imaged using the same confocal microscope settings at ×40 magnification.  
Reovirus protein was detected in both cell lines at all MOIs, as shown by the green staining.  No green 
staining was detected in the absence of reovirus infection.  Wheat germ agglutinin (WGA) was used as 
a cell membrane marker (red stain) and TO-PRO-3 was used to detect the cell nucleus (blue stain).   
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Figure 5.4.  Reovirus can infect HN5 parental cells and the more resistant-EYFP-YAP1 stable cell 
line at different multiplicities of infection (MOI).  Cells were treated with media alone (no reovirus) 
or infected with reovirus at MOI 5, 20 or 200 for 24 hours.  EYFP-YAP1 and HN5 cell lines were 
permeabilised, stained with an anti-reovirus T3D antiserum and an Alexa Fluor® 546 secondary 
antibody.  Cells were then imaged using the same confocal microscope settings at ×40 magnification.  
We did not distinguish a difference in the number of cells infected between the two cell lines, but the 
staining intensity appeared slightly brighter in HN5 than in EYFP-YAP1 cells.  No red staining was 
detected in the absence of reovirus infection.  TO-PRO-3 was used to detect the cell nucleus (blue 
stain).   
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5.3.4 The rate of intracellular reovirus protein production in PJ34, HN5 and 
PJ41 SCCHN cell lines did not correlate with their reovirus IC50 values 
As the differences in reovirus IC50 in the SCCHN cell lines are probably not due to 
the prevention of reovirus entry at the cell membrane, we questioned whether it was 
due to an obstruction of a step in the viral replication life cycle inside the host cell.  
Intracellular reovirus yield was quantitatively measured in infected SCCHN cell lines.  
Since increased reovirus replication has been shown to correlate with enhanced 
reovirus oncolysis in various cancer cell lines [135, 142, 338-340], we predicted to 
observe a similar trend in SCCHN cells.   
Infectious reovirus titre was determined by one-step growth curve analysis via the 
50% tissue culture infective dose (TCID50) assay (Section 2.20).  PJ34, HN5 and PJ41 
SCCHN cell lines were infected with reovirus at MOI 5 for 4, 20, 24, 48 or 72 hours.   
Intracellular viral samples were prepared as described in Section 2.20.1, and used to 
infect a monolayer of L929 mouse fibroblast cells.  The cytopathic effect (CPE) in 
each sample was determined using light microscopy after 3 days.  In this experiment, 
MOI 5 was used because reovirus was capable of infecting SCCHN cells at this 
concentration, as displayed in Figure 5.3 and Figure 5.4.  In addition, it was 
important to use an MOI that would not saturate the resistance associated with the 
PJ41 cell line or cause major cell death in the sensitive PJ34 cell line.       
Figure 5.5 demonstrates viral growth in PJ34, HN5 and PJ41 SCCHN cell lines over 
the 72 hour time-period.  One cycle of reovirus replication takes approximately 18 to 
24 hours in permissive cell lines [340].  Thus, by 20 hours, the viral titre in all cell 
lines increased by at least 2-logs as newly synthesised virus proteins would have been 
generated.  Surprisingly, the viral titre between the cell lines, especially in HN5 and 
PJ34, was not that different and lacked statistical significance (one-way ANOVA and 
Tukey’s post-hoc test).  The titres were not as well spread as what we would have 
expected them to be (less than 1-log difference), considering their variable reovirus 
IC50 values.  The extensive over-lap in the viral growth curves of the cell lines led us 
to believe that there was no distinct relationship between reovirus replication and 
reovirus oncolysis.   
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Lysates were also collected from PJ34, HN5 and PJ41 cells infected with reovirus at 
MOI 5 for 24, 48 or 72 hours.  Total intracellular reovirus protein in the samples was 
compared by western blotting (Section 2.14) by probing with an anti-reovirus T3D 
antiserum.   
We were unable to detect a clear band at 160kDa, which is the expected molecular 
weight of the λ reovirus protein.  The combination of MOPS running buffer and 
Novex® 4-12% Bis-Tris gels used in these assays is apparently capable of detecting 
proteins as large as 260kDa.  Perhaps a lower percentage gel would have improved 
the detection of the λ protein.  Nevertheless, bands at approximately 80kDa and 
40kDa corresponded to reovirus proteins µ and σ respectively.  Figure 5.6 A shows 
that there were subtle differences in total intracellular reovirus protein expression, but 
it was not as variable as we predicted.  The intensity of viral µ and σ bands in each 
sample was quantified and normalised to their corresponding α-tubulin bands by 
densitometry analysis (Section 2.14.4) (Figure 5.6 B).  Total intracellular reovirus 
protein production in these cells did not correlate with their reovirus IC50 values.  For 
example, there was little difference in the levels of µ and σ in PJ34 and HN5 at 24hpi 
and 72hpi, and between HN5 and PJ41 cells at 48hpi.  Admittedly, the α-tubulin 
western blot showed some uneven loading, despite using the BCA protein assay for 
equilibration (Section 2.14.1).  However, normalising the reovirus protein bands to 
their respective α-tubulin bands by densitometry showed that the western blotting data 
generally supported the results of the TCID50 assay.  This re-enforced our conclusion 
that direct reovirus replication is probably not the predominant route of cell death 
induced by reovirus infection in PJ34, HN5 and PJ41 SCCHN cell lines.  
165 
 
 
Figure 5.5.  Infectious intracellular reovirus yield in PJ34, HN5 and PJ41 SCCHN cell lines did 
not correlate with their reovirus IC50 values, as determined by the 50% tissue culture infective 
dose (TCID50) assay.  Intracellular infectious reovirus titre was evaluated in PJ34 (yellow triangles), 
HN5 (orange squares) and PJ41 (red circles) SCCHN cell lines infected with reovirus at MOI 5 for 4, 
20, 24, 48 or 72 hours.  There was extensive over-lap in the viral growth curves of the cell lines.  Viral 
titre is shown on a log10 scale.  The graph shows the mean of two assay repeats and error bars 
represent SD.      
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Figure 5.6.  Total intracellular reovirus protein did not correlate with the susceptibility to 
reovirus oncolysis in PJ34, HN5 and PJ41 SCCHN cell lines, as determined by western blotting.  
Whole cell lysates were collected from PJ34, HN5 and PJ41 cells infected with reovirus at MOI 5 for 
24, 48 or 72 hours.  A.  Reovirus proteins µ (80kDa band) and σ (40kDa band) were resolved on 
Novex® 4-12% Bis-Tris gels and probed with an anti-reovirus T3D antiserum.  The blots were imaged 
at the same exposure enabling direct comparison of band intensity between the samples.  B.  The 
intensity of viral µ and σ bands in PJ34 (yellow bars), HN5 (orange bars) and PJ41 (red bars) were  
quantified and normalised to their corresponding α-tubulin bands at each time-point by densitometry 
analysis.   
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5.3.5 Intracellular reovirus protein production was hindered by stable over-
expression of YAP1 
To test the specific effect of YAP1 over-expression on reovirus replication, we 
measured the rate of intracellular reovirus yield in stably-transfected cell lines using 
quantitative methodologies.   
To begin with, infectious reovirus titre was determined by one-step growth curve 
analysis via the TCID50 assay (Section 2.20) in the stable EV-clone-1, Flag-YAP1-
clone-2 and EYFP-YAP1-clone-6 cell lines, as well as in HN5 parental cells.  Cells 
were infected with reovirus at MOI 5 for 4, 20, 24, 48 or 72 hours.  Intracellular viral 
samples were prepared as described in Section 2.20.1.  An MOI 5 was used to 
evaluate the phenotypic restriction mediated by YAP1 over-expression, as high MOIs 
were previously shown to dampen this effect (Figure 4.10 and Figure 4.11).    
Figure 5.7 A demonstrates the rate of viral growth in stable EYFP-YAP1 cells and the 
HN5 parental cell line.  There was less intracellular reovirus produced over time in 
EYFP-YAP1 cells than in HN5 cells, which was statistically (un-paired t-test) and 
biologically significant.  Likewise, the virus yield was significantly and consistently 
lower, sometimes by more than 1-log, in stable Flag-YAP1 cells compared to stable 
EV-control cells at all time-points tested (Figure 5.7 B), with clear separation in the 
viral growth curves. This would partially explain the resistance to reovirus oncolysis 
after YAP1 over-expression of HN5 cells.   
Next, lysates were collected from HN5 parental cells, and stable EV-clone-1, Flag-
YAP1-clone-2 and EYFP-YAP1-clone-6 cell lines infected with reovirus at MOI 5 for 
24, 48 or 72 hours.  The production of total intracellular µ and σ reoviral proteins in 
the samples was determined by western blotting (Section 2.14).  The expression 
levels of µ and σ was considerably lower in stable EYFP-YAP1 than in HN5 parental 
cells at all time-points tested.  There was some non-specific effect caused by the 
stable EV-control cell line, although the expression of µ and σ was still lower in stable 
Flag-YAP1 cells (Figure 5.8 and Figure 5.9).  This supported the TCID50 data 
displayed in Figure 5.7, which suggested that infectious viral titre correlated with 
non-infectious viral titre.  
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Additionally, we measured total intracellular reovirus protein production in HN5 
parental cells, and in EV-clone-1, Flag-YAP1-clone-2 and EYFP-YAP1-clone-6 stable 
cell lines by flow cytometry (Section 2.19).  Cells were infected with reovirus at MOI 
5 for 16, 24, 48 and 72 hours, before being permeabilised and stained with an anti-
reovirus T3D antiserum, followed by an Alexa Fluor® 546 secondary antibody.  The 
samples were then analysed on the MACS Quant® flow cytometer.  Each cell line 
was also stained with secondary antibody alone, which served as a negative control.  
The mean fluorescence intensity (MFI) values for the negative control were subtracted 
from the positive MFI values in each cell line.   
In comparison to HN5 parental or stable EV-cell lines, total intracellular reovirus 
expression levels were substantially lower in stable EYFP-YAP1 and Flag-YAP1 cells 
respectively, at all time-points tested (Figure 5.10 A and B).  These results concurred 
with the TCID50 data displayed in Figure 5.7 and with the western blots presented in 
Figure 5.8 and Figure 5.9.  There were some non-specific effects caused by the stable 
EV-control cell line.  It is also important to note that the viral titre in HN5 cells in 
Figure 5.7 did vary slightly from the titre measured in Figure 5.5, which is likely due 
to the fact that these experiments were performed at separate times in the project, and 
with different cell passages.  However, the viral titre could be compared between cell 
lines within the same experiment.   
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Figure 5.7.  The rate of infectious intracellular reovirus was hindered by stable over-expression 
of YAP1 in the HN5 SCCHN cell line, as determined by the 50% tissue culture infective dose 
(TCID50) assay.  Intracellular infectious reovirus titre was compared in A.  HN5 parental (blue 
triangles) and stable EYFP-YAP1 (red circles) cells and B.  HN5 parental (blue triangles), stable empty 
vector (EV) cells (green triangles), or stable Flag-YAP1 (red circles) cells, infected with reovirus at 
MOI 5 for 4, 20, 24, 48 or 72 hours.  Viral titre was consistently lower in EYFP-YAP1 and Flag-YAP1 
cell lines compared to HN5 and EV-control cells respectively.  Viral titre is shown on a log10 scale.  
**p<0.01, ***p<0.001 and ****p<0.0001 by un-paired t-test.  The graphs show the mean of two assay 
repeats and error bars represent SD.      
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Figure 5.8.  The rate of total intracellular reovirus protein production was hindered by stable 
over-expression of YAP1 in the HN5 SCCHN cell line, as determined by western blotting.   Whole 
cell lysates were collected from HN5 parental and stable EYFP-YAP1 cell lines infected with reovirus 
at MOI 5 for 24, 48 or 72 hours.  A.  Reovirus proteins µ (80kDa band) and σ (40kDa band) were 
resolved on Novex® 4-12% Bis-Tris gels and probed with an anti-reovirus T3D antiserum.  The blots 
were imaged at the same exposure enabling direct comparison of band intensity between the samples.  
There was less µ and σ protein in stable EYFP-YAP1 than in HN5 cells at all time-points tested.  B.  
The intensity of viral µ and σ bands in HN5 (blue bars), EYFP-YAP1 (red bars) were quantified and 
normalised to their corresponding α-tubulin bands at each time-point by densitometry analysis.  The 
relative density is shown on a log10 scale.   
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Figure 5.9.  The rate of total intracellular reovirus protein production was hindered by stable 
over-expression of YAP1 in the HN5 SCCHN cell line, as determined by western blotting.  Whole 
cell lysates were collected from HN5 parental, stable empty vector (EV) and stable Flag-YAP1 cell 
lines infected with reovirus at MOI 5 for 24, 48 or 72 hours.  A.  Reovirus proteins µ (80kDa band) and 
σ (40kDa band) were resolved on Novex® 4-12% Bis-Tris gels and probed with an anti-reovirus T3D 
antiserum.  The blots were imaged at the same exposure enabling direct comparison of band intensity 
between the samples.  There was less µ and σ protein in stable Flag-YAP1 than in stable EV and HN5 
parental cells at all hours post-infection (hpi).  B.  The intensity of viral µ and σ bands in HN5 (blue 
bars), stable EV (green bars) and stable Flag-YAP1 (red bars) cells were quantified and normalised to 
their corresponding α-tubulin bands at each time-point by densitometry analysis.  The relative density 
is shown on a log10 scale.   
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Figure 5.10.  The rate of total intracellular reovirus protein production was hindered by stable 
over-expression of YAP1 in the HN5 SCCHN cell line, as determined by flow cytometry.  The 
mean fluorescence intensity (MFI) of total intracellular reovirus protein was measured at 16, 24, 48 and 
72 hours post-infection (hpi) with reovirus at MOI 5 by the MACS Quant® flow cytometer in A. HN5 
parental (blue bars) and EYFP-YAP1 (red bars) and B. HN5 parental (blue bars), stable empty-vector 
(EV) (green bars) and stable Flag-YAP1 (red bars) cell lines.  In comparison to HN5 parental or stable 
EV-cell lines, total intracellular reovirus expression levels were substantially lower in stable EYFP-
YAP1 and Flag-YAP1 cells at all time-points tested.  The graphs represent preliminary data generated 
from an independent experiment. 
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5.3.6 Extracellular reovirus secretion was indistinguishable in the SCCHN cell 
lines and was not hindered by stable over-expression of YAP1 
Certain studies have suggested that reovirus oncolysis not only depends on effective 
intracellular virus production, but also on the efficient release of progeny virus for 
cell-to-cell spread.  We therefore assessed whether there were any differences in 
extracellular virus in infected SCCHN cell supernatants, and whether extracellular 
virus secretion is affected by over-expression of YAP1 in HN5 cells.   
Extracellular reovirus titre was determined by the TCID50 assay (Section 2.20) in the 
most sensitive PJ34 and most resistant PJ41 SCCHN cell lines.  In a separate 
experiment, viral titre was also compared in stable EYFP-YAP1-clone-6 and HN5 
parental cell lines.   Cells were infected with reovirus at MOI 5 at various time-
intervals up to 72 hours.  Extracellular viral samples were prepared as described in 
Section 2.20.1 and used to infect a monolayer of L929 mouse fibroblast cells.  The 
cytopathic effect (CPE) in each sample was determined using light microscopy after 3 
days.  
Figure 5.11 A displays the rate of viral release in PJ34 and PJ41 cell lines.  There 
were statistical differences in extracellular virus yield between the cell lines at some 
time-points post infection, albeit only having up to half a log difference.  However, 
overall there was much overlap in viral release over-time and there was no clear 
distinction in extracellular viral yield at early or late times of infection.  Thus, we 
concluded there to be little difference in extracellular viral release between PJ34 and 
PJ41 cell lines, despite their variable susceptibilities to reovirus oncolysis.  Figure 
5.11 B shows the rate of viral release in HN5 parental and stable EYFP-YAP1 cell 
lines.  Since more intracellular virus was detected in the parental HN5 cell line than 
the stable EYFP-YAP1 cell line, we predicted to see a similar trend in the levels of 
extracellular virus.   Biologically, the difference in virus release between HN5 and 
EYFP-YAP1 cells were not that relevant (less than half a log), despite being 
statistically significant at some time points post-infection (un-paired t-test).  If 
anything, there was slightly more extracellular virus in stable EYFP-YAP1 cells, but 
the viral growth curves were not well separated.  This disproved our hypothesis, as 
over-expression of YAP1 did not drastically alter extracellular secretion of reovirus.   
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Figure 5.11.  There was little difference in extracellular reovirus secretion in PJ34 and PJ41 
SCCHN cell supernatants, or in HN5 parental and stable YAP1 over-expressing cell 
supernatants.  Extracellular reovrus titre was compared in A.  PJ34 (yellow triangles) and PJ41 (red 
circles) cell supernatants or in B.  HN5 parental (blue triangles) and stable EYFP-YAP1 (red circles) 
cell supernatants, infected with reovirus at MOI 5 for up to 72 hours by the TCID50 assay.  There was 
extensive overlap in the viral growth curves with no clear separation between the cell lines, which 
implied that there was no relationship between extracellular secretion of reovirus and reovirus 
oncolysis.  Viral titre is shown on a log10 scale.  *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 
by un-paired t-test.  The graphs show the mean of two assay repeats and error bars represent SD.      
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5.3.7 IFN-β secretion from SCCHN cell lines correlated with their respective 
reovirus IC50 values, but was not consistently altered by over-expression 
or knock-down of YAP1 
Infection with many viruses, including reovirus, can stimulate a cascade of events that 
can induce expression and secretion of type I IFN by the host cell, such as IFN-β.  
Thus, the profile of IFN-β secretion before and after reovirus infection was assessed 
in PJ34, HN5 and PJ41 SCCHN cell lines, which was compared to their respective 
reovirus IC50 values.  All SCCHN cell lines and human PBMCs (used as a positive 
control) were treated with media (un-infected sample) or infected with reovirus at 
various MOI for 24 hours.  The supernatants were then harvested and used to quantify 
the levels of secreted IFN-β by the Verikine™ Human IFN-β ELISA kit (Section 
2.21).  Figure 5.12 demonstrates the levels of IFN-β secreted by PJ34, HN5 and PJ41 
SCCHN cell lines, with and without reovirus infection.  As the MOI used to infect the 
cells increased, so did the level of IFN-β secreted by the cells.  PJ41 supernatants 
contained the highest levels of IFN-β, HN5 displayed intermediate levels and PJ34 
showed the lowest levels.  This correlated with their sensitivities to reovirus-mediated 
cell death.  All infected SCCHN cells produced IFN-β to equal or greater levels than 
the PBMC positive control.  IFN-β was virtually un-detectable in un-infected cell 
samples.  A small amount of IFN-β was observed in un-infected PJ41 cell 
supernatants, but the levels were below the limit of detection of the assay (<50 
pg/mL) and it was therefore considered to be a negative value.  IFN-β produced from 
infected cells at an earlier time-point (twelve-hours) was also measured, which 
showed a similar pattern in expression, but the levels were below the limit of 
detection (data not shown).   
Subsequently, in another assay, we determined whether the resistance associated with 
over-expression of YAP1 is due to increased type I interferon signalling.  IFN-β 
secretion was evaluated in HN5 parental, and stable EV-clone-1, EYFP-YAP1-clone-6 
and Flag-YAP1-clone-2 cell supernatants, pre- and post- infection with reovirus for 24 
hours (Section 2.16.3), by the Verikine™ Human IFN-β ELISA kit (Section 2.21).  
Non-infected and infected human PBMC cell supernatants were included as a positive 
control for IFN-β secretion (Section 2.21.1).  Figure 5.13 displays the level of IFN-β 
produced by these cells.  Compared to HN5 parental cells, there was no significant 
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alteration in IFN-β secretion in the stable EYFP-YAP1 cell line when infected with 
reovirus at MOI 5 and MOI 100.  In comparison to the stable EV-clone, stable Flag-
YAP1 cells produced almost 2-fold more IFN-β when infected with reovirus at MOI 
100 (p<0.05 by un-paired t-test), but there was no difference in IFN-β expression at 
MOI 5.  Again, there was a positive dose-response relationship between reovirus MOI 
and IFN-β secretion.  All infected cell lines produced greater amounts of IFN-β than 
the PBMC positive control.  Small traces of IFN-β were detected in un-infected cell 
line supernatants, but were regarded as negative values as they were below the limit of 
detection.    
In a separate experiment, we assessed whether the sensitivity associated with siRNA-
mediated knock-down of YAP1 in the PJ41 SCCHN cell line is a result of decreased 
type I interferon signalling.  PJ41 cells were transiently transfected with YAP1 siRNA 
(ID: s20368) or negative control siRNA, or treated with Neo FX transfection agent 
alone, or with media alone (Section 2.13.2).  After 48 hours post-transfection, the 
cells were infected with reovirus at MOI 5 or MOI 100, or treated with media alone 
(no reovirus sample) for 24 hours (Section 2.13.3), before measuring IFN-β secretion 
by the Verikine™ Human IFN-β ELISA kit (Section 2.21).  Compared to the negative 
control siRNA treated cells, there was no significant change in IFN-β production in 
the cells transfected with YAP1 siRNA at MOI 5 or MOI 100 (Figure 5.14).  A small 
amount of IFN-β was produced in un-infected media alone cell supernatants, but it 
was below the limit of detection and was therefore considered to be negative.   
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Figure 5.12.  The levels of IFN-β secreted by PJ34, HN5 and PJ41 SCCHN cell lines after 
infection with reovirus correlated with their sensitivities to reovirus oncolysis.  SCCHN cell lines 
and human PBMCs (used as a positive control for IFN-β) were treated with media (no reo, purple bars) 
or infected with reovirus at MOI 5 (green bars), 10 (orange bars), 50 (blue bars) or 100 (yellow bars) 
for 24 hours.  The supernatants were then harvested and used to quantify the levels of secreted IFN-β 
by the Verikine™ Human IFN-β ELISA kit.  The limit of detection (50pg/ml) of the assay is displayed 
on the graph as a solid line.  The IFN-β levels are shown on a log10 scale and error bars represent the 
SD from two independent experiments.   
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Figure 5.13.  Stable over-expression of YAP1 in the HN5 SCCHN cell line did not consistently 
increase the levels of IFN-β secretion after infection with reovirus.  HN5 parental, stable empty-
vector (EV), EYFP-YAP1, Flag-YAP1 and human PBMC positive control cells were treated with media 
(no reo, purple bars) or infected with reovirus at MOI 5 (green bars) or 100 (yellow bars) for 24 hours.  
The supernatants were then harvested and used to quantify the levels of secreted IFN-β by the 
Verikine™ Human IFN-β ELISA kit.  Compared to HN5 parental cells, there was no significant 
alteration in IFN-β secretion in EYFP-YAP1 cells infected with reovirus at either MOI.  In comparison 
to the EV-clone, Flag-YAP1 cells produced two-fold more IFN-β when infected with reovirus at MOI 
100 (*p<0.05 by un-paired t-test), but there was no difference in IFN-β expression at MOI 5.  The limit 
of detection (50pg/ml) of the assay is displayed on the graph as a solid line.  The IFN-β levels are 
shown on a log10 scale and error bars represent the SD from two independent experiments.   
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Figure 5.14.  siRNA-mediated knock-down of YAP1 in the PJ41 SCCHN cell line did not decrease 
the levels of IFN-β secretion after infection with reovirus.  PJ41 cells were transiently transfected 
with YAP1 siRNA (ID: s20368) or negative control siRNA, or treated with Neo FX transfection agent 
alone, or with media alone.  After 48 hours post-transfection, the cells were treated with media alone 
(no reo, purple bars), or infected with reovirus at MOI 5 (green bars) or MOI 100 (yellow bars) for 24 
hours, before measuring IFN-β secretion by the Verikine™ Human IFN-β ELISA kit.  There was no 
significant difference in IFN-β production between negative control siRNA treated cells or the cells 
transfected with YAP1 siRNA at either MOI.  The limit of detection (50pg/ml) of the assay is displayed 
on the graph as a solid line.  The IFN-β levels are shown on a log10 scale and error bars represent the 
SD from two independent experiments.   
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5.3.8 Detection of the YAP1 protein in SCCHN tissue and normal tissue 
Our results so far suggest that YAP1 has the potential to be used as a biomarker to 
predict the anti-tumour effects of reovirus in clinical applications of SCCHN.  The 
likely method of detection of the YAP1 protein would be staining of tumour tissue 
samples directly resected from SCCHN patients.  Therefore, we determined whether 
YAP1 could be detected not only in SCCHN cell lines, but also in SCCHN tissue, and 
whether there was any difference in YAP1 expression compared to in normal tissues.   
First, the enzymatic immunohistochemistry (IHC) staining protocol (Section 2.22) 
was optimised in prostate cancer (PCa) tissue, which was recommended as the 
positive control by the supplier of the YAP1 primary antibody (Abcam, UK).  The 
Human Protein Atlas [341] and published research [222] have also shown positive 
nuclear and cytoplasmic YAP1 staining in different PCa tissues.  Sections of the 
tissue were stained using different dilutions of the primary antibody.   Figure 5.15 
shows that the PCa tissue was positive for the YAP1 protein (cytoplasmic and nuclear 
brown staining), and the optimal primary antibody dilution was 1:400.  The procedure 
was also performed in the absence of the primary antibody as a negative control, 
which was completely negative and only displayed blue coloration as a result of 
counter staining with haematoxylin.   
The enzymatic IHC staining procedure (Section 2.22) for the detection of YAP1 was 
then performed on a head and neck cancer tissue microarray (US Biomax, cat: 
HN803a).  A system was utilised to score the tissues as 0, +1, +2 or +3, according to 
the intensity of brown coloration.  Upon inspection of the head and neck cancer cores, 
it was clear that some did not contain any evidence of tumour.  Therefore, these were 
excluded from the analysis as they would not represent a true evaluation for YAP1 
expression in head and neck cancer.  Out of a total of 64 carcinoma of the head and 
neck tissue cores, 8 (13%) stained positive for the YAP1 protein.  The cellular 
localisation of YAP1 in these tissues varied, as 4 cores displayed cytoplasmic, 1 
showed nuclear, and 3 exhibited both cytoplasmic and nuclear staining.  The array 
also contained 10 normal tissues derived from tongue or pharynx, and 1 normal 
adjacent tissue derived from tongue.  All stained negative for YAP1.  Examples of 0, 
+1, +2 and +3 IHC YAP1 intensity staining for both normal tissue and tumour tissue 
are shown in Figure 5.16.   Demographic details for the tissues on the HN803a array 
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are shown in Table 5.1, including the IHC YAP1 intensity scores and YAP1 cellular 
localisation.   
Enzymatic IHC (Section 2.22) was then used to stain a multiple organ normal tissue 
array (US Biomax, cat: FDA999c) for the YAP1 protein.  Out of a total of 99 tissue 
cores on the array, 9 were normal head and neck tissues.  All 9 normal head and neck 
tissues stained negative for YAP1.  All but two of the other remaining normal tissues 
on the array stained negative for YAP1.  The two normal tissues that stained positive 
for YAP1 originated from kidney and skin.  Both of these tissues showed +1 intensity 
and cytoplasmic YAP1 staining (data not shown).  Demographic details for the tissues 
on the FDA999C array are displayed in Table 5.2, including the IHC YAP1 staining 
intensity scores and cellular localisation.  All tissues were checked and confirmed by 
Dr Silvana Di Palma, a consultant pathologist at The Royal Surrey Hospital.   
YAP1 positive or negative staining of the tissue cores was compared by using the 
Chi-squared (χ2) statistical test, which confirmed that there was a significant 
difference between the head and neck carcinomas and normal tissues from all types of 
organ (p=0.0035) (Table 5.3).  Comparison of the head and neck carcinomas and the 
normal head and neck tissues alone however, did not quite reach statistical 
significance (p=0.097) (Table 5.3).  There were no significant differences between 
tumour grade, age of the patient, sex of the patient or tumour stage (Table 5.3).  IHC 
YAP1 staining intensity scores of the positive head and neck cancer tissues were then 
compared against the cellular localisation of YAP1, tumour grade, age of the patient 
and tumour stage.   Although the sample numbers were small, there were no apparent 
statistical differences in these parameters and YAP1 intensity score (Table 5.4).  No 
follow-up or treatment information was provided with the HN803a head and neck 
cancer array. 
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Figure 5.15.  Optimisation of the enzymatic immunohistochemistry (IHC) staining protocol in 
prostate cancer tissue for the detection of the YAP1 protein.  The enzymatic IHC staining protocol 
was performed on prostate cancer tissue sections as a positive control for the detection of the YAP1 
protein.  In the image on the right, the brown coloration represented positive YAP1 staining in the 
presence of the YAP1 antibody at an optimal dilution of 1:400.  As a negative control, the procedure 
was also performed in the absence of the primary antibody (left image), which showed no brown 
coloration.  Images were photographed at ×20 magnification.   
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Figure 5.16.  Examples of YAP1 protein expression from the FDA999c normal tissue array and 
the HN803a head and neck cancer tissue array, using enzymatic immunohistochemistry (IHC).  
Enzymatic IHC examples of A.  0 intensity staining of normal tongue B. 0 intensity staining of 
squamous cell carcinoma (SCC) of larynx C. +1 staining of SCC of larynx  D. +2 staining of SCC of 
submaxilla and E. +3 staining of SCC of laryngeal pharynx.  The staining intensity score is indicated as 
0, +1, +2, or +3.  YAP1 positive staining in the cytoplasm is shown by the yellow arrows, and nuclear 
staining is shown by the red arrows.  Images were taken at ×10, ×20 and ×40 magnification. 
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Table 5.1.  Demographic data from the HN803a head and neck cancer tissue array, with details of IHC YAP1 intensity scoring and cellular 
localisation.  The array contained a total of 64 cores, each representing a single case.  Tissues highlighted in orange were positive for YAP1.  Normal or 
normal adjacent head and neck tissue (NAT) on the array are highlighted in green.   
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Table 5.2.  Demographic data from the FDA999c multiple organ normal tissue array, with details 
of IHC YAP1 intensity scoring and cellular localisation.  The array contained a total of 99 cores, 
each representing a single case.  Tissues highlighted in orange were positive for YAP1.  Normal or 
normal adjacent head and neck tissue (NAT) on the array are highlighted in green.   
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Table 5.3.  Statistical comparisons of YAP1 protein expression in the tissue sections by the Chi-
squared (χ2) statistical test.  There was a significant difference in YAP positive (+ive) or YAP1 
negative (-ive) staining between head and neck (H&N) carcinoma tissues and all (n=110) of the normal 
tissues (χ2=8.523, p=0.0035, as highlighted in red).  However, there was no difference between H&N 
carcinoma tissues and the normal H&N tissues only (n=20), or between tumour grade, age of the 
patient, sex of the patient or tumour stage. 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n (total) n (YAP1 -ive) n (YAP1 +ive) χ2 p
Normal (all  H&N) 20 20 0
Carcinomas of the H&N 64 56 8
n (total) n (YAP1 -ive) n (YAP1 +ive) χ2 p
Normal (all  tissue types) 110 108 2
Carcinomas of the H&N 64 56 8
Tumour Grade (Carcinomas of the H&N) n (total) n (YAP1 -ive) n (YAP1 +ive) χ2 p
Grade 1 11 11 0
Grade 2 34 28 6
Grade 3 16 14 2
Age (Carcinomas of the H&N) n (total) n (YAP1 -ive) n (YAP1 +ive) χ2 p
30-39 1 1 0
40-49 15 10 5
50-59 20 19 1
60-69 16 15 1
70-79 11 10 1
≥ 80 1 1 0
Sex (Carcinomas of the H&N) n (total) n (YAP1 -ive) n (YAP1 +ive) χ2 p
Male 54 46 8
Female 10 10 0
Tumour Stage (Carcinomas of the H&N) n (total) n (YAP1 -ive) n (YAP1 +ive) χ2 p
Stage I 5 5 0
Stage II 20 18 2
Stage III 18 17 1
Stage IV 13 11 2
7.955 0.16
1.693 0.19
1.437 0.70
2.763 0.097
8.523 0.0035
2.279 0.32
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Table 5.4.  Statistical comparison of immunohistochemistry (IHC) YAP1 staining intensity in the 
head and neck (H&N) carcinoma tissue sections by the Chi-squared (χ2) statistical test.  There 
were no significant differences in the IHC YAP1 staining intensity scores of the positive H&N 
carcinoma tissues and cellular localisation of YAP1, tumour grade, age of the patient or tumour stage.  
It was impossible to calculate any statistical differences for sex of the patients, as no female tissue 
cores were positive for YAP1. 
 
 
 
 
 
 
YAP1 Cellular Localisation  (Carcinomas of the H&N) n (total) n (1) n (2) n (3) χ2 p
Cytoplasmic 4 3 1 0
Nuclear 1 1 0 0
Both 3 0 1 2
Tumour Grade  (Carcinomas of the H&N) n (total) n (1) n (2) n (3) χ2 p
Grade 1 0 0 0 0
Grade 2 6 3 2 1
Grade 3 2 1 0 1
Age  (Carcinomas of the H&N) n (total) n (1) n (2) n (3) χ2 p
40-49 5 3 1 1
50-59 1 0 0 1
60-69 1 1 0 0
70-79 1 0 1 0
Sex  (Carcinomas of the H&N) n (total) n (1) n (2) n (3) χ2 p
Male 8 4 2 2
Female 0 0 0 0
Tumour Stage  (Carcinomas of the H&N) n (total) n (1) n (2) n (3) χ2 p
Stage I 0 0 0 0
Stage II 2 1 1 0
Stage III 1 0 1 0
Stage IV 2 1 0 1
n/a n/a
IHC YAP1 Staining intensity score
3.750 0.44
IHC YAP1 Staining intensity score
7.200 0.30
IHC YAP1 Staining intensity score
IHC YAP1 Staining intensity score
6.167 0.19
IHC YAP1 Staining intensity score
1.333 0.51
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5.4  DISCUSSION 
The work illustrated in Chapters 3 and 4 suggested that the expression level of the 
YAP1 protein is an important host cell determinant of sensitivity to reovirus oncolysis 
in SCCHN cell lines.  Consequently, the objective of this chapter was to investigate 
the mechanism by which YAP1 mediates its effects on reovirus-induced cell death.  
To assess this, we performed several experiments on the PJ34, HN5 and PJ41 SCCHN 
cell lines.   The stable cell lines generated from HN5 were also included due to their 
reliable in vitro behaviour, and to allow us to study the specific effects of YAP1 over-
expression.  The ability of reovirus to enter the cells was determined by measurement 
of cell surface expression of JAM-A by flow cytometry.  Reovirus replication 
efficiency in the cell lines was ascertained by TCID50 one-step growth curves and 
western blotting.  Influence of type I interferon anti-viral responses was assessed by 
quantifying cellular IFN-β secretion.  Finally, in order to gain an insight into the 
applicability of using YAP1 as a predictive biomarker of reovirus therapy, YAP1 
protein expression in head and neck carcinoma tissue was compared to that in normal 
tissue by IHC staining.   
Total YAP1 protein expression was quantitatively measured pre- and post- infection 
with reovirus by flow cytometry in the SCCHN cell lines.  The results supported our 
earlier RT-qPCR data, and confirmed that PJ34, HN5 and PJ41 cells displayed low, 
medium and high levels of the YAP1 protein respectively, prior to infection with 
reovirus.  It was interesting to discover that both the EYFP-YAP1-clone 6 and Flag-
YAP1-clone 2 stable cell lines over-expressed YAP1 to similar levels as the PJ41 cell 
line.  This suggested that artificial over-expression of YAP1 in HN5 cells does not 
behave in the same way as PJ41 cells, which naturally express high levels of YAP1, 
as PJ41 cells (IC50 MOI 572.9 at 24hpi) were still more resistant to reovirus oncolysis 
than stable EYFP-YAP1 (IC50 MOI 187.5 at 24hpi) and Flag-YAP1 cells (IC50 MOI 
391.9 at 24hpi).  This implied that YAP1 is a factor that contributes to the degree of 
reovirus oncolysis, but other proteins may play a part in this too in different SCCHN 
cell lines.  We know that YAP1 is predominantly cytoplasmic in PJ41 cells, although 
there was some nuclear YAP1 detected too (Section 4.3.7).  However, the cellular 
localisation of plasmid-mediated YAP1 over-expression in HN5 is un-known.  
Different proportions of cytoplasmic and nuclear YAP1 may impact on its function 
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[251, 253, 275, 342], which may account for differences in the susceptibility to 
reovirus oncolysis in PJ41, EYFP-YAP1 and Flag-YAP1.  For future reference, it 
would be interesting to perform live cell imaging to establish YAP1 localisation pre- 
and post-infection with reovirus in these cell lines.  Post-reovirus infection, it was 
surprising to observe a marked decrease in the levels of YAP1, which then returned 
back to its pre-infection levels at later times of infection.  This pattern of expression 
was most evident in the cells that expressed the highest levels of YAP1 and were the 
most resistant to reovirus-induced cell death, i.e. PJ41, stable EYFP-YAP1 and stable 
Flag-YAP1 cell lines.  It is un-clear why a drop in the level of YAP1 occurs after 
incubation with reovirus, as this implies that YAP1 is not a protein that is induced in 
response to reovirus infection.  This is unlike other known anti-reoviral proteins such 
as interferon-beta (IFN-β) [331, 332], secretogranin 2 (SCG2) [343] and interferon-
inducible transmembrane protein 3 (IFITM3) [230], whose expression and secretion 
are stimulated after reoviral infection.  However, inhibition of host cell DNA 
synthesis is one of the earliest cytopathic effects observed after reovirus infection in 
cultured cells [99, 344].  Reovirus infection can also cause inhibition of cellular RNA 
and/or protein synthesis [99].  Therefore, perhaps YAP1 is one such protein that the 
virus naturally suppresses in cells that express a certain level of YAP1.  Down-
regulation of cellular FLICE inhibitory protein (cFLIP) and Akt by reovirus infection 
sensitised human ovarian and gastric cancer cell lines to TRAIL-induced apoptosis 
[345, 346].  It is possible that YAP1 has an anti-apoptotic function, as mentioned later 
in this discussion.  If YAP1 is only partially down-regulated by reovirus and some 
expression still remains, then this may be sufficient for the cell to survive infection 
and eventually, more YAP1 is synthesised by the cell, which my explain the increase 
in YAP1 at later time-points.  From our experiment, there is strong evidence to 
suggest that reovirus infection does not affect the regulation of the cytomegalovirus 
(CMV) promoter in the stable-plasmid-transfected cell lines, because the same pattern 
of YAP1 expression was observed in the un-transfected, PJ41 cell line.    
Attachment of reovirus to the host cell is a multistep process that is initiated by the 
reovirus 1 protein binding to sialic acid on the cell surface membrane with low 
affinity [110].  The head domain of 1 then makes contact with the JAM-A cellular 
receptor with high affinity before the virions become internalised [110].  We therefore 
determined whether the method of reovirus entry into SCCHN cells through the main 
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reovirus cellular receptor, JAM-A, would predict for their sensitivity to reovirus 
oncolysis.  It was hypothesised that the expression levels of JAM-A would be highest 
in PJ34 and lowest in PJ41 cells.  However, JAM-A expression did not correlate with 
the susceptibility of reovirus oncolysis in PJ34, HN5 or PJ41, as its expression was 
lowest in the most sensitive cell line (PJ34), and highest in the second most resistant 
cell line (HN5).  This was in agreement with the results published by Twigger et al, 
who found that the levels of JAM-A measured in HN5 and three other SCCHN cell 
lines (HN3, Cal27 and SIHN-5B) did not show a relationship with their corresponding 
reovirus IC50 values [145].   JAM-A is usually expressed in endothelial and epithelial 
cells of various tissue types.  Many cancers express high levels of JAM-A to aid their 
proliferation and metastasis [347].  However, other cancers such as gliomas and 
melanomas express limited JAM-A [347].  Expression of the JAM-A receptor was not 
a major determinant of reovirus sensitivity in glioblastoma stem-like cells or 
colorectal liver metastasis [348, 349], or in a number of different cancer cell types 
including breast, lung, prostate and bladder cancer cell lines [144].    In fact, reovirus 
can enter the cell via a different route independently of JAM-A cell-surface binding.  
Removal of the outer capsid protein 3 and cleavage of µ1 to µ1C can occur outside 
of the cell to generate intermediate subviral particles (ISVPs), which can directly 
penetrate the cell membrane [142].  Therefore, our findings that JAM-A expression 
did not correlate with the susceptibility of SCCHN cell lines to reovirus oncolysis, are 
not surprising.  Intriguingly, over-expression of YAP1 did not change the level of 
JAM-A expression compared to the parental HN5 or the stable EV-control cell lines.  
It was therefore deduced that YAP1-mediated restriction of reovirus oncolysis does 
not primarily occur at the cell surface, via the JAM-A receptor.    Further supporting 
this result, reovirus protein could be visually detected in the cells by 
immunofluorescence staining and confocal microscopy, even in the more resistant cell 
lines (PJ41 and stable EYFP-YAP1) at relatively low MOI.  Hence, it was believed 
that the variation in the susceptibility to reovirus-induced cell death was more likely 
due to a step in the viral replication life cycle being affected inside the host cell.   
The rate of infectious intracellular reovirus yield was quantified by the TCID50 assay 
in PJ34, HN5 and PJ41 SCCHN cell lines.  The intracellular titre was not as well 
spread as we originally predicted, considering the variation in reovirus IC50 values in 
these cell lines.  There was extensive overlap in the intracellular viral growth curves, 
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and the western blotting data highlighted that there was little difference in total 
reovirus proteins (infectious ISVPs and non-infectious viral cores) produced in these 
cells.  For example, the levels of µ and σ reovirus proteins in PJ34 and HN5 at 24hpi 
and 72hpi were very similar, as were the levels in HN5 and PJ41 at 48hpi.  
Correspondingly, there was little difference in extracellular viral secretion in PJ34, 
HN5 and PJ41 cells.  Overall, the lack of a clear association between viral replication 
and reovirus oncolysis suggested that the mode of killing in these cells is not 
influenced by direct reovirus replication, and that other pathways determine the cells’ 
fate after infection.  Likewise, HN5, HN3, Cal27 and SIHN-5B SCCHN cell lines all 
showed the same level of reovirus replication, despite there being a 3-log spread in 
their reovirus IC50 values [145].  Thus, it is not unexpected to see that PJ34, HN5, 
PJ41 SCCHN cells behave in a similar manner in our experiments.  Reovirus 
replication did not correlate closely with cell sensitivity to reovirus-induced cell death 
in the MeWo melanoma cell line [335], or in six different colorectal cancer cell lines 
[350].  This phenomenon is further substantiated by the fact that non-replicative ultra-
violet (UV)-inactivated reovirus is still able to cause significant (though reduced 
compared to non-UV irradiated counterparts) cell death in melanoma cell lines, 
possibly because the virus is unstable and exposes its dsRNA, which is recognised by 
cell sensors [335].  More specifically, reovirus-induced-apoptosis is not always 
intimately linked with reovirus replication, as demonstrated by numerous different 
studies [243, 321, 351, 352].  All of this research largely agrees with our findings.  On 
the contrary, several lines of evidence suggest that activated Ras signalling inhibits 
the anti-viral activity of PKR to allow for increased reovirus replication, which 
correlated with enhanced reovirus oncolysis in various cancer cell lines [135, 338].  
Activated Ras can enhance the disassembly of the virus particle within the endosomal 
compartment, the infectivity of progeny virions, and the release of progeny virions 
[142, 339, 340].  The fact that our data opposed these results is not unforeseen, as Ras 
status was not a key contributor to reovirus oncolysis in PJ34, HN5 and PJ41 SCCHN 
cell lines [145], as mentioned in Sections 1.3.3.2 and 3.1.   
We did not observe any major differences in extracellular reovirus yield in the 
supernatants of infected stable EYFP-YAP1 and HN5 parental cell lines.  This implied 
that over-expression of YAP1 does not interfere with secretion of reovirus.  In 
contrast, there was less intracellular reovirus protein produced over time in EYFP-
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YAP1 cells than in HN5 cells, which was statistically and biologically significant over 
the seventy-two hours infection period.  Similarly, virus yield was significantly and 
consistently lower in stable Flag-YAP1 cells compared to stable EV-control cells at all 
time-points tested, with a clear separation in the viral growth curves, which was 
confirmed using three different methodologies.  Thus, YAP1 over-expression may 
directly obstruct a step in virus replication in the host cell, but not with its secretion, 
which would in part explain the increased resistance to reovirus oncolysis.  
Considering that there was no difference in intracellular reovirus titre measured in 
PJ34, HN5 and PJ41 cell lines (whose expression levels of YAP1 also correlated with 
their respective reovirus IC50 values), suggested that forced over-expression of YAP1 
mediates its resistance to reovirus-induced cell killing differently to cells that 
endogenously express YAP1.  We do not fully understand why this is so, but again, it 
could be due to differences in the cytoplasmic and nuclear expression levels of YAP1.  
Perhaps more nuclear YAP1 would enhance cell proliferation to slow reovirus 
replication, whereas more cytoplasmic YAP1 would reduce cell proliferation to 
increase the rate of reovirus replication.  Alternatively, other signalling pathways may 
be activated after reovirus infection in PJ34, HN5 and PJ41 cells, which may be 
dampening the specific effect of YAP1 on intracellular reovirus replication.  Perhaps 
forced-YAP1 over-expression is able to surpass the molecular signalling repertoire 
that would normally contribute to reovirus-induced oncolysis.  Our knock-down and 
over-expression studies in Chapters 3 and 4 implied that YAP1 is an important 
determinant of reovirus oncolysis in PJ41 and PJ34 SCCHN cells.  Because we only 
measured reovirus yield after over-expression of YAP1 in HN5 cells, we do not know 
if reovirus replication would also be affected by knock-down of YAP1 in PJ41, or 
transient over-expression of YAP1 in PJ34, or whether the effect is cell line specific.   
As interferon stimulated genes (ISGs) such as IFITM3 have been shown to restrict 
reovirus replication comparably to YAP1 over-expression [230], it seemed logical to 
ascertain whether YAP1 functions as part of the type I interferon pathway.  The levels 
of IFN-β secretion were raised by two-fold in stable Flag-YAP1 cells compared to the 
stable EV-control cell line infected with reovirus at MOI 100, but there was no 
difference in IFN-β expression in these cell lines at MOI 5.  Moreover, we found no 
difference in IFN-β secretion between stable EYFP-YAP1 and HN5 parental cells.  
When IFN-β was measured in these infected cells at an earlier time-point (12 hpi), no 
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difference in expression was observed (data not shown), despite the levels being 
below the limit of detection of the assay.  As the increase in IFN-β in the Flag-YAP1 
cell line was not supported by the other stable YAP1 over-expressed cell line (EYFP-
YAP1), it was concluded that the resistance to reovirus oncolysis and the decreased 
intracellular reovirus yield associated with over-expression of YAP1, acts 
independently of, and is not linked to, the type I interferon anti-viral response.  In 
support of this, the reovirus sensitivity associated with siRNA-mediated knock-down 
of YAP1 in the PJ41 cell line was not due to type 1 interferon signalling, as the levels 
of IFN-β were not statistically different in negative control siRNA or YAP1 siRNA 
transfected cells.  On the other hand, IFN-β secretion correlated with the susceptibility 
to reovirus oncolysis in PJ34, HN5 and PJ41 SCCHN cell lines.  Viral supernatants of 
sensitive PJ34 contained the lowest amount of IFN-β, HN5 had intermediate levels, 
and resistant PJ41 cells expressed the highest levels.   This proposed that type I 
interferon signalling has an influence on the susceptibility to reovirus-induced cell 
death in these cell lines.  This did not agree with the results of Twigger et al, as they 
found no correlation with reovirus sensitivity and IFN-β secretion in four 
representative SCCHN cell lines (HN5, HN3, Cal27 and SIHN-5B) [145].   However, 
efficient interferon signalling would prevent translation of viral proteins.  As we did 
not detect any difference in intracellular or extracellular reovirus protein production in 
PJ34, HN5 and PJ41, this suggested that the effects of type I interferon are somewhat 
overridden.  It has been documented that reoviruses have evolved specific 
mechanisms to evade the type I interferon anti-viral response.  Firstly, the reovirus µ2 
protein, which is involved in viral RNA synthesis, can provoke an unusual build-up of 
the transcription factor IRF9 in the nucleus and repress ISG expression, possibly by 
disrupting IRF9-STAT2-STAT1 interactions that are needed for IFN signalling [332].  
Secondly, the reovirus σ3 protein can bind to dsRNA and inhibit activation of the 
host-cell anti-viral protein PKR [332, 353].  In addition, 65-70% of tumours are 
unable to produce or respond to type I interferon in order to escape anti-proliferative 
or pro-death signals; an aberration that many oncolytic viruses take advantage of 
[354], including recombinant vaccinia virus [355], vesicular stomatitis virus [356], 
and reovirus [334].  Ras transformed cells have been shown to be incapable of 
producing or responding to IFN-β by blocking signalling from RIG1, thus making the 
cells unable to recognise viral RNAs [333].  Therefore, even though the SCCHN cell 
lines used in this study were able to secrete IFN-β to levels that correlated with their 
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reovirus IC50 values, they may contain defects (presumably not in Ras signalling 
[145]) in anti-viral innate immune responses that render them non-responsive to type I 
interferon, allowing reovirus replication to proceed.   
So far, we have not found a common mechanism linking YAP1 expression and the 
susceptibility to reovirus oncolysis in all of the SCCHN cell lines.  We intend to 
perform gene expression profiling and microarray hybridisation on the stable cell 
lines, infected with and without reovirus, in order to help uncover the signalling 
pathways involved in this process.  Since reovirus-induced apoptosis is not always 
dependent on reovirus replication, perhaps YAP1 mediates its effects through 
suppression of reovirus-induced apoptosis.  Indeed, YAP has been shown to be a 
regulator of apoptosis.  When expressed in the nucleus, YAP can transcriptionally up-
regulate the expression of the anti-apoptotic factors Bcl-xL (encoded by the BCL2L1 
gene and a member of the Bcl-2 family), and Survivin (encoded by the BIRC5 gene 
and a member of the inhibitor of apoptosis (IAP) family) in certain cancer cell lines 
[300].  Lin et al demonstrated that YAP enhanced the expression of Bcl-xL to 
promote survival and resistance to RAF and MEK inhibitors in tumours harbouring 
BRAF and RAS mutations [357].  This implied that YAP and RAF-MEK signalling 
work together to regulate Bcl-xL [357].  Even though baseline levels of activated 
GTP-loaded Ras in PJ34, HN5 and PJ41 SCCHN cell lines did not correlate with their 
susceptibility to reovirus-induced cell death [145], perhaps activating Ras mutations 
are not always essential for YAP1 to restrict reovirus-induced apoptosis in these cells.  
Importantly, mitochondrial apoptotic signalling is involved in reovirus-induced 
apoptosis.  Over-expression of Bcl-2, an anti-apoptotic protein similar to Bcl-xL, can 
inhibit reovirus-induced apoptosis by preventing the release of Smac and cytochrome 
c [323], and by inhibiting the proteolytic cleavage and degradation of cellular IAPs, 
including Survivin, cIAP1 (encoded by the BIRC2 gene) and XIAP (encoded by the 
XIAP gene) [242] [243].  We therefore hypothesise that a certain level of YAP1 
expression might prevent apoptosis induced by oncolytic reovirus, by promoting 
expression of Bcl-xL, Bcl-2, Survivin or certain IAPs, which may inhibit downstream 
mitochondrial apoptotic signalling, to aid survival in SCCHN cell lines.  In HN5, 
HN3, Cal27 and SIHN-5B SCCHN cell lines, reovirus-induced cell death was not 
prevented by a pan-caspase inhibitor (z-VAD-FMK) and did not involve caspase 3 
activation, suggesting that reovirus killing in these cells is non-apoptotic [145].  
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Despite this finding, it would be of importance to verify whether YAP1 hinders 
reovirus-induced apoptosis in PJ34, HN5 and PJ41 SCCHN cell lines.  Unfortunately, 
there was insufficient time left in the project to fully test this theory, but it is 
something to consider for future investigation.   
Our results strongly suggest that host-cell expression levels of YAP1 influence the 
susceptibility of SCCHN cells to reovirus-induced cytotoxicity, but that other un-
known factors are also clearly inter-linked with YAP1 signalling.  There is 
considerable inter- and possible intra- tumour heterogeneity in SCCHN, and the 
signalling pathways in these tumour cells are extensively interconnected with high 
levels of redundancy.  This makes treatment of SCCHN and the identification of 
predictive biomarkers to oncolytic reovirus therapy challenging.  Multiple factors may 
cooperate with YAP1 to determine the cells’ fate after reovirus infection, and the 
importance of these factors may be variable in different SCCHN cell lines.  Despite 
not being able to fully understand the mechanism of how YAP1 expression influences 
reovirus oncolysis, this work provides reason to further test YAP1 as a biomarker of 
reovirus treatment response in SCCHN patient tumours.  Our preliminary work of 
YAP1 protein expression in tissue sections showed that a small population of head 
and neck carcinoma tissues express YAP1, but different types of normal tissues do not 
generally express it.  We did not find any relationship between immunohistochemistry 
YAP1 staining status and tumour grade, age of the patient, sex of the patient or 
tumour stage.  However, larger numbers of tissue samples would be needed to make 
more comprehensive conclusions.  Xu et al reported YAP1 to be a prognostic marker 
for overall survival and disease-free survival in hepatocellular carcinoma patients 
[283].  It would be interesting to analyse YAP1 and reovirus protein expression in 
tumour tissue obtained from a Reolysin® clinical study, and to see if there is a 
correlation with reovirus resistance, or survival outcome.   
It could be argued that the work performed in this study has limitations, as in vitro 
sensitivity to viral replication and oncolysis sometimes does not match the sensitivity 
of a tumour type in vivo.  Studying factors in cancer cells that influence reovirus 
oncolysis in culture does not fully take into consideration the requirement of the 
immune system in response to viral infection.  Carrying out experiments on a greater 
number of SCCHN cell lines would further substantiate our conclusions.   
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5.5   CONCLUSION 
This project has shown that the efficiency of reovirus-induced cancer cell death 
depends on the expression level of YAP1 in SCCHN cells, implying that YAP1 may 
be an appropriate predictive biomarker of reovirus oncolysis.   In this chapter, we 
were unable to define the exact mechanism behind this, which is likely to be 
complex, given the heterogenic nature of SCCHN tumour cells.  However, we were 
able to dismiss the possibility that reovirus entry is restricted at the cell surface via 
the JAM-A receptor.  Our data suggested that the cell lines are somewhat un-
responsive to, or reovirus itself evades, the effects of the type I interferon response, 
as there was no difference in the rate of reovirus production or release in the cells.  
Forced-over-expression of YAP1 did not affect type I interferon secretion, but did 
restrict reovirus yield somewhat in the HN5 cell line for reasons we cannot fully 
explain.  YAP1 can transcriptionally up-regulate the expression of anti-apoptotic 
factors that are also known to prevent reovirus-induced apoptosis.  Therefore, we 
predict that a certain level of YAP1 expression in SCCHN cell lines might prevent 
apoptosis induced by reovirus infection through the promotion of mitochondrial 
apoptotic signalling components.  This would be an interesting lead for the 
continuation of this project.  As a final point, our data provides novel information 
that may aid the clinical application of reovirus in patients with SCCHN.   
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6. COMBINING REOVIRUS WITH CHEMOTHERAPEUTIC TAXANE DRUGS 
IN PCa CELL LINES 
6.1   INTRODUCTION 
The full potential of using oncolytic viruses to treat cancer in the clinical setting is 
likely to be achieved when combined with other treatment modalities.  Many studies 
have shown that combining reovirus with standard of care therapies such as 
chemotherapy or radiotherapy has a synergistic anti-cancer effect compared to using 
the agents on their own [42].   
Prostate cancer (PCa) is the most common cancer in men in the UK [358].  The first 
line of standard care for patients with castration-resistant PCa (CRPC) is the 
chemotherapeutic Docetaxel, which has shown to have a median survival benefit of 2 
to 3 months [40].  A newer taxane analogue, Cabazitaxel, is sometimes provided as a 
treatment for metastatic CRPC in patients who had previously been treated with 
Docetaxel [182], as it displays activity in Docetaxel-resistant tumour cells [187, 188].  
The 5-year survival rate is around 30% for patients whose disease was metastatic at 
diagnosis [358].  Clearly more efficacious treatment strategies are required.   
Taxane chemotherapy drugs display anti-cancer properties by binding to cellular 
microtubules [182].  In turn, this inhibits microtubule disassembly and mitosis [183], 
and ultimately leads to cell death.  Reovirus also associates with and stabilises 
microtubules for efficient viral growth [189-191], and PCa cell lines have been shown 
to be susceptible to reovirus oncolysis [155].  The combination of reovirus and 
Docetaxel promoted synergistic PCa cell death in vitro and in vivo, through increased 
apoptosis, necrosis, microtubule stability and viral replication [192].  Conventional 
chemotherapy involves treating patients with the maximum tolerated dose (MTD).  
This is typically given in 3 week cycles, with extensive drug-free breaks in-between 
to allow the patient to recover from the cytotoxic side-effects.  However, these drug-
free periods allow tumour vasculature re-growth, leading to disease progression. 
Therefore, the MTD method may not be the optimum way to administer such drugs.  
Metronomic chemotherapy (MC) is defined as the frequent administration of 
chemotherapy agents at doses below the MTD and with no prolonged drug-free 
breaks.  Besides targeting cancer cells, MC mainly kills endothelial cells involved in 
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tumour angiogenesis [197] such as circulating endothelial cells (CEC) in the tumour 
vasculature and bone-marrow-derived endothelial progenitor cells (EPC) [195].  The 
way in which MC enhances the anti-cancer immune response is mentioned in the 
discussion of this chapter.  MC may have a long-standing effect on preventing tumour 
growth and has the potential benefit of being an inexpensive treatment [203].  
Monotherapy with Paclitaxel or Docetaxel has demonstrated effective anti-cancer 
responses in the metronomic setting [213, 214].  MC treatment with Cabazitaxel has 
not yet been explored, nor has the combination of MC with reovirus or any other 
oncolytic virus, which is the focus of this chapter.   
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6.2   STUDY OBJECTIVE 
The objective of this chapter was to compare treatment of reovirus in combination 
with either Cabazitaxel or Docetaxel in PCa cell lines.  In vitro, we aimed to test these 
combinations using the taxane drugs at the MTD (IC50) or at sub-lethal doses (<IC50) 
to determine whether an anti-cancer effect could be achieved.   
In order to test this, the following experiments were performed: 
1. Determination of the reovirus, Cabazitaxel and Docetaxel IC50 values in a 
selection of PCa cell lines, by the MTS assay and CalcuSyn software.   
2. Assessment of the interaction between the concurrent combination of reovirus 
and Cabazitaxel or Docetaxel at fixed-dose ratios in DU145 and LNCaP PCa cell 
lines, by the MTS assay and the Chou and Talalay equation. 
3. Comparison of concurrent and sequential combination treatments of reovirus and 
Cabazitaxel in the DU145 cell line, by the MTS assay and the Chou and Talalay 
equation.   
4. Assessment of the interaction between the concurrent combination of reovirus 
and Cabazitaxel or Docetaxel at non-fixed low doses in the DU145 cell line, by 
the MTS assay and Bliss Independence analysis.   
5. Measurement of acetylated α-tubulin in combination treated DU145 cell lysates 
by western blotting, to determine whether microtubule stability is a factor that 
contributes to a synergistic interaction at doses ≤IC50.   
6. Measurement of intracellular and extracellular reovirus yield in DU145 cells by 
the plaque assay, to determine whether viral replication or secretion is enhanced 
following combination treatment at doses ≤IC50.   
7. Assessment of DU145 cell survival by the MTS assay after using z-VAD-FMK 
and Necrostatin-1, to determine the roles of apoptosis or necroptosis in the 
synergistic effect caused by combination treatment.   
 
 
 
 
 
203 
 
6.3   RESULTS 
6.3.1 Determination of reovirus, Cabazitaxel and Docetaxel IC50 values in PCa 
cell lines 
To assess the maximum tolerated dose (MTD) of reovirus, Cabazitaxel and Docetaxel 
in PCa cell lines in vitro, the IC50 values were calculated.   Three human PCa cell 
lines (DU145, LNCaP and PC3), the TRAMP-C2 transgenic mouse PCa cell line, and 
the human prostatic stromal myofibroblast WPMY-1 cell line (non-cancerous and 
SV40 transformed), were treated with serial dilutions of reovirus, Cabazitaxel or 
Docetaxel for 96 hours.  Cells were also treated with media alone for the same time-
period as an untreated control.   Cell survival was then analysed by the MTS assay 
(Section 2.9).   
Figure 6.1, 6.2 and 6.3 displays the % cell survival curves of each cell line treated 
with reovirus, Cabazitaxel or Docetaxel respectively, relative to the untreated cells.  
The IC50 values were determined by CalcuSyn software, which uses the median-effect 
equation derived by Chou [217] (Section 2.27.4).  Starting with the most sensitive cell 
line, the order of susceptibility to reovirus was TRAMP-C2 (IC50 MOI 0.045), DU145 
(IC50 MOI 2.850), LNCaP (IC50 MOI 5.410), PC3 (IC50 MOI 17.710) and WPMY-1 
(IC50 MOI 47.300).  The order of susceptibility to Cabazitaxel was DU145 (IC50 
0.114µM), LNCaP (IC50 0.207µM), TRAMP-C2 (IC50 0.270µM), WPMY-1 (IC50 
13.730µM) and PC3 (IC50 92.990µM).  Comparatively, the order of susceptibility to 
Docetaxel was DU145 (IC50 0.035µM), TRAMP-C2 (IC50 0.232µM), LNCaP (IC50 
1.742µM), WPMY-1 (IC50 10.361µM) and PC3 (IC50 143.550µM).   
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Figure 6.1.  Dose-response curves and IC50 values generated from cells infected with reovirus 
alone.  A.  DU145, B. LNCaP, C. PC3, D. TRAMP-C2, and E. WPMY-1 were infected with serial 
dilutions of reovirus for 96 hours before assessing the cell survival relative to the un-treated cells by the 
MTS assay.  Error bars represent SEM from three assay repeats.  F.  The reovirus IC50 values were 
derived using CalcuSyn software.  The table shows the mean of three assay repeats ± SEM.  Starting 
with the most sensitive cell line, the order of susceptibility to reovirus was TRAMP-C2, DU145, 
LNCaP, PC3 and WPMY-1.   
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Figure 6.2.  Dose-response curves and IC50 values generated from cells infected with Cabazitaxel 
alone.  A.  DU145, B. LNCaP, C. PC3, D. TRAMP-C2, and E. WPMY-1 were infected with serial 
dilutions of Cabazitaxel for 96 hours before assessing the cell survival relative to the un-treated cells by 
the MTS assay.  Error bars represent SEM from three assay repeats.  F.  The Cabazitaxel IC50 values 
were derived using CalcuSyn software.  The table shows the mean of three assay repeats ± SEM.  
Starting with the most sensitive cell line, the order of susceptibility to Cabazitaxel was DU145, LNCaP, 
TRAMP-C2, WPMY-1 and PC3. 
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Figure 6.3.  Dose-response curves and IC50 values generated from cells treated with Docetaxel 
alone.  A.  DU145, B. LNCaP, C. PC3, D. TRAMP-C2, and E. WPMY-1 were infected with serial 
dilutions of Docetaxel for 96 hours before assessing the cell survival relative to the un-treated cells by 
MTS assay.  Error bars represent SEM from three assay repeats.  F.  The Docetaxel IC50 values were 
derived using CalcuSyn software.  The table shows the mean of three assay repeats ± SEM.  Starting 
with the most sensitive cell line, the order of susceptibility to Docetaxel was DU145, TRAMP-C2, 
LNCaP, WPMY-1 and PC3.   
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6.3.2 Concurrent combination of reovirus with Docetaxel or Cabazitaxel mostly 
had an anti-cancer synergistic effect in PCa cell lines, as determined by 
the Chou and Talalay equation 
Next, the effect of concurrently combining reovirus with Cabazitaxel or Docetaxel 
was assessed (Section 2.23.1).  DU145 and LNCaP PCa cell lines were treated with 
reovirus, Cabazitaxel or Docetaxel alone, at doses representing 0.25, 0.5, 1, 2 and 4 
fold the IC50 values.  Cells were also treated with reovirus in combination with 
Cabazitaxel, or reovirus in combination with Docetaxel, at doses representing 0.25, 
0.5, 1, 2 and 4 fold the IC50 values.  As an untreated control, cells were incubated with 
media alone.  After 96 hours, the cell survival was assessed by the MTS assay 
(Section 2.9) and the combination index (CI) values were determined using CalcuSyn 
software, which measures the degree of interaction between two agents by the CI 
equation of Chou and Talalay [234] (Section 2.27.5).  A CI value of 1 denoted an 
additive interaction, <1 a synergistic interaction, and >1 an antagonistic interaction.   
Figure 6.4 A, 6.5 A, 6.6 A and 6.7 A show the % cell survival curves of DU145 and 
LNCaP PCa cell lines treated with reovirus, Cabazitaxel or Docetaxel as single 
agents, or with reovirus in combination with either taxane drug, relative to the 
untreated cells.  For both cell lines, both combinations displayed a synergistic effect at 
the effective dose 50 (ED50) and ED75 (Figure 6.4 C, 6.5, 6.6 C and 6.7 C).  This is 
depicted on the isobologram curves where the combination data points are located 
below the lines of additivity (Figure 6.4 B, 6.5 B, 6.6 B and 6.7 B).  This suggested 
that the combinations had more effect on cell death than each agent used 
independently of the other.  When comparing the synergistic effect between the two 
combination treatments in DU145 cells, reovirus and Docetaxel was marginally more 
synergistic than reovirus and Cabazitaxel at ED50, ED75 and ED90 (CI=0.44, 0.33, 0.30 
and CI=0.61, 0.38, 0.31, respectively).  In the LNCaP cell line, reovirus and 
Docetaxel showed strong synergism at the ED50 (CI=0.22), whereas reovirus and 
Cabazitaxel showed a slightly lower synergistic effect (CI=0.44).  However, at ED75, 
both combinations showed a similar level of synergy (CI=0.39 and CI=0.41).  At 
ED90, reovirus and Docetaxel displayed moderate antagonism (CI=1.23), as depicted 
on the isobologram where the data point is located above the line of additivity, whilst 
reovirus and Cabazitaxel showed synergism (CI=0.37).   
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Figure 6.4.  Concurrent combination of reovirus and Cabazitaxel at doses 4, 2, 1, 0.5 and 0.25 
fold the IC50 had a synergistic anti-cancer effect in the DU145 PCa cell line.  A. % Cell survival 
was assessed by the MTS assay after 96 hours incubation with reovirus alone (orange circles), 
Cabazitaxel alone (blue squares) or reovirus and Cabazitaxel in combination (purple triangles), relative 
to the un-treated cells.  Error bars represent SEM from three assay repeats.  B.  The isobologram curve 
was generated using CalcuSyn software and shows the combination data points located below the line 
of additivity of the effective dose 50 (ED50), ED75 and ED90, which indicated synergism.  C.  The 
combination index (CI) values of the ED50, ED75 and ED90 displayed a synergistic anti-cancer effect, as 
determined using CalcuSyn software.  The CI ± SEM of three assay repeats is shown.   
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Figure 6.5.  Concurrent combination of reovirus and Docetaxel at doses 4, 2, 1, 0.5 and 0.25 fold 
the IC50 had a synergistic anti-cancer effect in the DU145 PCa cell line.  A. % Cell survival was 
assessed by the MTS assay after 96 hours incubation with reovirus alone (orange circles), Docetaxel 
alone (blue squares) or reovirus and Docetaxel in combination (purple triangles), relative to the un-
treated cells.  Error bars represent SEM from three assay repeats.  B.  The isobologram curve was 
generated using CalcuSyn software and shows the combination data points located below the line of 
additivity of the effective dose 50 (ED50), ED75 and ED90, which indicated synergism.  C.  The 
combination index (CI) values of the ED50, ED75 and ED90 displayed a synergistic anti-cancer effect, as 
determined using CalcuSyn software.  The CI ± SEM of three assay repeats is shown.   
DU145:  Reo + Doc 
ED CI ± SEM Combination effect 
ED50 0.44 ± 0.055 +++ Synergism 
ED75 0.33 ± 0.030 +++ Synergism 
ED90 0.30 ± 0.019 +++ Synergism 
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Figure 6.6.  Concurrent combination of reovirus and Cabazitaxel at doses 4, 2, 1, 0.5 and 0.25 
fold the IC50 had a synergistic anti-cancer effect in the LNCaP PCa cell line.  A. % Cell survival 
was assessed by the MTS assay after 96 hours incubation with reovirus alone (orange circles), 
Cabazitaxel alone (blue squares) or reovirus and Cabazitaxel in combination (purple triangles), relative 
to the un-treated cells.  Error bars represent SEM from three assay repeats.  B.  The isobologram curve 
was generated using CalcuSyn software and shows the combination data points located below the line 
of additivity of the effective dose 50 (ED50), ED75 and ED90, which indicated synergism.  C.  The 
combination index (CI) values of the ED50, ED75 and ED90 displayed a synergistic anti-cancer effect, as 
determined using CalcuSyn software.  The CI ± SEM of three assay repeats is shown.  
LNCaP:  Reo + Cab 
ED CI ± SEM Combination effect 
ED50 0.44 ± 0.031 +++ Synergism 
ED75 0.41 ± 0.012 +++ Synergism 
ED90 0.37 ± 0.009 +++ Synergism 
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Figure 6.7.  Concurrent combination of reovirus and Docetaxel at doses 4, 2, 1, 0.5 and 0.25 fold 
the IC50 had a synergistic anti-cancer effect in the LNCaP PCa cell line at the ED50 and ED75, but 
not at ED90.  A. % Cell survival was assessed by the MTS assay after 96 hours incubation with 
reovirus alone (orange circles), Docetaxel alone (blue squares) or reovirus and Docetaxel in 
combination (purple triangles), relative to the un-treated cells.  Error bars represent SEM from three 
assay repeats.  B.  The isobologram curve was generated using CalcuSyn software and shows the 
combination data points for ED50 and ED75 below the line of additivity, which indicated synergism.  
However, the combination data point for ED90 exhibited antagonism, as it was located above the line of 
additivity.  C.  The combination index (CI) values of the ED50 and ED75 displayed a synergistic anti-
cancer effect, whereas the CI value for ED90 showed moderate antagonism, as determined using 
CalcuSyn software.  The CI ± SEM of three assay repeats is shown.   
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6.3.3 Concurrent combination of reovirus and Cabazitaxel resulted in greater 
synergistic anti-cancer activity in the DU145 PCa cell line than sequential 
combination treatment  
In order to assess the most synergistic sequencing strategy (Section 2.23.2), we 
concurrently treated DU145 cells with reovirus and Cabazitaxel at doses representing 
1.00, 0.50, 0.25, 0.13 and 0.06 ×IC50, or treated sequentially at these doses with 
Cabazitaxel alone for 1 hour (sequential treatment 1), 4 hours (sequential treatment 2) 
or 24 hours (sequential treatment 3) before adding reovirus for a total of 96 hours.  
Alternatively, cells were treated at each dose with reovirus alone for 24 hours 
(sequential treatment 4) or 48 hours (sequential treatment 5) before adding 
Cabazitaxel for the remaining time period totalling 96 hours.  Cells were also treated 
with each dose of reovirus, Cabaziatxel or Docetaxel as single agents for the indicated 
time periods.  The cell survival was then assessed by the MTS assay (Section 2.9) and 
the combination index (CI) values were determined using CalcuSyn software via the 
Chou and Talalay equation [234] (Section 2.27.5).   
Figure 6.8 A shows the % cell survival curves of DU145 cells treated with the 
concurrent combination of reovirus and Cabazitaxel, and the five different sequential 
combination treatments, relative to untreated cells.  Concurrent combination treatment 
had a greater synergistic interaction than sequential combinations 1, 2, 3, 4 and 5 at 
the ED50, ED75 and ED90 (Figure 6.8 B).  Therefore, it was decided that all future 
combination treatments would be performed concurrently.   
 
 
 
 
 
 
 
 
 
 
 
 
213 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.0
6
×
IC
5
0
0
.1
3
×
IC
5
0
0
.2
5
×
IC
5
0
0
.5
0
×
IC
5
0
1
.0
0
×
IC
5
0
0
2 5
5 0
7 5
1 0 0
1 2 5
R e o v iru s  (M O I) , C a b a z ita x e l (µ M )
%
 c
e
ll
 s
u
r
v
iv
a
l
S e q u e n tia l tre a tm e n t 1
S e q u e n tia l tre a tm e n t 2
S e q u e n tia l tre a tm e n t 3
S e q u e n tia l tre a tm e n t 4
S e q u e n tia l tre a tm e n t 5
C o n c u rre n t tre a tm e n t
214 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8.  Concurrent combination treatment of reovirus and Cabazitaxel resulted in a more 
efficient anti-cancer synergistic interaction than sequential combination treatment, in the DU145 
PCa cell line.  A.  Cells were treated concurrently with reovirus and Cabazitaxel for 96 hours (black 
open circles), or treated sequentially with Cabazitaxel for 1 hour (sequential treatment 1, green circles), 
4 hours (sequential treatment 2, blue squares) or 24 hours (sequential treatment 3, red triangles) before 
adding reovirus for a total of 96 hours.  Cells were also treated with reovirus for 24 hours (sequential 
treatment 4, orange triangles) or 48 hours (sequential treatment 5, purple diamonds), before adding 
Cabazitaxel for a total of 96 hours.  The cell survival in each treatment was assessed by the MTS assay 
relative to the untreated cells.  Error bars represent SD from triplicate samples.  B.  The combination 
index (CI) values of the ED50, ED75 and ED90 were determined using CalcuSyn software. 
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ED50 0.27 
++++ 
Strong synergism 
0.78 
++ 
Moderate synergism 
ED75 0.23 
++++ 
Strong synergism 
1.10 
- 
Slight antagonism 
ED90 0.28 
++++ 
Strong synergism 
2.24 
--- 
Antagonism 
 
 Concurrent treatment Sequential treatment 3 
ED CI Combination effect CI Combination effect 
ED50 0.07 
+++++ 
Very strong synergism 
0.35 
+++ 
Synergism 
ED75 0.05 
+++++ 
Very strong synergism 
0.19 
++++ 
Strong synergism 
ED90 0.03 
+++++ 
Very strong synergism 
0.11 
++++ 
Strong synergism 
 
 Concurrent treatment Sequential treatment 4 
ED CI Combination effect CI Combination effect 
ED50 0.29 
++++ 
Strong synergism 
0.29 
++++ 
Strong synergism 
ED75 0.28 
++++ 
Strong synergism 
0.31 
+++ 
Synergism 
ED90 0.29 
++++ 
Strong synergism 
0.35 
+++ 
Synergism 
 
 Concurrent treatment Sequential treatment 5 
ED CI Combination effect CI Combination effect 
ED50 0.15 
++++ 
Strong synergism 
0.35 
+++ 
Synergism 
ED75 0.10 
++++ 
Strong synergism 
0.18 
++++ 
Strong synergism 
ED90 0.06 
+++++ 
Very strong synergism 
0.09 
+++++ 
Very strong synergism 
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6.3.4 Combination of reovirus with Cabazitaxel or Docetaxel at doses below the 
IC50 values had an anti-cancer synergistic effect on the DU145 PCa cell 
line, as determined by the Bliss Independence model 
We then assessed the effect of combining reovirus with Cabazitaxel at a greater range 
of doses, including doses much lower than the IC50 value of each agent (Section 
2.23.3).  The DU145 PCa cell line was treated with reovirus or Cabazitaxel alone, or 
in combination for 96 hours.  Each dose of Cabazitaxel representing 0.05, 0.11, 0.22, 
0.44, 0.88, 1.75, 2.63 and 3.51 ×IC50 (IC50 0.114µM), was combined with various 
doses of reovirus representing 0.13, 0.26, 0.44, 0.88, 1.75, 3.51 and 7.02 ×IC50 (IC50 
MOI 2.85).  Thus, in this experiment the combinations were not set at fixed ratios.  
Cells were also treated with media alone as an untreated control.  The cell survival 
was evaluated by the MTS assay (Section 2.9) and the interaction between the two 
agents was then assessed by the Bliss Independence analysis [224] (Section 2.27.6).  
The Bliss analysis spreadsheet was provided to us by Professor Kevin Harrington’s 
laboratory, with permission from MedImmune LLC, USA [223].   
Figure 6.9 A shows the % cell survival curves of DU145 cells treated with reovirus or 
Cabazitaxel as single agents, or with reovirus in combination with Cabazitaxel, 
relative to the untreated cells.  Figure 6.9 B and C display a table and contour map of 
the ΔE values for each combination, as well as the Bliss analysis range (the upper and 
lower confidence intervals (Ci)).  A positive ΔE value indicated synergism, whereas a 
negative ΔE value indicated antagonism.  When ΔE=0, the combination was 
considered to have Bliss Independence (or addition).  The contour map and table are 
colour coded according to the level of interaction between reovirus and Cabazitaxel 
and all values are expressed as a percentage (i.e. a 20% synergistic effect equates to 
ΔE=0.20).  Values highlighted in orange show the greatest synergistic effect (40% to 
50%), whereas values highlighted in black show an additive or antagonistic 
interaction (-10% to 0%).  All combinations demonstrated a synergistic effect apart 
from the lowest doses of reovirus and Cabazitaxel (0.13× and 0.05× IC50 of reovirus 
and Cabazitaxel respectively).  Thus, the data suggested that concentrations of 
reovirus 0.26× lower than the IC50, and concentrations of Cabazitaxel 0.11× lower 
than the IC50, were capable of generating a synergistic anti-cancer effect compared to 
treating DU145 cells with reovirus or Cabazitaxel as single agents.  
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The effect of combining reovirus with Docetaxel at a wide range of non-fixed dose 
ratios was then determined (Section 2.23.3).  DU145 cells were treated with reovirus 
or Docetaxel alone, or in combination for 96 hours.  Each dose of Docetaxel 
representing 0.07, 0.14, 0.29, 0.57, 0.86, 2.86 and 5.71 ×IC50 (IC50 0.035µM), was 
combined with various doses of reovirus representing 0.13, 0.26, 0.44, 0.88, 1.75, 
3.51 and 7.02 ×IC50 (IC50 MOI 2.85).  Additionally, cells were treated with media 
alone as an untreated control.  The cell survival was evaluated by the MTS assay 
(Section 2.9) and the interaction between the two agents was then assessed by the 
Bliss Independence analysis (Section 2.27.6).   
Figure 6.10 A shows the % cell survival curves of DU145 cells treated with reovirus 
or Docetaxel as single agents, or with reovirus in combination with Docetaxel, 
relative to the untreated cells.  The contour map of the ΔE values for each 
combination are shown in Figure 6.10 C.  The ΔE values and the Bliss analysis range 
are displayed in Figure 6.10 B.  All combinations showed a synergistic effect.  This 
implied that concentrations of reovirus 0.13× lower than the IC50, and concentrations 
of Docetaxel 0.07× lower than the IC50, were capable of generating a synergistic anti-
cancer effect compared to treating DU145 cells with reovirus or Docetaxel as single 
agents. 
Therefore, when comparing the two combination treatments using the Bliss 
Independence model in the DU145 PCa cell line, it appears that reovirus and 
Docetaxel can be combined at slightly lower doses than reovirus and Cabazitaxel, 
whist still maintaining a level of anti-cancer synergism.  However, there is a region 
where reovirus and Cabazitaxel had a higher level of synergy of 46.56% (0.44×IC50 
reovirus and 0.22×IC50 Cabazitaxel) compared to the combination of reovirus and 
Docetaxel, which reached a maximum synergistic effect of 29.00% (1.75×IC50 
reovirus and 0.07×IC50 Docetaxel).  Overall, the data indicates that both combinations 
have the potential to be used as metronomic treatments for PCa.   
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Figure 6.9.  Combination treatment of the DU145 PCa cell line with reovirus and Cabazitaxel at doses much lower than the IC50 values mostly had an anti-
cancer synergistic effect, as determined by Bliss Independence analysis.  Cells were treated with Cabazitaxel at doses representing 0.05, 0.11, 0.22, 0.44, 0.88, 
1.75, 2.63 and 3.51 fold the IC50 (IC50 0.114µM), combined with reovirus at doses representing 0.13, 0.26, 0.44, 0.88, 1.75, 3.51 and 7.02 fold the IC50 (IC50 MOI 
2.85).  Alternatively, cells were treated with Cabazitaxel or reovirus as single agents at the stated doses, or with media alone as an untreated control.  A.  After 96 
hours, the % cell survival in each treatment was assessed by the MTS assay, relative to the untreated cells.  The survival curves display error bars that represent SEM 
from two assay repeats.  B.  The interaction between Cabazitaxel and reovirus was assessed by the Bliss Independence analysis spreadsheet (MedImmune LLC, USA 
[223].  The ΔE values for each combination and the Bliss analysis range (the upper and lower confidence intervals (Ci)) are displayed in the table, which is colour 
coded according to the level of interaction.  Orange shows the highest level of synergism whereas black shows an additive or antagonistic interaction.  All 
combinations demonstrated a synergistic anti-cancer effect of up to 46.56%, apart from the lowest dose of reovirus and Cabazitaxel.  C.  The ΔE values for each 
combination of Cabazitaxel and reovirus were plotted onto a contour map, enabling easy visualisation of the level of interaction.   
7.02 × IC50 3.51 × IC50 1.75 × IC50 0.88 × IC50 0.44 × IC50 0.26 × IC50 0.13 × IC50
ΔE 5.83% 6.06% 7.17% 10.15% 12.59% 10.59% 5.36%
Upper Ci 7.21% 6.91% 9.09% 11.59% 15.76% 13.77% 8.88%
Lower Ci 4.55% 5.22% 5.36% 8.76% 9.54% 7.48% 1.97%
ΔE 5.51% 5.84% 7.06% 9.58% 11.99% 12.02% 6.79%
Upper Ci 6.96% 6.97% 8.84% 10.89% 15.47% 14.64% 10.34%
Lower Ci 4.12% 4.72% 5.35% 8.32% 8.61% 9.44% 3.34%
ΔE 3.70% 4.11% 5.66% 7.45% 8.79% 6.78% 4.33%
Upper Ci 4.53% 4.64% 6.79% 8.28% 10.77% 8.72% 7.56%
Lower Ci 2.88% 3.58% 4.54% 6.62% 6.82% 4.85% 1.11%
ΔE 8.98% 8.67% 12.16% 17.51% 21.25% 21.72% 14.31%
Upper Ci 11.34% 10.02% 15.55% 20.11% 26.10% 25.45% 19.14%
Lower Ci 6.76% 7.36% 8.95% 14.99% 16.61% 18.08% 9.70%
ΔE 13.77% 14.46% 19.39% 26.65% 33.90% 36.87% 27.48%
Upper Ci 16.25% 15.97% 23.02% 29.50% 38.66% 40.96% 34.05%
Lower Ci 11.44% 12.98% 15.94% 23.88% 29.36% 32.88% 21.13%
ΔE 20.14% 20.39% 26.84% 36.05% 46.56% 42.97% 25.63%
Upper Ci 23.25% 23.42% 32.00% 41.92% 56.19% 52.03% 34.95%
Lower Ci 17.15% 17.38% 21.84% 30.25% 37.10% 34.00% 16.50%
ΔE 22.53% 20.72% 20.82% 25.78% 36.11% 27.04% 8.25%
Upper Ci 28.26% 28.35% 31.34% 34.08% 44.61% 37.62% 19.01%
Lower Ci 17.04% 13.13% 10.58% 17.58% 27.93% 16.61% -2.19%
ΔE 14.74% 9.86% 13.17% 8.30% 12.17% 6.78% -3.30%
Upper Ci 20.05% 11.82% 19.42% 12.23% 20.44% 10.01% 3.65%
Lower Ci 9.49% 7.91% 7.00% 4.40% 3.98% 3.58% -10.16%
Reovirus (MOI)
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3.51 × IC50
2.63 × IC50
1.75 × IC50
0.88 × IC50
0.44 × IC50
0.22 × IC50
0.11 × IC50
0.05 × IC50
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Figure 6.10.  Combination treatment of the DU145 PCa cell line with reovirus and Docetaxel at doses much lower than the IC50 values had an anti-cancer 
synergistic effect, as determined by Bliss Independence analysis.  Cells were treated with Docetaxel at doses representing 0.07, 0.14, 0.29, 0.57, 0.86, 2.86 and 5.71 fold 
the IC50 (IC50 0.035µM), combined with reovirus at doses representing 0.13, 0.26, 0.44, 0.88, 1.75, 3.51 and 7.02 fold the IC50 (IC50 MOI 2.85).  Alternatively, cells were 
treated with Docetaxel or reovirus as single agents at the stated doses, or with media alone as an untreated control.  A.  After 96 hours the % cell survival in each treatment 
was assessed by the MTS assay, relative to the untreated cells.  The survival curves display error bars that represent SEM from two assay repeats.  B.  The interaction 
between Docetaxel and reovirus was assessed by the Bliss Independence analysis spreadsheet (MedImmune LLC, USA [223].  The ΔE values for each combination and the 
Bliss analysis range (the upper and lower confidence intervals (Ci)) are displayed in the table, which is colour coded according to the level of interaction, where purple shows 
the highest level of synergism.  All combinations demonstrated a synergistic anti-cancer effect of up to 29.00%.  C.  The ΔE values for each combination of Docetaxel and 
reovirus were plotted onto a contour map, enabling easy visualisation of the level of interaction.   
7.02 × IC50 3.51 × IC50 1.75 × IC50 0.88 × IC50 0.44 × IC50 0.26 × IC50 0.13 × IC50
ΔE 2.66% 2.48% 5.56% 6.52% 9.00% 9.05% 8.31%
Upper Ci 3.81% 3.83% 8.66% 10.13% 12.26% 11.84% 12.31%
Lower Ci 1.53% 1.18% 2.64% 3.14% 5.86% 6.41% 4.46%
ΔE 2.20% 2.97% 5.36% 5.52% 6.94% 7.48% 5.53%
Upper Ci 3.33% 4.15% 7.64% 8.67% 9.55% 10.74% 8.92%
Lower Ci 1.10% 1.83% 3.24% 2.61% 4.43% 4.36% 2.30%
ΔE 4.53% 4.87% 10.22% 10.59% 13.10% 11.95% 10.27%
Upper Ci 7.01% 6.91% 15.03% 17.14% 19.87% 18.55% 21.30%
Lower Ci 2.14% 2.96% 5.94% 4.75% 6.68% 5.78% -0.27%
ΔE 5.88% 6.30% 11.16% 11.50% 13.76% 15.62% 11.10%
Upper Ci 7.42% 8.61% 17.29% 18.75% 20.02% 22.97% 21.20%
Lower Ci 4.44% 4.13% 5.60% 5.00% 7.88% 8.72% 1.52%
ΔE 8.59% 10.33% 19.85% 20.52% 22.27% 25.27% 17.80%
Upper Ci 11.12% 13.10% 26.46% 28.89% 27.99% 35.42% 25.97%
Lower Ci 6.12% 7.65% 13.60% 12.63% 16.79% 15.41% 9.95%
ΔE 9.78% 11.85% 21.45% 14.96% 19.03% 19.94% 8.58%
Upper Ci 12.84% 15.42% 30.85% 25.35% 29.49% 31.45% 18.12%
Lower Ci 6.76% 8.36% 12.34% 4.96% 8.76% 8.67% -0.69%
ΔE 11.80% 16.72% 29.00% 14.44% 22.34% 19.29% 3.65%
Upper Ci 17.14% 22.59% 44.14% 28.72% 37.52% 36.97% 22.67%
Lower Ci 6.63% 11.11% 14.86% 1.47% 7.81% 2.40% -14.47%
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6.3.5 The synergistic anti-cancer effect of the combination of reovirus and 
Cabazitaxel or Docetaxel at the IC50 doses may be due to enhanced 
microtubule stability  
We next intended to determine the mechanism of the synergistic anti-cancer 
interaction of the combination of reovirus and Cabazitaxel or Docetaxel in the DU145 
PCa cell line.  The combination of Docetaxel and reovirus was previously shown to 
enhance microtubule stability and correlated with promotion of cell death [192].  
Therefore, cell lysates were collected from DU145 cells after 24 hours treatment with 
reovirus, Cabazitaxel or Docetaxel alone at the IC50 doses, or with reovirus in 
combination with either taxane drug at the IC50 doses.  Lysates were also prepared 
from cells treated with media alone.  The level of acetylated α-tubulin in each sample 
was quantified by western blotting and densitometry analysis (Section 2.14), which is 
proportional to, and is used as a marker of microtubule stability.    
As expected, all treatments caused an increase in acetylated α-tubulin compared to 
cells treated with media alone.  Cabazitaxel appeared to be a more efficient 
microtubule stabiliser than Docetaxel when used as single agent treatments.  The 
greatest increase in acetylated α-tubulin was observed in the combinations, with 
reovirus and Cabazitaxel showing a slightly more intense band than reovirus and 
Docetaxel (Figure 6.11 A and B).  This suggested that the synergistic anti-cancer 
effect associated with combination treatment is partly due to increased microtubule 
stability.   
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Figure 6.11.  Microtubule stability was enhanced after combination treatment with reovirus and 
Cabazitaxel or Docetaxel at the IC50 doses, in the DU145 PCa cell line.  Lysates were collected 
from cells treated with reovirus, Docetaxel or Cabazitaxel as single agents, or with reovirus in 
combination with Docetaxel or Cabazitaxel for 24 hours.  Lysates were also prepared from cells treated 
with media alone.  A. The level of acetylated α-tubulin in each sample was determined by western 
blotting.  B. The intensity of the acetylated α-tubulin bands were quantified and normalised to their 
corresponding β-actin bands by densitometry analysis.  All treatments caused an increase in acetylated 
α-tubulin compared to untreated (media alone) cells.  Reovirus and Cabazitaxel in combination resulted 
in a slightly greater amount of acetylated α-tubulin than the combination of reovirus and Docetaxel.    
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6.3.6 The synergistic anti-cancer effect of reovirus in combination with low 
doses of Cabazitaxel or Docetaxel may be due to increased microtubule 
stabilisation  
Having shown that the combination of reovirus and Cabazitaxel or Docetaxel at low 
doses had an anti-cancer synergistic effect, we determined whether enhanced 
microtubule stability contributed to this.  Firstly, lysates were collected from DU145 
cells treated with reovirus at the IC50 dose (IC50 MOI 2.85) in combination with serial 
dilutions of either taxane drug (1.0, 0.50, 0.25, 0.13, 0.06 and 0.03 ×IC50), for 24 
hours.   Lysates were also prepared from cells treated with media alone.  The level of 
acetylated α-tubulin in each sample was quantified by western blotting and 
densitometry analysis (Section 2.14).   
The western blot images in Figure 6.12 A and Figure 6.13 A show that all 
combination treatments resulted in a greater intensity acetylated α-tubulin band than 
cells treated with Cabazitaxel or Docetaxel alone at the IC50 doses.  This was 
confirmed by densitometry analysis (Figure 6.12 B and 6.13 B).  Therefore, reovirus 
(at the IC50 dose) in combination with Cabazitaxel or Docetaxel at doses as low as 
0.03 ×IC50, caused enhanced microtubule stabilisation compared to single agent 
treatment.  This may partially explain the synergistic anti-cancer interaction observed 
following combination treatment of reovirus and low doses of taxane drug.   
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Figure 6.12.  Microtubule stability was enhanced after combination treatment with reovirus and 
Cabazitaxel at low doses, in the DU145 PCa cell line.  Lysates were collected from cells treated with 
media alone, Cabazitaxel alone, or with reovirus (at the IC50 dose) in combination with Cabazitaxel at 
1.0, 0.50, 0.25, 0.13, 0.06 or 0.03 ×IC50 dose, for 24 hours.  A. The level of acetylated α-tubulin in each 
sample was determined by western blotting.  B. The intensity of the acetylated α-tubulin bands were 
quantified and normalised to their corresponding β-actin bands by densitometry analysis.  All 
combination treatments caused a greater increase in acetylated α-tubulin than cells treated with 
Cabazitaxel as a single agent or with media alone.   
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Figure 6.13.  Microtubule stability was enhanced after combination treatment with reovirus and 
Docetaxel at low doses, in the DU145 PCa cell line.  Lysates were collected from cells treated with 
media alone, Docetaxel alone, or with reovirus (at the IC50 dose) in combination with Docetaxel at 1.0, 
0.50, 0.25, 0.13, 0.06 or 0.03 ×IC50 dose, for 24 hours.  A. The level of acetylated α-tubulin in each 
sample was determined by western blotting.  B. The intensity of the acetylated α-tubulin bands were 
quantified and normalised to their corresponding β-actin bands by densitometry analysis.  All 
combination treatments caused a greater increase in acetylated α-tubulin than cells treated with 
Docetaxel as a single agent or with media alone.   
 
R
e
o
 (
1
.0
 ×
IC
5
0 )
 +
 D
o
c
 (
1
.0
 ×
IC
5
0 )
R
e
o
 (
1
.0
 ×
IC
5
0 )
 +
 D
o
c
 (
0
.5
0
 ×
IC
5
0 )
R
e
o
 (
1
.0
 ×
IC
5
0 )
 +
 D
o
c
 (
0
.2
5
 ×
IC
5
0 )
R
e
o
 (
1
.0
 ×
IC
5
0 )
 +
 D
o
c
 (
0
.1
3
 ×
IC
5
0 )
R
e
o
 (
1
.0
 ×
IC
5
0 )
 +
 D
o
c
 (
0
.0
6
 ×
IC
5
0 )
R
e
o
 (
1
.0
 ×
IC
5
0 )
 +
 D
o
c
 (
0
.0
3
 ×
IC
5
0 )
D
o
c
 (
1
.0
0
 ×
IC
5
0 )
m
e
d
ia
 a
lo
n
e
0
2 5
5 0
7 5
1 0 0
1 2 5
R
e
la
ti
v
e
 d
e
n
s
it
y
226 
 
6.3.7 The synergistic anti-cancer effect of reovirus and Cabazitaxel or Docetaxel 
in combination was not due to enhanced viral replication 
We then determined whether increased viral replication contributes to the anti-cancer 
synergistic effect caused by the combination of reovirus and Cabazitaxel or 
Docetaxel.  The reason for testing this was due to the fact that some studies have 
reported enhanced viral titres in cancer cells treated with the co-administration of 
reovirus and chemotherapeutic drugs [141, 192], whilst other studies have not found 
this connection [335, 352, 359].  We treated the DU145 PCa cell line with reovirus 
alone at the IC50 dose, or with reovirus (at the IC50) in combination with Cabazitaxel 
or Docetaxel at concentrations representing 1.00, 0.25 and 0.06 ×IC50.  Intracellular 
and extracellular virus samples were collected after 24, 48 and 72 hours treatment and 
the virus titre was determined by one-step growth curve analysis via the plaque assay 
(Section 2.24).   
Treatment with reovirus alone produced higher amounts of intracellular virus 
compared to all combination treatments with Cabazitaxel (Figure 6.14 A).  By 72 
hours, the viral yield was approximately 1-log higher in cells treated with reovirus 
alone than the combination of reovirus and Cabazitaxel at 1.00 ×IC50 dose, which 
suggested that viral replication did not contribute to synergistic cancer cell kill.  
Despite being lower in titre than reovirus alone, it was interesting to find that the 
higher the concentration of Cabazitaxel used in combination with reovirus, the lower 
the viral titre observed after 24 hours (although the treatment means were not 
statistically different from each other by one-way ANOVA and Tukey’s post-hoc 
test).  This implied that the mode of cell death may be compromised according to the 
dose of Cabazitaxel used when combined with reovirus.  A similar trend was observed 
when DU145 cells were treated with reovirus and Docetaxel at the same combination 
ratios (Figure 6.15 A), although the intracellular viral titre was not as well spread in 
comparison to treatment with reovirus and Cabazitaxel.  There was no clear separation 
in the extracellular viral growth curves of cells treated with reovirus alone and 
combination treated cell supernatants, indicating that there was no significant 
difference in viral release between treatment groups (Figure 6.14 B and 6.15 B).   
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Figure 6.14.  Combination treatment of the DU145 PCa cell line with reovirus and Cabazitaxel 
did not enhance the intracellular or extracellular viral yield compared to single agent reovirus 
treatment.  Cells were treated with reovirus alone at 1.00 ×IC50 dose (orange circles), or with reovirus 
at 1.00 ×IC50 in combination with Cabazitaxel at 1.00 ×IC50 (purple squares), 0.25 ×IC50 (green 
triangles) or 0.06 ×IC50 (blue triangles).  A.  Intracellular and B. Extracellular virus samples were 
collected after 24, 48 and 72 hours.  The virus titre was determined by one-step growth curve analysis 
via the plaque assay.  Reovirus alone produced higher amounts of intracellular virus compared to 
combination treatment with Cabazitaxel, which was most evident at 72 hours when 1.00 ×IC50 
Cabazitaxel was used, implying that viral replication was not a major factor that contributed to synergy.  
The overlap in the extracellular viral growth curves suggested a lack of a relationship between 
enhanced anti-cancer synergism and secretion of reovirus in the combination treatments.  Viral titre is 
shown on a log10 scale.  The graphs show the mean of two assay repeats and error bars represent SEM.   
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Figure 6.15.  Combination treatment of the DU145 PCa cell line with reovirus and Docetaxel did 
not enhance the intracellular or extracellular viral yield compared to single agent reovirus 
treatment.  Cells were treated with reovirus alone at 1.00 ×IC50 dose (orange circles), or with reovirus 
at 1.00 ×IC50 in combination with Docetaxel at 1.00 ×IC50 (purple squares), 0.25 ×IC50 (green triangles) 
or 0.06 ×IC50 (blue triangles).  A.  Intracellular and B. Extracellular virus samples were collected after 
24, 48 and 72 hours.  The virus titre was determined by one-step growth curve analysis via the plaque 
assay.  Combination treatment did not enhance the intracellular reovirus yield compared to when 
reovirus was used as a single agent, implying that viral replication was not a major factor that 
contributed to synergy.  The overlap in the extracellular viral growth curves suggested a lack of a 
relationship between enhanced anti-cancer synergism and secretion of reovirus in the combination 
treatments.  Viral titre is shown on a log10 scale.  The graphs show the mean of two assay repeats and 
error bars represent SEM. 
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6.3.8 Apoptosis contributes to synergistic cell death when high doses of the 
taxane drugs are used in combination with reovirus, but not at low doses 
The next step was to assess whether apoptosis or necroptosis was contributing to 
synergistic PCa cancer cell death after combination treatment.  The DU145 PCa cell 
line was treated with reovirus, Cabazitaxel or Docetaxel as single agents at doses 
representing 0.25, 0.5, 1.0, 2.0 and 4.0 fold the IC50 values.  In addition, cells were 
treated with reovirus in combination with Cabazitaxel or Docetaxel at 1.0, 0.50, 0.25, 
0.13, 0.06 and 0.03 ×IC50.  In each treatment, cells were incubated with the z-VAD-
FMK pan-caspase apoptosis inhibitor (Section 2.25), with the Necrostatin-1 (NCS-1) 
necroptosis inhibitor (Section 2.26), or with media alone, for a total of 96-hours.  The 
cell survival was then determined by the MTS assay (Section 2.9).    
Figure 6.16 shows the survival graphs of DU145 cells treated with z-VAD-FMK, 
NCS-1 or media alone.  In the single agent treated cells, incubation with z-VAD-FMK 
caused an increase in cell survival of up to 40% compared to media alone treated 
cells, when doses of ≥1.00 ×IC50 were used (p<0.05 by an un-paired t-test).  However, 
compared to untreated cells, z-VAD-FMK had little effect on cell survival when doses 
of <1.00 ×IC50 of each agent was used alone, which also had less statistical power.  
Thus, apoptosis may contribute to single agent cytotoxicity at high doses, but not at 
low doses.  In the combination treated cells, the effect of z-VAD-FMK was visible at 
doses between 0.25 and 1.00 ×IC50 (up to 33% cell survival and p<0.05 by an un-
paired t-test), but not at doses <0.25 ×IC50 (insignificant by un-paired t-test), in 
comparison to cells treated with media alone.   This suggested that apoptosis plays a 
role in synergistic anti-cancer cytotoxicity at high doses of reovirus and Cabazitaxel 
or Docetaxel, but does not contribute to synergistic cell death at low doses.  NCS-1 
had an insignificant effect on cell survival in all treatments (p≥0.05), apart from in 
cells treated with single-agent reovirus, where there was inhibition of cell death of up 
to 14% compared to untreated cells.  Hence, it was concluded that necroptosis was not 
a major factor involved in synergistic DU145 cell kill.   
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Figure 6.16.  High doses of reovirus in combination with Cabazitaxel or Docetaxel causes synergistic anti-cancer cell death by apoptosis, but low dose 
combination treatment is non-apoptotic.  Cells were treated with A. reovirus, B. Cabazitaxel or C. Docetaxel as single agents at doses representing 0.25, 0.50, 
1.00, 2.00 and 4.00 fold the IC50 values.  Cells were also treated with D. reovirus in combination with Cabazitaxel or E. reovirus in combination with Docetaxel, at 
doses representing 0.03, 0.06, 0.13, 0.25, 0.50 and 1.00 fold the IC50 values.  Each treatment condition was incubated with the pan-caspase apoptosis inhibitor z-
VAD-FMK, the necroptosis inhibitor Necrostatin-1 (NCS-1), or media alone.  After 96 hours, the % cell survival in each treatment was assessed by the MTS assay, 
relative to the untreated cells.  z-VAD-FMK caused a significant increase in cell survival compared to cells treated with media alone when high doses of reovirus, 
Cabazitaxel or Docetaxel was used alone or in combination.  Little effect was observed with NCS-1, indicating that necroptosis is not a major factor that contributes 
to cell death.  The survival curves display error bars that represent SEM from two assay repeats.  *p<0.05, p<0.01 and p<0.001 by un-paired t-test.   
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6.4  DISCUSSION 
The aim of this chapter was to compare the interaction of reovirus in combination 
with either Cabazitaxel or Docetaxel in PCa cell lines, and to explore whether low 
doses of each agent in combination could achieve an anti-cancer synergistic effect.  
The IC50 values of reovirus, Cabazitaxel or Docetaxel were determined, and then the 
level of interaction between the two combinations was assessed by the Chou and 
Talalay equation [234].  Bliss Independence analysis was also used to evaluate the 
interaction at a range of non-fixed low doses [223, 224].  We assessed whether the 
synergistic anti-cancer interaction of the combination treatments was due to enhanced 
stabilised microtubules, viral replication, necroptosis or apoptosis.   
Different human PCa cell lines have variable molecular and hormonal characteristics.  
For example, the LNCaP PCa cell line expresses the androgen receptor, is androgen-
sensitive and expresses PSA [360].  DU145 and PC3 PCa cells however, do not 
express the androgen receptor, are androgen-insensitive, and do not produce PSA 
[360, 361].  One study showed an inverse relationship between the expression levels 
of the androgen receptor and caveolin-1, a plasma-membrane protein that functions to 
exchange material between the cell and its environment via endocytosis.  LNCaP cells 
produced low caveolin-1, whereas DU145 and PC3 cells expressed high caveolin-1 
[360].  Interestingly, reovirus ISVPs can exploit caveolar endocytosis to initiate 
productive infection [116].  Hence, it would be logical to predict that PCa cells 
expressing high levels of caveolin-1 would be more sensitive to reovirus oncolysis 
than cells that exhibit low caveolin-1.  We found that TRAMP-C2 was the most 
susceptible PCa cell line to reovirus oncolysis, followed by DU145, LNCaP and PC3.  
Therefore, we did not find a distinct correlation between caveolin-1 expression and 
reovirus-induced cell death, as LNCaP were more susceptible to reovirus than PC3.  
Normal prostate cells were not available for direct comparison, but interestingly, the 
non-cancerous, SV40 transformed WPMY-1 cell line was more resistant to reovirus 
than the tumour cell lines.  This  may be due to the increased chromosomal instability 
of the cancer cell lines that could render them more prone to reovirus-induced cell 
death [308].  The cell lines, however, showed different sensitivities to the taxane 
drugs.  Going from the most sensitive to the most resistant cell line, the order of 
susceptibility to Cabazitaxel was DU145, LNCaP, TRAMP-C2, WPMY-1 and PC3.  
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Similarly, the order of susceptibility to Docetaxel starting with the most sensitive line 
was DU145, TRAMP-C2, LNCaP, WPMY-1 and PC3.  Having calculated the IC50 
values of each agent, DU145 and LNCaP PCa cell lines were treated concurrently 
with the two combinations (reovirus and Cabazitaxel or reovirus and Docetaxel) at 
fixed-dose ratios.   In both cell lines, the combinations caused a greater synergistic 
anti-cancer effect than cells treated with each agent alone, as determined using the 
Chou and Talalay equation [234].  The combination of reovirus and Docetaxel was 
only fractionally more synergistic than reovirus and Cabazitaxel at ED50, ED75 and 
ED90 in DU145 cells.  In LNCaP cells, reovirus and Docetaxel showed strong 
synergism at the ED50, whereas reovirus and Cabazitaxel showed a slightly lower 
level of synergy.  Both combinations showed a similar level of synergy at ED75.  At 
ED90, reovirus and Cabazitaxel was synergistic in LNCaP cells, but reovirus and 
Docetaxel showed moderate antagonism.  Therefore, the anti-cancer interaction 
between reovirus and the taxane drugs at concentrations based around the IC50 values, 
varied slightly in different PCa cell lines.  The newer taxane entity, Cabazitaxel, has 
been shown to maintain activity against docetaxel-resistant cancer cell lines [187, 
188].  Thus, we predicted that the combination of reovirus and Cabazitaxel would be 
consistently more synergistic than the combination of reovirus and Docetaxel.   
However, there was no definitive difference in the anti-cancer effect caused by the 
two combination treatments, suggesting that Cabazitaxel and Docetaxel behave 
similarly when combined with reovirus at fixed dose ratios around the IC50. 
We questioned whether there was an optimal sequence to treat cells with reovirus and 
Cabazitaxel or Docetaxel.  Clinical trial data has suggested that androgen-deprivation 
therapy (ADT) may reduce the efficacy of subsequent taxane treatment for advanced 
PCa [185].  This may be because taxanes can inhibit the activity of the androgen 
receptor through accumulation of the transcription repressor, forkhead box protein O1 
(FOXO1), in the nucleus of PCa cell lines [362].  In turn, this prevents androgen 
signalling, which leads to the regression of PCa cancer.  Therefore, treatment with 
taxane drugs before the administration of ADT may generate a better anti-cancer 
response than giving ADT before taxane treatment.  We tested five different 
sequential combinations of reovirus and Cabazitaxel in the DU145 PCa cell line.  
None of the sequential combinations enhanced the synergistic cancer cell kill in 
comparison to concurrent combination treatment, suggesting that reovirus does not 
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counteract the activity of taxane drugs, or vice versa.   It was therefore decided that 
concurrent treatment was the best sequencing strategy.  This may influence the way in 
which reovirus and taxane drugs are administered in vivo, should this project be taken 
further in the future.     
Bliss Independence analysis was also used to evaluate the interaction of reovirus and 
Cabazitaxel or Docetaxel at a variety of non-fixed doses [223, 224].  The Bliss 
Independent model is more flexible than that of Chou and Talalay, and allows the 
interaction to be determined at doses below a 50% effect (ED50).  Our data suggested 
that concentrations of 0.26 ×IC50 reovirus and 0.11 ×IC50 Cabazitaxel in combination, 
showed a synergistic anti-cancer effect compared to single agent treatment at these 
doses in DU145 cells.  In comparison, DU145 cells treated with 0.13 ×IC50 reovirus 
and 0.07 ×IC50 Docetaxel in combination generated a synergistic anti-cancer effect 
compared to single agent treatment.  However, the combination of reovirus and 
Cabazitaxel reached a greater level of synergism (46.56%) than the combination of 
reovirus and Docetaxel at low doses (29.00%).  Therefore, again, it was difficult to 
reach a conclusion as to which taxane drug was more efficient when combined with 
reovirus at doses below the IC50 values.  The data implied that both combinations 
have the potential to be used as metronomic treatments for PCa.  The original plan 
was to test the combinations in the other PCa cell lines, but there was not enough time 
left in the project to perform these experiments, which is a possible limitation to the 
study.   
Since reovirus and taxane drugs have been shown to stabilise cellular microtubules 
[141, 192], we predicted that the combination of two microtubule stabilisers would 
enhance this effect to promote DU145 cancer cell death.  As expected, combination 
treatment at the IC50 doses showed greater microtubule stabilisation than single agent 
treatment, with reovirus and Cabazitaxel being slightly more efficient than reovirus 
and Docetaxel.  Both combinations however, enhanced microtubule stability when the 
IC50 dose of reovirus was combined with Cabazitaxel or Docetaxel at doses as low as 
0.03 ×IC50, compared to treatment with each agent alone.  This may partially explain 
the synergistic anti-cancer activity after combination treatment at concentrations less 
than or equal to the IC50 values.  
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Previous studies have demonstrated that increased viral replication in cancer cells 
treated with reovirus and chemotherapeutic agents in combination, correlated with 
enhanced cell kill [141, 192].  This has also been shown with oncolytic HSV-1 strains 
G207 and NV1066 in combination with various chemotherapy drugs [363-365].  In 
contrast to these previously published findings, we found that the intracellular and 
extracellular viral titres recovered from DU145 cells treated with the combination of 
reovirus and Cabazitaxel or Docetaxel, was generally less than in cells treated with 
reovirus alone.  This suggested that synergistic PCa cancer cell death caused by 
combination treatment is not due to increased viral replication or secretion.   As 
mentioned in Chapter 5, reovirus yield and cytotoxicity are not closely linked in 
some cell types [335, 352].  Mainou et al found that impairment of microtubule 
activity by microtubule stabilisers such as taxanes might diminish infection by viruses 
that require access to late endosomes to establish a productive infection [359].   
Numerous combination studies have shown that chemotherapy agents have no effect 
on viral replication [366-369].  In fact, treating malignant pleural mesothelioma cell 
lines with the combination of high doses of replication-competent oncolytic HSV-1 
and cisplatin, showed strong synergistic cytotoxicity despite a reduction in viral 
replication, compared to when lower doses of virus was used in combination [364].  
Higher doses of virus resulted in a lower viral titre due to higher loss of cellular 
substrates at an earlier time point.  Moreover, they showed that loss of cellular 
substrates was due to high apoptotic cell fractions, which hindered HSV-1 oncolysis 
by limiting viral replication [364].  We hypothesised that a similar effect was taking 
place when DU145 cells were treated with reovirus in combination with the taxane 
drugs at higher doses.  Indeed, we found that cell death caused by high doses of each 
agent alone or in combination was partly due to apoptosis, as shown by using a pan-
caspase apoptotic inhibitor (z-VAD-FMK).  Apoptosis is a major mechanism of 
reovirus-induced cell death, as demonstrated in multiple cancer cell types, including 
PCa cell lines [155, 242, 243, 323, 324].  Additionally, taxanes initiate mitotic arrest 
and subsequent apoptosis.  Firstly, Paclitaxel has been shown to promote apoptosis in 
the HeLa cervical adenocarcinoma cell line via activation of cyclin-dependent kinase 
1 (Cdk1) (also known as p34cdc2 kinase), a serine/threonine kinase that plays a key 
role in cell cycle progression [370].  Secondly, the Bax pro-apoptotic protein 
enhanced apoptotic cell death in response to Paclitaxel in ovarian cancer cell lines 
[371].  Thirdly, Paclitaxel treatment of PCa cell lines induced the phosphorylation of 
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the anti-apoptotic Bcl-2 protein.  This inhibited Bcl-2 binding to Bax, thus disturbing 
the balance of pro- and anti- apoptotic interactions, leading to apoptosis [372].  
Conversely, we found that z-VAD-FMK had little effect on DU145 cell survival after 
low dose treatment of each agent alone or in combination.  This somewhat correlated 
with the viral titres observed with low dose combination treated cells, which were 
more elevated than in high dose combination treated cells.  Hence, synergistic cell 
death caused by low dose combination treatment may favour an alternative mode of 
death such as direct viral replication, as there are more cellular substrates available for 
reovirus to replicate.  Certain studies have indicated that the necroptosis cell death 
pathway can be initiated by reovirus infection [235, 314].  In cells treated with 
reovirus alone, there was an increase in cell survival of up to 14% after Necrostatin-1 
treatment, indicating that necroptosis may have some involvement in reovirus 
oncolysis.  However, we were surprised to find that Necrostatin-1 treatment had little 
effect on cell survival following the co-administration of reovirus and Cabazitaxel or 
Docetaxel, suggesting that necroptosis is not a major contributor of synergistic cell 
death in the DU145 PCa cell line.   
In addition to the targeting of endothelial cells involved in angiogenesis, metronomic 
chemotherapy (MC) can stimulate the immune system to initiate an anti-tumour 
response.  Regulatory T cells (Tregs) have an immunosuppressive function and 
prevent autoimmunity by establishing immunologic self-tolerance [373].  High levels 
of Tregs in the tumour microenvironment is associated with poor patient prognosis 
[374].  They can supress the anti-cancer immune response by down-regulating the 
activity of effector T cells, thus impeding the body’s innate ability to control cancer 
cell growth [374].  Several studies have demonstrated that low doses of 
cyclophosphamide (an alkylating agent) reduces immunosuppressive CD4+ CD25+ 
Treg cells, leading to restoration of T and NK cell effector immune functions in end-
stage tumour bearing patients [198], and in mouse models of cancer [199, 200].  MC 
cyclophosphamide treatment may also promote the recruitment and maturation of 
dendritic cells to the tumour site, leading to tumour regression [201].  Combination 
treatment of reovirus and high doses of cyclophosphamide caused wide spread viral 
dissemination and cytotoxicity to various organs in C57Bl/6 mice bearing established 
sub-cutaneous B16 tumours.  However, the metronomic dosing of cyclophosphamide 
achieved a balance where the immune response was suppressed enough to allow 
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access of the virus to tumours to enhance viral oncolysis, and caused minimal toxicity 
[42, 202].  Treatment of mouse melanoma B16F10 cells with Paclitaxel or Docetaxel 
showed enhanced cell-surface expression of calreticulin, a marker of immunogenic 
cell death (ICD) and an effective anti-cancer immune response [375].  The 
combination of reovirus and an inhibitor of programmed death-1 (PD-1) enhanced the 
CD8+ Th1 anti-tumour response in an in vivo melanoma mouse model, resulting in 
improved survival, compared to reovirus or anti-PD-1 therapy alone [376].  Therefore, 
we predict that the synergistic combination of reovirus and Cabazitaxel or Docetaxel 
at low doses may also promote the immune system to help destroy PCa cancer cells.  
For future reference, it would be beneficial to test this in culture in cell lines, and in in 
vivo PCa mouse models, which may better recapitulate the characteristics of the 
disease.    
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6.5   CONCLUSION 
The concurrent co-administration of reovirus and Cabazitaxel or Docetaxel at doses 
considerably less than the IC50, resulted in a synergistic anti-cancer effect in PCa cell 
lines compared to single agent treatment.  The biological mechanism of this 
interaction may change depending on the dose of the taxane drugs used.  The mode 
of cell death in low-dose combination treated cells was more influenced by direct 
reovirus replication (albeit not to greater levels of single agent reovirus), whereas 
high-dose combination treated cells were more likely to be killed by apoptosis.  
Microtubule stabilisation was enhanced in both combinations at doses ≤IC50, 
suggesting that this is also a factor that contributes to the synergistic interaction.  We 
conclude that both Cabazitaxel and Docetaxel had equal potential to be used as 
metronomic treatments for PCa when combined with oncolytic reovirus.  In vivo 
investigations into whether MC combination treatment modulates angiogenesis or the 
immune system will further support our data.   
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7.  GENERAL DISCUSSION 
Oncolytic viruses are an attractive treatment option for patients with advanced-stage 
malignancies such as SCCHN or PCa, whose prognosis is poor.  Despite the 
promising development of Reovirus T3D as an anti-tumour agent, there remain 
several important areas that warrant further investigation in order to maximise its 
oncolytic potential.   
The best characterised model of reovirus oncolysis is the ability of reovirus to exploit 
cells with a constitutively activated Ras pathway [132-138]; an aberration often 
present in cancer cells that facilitates their chronic proliferative signalling [1].  
However, a number of reports have argued that reovirus oncolysis can occur 
independently of activated Ras and EGFR signalling pathways in different cancers 
[139-144], including SCCHN [145].  Hence, the mechanism of reovirus-induced 
cancer cell death is still poorly understood, and this may explain the lack of success in 
finding a robust predictive biomarker of reovirus treatment response.  Biomarkers 
have proved to be valuable tools in stratifying the most responsive patient subgroup to 
a cancer treatment, and several are operational in the UK [148].  This study addressed 
the question of whether a host-cell factor could be identified in a panel of SCCHN 
cell lines that may predict for the susceptibility to reovirus oncolysis.   
Additionally, there is a growing realisation that reovirus will not display sufficient 
efficacy when used as a monotherapy [41, 42, 153].  Of the thirty-six clinical trials 
involving Reolysin®, twenty-four have evaluated Reolysin® in combination with 
conventional treatments such as chemotherapy or radiation, which have shown to 
enhance the tumour cell killing effect [166].  However, administering chemotherapy 
drugs at the standard maximum tolerated dose often causes cytotoxicity, and the 
extensive drug-free breaks designed to help patients recover can eventually lead to 
tumour vasculature re-growth and disease progression [193, 194, 203].  This study 
aimed to assess whether the co-administration of reovirus and low, metronomic doses 
of chemotherapeutic taxane drugs achieves a synergistic anti-cancer effect in PCa cell 
lines, compared to single-agent treatment.  This has the potential to limit toxic side-
effects and tumour-associated angiogenesis [195], stimulate an anti-tumour immune 
response [198-202], and help sustain clinical responses.   
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7.1. Yes-associated protein 1 (YAP1) as a predictive biomarker of reovirus 
treatment response in SCCHN 
Preliminary work revealed that the mRNA expression of eight genes increased in a 
panel of SCCHN cell lines, as they became progressively more resistant to reovirus 
oncolysis, suggesting that they were potential targets of reovirus susceptibility 
(R.Morgan, 2007, unpublished) [145] (Section 3.1 and 3.3.1).  Having reproduced 
and shown congruence with these previous findings in three SCCHN cell lines 
(Section 3.3.2 and 3.3.3), this hypothesis was tested by performing knock-down of 
the eight genes in the PJ41 cell line.  Subsequent infection with reovirus showed that 
knock-down of yes-associated protein-1 (YAP1) significantly sensitised the cells to 
reovirus, implying that YAP1 may hinder efficient reovirus oncolysis in SCCHN 
(Section 3.3.6).  Knock-down of the YAP1 protein proved to be less effective than its 
gene equivalent (Section 3.3.7), possibly due to the high level of redundancy in the 
upstream signalling pathways that control YAP1 [276].  The Hippo signalling 
pathway is a major upstream regulator of all YAP isoforms, which shuttle between the 
cytoplasm and the nucleus of the cell.  Absence of Hippo signalling leads to nuclear 
migration of YAP, where it acts as a cofactor to stimulate expression of genes that 
promote proliferation [219, 253, 275].  Conversely, core Hippo kinases can 
phosphorylate and sequester YAP to the cytoplasm, where it stays inactive [251, 272, 
273].  Elevated nuclear YAP is often observed in cancers of the head and neck [377], 
lung [378], colon [379], liver [380] and stomach [381], compared to in normal tissues, 
and is associated with a poor prognosis [251, 271, 283, 381]. 
Over-expression of YAP1 and its corresponding protein caused enhanced resistance to 
reovirus oncolysis in PJ34 and HN5 cell lines (Section 4.3.2 an 4.3.4).  These results 
further strengthened the conclusion that the expression level of YAP1 is important in 
determining the susceptibility of SCCHN cells to reovirus oncolysis.  There appears 
to be no evidence linking YAP1 signalling to oncolytic virus modulation, and thus, 
our work is the first example.  The mechanism behind this was then studied in detail. 
It is unlikely that YAP1-mediated restriction of reovirus oncolysis occurs at the cell 
surface, as JAM-A receptor expression did not correlate with the SCCHN cell line 
reovirus IC50 values, and over-expression of YAP1 did not alter the levels of JAM-A 
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(Section 5.3.2).  This is in agreement with the work of Twigger et al and others [144, 
145, 348, 349].   
The lack of a clear association between viral yield and reovirus oncolysis in PJ34, 
HN5 and PJ41, suggested that the mode of killing in these cells is not influenced by 
direct reovirus replication, which corresponded with several previously published 
reports [145, 335, 350, 352].  Stable over-expression of YAP1 in the HN5 cell line 
impeded reovirus replication to some extent, which would partially explain the 
increased resistance to oncolysis (Section 5.3.4 and 5.3.5).  Artificial over-expression 
of YAP1 may behave differently to a cell that expresses similar levels of YAP1, but 
endogenously.  Differences in the cytoplasmic and nuclear expression levels of YAP1 
may play a part in this, and may affect the physiological response to reovirus 
infection.  A possible limitation to our work was that immunofluorescent staining to 
establish YAP1 localisation after YAP1 over-expression or knock-down, was not 
performed.  Doing so may shed further light on the function of YAP1 in regards to 
reovirus oncolysis. 
Interferon-β (IFN-β) secretion was not significantly altered by over-expression or 
knock-down of YAP1 in SCCHN cell lines after reovirus infection.  The level of IFN-
β production correlated with the susceptibility to reovirus oncolysis in PJ34, HN5 and 
PJ41 SCCHN cell lines (Section 5.3.7).  However, as there were no differences in 
reoviral yield between these cell lines, this indicated that they may contain defects 
that render them non-responsive to type I interferon, which is a common survival 
device employed by tumours [354, 382].  Therefore, YAP1-mediated resistance to 
reovirus is probably not linked to the type I interferon anti-viral response. 
To test the possibility of using YAP1 as a biomarker, YAP1 protein expression in 
head and neck carcinoma tissue was ascertained.  13% of these tumour tissues 
expressed YAP1, whereas normal head and neck specimens did not (Section 5.3.8).  
Hence, since YAP1 can be measured easily in tumour tissue, that its expression can be 
distinguished from normal tissue, and that it is part of a signalling pathway involved 
in cancer progression, suggests that YAP1 meets some of the criteria required of a 
biomarker of reovirus treatment response in SCCHN.  Further validation of the IHC 
staining cut-off value and how the tumour tissue would be prepared and processed, 
would also be needed.  No correlation between YAP1 expression and clinico-
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pathological data was found, although larger sample numbers would be necessary to 
make more reliable conclusions.  The next step would be to determine whether there 
is an inverse correlation between YAP1 and reovirus protein expression in reovirus-
infected tumours.  The utilisation of a predictive biomarker in the clinic may help 
target the patients whose tumours are most responsive to reovirus therapy, which 
could improve economic factors such as cost and time, as well as strengthening 
clinical trial outcome of Reolysin®.   
 
7.2. Combination of reovirus with metronomic doses of taxane drugs in PCa 
cell lines 
The combination of reovirus and Cabazitaxel, or reovirus and Docetaxel, had an anti-
cancer synergistic effect compared to single agent treatment, at doses considerably 
lower than their IC50 values in the DU145 PCa cell line (Section 6.3.4).  It was 
concluded that the taxane drugs had approximately equal potential to be used as 
metronomic treatments for PCa when added concurrently with reovirus.  To our 
knowledge, this has not been previously explored and therefore, represents a novel 
area of research.  Given that PCa is a heterogeneous disease and that different human 
PCa cell lines have variable molecular and hormonal characteristics, testing the 
treatment combinations in more PCa cell lines would help support our data.   
An investigation into the mechanism of synergy showed that the mode of DU145 cell 
death may change depending on the dose of taxane drug used.  Direct reovirus 
replication seemed to have more of an effect in cells treated with low-dose 
combinations (Section 6.3.7), while apoptotic pathways had greater influence in the 
high-dose combination treated cells (Section 6.3.8).  A similar effect has been 
documented elsewhere in tumour cell lines treated with oncolytic HSV-1 and cisplatin 
[364].  Microtubule stabilisation was also a factor that contributed to synergistic 
cancer cell kill after combination treatment at doses equal to or less than the IC50 
(Section 6.3.6).  A disadvantage of this work is that cell lines do not fully take into 
account the impact of the immune system.  However, our data provides reason to 
assess metronomic combination treatment of reovirus and taxane drugs in an in vivo 
system, which would be a closer representation of the human body.  This may help 
improve the way drugs are administered in the clinic, to maximise patient survival.   
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7.3. Future work 
The aim of this work was to find ways of enhancing the oncolytic effect of reovirus 
via identification of a predictive biomarker of treatment response, and combination 
with low, metronomic doses of taxane drugs.  Due to time coming to an end, our work 
has some unfinished elements that may raise some important questions for new 
students wishing to continue this project.  
7.3.1. Short-term 
We were unable to unearth the complete mechanism of YAP1-mediated resistance to 
reovirus oncolysis in SCCHN.  However, there are potential factors linking upstream 
YAP1 signalling and reovirus infection that would be worth further exploration.  
Firstly, YAP1 may be suppressing the efficiency of reovirus-induced apoptosis in 
SCCHN cell lines.  Nuclear YAP can transcriptionally up-regulate the expression of 
anti-apoptotic factors in tumour cell lines [300, 357], and these factors are also known 
to inhibit apoptosis induced by reovirus infection [242, 243, 323].  It is possible that a 
threshold level of YAP1 might prevent reovirus-induced apoptosis by promoting 
expression of anti-apoptotic proteins, hence aiding SCCHN cell survival.  A PCR 
experiment would verify whether these anti-apoptotic factors are up-regulated after 
over-expression of YAP1, or down-regulated after YAP1 knock-down.   
Secondly, studies in Drosophila and human cell lines have shown that the actin 
cytoskeleton is an upstream regulator of the Hippo pathway [337].  Increased levels of 
filamentous (F)-actin in HeLa cells using an actin-stabilising drug resulted in 
inhibition of Hippo signalling and caused activation, decreased phosphorylation and 
nuclear localisation of YAP, to promote cell growth [383].  Other groups have 
concluded that activation of the Hippo pathway and cytoplasmic retention of YAP 
decreases the levels of F-actin [384, 385], suggesting that a negative feedback loop 
between the Hippo pathway and the actin cytoskeleton may exist [337].  The reoviral 
µ2 protein is capable of interacting with and stabilising cellular microtubules to aid 
reovirus replication [123, 191, 192].  Thus, perhaps reovirus-induced cell death is 
somehow influenced by YAP1 via the dynamic behaviour of cytoskeletal components.  
Treating infected cells with cytoskeletal inhibitors such as taxanes, phalloidin or 
cytochalasin D, may confirm this theory.  Indeed, as microtubule stabilisation is a 
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mode of death by taxane drugs, it would be of value to investigate whether YAP1 
signalling influences taxane efficacy in PCa cell lines.   
Thirdly, there is evidence suggesting that HPV infection may control upstream 
signalling of YAP1 [286].  Since HPV-negative SCCHN cell lines were significantly 
more susceptible to reovirus oncolysis than HPV-positive SCCHN cell lines [236], it 
may be worth investigating whether HPV status is linked to YAP1 mediated-
resistance to reovirus oncolysis, in PJ34, HN5 and PJ41 cells.   
Figure 7.1.  Potential mechanism of YAP1-mediated resistance to reovirus oncolysis in SCCHN 
cell lines.  Reovirus infection causes TRAIL ligands to bind to cell surface death receptors, resulting in 
recruitment of FADD and pro-caspase 8.  Activated caspase 8 induces cleavage of the pro-apoptotic 
protein Bid, which migrates to mitochondria to disrupt the interactions between pro- and anti- apoptotic 
Bcl-2 family member proteins.  This leads to mitochondrial release of cytochrome c and smac, and 
activation of effector caspase 3 for apoptosis.  However, inhibition of Hippo pathway signalling after 
reovirus infection, possibly via interactions with cytoskeletal components or HPV infection, activates 
nuclear YAP1.  YAP1 up-regulates anti-apoptotic factors such as Bcl-2 or Bcl-xL, which prevent 
mitochondrial release of cytochrome c and smac.  Therefore a certain level of YAP1 expression might 
prevent apoptosis induced by reovirus.      
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As the effects on reovirus-induced cell death after knock-down or over-expression of 
YAP1 were significant, albeit modest, multiple factors must cooperate with YAP1 to 
mediate reovirus oncolysis.  It would be insightful to confirm which upstream 
signalling pathways are acting upon YAP1 in the SCCHN cell lines, and after forced 
YAP1 over-expression or knock-down, pre and post reovirus infection.  Gene 
expression profiling and microarray hybridisation would be a good starting point in 
determining the associated up- and down- regulated genes.  Concentrating more 
specifically on the known signalling activities of YAP1 such as the Hippo pathway 
via a PCR array may be a less expensive alternative.  Elaborating on the wider 
signalling network linking YAP1 with reovirus infection may enhance our 
understanding of the oncolysis process, and perhaps a predictive biomarker composed 
of several related factors would be more compelling than a single marker on its own.   
In vivo experiments would support our data on the metronomic combination of taxane 
drugs with oncolytic reovirus.  A feasible model would be to treat C57BL/6 mice 
bearing TRAMP-C2 tumours, with reovirus intratumourally.  The first cohort would 
be given frequent intraperitoneal injections of the taxane agent at low doses, whereas 
a second cohort would be treated with the taxane at the maximum tolerated dose 
(MTD) with longer drug-free periods before the next cycle.  Anti-tumour responses 
could be compared between the treatment groups, as well as the anti-angiogenic and 
immune factors in blood and tumour samples.  Initial pilot studies would be needed to 
establish the MTD, the minimally effective dose, and the frequency of treatment.   
7.3.2. Long-term 
Over-expression of YAP1 in COS-1 cells caused significant resistance to reovirus 
oncolysis (Section 4.3.6), implying that this may give rise to a cancer-like phenotype, 
and that YAP1 may be a universal factor that promotes resistance to reovirus in cells 
other than SCCHN.  To test this theory, similar experiments to the ones carried out in 
this thesis could be applied to different cancer cell types.   
Until very recently, the interaction between YAP1 and the androgen receptor (AR) 
remained un-explored.  Kuser-Abali et al identified YAP1 as a binding partner and a 
positive regulator of the AR that therefore plays a critical role in PCa progression 
[386].  YAP also plays a role in chemo-resistance; knock-down of the YAP2 isoform 
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sensitised ovarian cancer cell lines to cisplatin treatment [387].  Therefore, it would be 
interesting to determine whether YAP1 contributes to reovirus resistance in PCa.   
S1P treatment sensitised PJ41 cells to reovirus oncolysis, but we were unable to prove 
that this was due to S1P-mediated activation of nuclear YAP1 activity (Section 4.3.8).  
Repeating the experiment with longer incubations of S1P before assessing the de-
phosphorylation of YAP1 may confirm this.  As there was some nuclear YAP1 
present in these cells, determining the effect of a nuclear YAP1 inhibitor on reovirus 
oncolysis may also be of interest.  Inhibitors of YAP may slow the development of 
cancer [291, 386], and in the context of this project, may sensitise SCCHN cell lines 
to reovirus.  Contemplating this, patients with tumours expressing high levels of 
YAP1 could be pre-treated with YAP1 inhibitors as a way of enhancing the oncolytic 
effect of reovirus.   
In summary, this thesis provides foundations and further questions about optimising 
reovirus T3D as an anti-cancer therapeutic.   
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